,source,target,value,type,source layer,target layer,normalized value
0,IGLC7,Initial triggering of complement,0.0060299186214454814,0,0,1,0.006809632044631794
1,IGLC7,Initial triggering of complement,0.004582400124066221,1,0,1,0.005174938616117803
2,IGLC7,Regulation of Complement cascade,0.0060299186214454814,0,0,1,0.006809632044631794
3,IGLC7,Regulation of Complement cascade,0.004582400124066221,1,0,1,0.005174938616117803
4,IGLC7,FCGR activation,0.0060299186214454814,0,0,1,0.006809632044631794
5,IGLC7,FCGR activation,0.004582400124066221,1,0,1,0.005174938616117803
6,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.0060299186214454814,0,0,1,0.006809632044631794
7,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.004582400124066221,1,0,1,0.005174938616117803
8,IGLC7,Role of phospholipids in phagocytosis,0.0060299186214454814,0,0,1,0.006809632044631794
9,IGLC7,Role of phospholipids in phagocytosis,0.004582400124066221,1,0,1,0.005174938616117803
10,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.0060299186214454814,0,0,1,0.006809632044631794
11,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.004582400124066221,1,0,1,0.005174938616117803
12,IGLC7,FCERI mediated MAPK activation,0.0060299186214454814,0,0,1,0.006809632044631794
13,IGLC7,FCERI mediated MAPK activation,0.004582400124066221,1,0,1,0.005174938616117803
14,IGLC7,FCERI mediated Ca+2 mobilization,0.0060299186214454814,0,0,1,0.006809632044631794
15,IGLC7,FCERI mediated Ca+2 mobilization,0.004582400124066221,1,0,1,0.005174938616117803
16,IGLC7,FCERI mediated NF-kB activation,0.0060299186214454814,0,0,1,0.006809632044631794
17,IGLC7,FCERI mediated NF-kB activation,0.004582400124066221,1,0,1,0.005174938616117803
18,IGLC7,Parasite infection,0.0060299186214454814,0,0,1,0.006809632044631794
19,IGLC7,Parasite infection,0.004582400124066221,1,0,1,0.005174938616117803
20,IGLC7,Leishmania parasite growth and survival,0.0060299186214454814,0,0,1,0.006809632044631794
21,IGLC7,Leishmania parasite growth and survival,0.004582400124066221,1,0,1,0.005174938616117803
22,IGLC7,Potential therapeutics for SARS,0.0060299186214454814,0,0,1,0.006809632044631794
23,IGLC7,Potential therapeutics for SARS,0.004582400124066221,1,0,1,0.005174938616117803
24,IGLC7,CD22 mediated BCR regulation,0.0060299186214454814,0,0,1,0.006809632044631794
25,IGLC7,CD22 mediated BCR regulation,0.004582400124066221,1,0,1,0.005174938616117803
26,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0060299186214454814,0,0,1,0.006809632044631794
27,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004582400124066221,1,0,1,0.005174938616117803
28,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0060299186214454814,0,0,1,0.006809632044631794
29,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004582400124066221,1,0,1,0.005174938616117803
30,IGLC7,Scavenging of heme from plasma,0.0060299186214454814,0,0,1,0.006809632044631794
31,IGLC7,Scavenging of heme from plasma,0.004582400124066221,1,0,1,0.005174938616117803
32,RB27B,Platelet degranulation ,4.575917975976177e-05,0,0,1,5.167618277963482e-05
33,RB27B,Platelet degranulation ,3.439324896342829e-05,1,0,1,3.884055241266543e-05
34,RB27B,RAB GEFs exchange GTP for GDP on RABs,4.575917975976177e-05,0,0,1,5.167618277963482e-05
35,RB27B,RAB GEFs exchange GTP for GDP on RABs,3.439324896342829e-05,1,0,1,3.884055241266543e-05
36,RB27B,RAB geranylgeranylation,4.575917975976177e-05,0,0,1,5.167618277963482e-05
37,RB27B,RAB geranylgeranylation,3.439324896342829e-05,1,0,1,3.884055241266543e-05
38,QSOX1,Platelet degranulation ,0.00022440099214682488,0,0,1,0.00025341771305760605
39,QSOX1,Platelet degranulation ,0.00020610058258976812,1,0,1,0.00023275092413836413
40,QSOX1,Neutrophil degranulation,0.00022440099214682488,0,0,1,0.00025341771305760605
41,QSOX1,Neutrophil degranulation,0.00020610058258976812,1,0,1,0.00023275092413836413
42,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00022440099214682488,0,0,1,0.00025341771305760605
43,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00020610058258976812,1,0,1,0.00023275092413836413
44,QSOX1,Post-translational protein phosphorylation,0.00022440099214682488,0,0,1,0.00025341771305760605
45,QSOX1,Post-translational protein phosphorylation,0.00020610058258976812,1,0,1,0.00023275092413836413
46,NRP1,Neurophilin interactions with VEGF and VEGFR,0.00047282369650917925,0,0,1,0.000533963324771758
47,NRP1,Neurophilin interactions with VEGF and VEGFR,0.0013661222971566688,1,0,1,0.0015427720928966704
48,NRP1,Semaphorin interactions,0.00047282369650917925,0,0,1,0.000533963324771758
49,NRP1,Semaphorin interactions,0.0013661222971566688,1,0,1,0.0015427720928966704
50,NRP1,L1CAM interactions,0.00047282369650917925,0,0,1,0.000533963324771758
51,NRP1,L1CAM interactions,0.0013661222971566688,1,0,1,0.0015427720928966704
52,NRP1,Signaling by ROBO receptors,0.00047282369650917925,0,0,1,0.000533963324771758
53,NRP1,Signaling by ROBO receptors,0.0013661222971566688,1,0,1,0.0015427720928966704
54,NRP1,SARS-CoV-2 Infection,0.00047282369650917925,0,0,1,0.000533963324771758
55,NRP1,SARS-CoV-2 Infection,0.0013661222971566688,1,0,1,0.0015427720928966704
56,APOL1,Scavenging of heme from plasma,0.00022706762873980036,0,0,1,0.00025642916563846363
57,APOL1,Scavenging of heme from plasma,0.0002424156426071534,1,0,1,0.00027376179209893925
58,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00022706762873980036,0,0,1,0.00025642916563846363
59,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002424156426071534,1,0,1,0.00027376179209893925
60,APOL1,Post-translational protein phosphorylation,0.00022706762873980036,0,0,1,0.00025642916563846363
61,APOL1,Post-translational protein phosphorylation,0.0002424156426071534,1,0,1,0.00027376179209893925
62,ARPC3,RHO GTPase Effectors,6.130890427295028e-05,0,0,1,6.92366025759507e-05
63,ARPC3,RHO GTPase Effectors,0.000458510948326155,1,0,1,0.0005177998315651941
64,ARPC3,Regulation of actin dynamics for phagocytic cup formation,6.130890427295028e-05,0,0,1,6.92366025759507e-05
65,ARPC3,Regulation of actin dynamics for phagocytic cup formation,0.000458510948326155,1,0,1,0.0005177998315651941
66,ARPC3,EPH-Ephrin signaling,6.130890427295028e-05,0,0,1,6.92366025759507e-05
67,ARPC3,EPH-Ephrin signaling,0.000458510948326155,1,0,1,0.0005177998315651941
68,ARPC3,Parasite infection,6.130890427295028e-05,0,0,1,6.92366025759507e-05
69,ARPC3,Parasite infection,0.000458510948326155,1,0,1,0.0005177998315651941
70,ACTN4,Platelet degranulation ,0.000181556338972727,0,0,1,0.00020503292687527893
71,ACTN4,Platelet degranulation ,0.0018153667496044548,1,0,1,0.00205010720159639
72,ACTN4,Nephrin family interactions,0.000181556338972727,0,0,1,0.00020503292687527893
73,ACTN4,Nephrin family interactions,0.0018153667496044548,1,0,1,0.00205010720159639
74,FLNB,Antiviral mechanism by IFN-stimulated genes,0.0002818559590606834,0,0,1,0.0003183020354476952
75,FLNB,Antiviral mechanism by IFN-stimulated genes,0.0005400654896626929,1,0,1,0.0006098999829827281
76,PGRP1,Neutrophil degranulation,0.0009880396270082062,0,0,1,0.0011158005153688554
77,PGRP1,Neutrophil degranulation,0.0005801846248867122,1,0,1,0.0006552068214287349
78,FCN3,Initial triggering of complement,1.1790634333069392e-05,0,0,1,1.3315251236634138e-05
79,FCN3,Initial triggering of complement,8.268357309770543e-06,1,0,1,9.33751754009274e-06
80,IDHC,NADPH regeneration,0.00017053823367100426,0,0,1,0.0001925900984319735
81,IDHC,NADPH regeneration,0.0001097346894369777,1,0,1,0.0001239242027148007
82,IDHC,KEAP1-NFE2L2 pathway,0.00017053823367100426,0,0,1,0.0001925900984319735
83,IDHC,KEAP1-NFE2L2 pathway,0.0001097346894369777,1,0,1,0.0001239242027148007
84,IDHC,Neutrophil degranulation,0.00017053823367100426,0,0,1,0.0001925900984319735
85,IDHC,Neutrophil degranulation,0.0001097346894369777,1,0,1,0.0001239242027148007
86,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.00017053823367100426,0,0,1,0.0001925900984319735
87,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0001097346894369777,1,0,1,0.0001239242027148007
88,UTS2,Class A/1 (Rhodopsin-like receptors),0.0009619058838893003,0,0,1,0.0010862874844706015
89,UTS2,Class A/1 (Rhodopsin-like receptors),0.001010647732485309,1,0,1,0.001141332017399042
90,UTS2,G alpha (q) signalling events,0.0009619058838893003,0,0,1,0.0010862874844706015
91,UTS2,G alpha (q) signalling events,0.001010647732485309,1,0,1,0.001141332017399042
92,APOM,Retinoid metabolism and transport,0.00014673311004121458,0,0,1,0.00016570679487969806
93,APOM,Retinoid metabolism and transport,0.0002628660504053861,1,0,1,0.0002968565900574646
94,VNN1,Vitamin B5 (pantothenate) metabolism,0.0003063060503659772,0,0,1,0.0003459137058033375
95,VNN1,Vitamin B5 (pantothenate) metabolism,0.00016622626193979446,1,0,1,0.00018772055661561086
96,VNN1,Neutrophil degranulation,0.0003063060503659772,0,0,1,0.0003459137058033375
97,VNN1,Neutrophil degranulation,0.00016622626193979446,1,0,1,0.00018772055661561086
98,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.0003063060503659772,0,0,1,0.0003459137058033375
99,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.00016622626193979446,1,0,1,0.00018772055661561086
100,FSTL3,Antagonism of Activin by Follistatin,0.0004848211135837571,0,0,1,0.0005475120972996821
101,FSTL3,Antagonism of Activin by Follistatin,0.00034891897120346377,1,0,1,0.0003940367949306574
102,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0004848211135837571,0,0,1,0.0005475120972996821
103,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00034891897120346377,1,0,1,0.0003940367949306574
104,FSTL3,Post-translational protein phosphorylation,0.0004848211135837571,0,0,1,0.0005475120972996821
105,FSTL3,Post-translational protein phosphorylation,0.00034891897120346377,1,0,1,0.0003940367949306574
106,K2C75,Formation of the cornified envelope,5.455424280593858e-05,0,0,1,6.160851303377772e-05
107,K2C75,Formation of the cornified envelope,0.00010923491848692083,1,0,1,0.00012335980765573975
108,PAK4,RHO GTPase cycle,0.0011076730827645513,0,0,1,0.001250903468670928
109,PAK4,RHO GTPase cycle,0.0009810783026042201,1,0,1,0.0011079390398315459
110,PAK4,Signaling by ROBO receptors,0.0011076730827645513,0,0,1,0.001250903468670928
111,PAK4,Signaling by ROBO receptors,0.0009810783026042201,1,0,1,0.0011079390398315459
112,ADH1B,Ethanol oxidation,5.588919757293195e-05,0,0,1,6.311608740254637e-05
113,ADH1B,Ethanol oxidation,0.00015541337824967005,1,0,1,0.0001755094864679516
114,LDHA,Pyruvate metabolism,0.0006656135395266764,0,0,1,0.0007516823314963915
115,LDHA,Pyruvate metabolism,0.0026872464544896208,1,0,1,0.003034727451086073
116,AL1A1,Ethanol oxidation,0.004051943166006527,0,0,1,0.004575889619493818
117,AL1A1,Ethanol oxidation,0.0016311022052943214,1,0,1,0.0018420158782473251
118,AL1A1,RA biosynthesis pathway,0.004051943166006527,0,0,1,0.004575889619493818
119,AL1A1,RA biosynthesis pathway,0.0016311022052943214,1,0,1,0.0018420158782473251
120,AL1A1,Fructose catabolism,0.004051943166006527,0,0,1,0.004575889619493818
121,AL1A1,Fructose catabolism,0.0016311022052943214,1,0,1,0.0018420158782473251
122,DHE3,Transcriptional activation of mitochondrial biogenesis,0.0007594965741352703,0,0,1,0.0008577051422594169
123,DHE3,Transcriptional activation of mitochondrial biogenesis,0.0003462989452554428,1,0,1,0.0003910779800985704
124,DHE3,Glutamate and glutamine metabolism,0.0007594965741352703,0,0,1,0.0008577051422594169
125,DHE3,Glutamate and glutamine metabolism,0.0003462989452554428,1,0,1,0.0003910779800985704
126,CERU,Metal ion SLC transporters,0.00431806185189472,0,0,1,0.00487641943504631
127,CERU,Metal ion SLC transporters,0.005322942554503151,1,0,1,0.006011238702619463
128,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.00431806185189472,0,0,1,0.00487641943504631
129,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.005322942554503151,1,0,1,0.006011238702619463
130,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.00431806185189472,0,0,1,0.00487641943504631
131,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.005322942554503151,1,0,1,0.006011238702619463
132,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00431806185189472,0,0,1,0.00487641943504631
133,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005322942554503151,1,0,1,0.006011238702619463
134,CERU,Post-translational protein phosphorylation,0.00431806185189472,0,0,1,0.00487641943504631
135,CERU,Post-translational protein phosphorylation,0.005322942554503151,1,0,1,0.006011238702619463
136,OTC,Urea cycle,0.0007316961249680528,0,0,1,0.0008263098877976145
137,OTC,Urea cycle,0.0013409973040777424,1,0,1,0.0015143982509375235
138,OTC,Mitochondrial protein import,0.0007316961249680528,0,0,1,0.0008263098877976145
139,OTC,Mitochondrial protein import,0.0013409973040777424,1,0,1,0.0015143982509375235
140,F13A,Interleukin-4 and Interleukin-13 signaling,0.004537504986562689,0,0,1,0.005124238202698472
141,F13A,Interleukin-4 and Interleukin-13 signaling,0.0027914862521235366,1,0,1,0.0031524462315301923
142,F13A,Platelet degranulation ,0.004537504986562689,0,0,1,0.005124238202698472
143,F13A,Platelet degranulation ,0.0027914862521235366,1,0,1,0.0031524462315301923
144,F13A,Common Pathway of Fibrin Clot Formation,0.004537504986562689,0,0,1,0.005124238202698472
145,F13A,Common Pathway of Fibrin Clot Formation,0.0027914862521235366,1,0,1,0.0031524462315301923
146,PGK1,Glycolysis,0.0005909019743883037,0,0,1,0.000667310004105197
147,PGK1,Glycolysis,0.0009024220967587311,1,0,1,0.0010191120002874866
148,PGK1,Gluconeogenesis,0.0005909019743883037,0,0,1,0.000667310004105197
149,PGK1,Gluconeogenesis,0.0009024220967587311,1,0,1,0.0010191120002874866
150,PGK1,Response of Mtb to phagocytosis,0.0005909019743883037,0,0,1,0.000667310004105197
151,PGK1,Response of Mtb to phagocytosis,0.0009024220967587311,1,0,1,0.0010191120002874866
152,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.01088863176368813,0,0,1,0.012296613011741071
153,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.009890817681494107,1,0,1,0.011169774131274646
154,THRB,Regulation of Complement cascade,0.01088863176368813,0,0,1,0.012296613011741071
155,THRB,Regulation of Complement cascade,0.009890817681494107,1,0,1,0.011169774131274646
156,THRB,Class A/1 (Rhodopsin-like receptors),0.01088863176368813,0,0,1,0.012296613011741071
157,THRB,Class A/1 (Rhodopsin-like receptors),0.009890817681494107,1,0,1,0.011169774131274646
158,THRB,G alpha (q) signalling events,0.01088863176368813,0,0,1,0.012296613011741071
159,THRB,G alpha (q) signalling events,0.009890817681494107,1,0,1,0.011169774131274646
160,THRB,Defective factor XII causes hereditary angioedema,0.01088863176368813,0,0,1,0.012296613011741071
161,THRB,Defective factor XII causes hereditary angioedema,0.009890817681494107,1,0,1,0.011169774131274646
162,THRB,Defective factor VIII causes hemophilia A,0.01088863176368813,0,0,1,0.012296613011741071
163,THRB,Defective factor VIII causes hemophilia A,0.009890817681494107,1,0,1,0.011169774131274646
164,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.01088863176368813,0,0,1,0.012296613011741071
165,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.009890817681494107,1,0,1,0.011169774131274646
166,THRB,Common Pathway of Fibrin Clot Formation,0.01088863176368813,0,0,1,0.012296613011741071
167,THRB,Common Pathway of Fibrin Clot Formation,0.009890817681494107,1,0,1,0.011169774131274646
168,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01088863176368813,0,0,1,0.012296613011741071
169,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009890817681494107,1,0,1,0.011169774131274646
170,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.01088863176368813,0,0,1,0.012296613011741071
171,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.009890817681494107,1,0,1,0.011169774131274646
172,C1R,Initial triggering of complement,0.0008578812563199545,0,0,1,0.0009688116971842224
173,C1R,Initial triggering of complement,0.0006908628059316442,1,0,1,0.0007801965162489375
174,C1R,Regulation of Complement cascade,0.0008578812563199545,0,0,1,0.0009688116971842224
175,C1R,Regulation of Complement cascade,0.0006908628059316442,1,0,1,0.0007801965162489375
176,HPT,Neutrophil degranulation,0.0006997632635691585,0,0,1,0.0007902478694006616
177,HPT,Neutrophil degranulation,0.001037107346756013,1,0,1,0.0011712130570179797
178,HPT,Scavenging of heme from plasma,0.0006997632635691585,0,0,1,0.0007902478694006616
179,HPT,Scavenging of heme from plasma,0.001037107346756013,1,0,1,0.0011712130570179797
180,HPTR,Scavenging of heme from plasma,0.0003284722366844144,0,0,1,0.0003709461452336934
181,HPTR,Scavenging of heme from plasma,0.0006583985774562875,1,0,1,0.0007435344210518646
182,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.004203986585015244,0,0,1,0.004747593385872168
183,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0035309520735562947,1,0,1,0.003987530495458681
184,FA9,Defective factor VIII causes hemophilia A,0.004203986585015244,0,0,1,0.004747593385872168
185,FA9,Defective factor VIII causes hemophilia A,0.0035309520735562947,1,0,1,0.003987530495458681
186,FA9,Defective factor IX causes hemophilia B,0.004203986585015244,0,0,1,0.004747593385872168
187,FA9,Defective factor IX causes hemophilia B,0.0035309520735562947,1,0,1,0.003987530495458681
188,FA9,Defective factor IX causes thrombophilia,0.004203986585015244,0,0,1,0.004747593385872168
189,FA9,Defective factor IX causes thrombophilia,0.0035309520735562947,1,0,1,0.003987530495458681
190,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.004203986585015244,0,0,1,0.004747593385872168
191,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.0035309520735562947,1,0,1,0.003987530495458681
192,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.004203986585015244,0,0,1,0.004747593385872168
193,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.0035309520735562947,1,0,1,0.003987530495458681
194,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.019335571154692036,0,0,1,0.02183580462727469
195,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.01760230598213334,1,0,1,0.01987841534859972
196,FA10,Defective factor VIII causes hemophilia A,0.019335571154692036,0,0,1,0.02183580462727469
197,FA10,Defective factor VIII causes hemophilia A,0.01760230598213334,1,0,1,0.01987841534859972
198,FA10,Defective factor IX causes hemophilia B,0.019335571154692036,0,0,1,0.02183580462727469
199,FA10,Defective factor IX causes hemophilia B,0.01760230598213334,1,0,1,0.01987841534859972
200,FA10,Defective factor IX causes thrombophilia,0.019335571154692036,0,0,1,0.02183580462727469
201,FA10,Defective factor IX causes thrombophilia,0.01760230598213334,1,0,1,0.01987841534859972
202,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.019335571154692036,0,0,1,0.02183580462727469
203,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.01760230598213334,1,0,1,0.01987841534859972
204,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.019335571154692036,0,0,1,0.02183580462727469
205,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.01760230598213334,1,0,1,0.01987841534859972
206,FA10,Common Pathway of Fibrin Clot Formation,0.019335571154692036,0,0,1,0.02183580462727469
207,FA10,Common Pathway of Fibrin Clot Formation,0.01760230598213334,1,0,1,0.01987841534859972
208,CFAD,Initial triggering of complement,0.0005222564984348172,0,0,1,0.0005897881564455339
209,CFAD,Initial triggering of complement,0.00036276621407348197,1,0,1,0.00040967458951748887
210,CFAD,Platelet degranulation ,0.0005222564984348172,0,0,1,0.0005897881564455339
211,CFAD,Platelet degranulation ,0.00036276621407348197,1,0,1,0.00040967458951748887
212,CFAD,Neutrophil degranulation,0.0005222564984348172,0,0,1,0.0005897881564455339
213,CFAD,Neutrophil degranulation,0.00036276621407348197,1,0,1,0.00040967458951748887
214,PLMN,Platelet degranulation ,0.0009895996384002132,0,0,1,0.001117562247861765
215,PLMN,Platelet degranulation ,0.00028959737495701314,1,0,1,0.000327044474121906
216,PLMN,Dissolution of Fibrin Clot,0.0009895996384002132,0,0,1,0.001117562247861765
217,PLMN,Dissolution of Fibrin Clot,0.00028959737495701314,1,0,1,0.000327044474121906
218,PLMN,Activation of Matrix Metalloproteinases,0.0009895996384002132,0,0,1,0.001117562247861765
219,PLMN,Activation of Matrix Metalloproteinases,0.00028959737495701314,1,0,1,0.000327044474121906
220,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0009895996384002132,0,0,1,0.001117562247861765
221,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00028959737495701314,1,0,1,0.000327044474121906
222,PLMN,Signaling by PDGF,0.0009895996384002132,0,0,1,0.001117562247861765
223,PLMN,Signaling by PDGF,0.00028959737495701314,1,0,1,0.000327044474121906
224,FA12,Defective factor XII causes hereditary angioedema,0.00022657200479281832,0,0,1,0.0002558694538208858
225,FA12,Defective factor XII causes hereditary angioedema,0.00023446475100156235,1,0,1,0.0002647827909448826
226,FA12,Defective SERPING1 causes hereditary angioedema,0.00022657200479281832,0,0,1,0.0002558694538208858
227,FA12,Defective SERPING1 causes hereditary angioedema,0.00023446475100156235,1,0,1,0.0002647827909448826
228,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.00022657200479281832,0,0,1,0.0002558694538208858
229,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.00023446475100156235,1,0,1,0.0002647827909448826
230,CFAB,Initial triggering of complement,0.0030844108107234446,0,0,1,0.0034832481189399746
231,CFAB,Initial triggering of complement,0.0018114795442679818,1,0,1,0.002045717351635701
232,CFAB,Activation of C3 and C5,0.0030844108107234446,0,0,1,0.0034832481189399746
233,CFAB,Activation of C3 and C5,0.0018114795442679818,1,0,1,0.002045717351635701
234,CFAB,Regulation of Complement cascade,0.0030844108107234446,0,0,1,0.0034832481189399746
235,CFAB,Regulation of Complement cascade,0.0018114795442679818,1,0,1,0.002045717351635701
236,CAH1,Interleukin-12 family signaling,0.0012296663996221931,0,0,1,0.0013886714307044816
237,CAH1,Interleukin-12 family signaling,0.0006682665658343762,1,0,1,0.00075467841388064
238,CAH1,Reversible hydration of carbon dioxide,0.0012296663996221931,0,0,1,0.0013886714307044816
239,CAH1,Reversible hydration of carbon dioxide,0.0006682665658343762,1,0,1,0.00075467841388064
240,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.0012296663996221931,0,0,1,0.0013886714307044816
241,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.0006682665658343762,1,0,1,0.00075467841388064
242,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.0012296663996221931,0,0,1,0.0013886714307044816
243,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.0006682665658343762,1,0,1,0.00075467841388064
244,CAH2,Reversible hydration of carbon dioxide,0.005369240516172675,0,0,1,0.006063523335825732
245,CAH2,Reversible hydration of carbon dioxide,0.006114645690898302,1,0,1,0.006905314955698239
246,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.005369240516172675,0,0,1,0.006063523335825732
247,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.006114645690898302,1,0,1,0.006905314955698239
248,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.005369240516172675,0,0,1,0.006063523335825732
249,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.006114645690898302,1,0,1,0.006905314955698239
250,ASSY,Urea cycle,3.119797136069944e-05,0,0,1,3.523210159914174e-05
251,ASSY,Urea cycle,3.7879764400034636e-06,1,0,1,4.2777900282797485e-06
252,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.002611422245286929,0,0,1,0.002949098606459686
253,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.0026598984097034152,1,0,1,0.0030038431002638514
254,ANT3,Common Pathway of Fibrin Clot Formation,0.002611422245286929,0,0,1,0.002949098606459686
255,ANT3,Common Pathway of Fibrin Clot Formation,0.0026598984097034152,1,0,1,0.0030038431002638514
256,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002611422245286929,0,0,1,0.002949098606459686
257,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0026598984097034152,1,0,1,0.0030038431002638514
258,ANT3,Post-translational protein phosphorylation,0.002611422245286929,0,0,1,0.002949098606459686
259,ANT3,Post-translational protein phosphorylation,0.0026598984097034152,1,0,1,0.0030038431002638514
260,A1AT,COPII-mediated vesicle transport,0.0018564598384390994,0,0,1,0.002096513933114471
261,A1AT,COPII-mediated vesicle transport,0.0027209604381154312,1,0,1,0.003072800904089901
262,A1AT,Cargo concentration in the ER,0.0018564598384390994,0,0,1,0.002096513933114471
263,A1AT,Cargo concentration in the ER,0.0027209604381154312,1,0,1,0.003072800904089901
264,A1AT,Platelet degranulation ,0.0018564598384390994,0,0,1,0.002096513933114471
265,A1AT,Platelet degranulation ,0.0027209604381154312,1,0,1,0.003072800904089901
266,A1AT,Neutrophil degranulation,0.0018564598384390994,0,0,1,0.002096513933114471
267,A1AT,Neutrophil degranulation,0.0027209604381154312,1,0,1,0.003072800904089901
268,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0018564598384390994,0,0,1,0.002096513933114471
269,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0027209604381154312,1,0,1,0.003072800904089901
270,A1AT,Post-translational protein phosphorylation,0.0018564598384390994,0,0,1,0.002096513933114471
271,A1AT,Post-translational protein phosphorylation,0.0027209604381154312,1,0,1,0.003072800904089901
272,AACT,Platelet degranulation ,0.0005317422929602812,0,0,1,0.0006005005349077673
273,AACT,Platelet degranulation ,0.00025452785846794213,1,0,1,0.0002874402077518113
274,AACT,Neutrophil degranulation,0.0005317422929602812,0,0,1,0.0006005005349077673
275,AACT,Neutrophil degranulation,0.00025452785846794213,1,0,1,0.0002874402077518113
276,ANGT,Class A/1 (Rhodopsin-like receptors),0.00020144822572196256,0,0,1,0.0002274969828501023
277,ANGT,Class A/1 (Rhodopsin-like receptors),0.0002608581602876695,1,0,1,0.0002945890647812405
278,ANGT,G alpha (q) signalling events,0.00020144822572196256,0,0,1,0.0002274969828501023
279,ANGT,G alpha (q) signalling events,0.0002608581602876695,1,0,1,0.0002945890647812405
280,ANGT,G alpha (i) signalling events,0.00020144822572196256,0,0,1,0.0002274969828501023
281,ANGT,G alpha (i) signalling events,0.0002608581602876695,1,0,1,0.0002945890647812405
282,ANGT,PPARA activates gene expression,0.00020144822572196256,0,0,1,0.0002274969828501023
283,ANGT,PPARA activates gene expression,0.0002608581602876695,1,0,1,0.0002945890647812405
284,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.00020144822572196256,0,0,1,0.0002274969828501023
285,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.0002608581602876695,1,0,1,0.0002945890647812405
286,A2MG,Platelet degranulation ,0.004410794078877895,0,0,1,0.0049811426301801295
287,A2MG,Platelet degranulation ,0.005171010746149653,1,0,1,0.005839660978985968
288,A2MG,HDL assembly,0.004410794078877895,0,0,1,0.0049811426301801295
289,A2MG,HDL assembly,0.005171010746149653,1,0,1,0.005839660978985968
290,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.004410794078877895,0,0,1,0.0049811426301801295
291,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.005171010746149653,1,0,1,0.005839660978985968
292,CO3,Initial triggering of complement,0.0012170835138077486,0,0,1,0.0013744614839646956
293,CO3,Initial triggering of complement,0.0010656197378658052,1,0,1,0.0012034123128221602
294,CO3,Activation of C3 and C5,0.0012170835138077486,0,0,1,0.0013744614839646956
295,CO3,Activation of C3 and C5,0.0010656197378658052,1,0,1,0.0012034123128221602
296,CO3,Regulation of Complement cascade,0.0012170835138077486,0,0,1,0.0013744614839646956
297,CO3,Regulation of Complement cascade,0.0010656197378658052,1,0,1,0.0012034123128221602
298,CO3,Class A/1 (Rhodopsin-like receptors),0.0012170835138077486,0,0,1,0.0013744614839646956
299,CO3,Class A/1 (Rhodopsin-like receptors),0.0010656197378658052,1,0,1,0.0012034123128221602
300,CO3,G alpha (i) signalling events,0.0012170835138077486,0,0,1,0.0013744614839646956
301,CO3,G alpha (i) signalling events,0.0010656197378658052,1,0,1,0.0012034123128221602
302,CO3,Cell recruitment (pro-inflammatory response),0.0012170835138077486,0,0,1,0.0013744614839646956
303,CO3,Cell recruitment (pro-inflammatory response),0.0010656197378658052,1,0,1,0.0012034123128221602
304,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0012170835138077486,0,0,1,0.0013744614839646956
305,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0010656197378658052,1,0,1,0.0012034123128221602
306,CO3,Neutrophil degranulation,0.0012170835138077486,0,0,1,0.0013744614839646956
307,CO3,Neutrophil degranulation,0.0010656197378658052,1,0,1,0.0012034123128221602
308,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0012170835138077486,0,0,1,0.0013744614839646956
309,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0010656197378658052,1,0,1,0.0012034123128221602
310,CO3,Post-translational protein phosphorylation,0.0012170835138077486,0,0,1,0.0013744614839646956
311,CO3,Post-translational protein phosphorylation,0.0010656197378658052,1,0,1,0.0012034123128221602
312,CO5,Terminal pathway of complement,0.0007674029670459757,0,0,1,0.0008666338907056576
313,CO5,Terminal pathway of complement,0.00026496473015881955,1,0,1,0.00029922664474602603
314,CO5,Activation of C3 and C5,0.0007674029670459757,0,0,1,0.0008666338907056576
315,CO5,Activation of C3 and C5,0.00026496473015881955,1,0,1,0.00029922664474602603
316,CO5,Regulation of Complement cascade,0.0007674029670459757,0,0,1,0.0008666338907056576
317,CO5,Regulation of Complement cascade,0.00026496473015881955,1,0,1,0.00029922664474602603
318,CO5,Class A/1 (Rhodopsin-like receptors),0.0007674029670459757,0,0,1,0.0008666338907056576
319,CO5,Class A/1 (Rhodopsin-like receptors),0.00026496473015881955,1,0,1,0.00029922664474602603
320,CO5,G alpha (i) signalling events,0.0007674029670459757,0,0,1,0.0008666338907056576
321,CO5,G alpha (i) signalling events,0.00026496473015881955,1,0,1,0.00029922664474602603
322,TIMP1,Interleukin-10 signaling,0.0026292010163996367,0,0,1,0.002969176305195568
323,TIMP1,Interleukin-10 signaling,0.0029886700504547785,1,0,1,0.00337512736474203
324,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.0026292010163996367,0,0,1,0.002969176305195568
325,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.0029886700504547785,1,0,1,0.00337512736474203
326,TIMP1,Platelet degranulation ,0.0026292010163996367,0,0,1,0.002969176305195568
327,TIMP1,Platelet degranulation ,0.0029886700504547785,1,0,1,0.00337512736474203
328,TIMP1,Activation of Matrix Metalloproteinases,0.0026292010163996367,0,0,1,0.002969176305195568
329,TIMP1,Activation of Matrix Metalloproteinases,0.0029886700504547785,1,0,1,0.00337512736474203
330,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0026292010163996367,0,0,1,0.002969176305195568
331,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0029886700504547785,1,0,1,0.00337512736474203
332,TIMP1,Post-translational protein phosphorylation,0.0026292010163996367,0,0,1,0.002969176305195568
333,TIMP1,Post-translational protein phosphorylation,0.0029886700504547785,1,0,1,0.00337512736474203
334,CYTC,Neutrophil degranulation,0.003911151616646259,0,0,1,0.004416892673377949
335,CYTC,Neutrophil degranulation,0.003601979836280476,1,0,1,0.004067742677325431
336,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003911151616646259,0,0,1,0.004416892673377949
337,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003601979836280476,1,0,1,0.004067742677325431
338,CYTC,Amyloid fiber formation,0.003911151616646259,0,0,1,0.004416892673377949
339,CYTC,Amyloid fiber formation,0.003601979836280476,1,0,1,0.004067742677325431
340,CYTC,Post-translational protein phosphorylation,0.003911151616646259,0,0,1,0.004416892673377949
341,CYTC,Post-translational protein phosphorylation,0.003601979836280476,1,0,1,0.004067742677325431
342,KNG1,Class A/1 (Rhodopsin-like receptors),0.00395631955347531,0,0,1,0.004467901161108962
343,KNG1,Class A/1 (Rhodopsin-like receptors),0.005530101253373636,1,0,1,0.006245184565360563
344,KNG1,G alpha (q) signalling events,0.00395631955347531,0,0,1,0.004467901161108962
345,KNG1,G alpha (q) signalling events,0.005530101253373636,1,0,1,0.006245184565360563
346,KNG1,G alpha (i) signalling events,0.00395631955347531,0,0,1,0.004467901161108962
347,KNG1,G alpha (i) signalling events,0.005530101253373636,1,0,1,0.006245184565360563
348,KNG1,Platelet degranulation ,0.00395631955347531,0,0,1,0.004467901161108962
349,KNG1,Platelet degranulation ,0.005530101253373636,1,0,1,0.006245184565360563
350,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.00395631955347531,0,0,1,0.004467901161108962
351,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.005530101253373636,1,0,1,0.006245184565360563
352,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00395631955347531,0,0,1,0.004467901161108962
353,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005530101253373636,1,0,1,0.006245184565360563
354,KNG1,Post-translational protein phosphorylation,0.00395631955347531,0,0,1,0.004467901161108962
355,KNG1,Post-translational protein phosphorylation,0.005530101253373636,1,0,1,0.006245184565360563
356,IGF2,IGF1R signaling cascade,0.0023041738889097467,0,0,1,0.0026021207474541926
357,IGF2,IGF1R signaling cascade,0.002578518346075873,1,0,1,0.0029119399878235973
358,IGF2,Platelet degranulation ,0.0023041738889097467,0,0,1,0.0026021207474541926
359,IGF2,Platelet degranulation ,0.002578518346075873,1,0,1,0.0029119399878235973
360,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0023041738889097467,0,0,1,0.0026021207474541926
361,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002578518346075873,1,0,1,0.0029119399878235973
362,IGJ,Scavenging of heme from plasma,9.78993479683535e-05,0,0,1,0.00011055846337674924
363,IGJ,Scavenging of heme from plasma,0.00020344279335007243,1,0,1,0.00022974946293951123
364,KVD33,Initial triggering of complement,0.000955508418601635,0,0,1,0.0010790627792362111
365,KVD33,Initial triggering of complement,0.0008101110259726254,1,0,1,0.0009148644199862037
366,KVD33,Regulation of Complement cascade,0.000955508418601635,0,0,1,0.0010790627792362111
367,KVD33,Regulation of Complement cascade,0.0008101110259726254,1,0,1,0.0009148644199862037
368,KVD33,FCGR activation,0.000955508418601635,0,0,1,0.0010790627792362111
369,KVD33,FCGR activation,0.0008101110259726254,1,0,1,0.0009148644199862037
370,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.000955508418601635,0,0,1,0.0010790627792362111
371,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.0008101110259726254,1,0,1,0.0009148644199862037
372,KVD33,Role of phospholipids in phagocytosis,0.000955508418601635,0,0,1,0.0010790627792362111
373,KVD33,Role of phospholipids in phagocytosis,0.0008101110259726254,1,0,1,0.0009148644199862037
374,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.000955508418601635,0,0,1,0.0010790627792362111
375,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.0008101110259726254,1,0,1,0.0009148644199862037
376,KVD33,FCERI mediated MAPK activation,0.000955508418601635,0,0,1,0.0010790627792362111
377,KVD33,FCERI mediated MAPK activation,0.0008101110259726254,1,0,1,0.0009148644199862037
378,KVD33,FCERI mediated Ca+2 mobilization,0.000955508418601635,0,0,1,0.0010790627792362111
379,KVD33,FCERI mediated Ca+2 mobilization,0.0008101110259726254,1,0,1,0.0009148644199862037
380,KVD33,FCERI mediated NF-kB activation,0.000955508418601635,0,0,1,0.0010790627792362111
381,KVD33,FCERI mediated NF-kB activation,0.0008101110259726254,1,0,1,0.0009148644199862037
382,KVD33,Parasite infection,0.000955508418601635,0,0,1,0.0010790627792362111
383,KVD33,Parasite infection,0.0008101110259726254,1,0,1,0.0009148644199862037
384,KVD33,Leishmania parasite growth and survival,0.000955508418601635,0,0,1,0.0010790627792362111
385,KVD33,Leishmania parasite growth and survival,0.0008101110259726254,1,0,1,0.0009148644199862037
386,KVD33,Potential therapeutics for SARS,0.000955508418601635,0,0,1,0.0010790627792362111
387,KVD33,Potential therapeutics for SARS,0.0008101110259726254,1,0,1,0.0009148644199862037
388,KVD33,CD22 mediated BCR regulation,0.000955508418601635,0,0,1,0.0010790627792362111
389,KVD33,CD22 mediated BCR regulation,0.0008101110259726254,1,0,1,0.0009148644199862037
390,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.000955508418601635,0,0,1,0.0010790627792362111
391,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008101110259726254,1,0,1,0.0009148644199862037
392,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.000955508418601635,0,0,1,0.0010790627792362111
393,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008101110259726254,1,0,1,0.0009148644199862037
394,KVD33,Scavenging of heme from plasma,0.000955508418601635,0,0,1,0.0010790627792362111
395,KVD33,Scavenging of heme from plasma,0.0008101110259726254,1,0,1,0.0009148644199862037
396,KVD16,Initial triggering of complement,0.0007703306877429817,0,0,1,0.0008699401875112494
397,KVD16,Initial triggering of complement,0.0005833924853117064,1,0,1,0.0006588294821172318
398,KVD16,Regulation of Complement cascade,0.0007703306877429817,0,0,1,0.0008699401875112494
399,KVD16,Regulation of Complement cascade,0.0005833924853117064,1,0,1,0.0006588294821172318
400,KVD16,FCGR activation,0.0007703306877429817,0,0,1,0.0008699401875112494
401,KVD16,FCGR activation,0.0005833924853117064,1,0,1,0.0006588294821172318
402,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.0007703306877429817,0,0,1,0.0008699401875112494
403,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.0005833924853117064,1,0,1,0.0006588294821172318
404,KVD16,Role of phospholipids in phagocytosis,0.0007703306877429817,0,0,1,0.0008699401875112494
405,KVD16,Role of phospholipids in phagocytosis,0.0005833924853117064,1,0,1,0.0006588294821172318
406,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007703306877429817,0,0,1,0.0008699401875112494
407,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.0005833924853117064,1,0,1,0.0006588294821172318
408,KVD16,FCERI mediated MAPK activation,0.0007703306877429817,0,0,1,0.0008699401875112494
409,KVD16,FCERI mediated MAPK activation,0.0005833924853117064,1,0,1,0.0006588294821172318
410,KVD16,FCERI mediated Ca+2 mobilization,0.0007703306877429817,0,0,1,0.0008699401875112494
411,KVD16,FCERI mediated Ca+2 mobilization,0.0005833924853117064,1,0,1,0.0006588294821172318
412,KVD16,FCERI mediated NF-kB activation,0.0007703306877429817,0,0,1,0.0008699401875112494
413,KVD16,FCERI mediated NF-kB activation,0.0005833924853117064,1,0,1,0.0006588294821172318
414,KVD16,Parasite infection,0.0007703306877429817,0,0,1,0.0008699401875112494
415,KVD16,Parasite infection,0.0005833924853117064,1,0,1,0.0006588294821172318
416,KVD16,Leishmania parasite growth and survival,0.0007703306877429817,0,0,1,0.0008699401875112494
417,KVD16,Leishmania parasite growth and survival,0.0005833924853117064,1,0,1,0.0006588294821172318
418,KVD16,Potential therapeutics for SARS,0.0007703306877429817,0,0,1,0.0008699401875112494
419,KVD16,Potential therapeutics for SARS,0.0005833924853117064,1,0,1,0.0006588294821172318
420,KVD16,CD22 mediated BCR regulation,0.0007703306877429817,0,0,1,0.0008699401875112494
421,KVD16,CD22 mediated BCR regulation,0.0005833924853117064,1,0,1,0.0006588294821172318
422,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007703306877429817,0,0,1,0.0008699401875112494
423,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0005833924853117064,1,0,1,0.0006588294821172318
424,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007703306877429817,0,0,1,0.0008699401875112494
425,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0005833924853117064,1,0,1,0.0006588294821172318
426,KVD16,Scavenging of heme from plasma,0.0007703306877429817,0,0,1,0.0008699401875112494
427,KVD16,Scavenging of heme from plasma,0.0005833924853117064,1,0,1,0.0006588294821172318
428,KV105,Initial triggering of complement,0.002091239929056433,0,0,1,0.0023616528394379025
429,KV105,Initial triggering of complement,0.002436402031686748,1,0,1,0.0027514469746861897
430,KV105,Regulation of Complement cascade,0.002091239929056433,0,0,1,0.0023616528394379025
431,KV105,Regulation of Complement cascade,0.002436402031686748,1,0,1,0.0027514469746861897
432,KV105,FCGR activation,0.002091239929056433,0,0,1,0.0023616528394379025
433,KV105,FCGR activation,0.002436402031686748,1,0,1,0.0027514469746861897
434,KV105,Regulation of actin dynamics for phagocytic cup formation,0.002091239929056433,0,0,1,0.0023616528394379025
435,KV105,Regulation of actin dynamics for phagocytic cup formation,0.002436402031686748,1,0,1,0.0027514469746861897
436,KV105,Role of phospholipids in phagocytosis,0.002091239929056433,0,0,1,0.0023616528394379025
437,KV105,Role of phospholipids in phagocytosis,0.002436402031686748,1,0,1,0.0027514469746861897
438,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.002091239929056433,0,0,1,0.0023616528394379025
439,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.002436402031686748,1,0,1,0.0027514469746861897
440,KV105,FCERI mediated MAPK activation,0.002091239929056433,0,0,1,0.0023616528394379025
441,KV105,FCERI mediated MAPK activation,0.002436402031686748,1,0,1,0.0027514469746861897
442,KV105,FCERI mediated Ca+2 mobilization,0.002091239929056433,0,0,1,0.0023616528394379025
443,KV105,FCERI mediated Ca+2 mobilization,0.002436402031686748,1,0,1,0.0027514469746861897
444,KV105,FCERI mediated NF-kB activation,0.002091239929056433,0,0,1,0.0023616528394379025
445,KV105,FCERI mediated NF-kB activation,0.002436402031686748,1,0,1,0.0027514469746861897
446,KV105,Parasite infection,0.002091239929056433,0,0,1,0.0023616528394379025
447,KV105,Parasite infection,0.002436402031686748,1,0,1,0.0027514469746861897
448,KV105,Leishmania parasite growth and survival,0.002091239929056433,0,0,1,0.0023616528394379025
449,KV105,Leishmania parasite growth and survival,0.002436402031686748,1,0,1,0.0027514469746861897
450,KV105,Potential therapeutics for SARS,0.002091239929056433,0,0,1,0.0023616528394379025
451,KV105,Potential therapeutics for SARS,0.002436402031686748,1,0,1,0.0027514469746861897
452,KV105,CD22 mediated BCR regulation,0.002091239929056433,0,0,1,0.0023616528394379025
453,KV105,CD22 mediated BCR regulation,0.002436402031686748,1,0,1,0.0027514469746861897
454,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002091239929056433,0,0,1,0.0023616528394379025
455,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002436402031686748,1,0,1,0.0027514469746861897
456,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002091239929056433,0,0,1,0.0023616528394379025
457,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002436402031686748,1,0,1,0.0027514469746861897
458,KV105,Scavenging of heme from plasma,0.002091239929056433,0,0,1,0.0023616528394379025
459,KV105,Scavenging of heme from plasma,0.002436402031686748,1,0,1,0.0027514469746861897
460,KVD12,Initial triggering of complement,0.0004751367949691411,0,0,1,0.0005365755241038228
461,KVD12,Initial triggering of complement,0.00010039375281065373,1,0,1,0.00011337541335779898
462,KVD12,Regulation of Complement cascade,0.0004751367949691411,0,0,1,0.0005365755241038228
463,KVD12,Regulation of Complement cascade,0.00010039375281065373,1,0,1,0.00011337541335779898
464,KVD12,FCGR activation,0.0004751367949691411,0,0,1,0.0005365755241038228
465,KVD12,FCGR activation,0.00010039375281065373,1,0,1,0.00011337541335779898
466,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.0004751367949691411,0,0,1,0.0005365755241038228
467,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.00010039375281065373,1,0,1,0.00011337541335779898
468,KVD12,Role of phospholipids in phagocytosis,0.0004751367949691411,0,0,1,0.0005365755241038228
469,KVD12,Role of phospholipids in phagocytosis,0.00010039375281065373,1,0,1,0.00011337541335779898
470,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.0004751367949691411,0,0,1,0.0005365755241038228
471,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.00010039375281065373,1,0,1,0.00011337541335779898
472,KVD12,FCERI mediated MAPK activation,0.0004751367949691411,0,0,1,0.0005365755241038228
473,KVD12,FCERI mediated MAPK activation,0.00010039375281065373,1,0,1,0.00011337541335779898
474,KVD12,FCERI mediated Ca+2 mobilization,0.0004751367949691411,0,0,1,0.0005365755241038228
475,KVD12,FCERI mediated Ca+2 mobilization,0.00010039375281065373,1,0,1,0.00011337541335779898
476,KVD12,FCERI mediated NF-kB activation,0.0004751367949691411,0,0,1,0.0005365755241038228
477,KVD12,FCERI mediated NF-kB activation,0.00010039375281065373,1,0,1,0.00011337541335779898
478,KVD12,Parasite infection,0.0004751367949691411,0,0,1,0.0005365755241038228
479,KVD12,Parasite infection,0.00010039375281065373,1,0,1,0.00011337541335779898
480,KVD12,Leishmania parasite growth and survival,0.0004751367949691411,0,0,1,0.0005365755241038228
481,KVD12,Leishmania parasite growth and survival,0.00010039375281065373,1,0,1,0.00011337541335779898
482,KVD12,Potential therapeutics for SARS,0.0004751367949691411,0,0,1,0.0005365755241038228
483,KVD12,Potential therapeutics for SARS,0.00010039375281065373,1,0,1,0.00011337541335779898
484,KVD12,CD22 mediated BCR regulation,0.0004751367949691411,0,0,1,0.0005365755241038228
485,KVD12,CD22 mediated BCR regulation,0.00010039375281065373,1,0,1,0.00011337541335779898
486,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004751367949691411,0,0,1,0.0005365755241038228
487,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00010039375281065373,1,0,1,0.00011337541335779898
488,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004751367949691411,0,0,1,0.0005365755241038228
489,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00010039375281065373,1,0,1,0.00011337541335779898
490,KVD12,Scavenging of heme from plasma,0.0004751367949691411,0,0,1,0.0005365755241038228
491,KVD12,Scavenging of heme from plasma,0.00010039375281065373,1,0,1,0.00011337541335779898
492,KVD40,Initial triggering of complement,0.0031086723241886493,0,0,1,0.0035106468269351944
493,KVD40,Initial triggering of complement,0.002435054147750394,1,0,1,0.002749924799310091
494,KVD40,Regulation of Complement cascade,0.0031086723241886493,0,0,1,0.0035106468269351944
495,KVD40,Regulation of Complement cascade,0.002435054147750394,1,0,1,0.002749924799310091
496,KVD40,FCGR activation,0.0031086723241886493,0,0,1,0.0035106468269351944
497,KVD40,FCGR activation,0.002435054147750394,1,0,1,0.002749924799310091
498,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.0031086723241886493,0,0,1,0.0035106468269351944
499,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.002435054147750394,1,0,1,0.002749924799310091
500,KVD40,Role of phospholipids in phagocytosis,0.0031086723241886493,0,0,1,0.0035106468269351944
501,KVD40,Role of phospholipids in phagocytosis,0.002435054147750394,1,0,1,0.002749924799310091
502,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.0031086723241886493,0,0,1,0.0035106468269351944
503,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.002435054147750394,1,0,1,0.002749924799310091
504,KVD40,FCERI mediated MAPK activation,0.0031086723241886493,0,0,1,0.0035106468269351944
505,KVD40,FCERI mediated MAPK activation,0.002435054147750394,1,0,1,0.002749924799310091
506,KVD40,FCERI mediated Ca+2 mobilization,0.0031086723241886493,0,0,1,0.0035106468269351944
507,KVD40,FCERI mediated Ca+2 mobilization,0.002435054147750394,1,0,1,0.002749924799310091
508,KVD40,FCERI mediated NF-kB activation,0.0031086723241886493,0,0,1,0.0035106468269351944
509,KVD40,FCERI mediated NF-kB activation,0.002435054147750394,1,0,1,0.002749924799310091
510,KVD40,Parasite infection,0.0031086723241886493,0,0,1,0.0035106468269351944
511,KVD40,Parasite infection,0.002435054147750394,1,0,1,0.002749924799310091
512,KVD40,Leishmania parasite growth and survival,0.0031086723241886493,0,0,1,0.0035106468269351944
513,KVD40,Leishmania parasite growth and survival,0.002435054147750394,1,0,1,0.002749924799310091
514,KVD40,Potential therapeutics for SARS,0.0031086723241886493,0,0,1,0.0035106468269351944
515,KVD40,Potential therapeutics for SARS,0.002435054147750394,1,0,1,0.002749924799310091
516,KVD40,CD22 mediated BCR regulation,0.0031086723241886493,0,0,1,0.0035106468269351944
517,KVD40,CD22 mediated BCR regulation,0.002435054147750394,1,0,1,0.002749924799310091
518,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0031086723241886493,0,0,1,0.0035106468269351944
519,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002435054147750394,1,0,1,0.002749924799310091
520,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0031086723241886493,0,0,1,0.0035106468269351944
521,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002435054147750394,1,0,1,0.002749924799310091
522,KVD40,Scavenging of heme from plasma,0.0031086723241886493,0,0,1,0.0035106468269351944
523,KVD40,Scavenging of heme from plasma,0.002435054147750394,1,0,1,0.002749924799310091
524,KV320,Initial triggering of complement,0.00468985417321192,0,0,1,0.005296287274752367
525,KV320,Initial triggering of complement,0.0040872562830312755,1,0,1,0.004615768985764588
526,KV320,Regulation of Complement cascade,0.00468985417321192,0,0,1,0.005296287274752367
527,KV320,Regulation of Complement cascade,0.0040872562830312755,1,0,1,0.004615768985764588
528,KV320,FCGR activation,0.00468985417321192,0,0,1,0.005296287274752367
529,KV320,FCGR activation,0.0040872562830312755,1,0,1,0.004615768985764588
530,KV320,Regulation of actin dynamics for phagocytic cup formation,0.00468985417321192,0,0,1,0.005296287274752367
531,KV320,Regulation of actin dynamics for phagocytic cup formation,0.0040872562830312755,1,0,1,0.004615768985764588
532,KV320,Role of phospholipids in phagocytosis,0.00468985417321192,0,0,1,0.005296287274752367
533,KV320,Role of phospholipids in phagocytosis,0.0040872562830312755,1,0,1,0.004615768985764588
534,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.00468985417321192,0,0,1,0.005296287274752367
535,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.0040872562830312755,1,0,1,0.004615768985764588
536,KV320,FCERI mediated MAPK activation,0.00468985417321192,0,0,1,0.005296287274752367
537,KV320,FCERI mediated MAPK activation,0.0040872562830312755,1,0,1,0.004615768985764588
538,KV320,FCERI mediated Ca+2 mobilization,0.00468985417321192,0,0,1,0.005296287274752367
539,KV320,FCERI mediated Ca+2 mobilization,0.0040872562830312755,1,0,1,0.004615768985764588
540,KV320,FCERI mediated NF-kB activation,0.00468985417321192,0,0,1,0.005296287274752367
541,KV320,FCERI mediated NF-kB activation,0.0040872562830312755,1,0,1,0.004615768985764588
542,KV320,Parasite infection,0.00468985417321192,0,0,1,0.005296287274752367
543,KV320,Parasite infection,0.0040872562830312755,1,0,1,0.004615768985764588
544,KV320,Leishmania parasite growth and survival,0.00468985417321192,0,0,1,0.005296287274752367
545,KV320,Leishmania parasite growth and survival,0.0040872562830312755,1,0,1,0.004615768985764588
546,KV320,Potential therapeutics for SARS,0.00468985417321192,0,0,1,0.005296287274752367
547,KV320,Potential therapeutics for SARS,0.0040872562830312755,1,0,1,0.004615768985764588
548,KV320,CD22 mediated BCR regulation,0.00468985417321192,0,0,1,0.005296287274752367
549,KV320,CD22 mediated BCR regulation,0.0040872562830312755,1,0,1,0.004615768985764588
550,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00468985417321192,0,0,1,0.005296287274752367
551,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0040872562830312755,1,0,1,0.004615768985764588
552,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00468985417321192,0,0,1,0.005296287274752367
553,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0040872562830312755,1,0,1,0.004615768985764588
554,KV320,Scavenging of heme from plasma,0.00468985417321192,0,0,1,0.005296287274752367
555,KV320,Scavenging of heme from plasma,0.0040872562830312755,1,0,1,0.004615768985764588
556,LV147,Initial triggering of complement,0.0015961106747929845,0,0,1,0.0018024996820344655
557,LV147,Initial triggering of complement,0.0014886589044439701,1,0,1,0.0016811535968619827
558,LV147,Regulation of Complement cascade,0.0015961106747929845,0,0,1,0.0018024996820344655
559,LV147,Regulation of Complement cascade,0.0014886589044439701,1,0,1,0.0016811535968619827
560,LV147,FCGR activation,0.0015961106747929845,0,0,1,0.0018024996820344655
561,LV147,FCGR activation,0.0014886589044439701,1,0,1,0.0016811535968619827
562,LV147,Regulation of actin dynamics for phagocytic cup formation,0.0015961106747929845,0,0,1,0.0018024996820344655
563,LV147,Regulation of actin dynamics for phagocytic cup formation,0.0014886589044439701,1,0,1,0.0016811535968619827
564,LV147,Role of phospholipids in phagocytosis,0.0015961106747929845,0,0,1,0.0018024996820344655
565,LV147,Role of phospholipids in phagocytosis,0.0014886589044439701,1,0,1,0.0016811535968619827
566,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.0015961106747929845,0,0,1,0.0018024996820344655
567,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.0014886589044439701,1,0,1,0.0016811535968619827
568,LV147,FCERI mediated MAPK activation,0.0015961106747929845,0,0,1,0.0018024996820344655
569,LV147,FCERI mediated MAPK activation,0.0014886589044439701,1,0,1,0.0016811535968619827
570,LV147,FCERI mediated Ca+2 mobilization,0.0015961106747929845,0,0,1,0.0018024996820344655
571,LV147,FCERI mediated Ca+2 mobilization,0.0014886589044439701,1,0,1,0.0016811535968619827
572,LV147,FCERI mediated NF-kB activation,0.0015961106747929845,0,0,1,0.0018024996820344655
573,LV147,FCERI mediated NF-kB activation,0.0014886589044439701,1,0,1,0.0016811535968619827
574,LV147,Parasite infection,0.0015961106747929845,0,0,1,0.0018024996820344655
575,LV147,Parasite infection,0.0014886589044439701,1,0,1,0.0016811535968619827
576,LV147,Leishmania parasite growth and survival,0.0015961106747929845,0,0,1,0.0018024996820344655
577,LV147,Leishmania parasite growth and survival,0.0014886589044439701,1,0,1,0.0016811535968619827
578,LV147,Potential therapeutics for SARS,0.0015961106747929845,0,0,1,0.0018024996820344655
579,LV147,Potential therapeutics for SARS,0.0014886589044439701,1,0,1,0.0016811535968619827
580,LV147,CD22 mediated BCR regulation,0.0015961106747929845,0,0,1,0.0018024996820344655
581,LV147,CD22 mediated BCR regulation,0.0014886589044439701,1,0,1,0.0016811535968619827
582,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0015961106747929845,0,0,1,0.0018024996820344655
583,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0014886589044439701,1,0,1,0.0016811535968619827
584,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0015961106747929845,0,0,1,0.0018024996820344655
585,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0014886589044439701,1,0,1,0.0016811535968619827
586,LV147,Scavenging of heme from plasma,0.0015961106747929845,0,0,1,0.0018024996820344655
587,LV147,Scavenging of heme from plasma,0.0014886589044439701,1,0,1,0.0016811535968619827
588,LV319,Initial triggering of complement,0.0016703640012749972,0,0,1,0.001886354517095442
589,LV319,Initial triggering of complement,0.002008080668712338,1,0,1,0.0022677404668839797
590,LV319,Regulation of Complement cascade,0.0016703640012749972,0,0,1,0.001886354517095442
591,LV319,Regulation of Complement cascade,0.002008080668712338,1,0,1,0.0022677404668839797
592,LV319,FCGR activation,0.0016703640012749972,0,0,1,0.001886354517095442
593,LV319,FCGR activation,0.002008080668712338,1,0,1,0.0022677404668839797
594,LV319,Regulation of actin dynamics for phagocytic cup formation,0.0016703640012749972,0,0,1,0.001886354517095442
595,LV319,Regulation of actin dynamics for phagocytic cup formation,0.002008080668712338,1,0,1,0.0022677404668839797
596,LV319,Role of phospholipids in phagocytosis,0.0016703640012749972,0,0,1,0.001886354517095442
597,LV319,Role of phospholipids in phagocytosis,0.002008080668712338,1,0,1,0.0022677404668839797
598,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.0016703640012749972,0,0,1,0.001886354517095442
599,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.002008080668712338,1,0,1,0.0022677404668839797
600,LV319,FCERI mediated MAPK activation,0.0016703640012749972,0,0,1,0.001886354517095442
601,LV319,FCERI mediated MAPK activation,0.002008080668712338,1,0,1,0.0022677404668839797
602,LV319,FCERI mediated Ca+2 mobilization,0.0016703640012749972,0,0,1,0.001886354517095442
603,LV319,FCERI mediated Ca+2 mobilization,0.002008080668712338,1,0,1,0.0022677404668839797
604,LV319,FCERI mediated NF-kB activation,0.0016703640012749972,0,0,1,0.001886354517095442
605,LV319,FCERI mediated NF-kB activation,0.002008080668712338,1,0,1,0.0022677404668839797
606,LV319,Parasite infection,0.0016703640012749972,0,0,1,0.001886354517095442
607,LV319,Parasite infection,0.002008080668712338,1,0,1,0.0022677404668839797
608,LV319,Leishmania parasite growth and survival,0.0016703640012749972,0,0,1,0.001886354517095442
609,LV319,Leishmania parasite growth and survival,0.002008080668712338,1,0,1,0.0022677404668839797
610,LV319,Potential therapeutics for SARS,0.0016703640012749972,0,0,1,0.001886354517095442
611,LV319,Potential therapeutics for SARS,0.002008080668712338,1,0,1,0.0022677404668839797
612,LV319,CD22 mediated BCR regulation,0.0016703640012749972,0,0,1,0.001886354517095442
613,LV319,CD22 mediated BCR regulation,0.002008080668712338,1,0,1,0.0022677404668839797
614,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0016703640012749972,0,0,1,0.001886354517095442
615,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002008080668712338,1,0,1,0.0022677404668839797
616,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0016703640012749972,0,0,1,0.001886354517095442
617,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002008080668712338,1,0,1,0.0022677404668839797
618,LV319,Scavenging of heme from plasma,0.0016703640012749972,0,0,1,0.001886354517095442
619,LV319,Scavenging of heme from plasma,0.002008080668712338,1,0,1,0.0022677404668839797
620,LV325,Initial triggering of complement,0.0007845158127939187,0,0,1,0.0008859595549634778
621,LV325,Initial triggering of complement,0.00043388743165104904,1,0,1,0.0004899923106467557
622,LV325,Regulation of Complement cascade,0.0007845158127939187,0,0,1,0.0008859595549634778
623,LV325,Regulation of Complement cascade,0.00043388743165104904,1,0,1,0.0004899923106467557
624,LV325,FCGR activation,0.0007845158127939187,0,0,1,0.0008859595549634778
625,LV325,FCGR activation,0.00043388743165104904,1,0,1,0.0004899923106467557
626,LV325,Regulation of actin dynamics for phagocytic cup formation,0.0007845158127939187,0,0,1,0.0008859595549634778
627,LV325,Regulation of actin dynamics for phagocytic cup formation,0.00043388743165104904,1,0,1,0.0004899923106467557
628,LV325,Role of phospholipids in phagocytosis,0.0007845158127939187,0,0,1,0.0008859595549634778
629,LV325,Role of phospholipids in phagocytosis,0.00043388743165104904,1,0,1,0.0004899923106467557
630,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007845158127939187,0,0,1,0.0008859595549634778
631,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.00043388743165104904,1,0,1,0.0004899923106467557
632,LV325,FCERI mediated MAPK activation,0.0007845158127939187,0,0,1,0.0008859595549634778
633,LV325,FCERI mediated MAPK activation,0.00043388743165104904,1,0,1,0.0004899923106467557
634,LV325,FCERI mediated Ca+2 mobilization,0.0007845158127939187,0,0,1,0.0008859595549634778
635,LV325,FCERI mediated Ca+2 mobilization,0.00043388743165104904,1,0,1,0.0004899923106467557
636,LV325,FCERI mediated NF-kB activation,0.0007845158127939187,0,0,1,0.0008859595549634778
637,LV325,FCERI mediated NF-kB activation,0.00043388743165104904,1,0,1,0.0004899923106467557
638,LV325,Parasite infection,0.0007845158127939187,0,0,1,0.0008859595549634778
639,LV325,Parasite infection,0.00043388743165104904,1,0,1,0.0004899923106467557
640,LV325,Leishmania parasite growth and survival,0.0007845158127939187,0,0,1,0.0008859595549634778
641,LV325,Leishmania parasite growth and survival,0.00043388743165104904,1,0,1,0.0004899923106467557
642,LV325,Potential therapeutics for SARS,0.0007845158127939187,0,0,1,0.0008859595549634778
643,LV325,Potential therapeutics for SARS,0.00043388743165104904,1,0,1,0.0004899923106467557
644,LV325,CD22 mediated BCR regulation,0.0007845158127939187,0,0,1,0.0008859595549634778
645,LV325,CD22 mediated BCR regulation,0.00043388743165104904,1,0,1,0.0004899923106467557
646,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007845158127939187,0,0,1,0.0008859595549634778
647,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00043388743165104904,1,0,1,0.0004899923106467557
648,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007845158127939187,0,0,1,0.0008859595549634778
649,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00043388743165104904,1,0,1,0.0004899923106467557
650,LV325,Scavenging of heme from plasma,0.0007845158127939187,0,0,1,0.0008859595549634778
651,LV325,Scavenging of heme from plasma,0.00043388743165104904,1,0,1,0.0004899923106467557
652,HV169,Initial triggering of complement,0.0029719641556559123,0,0,1,0.003356261273224308
653,HV169,Initial triggering of complement,0.0019692139912738382,1,0,1,0.002223848038350652
654,HV169,Regulation of Complement cascade,0.0029719641556559123,0,0,1,0.003356261273224308
655,HV169,Regulation of Complement cascade,0.0019692139912738382,1,0,1,0.002223848038350652
656,HV169,FCGR activation,0.0029719641556559123,0,0,1,0.003356261273224308
657,HV169,FCGR activation,0.0019692139912738382,1,0,1,0.002223848038350652
658,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0029719641556559123,0,0,1,0.003356261273224308
659,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0019692139912738382,1,0,1,0.002223848038350652
660,HV169,Role of phospholipids in phagocytosis,0.0029719641556559123,0,0,1,0.003356261273224308
661,HV169,Role of phospholipids in phagocytosis,0.0019692139912738382,1,0,1,0.002223848038350652
662,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0029719641556559123,0,0,1,0.003356261273224308
663,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0019692139912738382,1,0,1,0.002223848038350652
664,HV169,FCERI mediated MAPK activation,0.0029719641556559123,0,0,1,0.003356261273224308
665,HV169,FCERI mediated MAPK activation,0.0019692139912738382,1,0,1,0.002223848038350652
666,HV169,FCERI mediated Ca+2 mobilization,0.0029719641556559123,0,0,1,0.003356261273224308
667,HV169,FCERI mediated Ca+2 mobilization,0.0019692139912738382,1,0,1,0.002223848038350652
668,HV169,FCERI mediated NF-kB activation,0.0029719641556559123,0,0,1,0.003356261273224308
669,HV169,FCERI mediated NF-kB activation,0.0019692139912738382,1,0,1,0.002223848038350652
670,HV169,Parasite infection,0.0029719641556559123,0,0,1,0.003356261273224308
671,HV169,Parasite infection,0.0019692139912738382,1,0,1,0.002223848038350652
672,HV169,Leishmania parasite growth and survival,0.0029719641556559123,0,0,1,0.003356261273224308
673,HV169,Leishmania parasite growth and survival,0.0019692139912738382,1,0,1,0.002223848038350652
674,HV169,Potential therapeutics for SARS,0.0029719641556559123,0,0,1,0.003356261273224308
675,HV169,Potential therapeutics for SARS,0.0019692139912738382,1,0,1,0.002223848038350652
676,HV169,CD22 mediated BCR regulation,0.0029719641556559123,0,0,1,0.003356261273224308
677,HV169,CD22 mediated BCR regulation,0.0019692139912738382,1,0,1,0.002223848038350652
678,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0029719641556559123,0,0,1,0.003356261273224308
679,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0019692139912738382,1,0,1,0.002223848038350652
680,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0029719641556559123,0,0,1,0.003356261273224308
681,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0019692139912738382,1,0,1,0.002223848038350652
682,HV169,Scavenging of heme from plasma,0.0029719641556559123,0,0,1,0.003356261273224308
683,HV169,Scavenging of heme from plasma,0.0019692139912738382,1,0,1,0.002223848038350652
684,HV146,Initial triggering of complement,0.00012329186651484098,0,0,1,0.00013923442384047732
685,HV146,Initial triggering of complement,0.00022479519196070579,1,0,1,0.00025386288584568385
686,HV146,Regulation of Complement cascade,0.00012329186651484098,0,0,1,0.00013923442384047732
687,HV146,Regulation of Complement cascade,0.00022479519196070579,1,0,1,0.00025386288584568385
688,HV146,FCGR activation,0.00012329186651484098,0,0,1,0.00013923442384047732
689,HV146,FCGR activation,0.00022479519196070579,1,0,1,0.00025386288584568385
690,HV146,Regulation of actin dynamics for phagocytic cup formation,0.00012329186651484098,0,0,1,0.00013923442384047732
691,HV146,Regulation of actin dynamics for phagocytic cup formation,0.00022479519196070579,1,0,1,0.00025386288584568385
692,HV146,Role of phospholipids in phagocytosis,0.00012329186651484098,0,0,1,0.00013923442384047732
693,HV146,Role of phospholipids in phagocytosis,0.00022479519196070579,1,0,1,0.00025386288584568385
694,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.00012329186651484098,0,0,1,0.00013923442384047732
695,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.00022479519196070579,1,0,1,0.00025386288584568385
696,HV146,FCERI mediated MAPK activation,0.00012329186651484098,0,0,1,0.00013923442384047732
697,HV146,FCERI mediated MAPK activation,0.00022479519196070579,1,0,1,0.00025386288584568385
698,HV146,FCERI mediated Ca+2 mobilization,0.00012329186651484098,0,0,1,0.00013923442384047732
699,HV146,FCERI mediated Ca+2 mobilization,0.00022479519196070579,1,0,1,0.00025386288584568385
700,HV146,FCERI mediated NF-kB activation,0.00012329186651484098,0,0,1,0.00013923442384047732
701,HV146,FCERI mediated NF-kB activation,0.00022479519196070579,1,0,1,0.00025386288584568385
702,HV146,Parasite infection,0.00012329186651484098,0,0,1,0.00013923442384047732
703,HV146,Parasite infection,0.00022479519196070579,1,0,1,0.00025386288584568385
704,HV146,Leishmania parasite growth and survival,0.00012329186651484098,0,0,1,0.00013923442384047732
705,HV146,Leishmania parasite growth and survival,0.00022479519196070579,1,0,1,0.00025386288584568385
706,HV146,Potential therapeutics for SARS,0.00012329186651484098,0,0,1,0.00013923442384047732
707,HV146,Potential therapeutics for SARS,0.00022479519196070579,1,0,1,0.00025386288584568385
708,HV146,CD22 mediated BCR regulation,0.00012329186651484098,0,0,1,0.00013923442384047732
709,HV146,CD22 mediated BCR regulation,0.00022479519196070579,1,0,1,0.00025386288584568385
710,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00012329186651484098,0,0,1,0.00013923442384047732
711,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00022479519196070579,1,0,1,0.00025386288584568385
712,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00012329186651484098,0,0,1,0.00013923442384047732
713,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00022479519196070579,1,0,1,0.00025386288584568385
714,HV146,Scavenging of heme from plasma,0.00012329186651484098,0,0,1,0.00013923442384047732
715,HV146,Scavenging of heme from plasma,0.00022479519196070579,1,0,1,0.00025386288584568385
716,HV348,Initial triggering of complement,0.0031516402591235874,0,0,1,0.003559170836128949
717,HV348,Initial triggering of complement,0.003817757067383059,1,0,1,0.004311421512756519
718,HV348,Regulation of Complement cascade,0.0031516402591235874,0,0,1,0.003559170836128949
719,HV348,Regulation of Complement cascade,0.003817757067383059,1,0,1,0.004311421512756519
720,HV348,FCGR activation,0.0031516402591235874,0,0,1,0.003559170836128949
721,HV348,FCGR activation,0.003817757067383059,1,0,1,0.004311421512756519
722,HV348,Regulation of actin dynamics for phagocytic cup formation,0.0031516402591235874,0,0,1,0.003559170836128949
723,HV348,Regulation of actin dynamics for phagocytic cup formation,0.003817757067383059,1,0,1,0.004311421512756519
724,HV348,Role of phospholipids in phagocytosis,0.0031516402591235874,0,0,1,0.003559170836128949
725,HV348,Role of phospholipids in phagocytosis,0.003817757067383059,1,0,1,0.004311421512756519
726,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.0031516402591235874,0,0,1,0.003559170836128949
727,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.003817757067383059,1,0,1,0.004311421512756519
728,HV348,FCERI mediated MAPK activation,0.0031516402591235874,0,0,1,0.003559170836128949
729,HV348,FCERI mediated MAPK activation,0.003817757067383059,1,0,1,0.004311421512756519
730,HV348,FCERI mediated Ca+2 mobilization,0.0031516402591235874,0,0,1,0.003559170836128949
731,HV348,FCERI mediated Ca+2 mobilization,0.003817757067383059,1,0,1,0.004311421512756519
732,HV348,FCERI mediated NF-kB activation,0.0031516402591235874,0,0,1,0.003559170836128949
733,HV348,FCERI mediated NF-kB activation,0.003817757067383059,1,0,1,0.004311421512756519
734,HV348,Parasite infection,0.0031516402591235874,0,0,1,0.003559170836128949
735,HV348,Parasite infection,0.003817757067383059,1,0,1,0.004311421512756519
736,HV348,Leishmania parasite growth and survival,0.0031516402591235874,0,0,1,0.003559170836128949
737,HV348,Leishmania parasite growth and survival,0.003817757067383059,1,0,1,0.004311421512756519
738,HV348,Potential therapeutics for SARS,0.0031516402591235874,0,0,1,0.003559170836128949
739,HV348,Potential therapeutics for SARS,0.003817757067383059,1,0,1,0.004311421512756519
740,HV348,CD22 mediated BCR regulation,0.0031516402591235874,0,0,1,0.003559170836128949
741,HV348,CD22 mediated BCR regulation,0.003817757067383059,1,0,1,0.004311421512756519
742,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0031516402591235874,0,0,1,0.003559170836128949
743,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003817757067383059,1,0,1,0.004311421512756519
744,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0031516402591235874,0,0,1,0.003559170836128949
745,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003817757067383059,1,0,1,0.004311421512756519
746,HV348,Scavenging of heme from plasma,0.0031516402591235874,0,0,1,0.003559170836128949
747,HV348,Scavenging of heme from plasma,0.003817757067383059,1,0,1,0.004311421512756519
748,HV323,Initial triggering of complement,0.00558858842086366,0,0,1,0.006311234559555068
749,HV323,Initial triggering of complement,0.0061843501722518715,1,0,1,0.006984032746049766
750,HV323,Regulation of Complement cascade,0.00558858842086366,0,0,1,0.006311234559555068
751,HV323,Regulation of Complement cascade,0.0061843501722518715,1,0,1,0.006984032746049766
752,HV323,FCGR activation,0.00558858842086366,0,0,1,0.006311234559555068
753,HV323,FCGR activation,0.0061843501722518715,1,0,1,0.006984032746049766
754,HV323,Regulation of actin dynamics for phagocytic cup formation,0.00558858842086366,0,0,1,0.006311234559555068
755,HV323,Regulation of actin dynamics for phagocytic cup formation,0.0061843501722518715,1,0,1,0.006984032746049766
756,HV323,Role of phospholipids in phagocytosis,0.00558858842086366,0,0,1,0.006311234559555068
757,HV323,Role of phospholipids in phagocytosis,0.0061843501722518715,1,0,1,0.006984032746049766
758,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.00558858842086366,0,0,1,0.006311234559555068
759,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.0061843501722518715,1,0,1,0.006984032746049766
760,HV323,FCERI mediated MAPK activation,0.00558858842086366,0,0,1,0.006311234559555068
761,HV323,FCERI mediated MAPK activation,0.0061843501722518715,1,0,1,0.006984032746049766
762,HV323,FCERI mediated Ca+2 mobilization,0.00558858842086366,0,0,1,0.006311234559555068
763,HV323,FCERI mediated Ca+2 mobilization,0.0061843501722518715,1,0,1,0.006984032746049766
764,HV323,FCERI mediated NF-kB activation,0.00558858842086366,0,0,1,0.006311234559555068
765,HV323,FCERI mediated NF-kB activation,0.0061843501722518715,1,0,1,0.006984032746049766
766,HV323,Parasite infection,0.00558858842086366,0,0,1,0.006311234559555068
767,HV323,Parasite infection,0.0061843501722518715,1,0,1,0.006984032746049766
768,HV323,Leishmania parasite growth and survival,0.00558858842086366,0,0,1,0.006311234559555068
769,HV323,Leishmania parasite growth and survival,0.0061843501722518715,1,0,1,0.006984032746049766
770,HV323,Potential therapeutics for SARS,0.00558858842086366,0,0,1,0.006311234559555068
771,HV323,Potential therapeutics for SARS,0.0061843501722518715,1,0,1,0.006984032746049766
772,HV323,CD22 mediated BCR regulation,0.00558858842086366,0,0,1,0.006311234559555068
773,HV323,CD22 mediated BCR regulation,0.0061843501722518715,1,0,1,0.006984032746049766
774,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00558858842086366,0,0,1,0.006311234559555068
775,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0061843501722518715,1,0,1,0.006984032746049766
776,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00558858842086366,0,0,1,0.006311234559555068
777,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0061843501722518715,1,0,1,0.006984032746049766
778,HV323,Scavenging of heme from plasma,0.00558858842086366,0,0,1,0.006311234559555068
779,HV323,Scavenging of heme from plasma,0.0061843501722518715,1,0,1,0.006984032746049766
780,HV313,Initial triggering of complement,0.0042783704829425315,0,0,1,0.0048315956762395385
781,HV313,Initial triggering of complement,0.004177603593137429,1,0,1,0.004717798876492644
782,HV313,Regulation of Complement cascade,0.0042783704829425315,0,0,1,0.0048315956762395385
783,HV313,Regulation of Complement cascade,0.004177603593137429,1,0,1,0.004717798876492644
784,HV313,FCGR activation,0.0042783704829425315,0,0,1,0.0048315956762395385
785,HV313,FCGR activation,0.004177603593137429,1,0,1,0.004717798876492644
786,HV313,Regulation of actin dynamics for phagocytic cup formation,0.0042783704829425315,0,0,1,0.0048315956762395385
787,HV313,Regulation of actin dynamics for phagocytic cup formation,0.004177603593137429,1,0,1,0.004717798876492644
788,HV313,Role of phospholipids in phagocytosis,0.0042783704829425315,0,0,1,0.0048315956762395385
789,HV313,Role of phospholipids in phagocytosis,0.004177603593137429,1,0,1,0.004717798876492644
790,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.0042783704829425315,0,0,1,0.0048315956762395385
791,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.004177603593137429,1,0,1,0.004717798876492644
792,HV313,FCERI mediated MAPK activation,0.0042783704829425315,0,0,1,0.0048315956762395385
793,HV313,FCERI mediated MAPK activation,0.004177603593137429,1,0,1,0.004717798876492644
794,HV313,FCERI mediated Ca+2 mobilization,0.0042783704829425315,0,0,1,0.0048315956762395385
795,HV313,FCERI mediated Ca+2 mobilization,0.004177603593137429,1,0,1,0.004717798876492644
796,HV313,FCERI mediated NF-kB activation,0.0042783704829425315,0,0,1,0.0048315956762395385
797,HV313,FCERI mediated NF-kB activation,0.004177603593137429,1,0,1,0.004717798876492644
798,HV313,Parasite infection,0.0042783704829425315,0,0,1,0.0048315956762395385
799,HV313,Parasite infection,0.004177603593137429,1,0,1,0.004717798876492644
800,HV313,Leishmania parasite growth and survival,0.0042783704829425315,0,0,1,0.0048315956762395385
801,HV313,Leishmania parasite growth and survival,0.004177603593137429,1,0,1,0.004717798876492644
802,HV313,Potential therapeutics for SARS,0.0042783704829425315,0,0,1,0.0048315956762395385
803,HV313,Potential therapeutics for SARS,0.004177603593137429,1,0,1,0.004717798876492644
804,HV313,CD22 mediated BCR regulation,0.0042783704829425315,0,0,1,0.0048315956762395385
805,HV313,CD22 mediated BCR regulation,0.004177603593137429,1,0,1,0.004717798876492644
806,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0042783704829425315,0,0,1,0.0048315956762395385
807,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004177603593137429,1,0,1,0.004717798876492644
808,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0042783704829425315,0,0,1,0.0048315956762395385
809,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004177603593137429,1,0,1,0.004717798876492644
810,HV313,Scavenging of heme from plasma,0.0042783704829425315,0,0,1,0.0048315956762395385
811,HV313,Scavenging of heme from plasma,0.004177603593137429,1,0,1,0.004717798876492644
812,HV353,Initial triggering of complement,0.008820229894268861,0,0,1,0.009960751363280331
813,HV353,Initial triggering of complement,0.0069011170050687146,1,0,1,0.007793482872941986
814,HV353,Regulation of Complement cascade,0.008820229894268861,0,0,1,0.009960751363280331
815,HV353,Regulation of Complement cascade,0.0069011170050687146,1,0,1,0.007793482872941986
816,HV353,FCGR activation,0.008820229894268861,0,0,1,0.009960751363280331
817,HV353,FCGR activation,0.0069011170050687146,1,0,1,0.007793482872941986
818,HV353,Regulation of actin dynamics for phagocytic cup formation,0.008820229894268861,0,0,1,0.009960751363280331
819,HV353,Regulation of actin dynamics for phagocytic cup formation,0.0069011170050687146,1,0,1,0.007793482872941986
820,HV353,Role of phospholipids in phagocytosis,0.008820229894268861,0,0,1,0.009960751363280331
821,HV353,Role of phospholipids in phagocytosis,0.0069011170050687146,1,0,1,0.007793482872941986
822,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.008820229894268861,0,0,1,0.009960751363280331
823,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.0069011170050687146,1,0,1,0.007793482872941986
824,HV353,FCERI mediated MAPK activation,0.008820229894268861,0,0,1,0.009960751363280331
825,HV353,FCERI mediated MAPK activation,0.0069011170050687146,1,0,1,0.007793482872941986
826,HV353,FCERI mediated Ca+2 mobilization,0.008820229894268861,0,0,1,0.009960751363280331
827,HV353,FCERI mediated Ca+2 mobilization,0.0069011170050687146,1,0,1,0.007793482872941986
828,HV353,FCERI mediated NF-kB activation,0.008820229894268861,0,0,1,0.009960751363280331
829,HV353,FCERI mediated NF-kB activation,0.0069011170050687146,1,0,1,0.007793482872941986
830,HV353,Parasite infection,0.008820229894268861,0,0,1,0.009960751363280331
831,HV353,Parasite infection,0.0069011170050687146,1,0,1,0.007793482872941986
832,HV353,Leishmania parasite growth and survival,0.008820229894268861,0,0,1,0.009960751363280331
833,HV353,Leishmania parasite growth and survival,0.0069011170050687146,1,0,1,0.007793482872941986
834,HV353,Potential therapeutics for SARS,0.008820229894268861,0,0,1,0.009960751363280331
835,HV353,Potential therapeutics for SARS,0.0069011170050687146,1,0,1,0.007793482872941986
836,HV353,CD22 mediated BCR regulation,0.008820229894268861,0,0,1,0.009960751363280331
837,HV353,CD22 mediated BCR regulation,0.0069011170050687146,1,0,1,0.007793482872941986
838,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008820229894268861,0,0,1,0.009960751363280331
839,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0069011170050687146,1,0,1,0.007793482872941986
840,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008820229894268861,0,0,1,0.009960751363280331
841,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0069011170050687146,1,0,1,0.007793482872941986
842,HV353,Scavenging of heme from plasma,0.008820229894268861,0,0,1,0.009960751363280331
843,HV353,Scavenging of heme from plasma,0.0069011170050687146,1,0,1,0.007793482872941986
844,HV307,Initial triggering of complement,0.002876921553787572,0,0,1,0.00324892895451174
845,HV307,Initial triggering of complement,0.002964855423480802,1,0,1,0.0033482333289923285
846,HV307,Regulation of Complement cascade,0.002876921553787572,0,0,1,0.00324892895451174
847,HV307,Regulation of Complement cascade,0.002964855423480802,1,0,1,0.0033482333289923285
848,HV307,FCGR activation,0.002876921553787572,0,0,1,0.00324892895451174
849,HV307,FCGR activation,0.002964855423480802,1,0,1,0.0033482333289923285
850,HV307,Regulation of actin dynamics for phagocytic cup formation,0.002876921553787572,0,0,1,0.00324892895451174
851,HV307,Regulation of actin dynamics for phagocytic cup formation,0.002964855423480802,1,0,1,0.0033482333289923285
852,HV307,Role of phospholipids in phagocytosis,0.002876921553787572,0,0,1,0.00324892895451174
853,HV307,Role of phospholipids in phagocytosis,0.002964855423480802,1,0,1,0.0033482333289923285
854,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.002876921553787572,0,0,1,0.00324892895451174
855,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.002964855423480802,1,0,1,0.0033482333289923285
856,HV307,FCERI mediated MAPK activation,0.002876921553787572,0,0,1,0.00324892895451174
857,HV307,FCERI mediated MAPK activation,0.002964855423480802,1,0,1,0.0033482333289923285
858,HV307,FCERI mediated Ca+2 mobilization,0.002876921553787572,0,0,1,0.00324892895451174
859,HV307,FCERI mediated Ca+2 mobilization,0.002964855423480802,1,0,1,0.0033482333289923285
860,HV307,FCERI mediated NF-kB activation,0.002876921553787572,0,0,1,0.00324892895451174
861,HV307,FCERI mediated NF-kB activation,0.002964855423480802,1,0,1,0.0033482333289923285
862,HV307,Parasite infection,0.002876921553787572,0,0,1,0.00324892895451174
863,HV307,Parasite infection,0.002964855423480802,1,0,1,0.0033482333289923285
864,HV307,Leishmania parasite growth and survival,0.002876921553787572,0,0,1,0.00324892895451174
865,HV307,Leishmania parasite growth and survival,0.002964855423480802,1,0,1,0.0033482333289923285
866,HV307,Potential therapeutics for SARS,0.002876921553787572,0,0,1,0.00324892895451174
867,HV307,Potential therapeutics for SARS,0.002964855423480802,1,0,1,0.0033482333289923285
868,HV307,CD22 mediated BCR regulation,0.002876921553787572,0,0,1,0.00324892895451174
869,HV307,CD22 mediated BCR regulation,0.002964855423480802,1,0,1,0.0033482333289923285
870,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002876921553787572,0,0,1,0.00324892895451174
871,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002964855423480802,1,0,1,0.0033482333289923285
872,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002876921553787572,0,0,1,0.00324892895451174
873,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002964855423480802,1,0,1,0.0033482333289923285
874,HV307,Scavenging of heme from plasma,0.002876921553787572,0,0,1,0.00324892895451174
875,HV307,Scavenging of heme from plasma,0.002964855423480802,1,0,1,0.0033482333289923285
876,PIGR,Neutrophil degranulation,0.0005887677514572734,0,0,1,0.000664899810241246
877,PIGR,Neutrophil degranulation,0.00034590349530257353,1,0,1,0.00039063139551921477
878,IGKC,Initial triggering of complement,0.0038589234745306043,0,0,1,0.0043579110431918545
879,IGKC,Initial triggering of complement,0.0030658094415253237,1,0,1,0.003462241454054805
880,IGKC,Regulation of Complement cascade,0.0038589234745306043,0,0,1,0.0043579110431918545
881,IGKC,Regulation of Complement cascade,0.0030658094415253237,1,0,1,0.003462241454054805
882,IGKC,FCGR activation,0.0038589234745306043,0,0,1,0.0043579110431918545
883,IGKC,FCGR activation,0.0030658094415253237,1,0,1,0.003462241454054805
884,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.0038589234745306043,0,0,1,0.0043579110431918545
885,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.0030658094415253237,1,0,1,0.003462241454054805
886,IGKC,Role of phospholipids in phagocytosis,0.0038589234745306043,0,0,1,0.0043579110431918545
887,IGKC,Role of phospholipids in phagocytosis,0.0030658094415253237,1,0,1,0.003462241454054805
888,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.0038589234745306043,0,0,1,0.0043579110431918545
889,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.0030658094415253237,1,0,1,0.003462241454054805
890,IGKC,FCERI mediated MAPK activation,0.0038589234745306043,0,0,1,0.0043579110431918545
891,IGKC,FCERI mediated MAPK activation,0.0030658094415253237,1,0,1,0.003462241454054805
892,IGKC,FCERI mediated Ca+2 mobilization,0.0038589234745306043,0,0,1,0.0043579110431918545
893,IGKC,FCERI mediated Ca+2 mobilization,0.0030658094415253237,1,0,1,0.003462241454054805
894,IGKC,FCERI mediated NF-kB activation,0.0038589234745306043,0,0,1,0.0043579110431918545
895,IGKC,FCERI mediated NF-kB activation,0.0030658094415253237,1,0,1,0.003462241454054805
896,IGKC,Parasite infection,0.0038589234745306043,0,0,1,0.0043579110431918545
897,IGKC,Parasite infection,0.0030658094415253237,1,0,1,0.003462241454054805
898,IGKC,Leishmania parasite growth and survival,0.0038589234745306043,0,0,1,0.0043579110431918545
899,IGKC,Leishmania parasite growth and survival,0.0030658094415253237,1,0,1,0.003462241454054805
900,IGKC,Potential therapeutics for SARS,0.0038589234745306043,0,0,1,0.0043579110431918545
901,IGKC,Potential therapeutics for SARS,0.0030658094415253237,1,0,1,0.003462241454054805
902,IGKC,CD22 mediated BCR regulation,0.0038589234745306043,0,0,1,0.0043579110431918545
903,IGKC,CD22 mediated BCR regulation,0.0030658094415253237,1,0,1,0.003462241454054805
904,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0038589234745306043,0,0,1,0.0043579110431918545
905,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0030658094415253237,1,0,1,0.003462241454054805
906,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0038589234745306043,0,0,1,0.0043579110431918545
907,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0030658094415253237,1,0,1,0.003462241454054805
908,IGKC,Scavenging of heme from plasma,0.0038589234745306043,0,0,1,0.0043579110431918545
909,IGKC,Scavenging of heme from plasma,0.0030658094415253237,1,0,1,0.003462241454054805
910,IGHG1,Initial triggering of complement,0.004570153955521469,0,0,1,0.005161108926700482
911,IGHG1,Initial triggering of complement,0.004209110093503058,1,0,1,0.004753379402196746
912,IGHG1,Regulation of Complement cascade,0.004570153955521469,0,0,1,0.005161108926700482
913,IGHG1,Regulation of Complement cascade,0.004209110093503058,1,0,1,0.004753379402196746
914,IGHG1,FCGR activation,0.004570153955521469,0,0,1,0.005161108926700482
915,IGHG1,FCGR activation,0.004209110093503058,1,0,1,0.004753379402196746
916,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.004570153955521469,0,0,1,0.005161108926700482
917,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.004209110093503058,1,0,1,0.004753379402196746
918,IGHG1,Role of phospholipids in phagocytosis,0.004570153955521469,0,0,1,0.005161108926700482
919,IGHG1,Role of phospholipids in phagocytosis,0.004209110093503058,1,0,1,0.004753379402196746
920,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.004570153955521469,0,0,1,0.005161108926700482
921,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.004209110093503058,1,0,1,0.004753379402196746
922,IGHG1,Parasite infection,0.004570153955521469,0,0,1,0.005161108926700482
923,IGHG1,Parasite infection,0.004209110093503058,1,0,1,0.004753379402196746
924,IGHG1,Leishmania parasite growth and survival,0.004570153955521469,0,0,1,0.005161108926700482
925,IGHG1,Leishmania parasite growth and survival,0.004209110093503058,1,0,1,0.004753379402196746
926,IGHG2,Initial triggering of complement,0.001483067988254352,0,0,1,0.0016748397335358226
927,IGHG2,Initial triggering of complement,0.0020115648520115273,1,0,1,0.0022716751810539434
928,IGHG2,Regulation of Complement cascade,0.001483067988254352,0,0,1,0.0016748397335358226
929,IGHG2,Regulation of Complement cascade,0.0020115648520115273,1,0,1,0.0022716751810539434
930,IGHG2,FCGR activation,0.001483067988254352,0,0,1,0.0016748397335358226
931,IGHG2,FCGR activation,0.0020115648520115273,1,0,1,0.0022716751810539434
932,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.001483067988254352,0,0,1,0.0016748397335358226
933,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.0020115648520115273,1,0,1,0.0022716751810539434
934,IGHG2,Role of phospholipids in phagocytosis,0.001483067988254352,0,0,1,0.0016748397335358226
935,IGHG2,Role of phospholipids in phagocytosis,0.0020115648520115273,1,0,1,0.0022716751810539434
936,IGHG2,Parasite infection,0.001483067988254352,0,0,1,0.0016748397335358226
937,IGHG2,Parasite infection,0.0020115648520115273,1,0,1,0.0022716751810539434
938,IGHG2,Leishmania parasite growth and survival,0.001483067988254352,0,0,1,0.0016748397335358226
939,IGHG2,Leishmania parasite growth and survival,0.0020115648520115273,1,0,1,0.0022716751810539434
940,IGHG3,Initial triggering of complement,0.0002500719137568931,0,0,1,0.0002824080761761793
941,IGHG3,Initial triggering of complement,0.0004715964754045741,1,0,1,0.0005325774148309429
942,IGHG3,Regulation of Complement cascade,0.0002500719137568931,0,0,1,0.0002824080761761793
943,IGHG3,Regulation of Complement cascade,0.0004715964754045741,1,0,1,0.0005325774148309429
944,IGHG3,FCGR activation,0.0002500719137568931,0,0,1,0.0002824080761761793
945,IGHG3,FCGR activation,0.0004715964754045741,1,0,1,0.0005325774148309429
946,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.0002500719137568931,0,0,1,0.0002824080761761793
947,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.0004715964754045741,1,0,1,0.0005325774148309429
948,IGHG3,Role of phospholipids in phagocytosis,0.0002500719137568931,0,0,1,0.0002824080761761793
949,IGHG3,Role of phospholipids in phagocytosis,0.0004715964754045741,1,0,1,0.0005325774148309429
950,IGHG3,Parasite infection,0.0002500719137568931,0,0,1,0.0002824080761761793
951,IGHG3,Parasite infection,0.0004715964754045741,1,0,1,0.0005325774148309429
952,IGHG3,Leishmania parasite growth and survival,0.0002500719137568931,0,0,1,0.0002824080761761793
953,IGHG3,Leishmania parasite growth and survival,0.0004715964754045741,1,0,1,0.0005325774148309429
954,IGHG4,Initial triggering of complement,0.0015031199857674271,0,0,1,0.0016974846037896736
955,IGHG4,Initial triggering of complement,0.0018721729752934583,1,0,1,0.002114258895685703
956,IGHG4,Regulation of Complement cascade,0.0015031199857674271,0,0,1,0.0016974846037896736
957,IGHG4,Regulation of Complement cascade,0.0018721729752934583,1,0,1,0.002114258895685703
958,IGHG4,FCGR activation,0.0015031199857674271,0,0,1,0.0016974846037896736
959,IGHG4,FCGR activation,0.0018721729752934583,1,0,1,0.002114258895685703
960,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.0015031199857674271,0,0,1,0.0016974846037896736
961,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.0018721729752934583,1,0,1,0.002114258895685703
962,IGHG4,Role of phospholipids in phagocytosis,0.0015031199857674271,0,0,1,0.0016974846037896736
963,IGHG4,Role of phospholipids in phagocytosis,0.0018721729752934583,1,0,1,0.002114258895685703
964,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.0015031199857674271,0,0,1,0.0016974846037896736
965,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.0018721729752934583,1,0,1,0.002114258895685703
966,IGHG4,Parasite infection,0.0015031199857674271,0,0,1,0.0016974846037896736
967,IGHG4,Parasite infection,0.0018721729752934583,1,0,1,0.002114258895685703
968,IGHG4,Leishmania parasite growth and survival,0.0015031199857674271,0,0,1,0.0016974846037896736
969,IGHG4,Leishmania parasite growth and survival,0.0018721729752934583,1,0,1,0.002114258895685703
970,IGHM,Potential therapeutics for SARS,0.0003017376093616411,0,0,1,0.0003407545313251786
971,IGHM,Potential therapeutics for SARS,0.00025105678321382083,1,0,1,0.00028352029659484666
972,IGHM,CD22 mediated BCR regulation,0.0003017376093616411,0,0,1,0.0003407545313251786
973,IGHM,CD22 mediated BCR regulation,0.00025105678321382083,1,0,1,0.00028352029659484666
974,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0003017376093616411,0,0,1,0.0003407545313251786
975,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00025105678321382083,1,0,1,0.00028352029659484666
976,IGHA1,Scavenging of heme from plasma,0.0004937642345879134,0,0,1,0.0005576116305093564
977,IGHA1,Scavenging of heme from plasma,0.0010282874988065648,1,0,1,0.001161252736987832
978,IGHA2,Scavenging of heme from plasma,0.0004864369310258913,0,0,1,0.000549336851980964
979,IGHA2,Scavenging of heme from plasma,0.0009984779874034088,1,0,1,0.001127588633567961
980,IGHD,Potential therapeutics for SARS,0.0017976686262839482,0,0,1,0.002030120579013368
981,IGHD,Potential therapeutics for SARS,0.001308994238232274,1,0,1,0.0014782569501357687
982,IGHD,CD22 mediated BCR regulation,0.0017976686262839482,0,0,1,0.002030120579013368
983,IGHD,CD22 mediated BCR regulation,0.001308994238232274,1,0,1,0.0014782569501357687
984,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0017976686262839482,0,0,1,0.002030120579013368
985,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001308994238232274,1,0,1,0.0014782569501357687
986,P01891,Antigen processing-Cross presentation,0.001807813783209336,0,0,1,0.00204157758034855
987,P01891,Antigen processing-Cross presentation,0.001973542094946872,1,0,1,0.00222873579808916
988,P01891,Interferon gamma signaling,0.001807813783209336,0,0,1,0.00204157758034855
989,P01891,Interferon gamma signaling,0.001973542094946872,1,0,1,0.00222873579808916
990,P01891,Interferon alpha/beta signaling,0.001807813783209336,0,0,1,0.00204157758034855
991,P01891,Interferon alpha/beta signaling,0.001973542094946872,1,0,1,0.00222873579808916
992,P01891,SARS-CoV-2 Infection,0.001807813783209336,0,0,1,0.00204157758034855
993,P01891,SARS-CoV-2 Infection,0.001973542094946872,1,0,1,0.00222873579808916
994,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.001807813783209336,0,0,1,0.00204157758034855
995,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.001973542094946872,1,0,1,0.00222873579808916
996,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001807813783209336,0,0,1,0.00204157758034855
997,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001973542094946872,1,0,1,0.00222873579808916
998,MYG,Intracellular oxygen transport,0.002953498146785092,0,0,1,0.0033354074717656984
999,MYG,Intracellular oxygen transport,0.002339835414015286,1,0,1,0.0026423935735675422
1000,CO1A1,Collagen chain trimerization,0.021977562366613673,0,0,1,0.024819424995608023
1001,CO1A1,Collagen chain trimerization,0.017398042607208036,1,0,1,0.0196477391967709
1002,CO1A1,Anchoring fibril formation,0.021977562366613673,0,0,1,0.024819424995608023
1003,CO1A1,Anchoring fibril formation,0.017398042607208036,1,0,1,0.0196477391967709
1004,CO1A1,Crosslinking of collagen fibrils,0.021977562366613673,0,0,1,0.024819424995608023
1005,CO1A1,Crosslinking of collagen fibrils,0.017398042607208036,1,0,1,0.0196477391967709
1006,CO1A1,Transcriptional regulation by RUNX2,0.021977562366613673,0,0,1,0.024819424995608023
1007,CO1A1,Transcriptional regulation by RUNX2,0.017398042607208036,1,0,1,0.0196477391967709
1008,CO1A1,MET promotes cell motility,0.021977562366613673,0,0,1,0.024819424995608023
1009,CO1A1,MET promotes cell motility,0.017398042607208036,1,0,1,0.0196477391967709
1010,CO1A1,Platelet Adhesion to exposed collagen,0.021977562366613673,0,0,1,0.024819424995608023
1011,CO1A1,Platelet Adhesion to exposed collagen,0.017398042607208036,1,0,1,0.0196477391967709
1012,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.021977562366613673,0,0,1,0.024819424995608023
1013,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.017398042607208036,1,0,1,0.0196477391967709
1014,CO1A1,Collagen degradation,0.021977562366613673,0,0,1,0.024819424995608023
1015,CO1A1,Collagen degradation,0.017398042607208036,1,0,1,0.0196477391967709
1016,CO1A1,Integrin cell surface interactions,0.021977562366613673,0,0,1,0.024819424995608023
1017,CO1A1,Integrin cell surface interactions,0.017398042607208036,1,0,1,0.0196477391967709
1018,CO1A1,ECM proteoglycans,0.021977562366613673,0,0,1,0.024819424995608023
1019,CO1A1,ECM proteoglycans,0.017398042607208036,1,0,1,0.0196477391967709
1020,CO1A1,Scavenging by Class A Receptors,0.021977562366613673,0,0,1,0.024819424995608023
1021,CO1A1,Scavenging by Class A Receptors,0.017398042607208036,1,0,1,0.0196477391967709
1022,CO1A1,Syndecan interactions,0.021977562366613673,0,0,1,0.024819424995608023
1023,CO1A1,Syndecan interactions,0.017398042607208036,1,0,1,0.0196477391967709
1024,CO1A1,GPVI-mediated activation cascade,0.021977562366613673,0,0,1,0.024819424995608023
1025,CO1A1,GPVI-mediated activation cascade,0.017398042607208036,1,0,1,0.0196477391967709
1026,CO1A1,GP1b-IX-V activation signalling,0.021977562366613673,0,0,1,0.024819424995608023
1027,CO1A1,GP1b-IX-V activation signalling,0.017398042607208036,1,0,1,0.0196477391967709
1028,K1C14,Type I hemidesmosome assembly,0.000420724599866544,0,0,1,0.000475127426600215
1029,K1C14,Type I hemidesmosome assembly,0.001441610091233503,1,0,1,0.0016280210214138762
1030,K1C14,Formation of the cornified envelope,0.000420724599866544,0,0,1,0.000475127426600215
1031,K1C14,Formation of the cornified envelope,0.001441610091233503,1,0,1,0.0016280210214138762
1032,K2C6A,Formation of the cornified envelope,1.829510784971966e-05,0,0,1,2.0660801661628538e-05
1033,K2C6A,Formation of the cornified envelope,3.862540204651393e-05,1,0,1,4.3619954434754195e-05
1034,APOA1,PPARA activates gene expression,0.03115238999264778,0,0,1,0.03518062622044942
1035,APOA1,PPARA activates gene expression,0.03334879539321947,1,0,1,0.03766104321074538
1036,APOA1,Defective ABCA1 causes TGD,0.03115238999264778,0,0,1,0.03518062622044942
1037,APOA1,Defective ABCA1 causes TGD,0.03334879539321947,1,0,1,0.03766104321074538
1038,APOA1,Platelet degranulation ,0.03115238999264778,0,0,1,0.03518062622044942
1039,APOA1,Platelet degranulation ,0.03334879539321947,1,0,1,0.03766104321074538
1040,APOA1,Chylomicron assembly,0.03115238999264778,0,0,1,0.03518062622044942
1041,APOA1,Chylomicron assembly,0.03334879539321947,1,0,1,0.03766104321074538
1042,APOA1,HDL assembly,0.03115238999264778,0,0,1,0.03518062622044942
1043,APOA1,HDL assembly,0.03334879539321947,1,0,1,0.03766104321074538
1044,APOA1,Chylomicron remodeling,0.03115238999264778,0,0,1,0.03518062622044942
1045,APOA1,Chylomicron remodeling,0.03334879539321947,1,0,1,0.03766104321074538
1046,APOA1,HDL remodeling,0.03115238999264778,0,0,1,0.03518062622044942
1047,APOA1,HDL remodeling,0.03334879539321947,1,0,1,0.03766104321074538
1048,APOA1,HDL clearance,0.03115238999264778,0,0,1,0.03518062622044942
1049,APOA1,HDL clearance,0.03334879539321947,1,0,1,0.03766104321074538
1050,APOA1,Scavenging of heme from plasma,0.03115238999264778,0,0,1,0.03518062622044942
1051,APOA1,Scavenging of heme from plasma,0.03334879539321947,1,0,1,0.03766104321074538
1052,APOA1,Scavenging by Class B Receptors,0.03115238999264778,0,0,1,0.03518062622044942
1053,APOA1,Scavenging by Class B Receptors,0.03334879539321947,1,0,1,0.03766104321074538
1054,APOA1,Scavenging by Class A Receptors,0.03115238999264778,0,0,1,0.03518062622044942
1055,APOA1,Scavenging by Class A Receptors,0.03334879539321947,1,0,1,0.03766104321074538
1056,APOA1,Retinoid metabolism and transport,0.03115238999264778,0,0,1,0.03518062622044942
1057,APOA1,Retinoid metabolism and transport,0.03334879539321947,1,0,1,0.03766104321074538
1058,APOA1,Heme signaling,0.03115238999264778,0,0,1,0.03518062622044942
1059,APOA1,Heme signaling,0.03334879539321947,1,0,1,0.03766104321074538
1060,APOA1,ABC transporters in lipid homeostasis,0.03115238999264778,0,0,1,0.03518062622044942
1061,APOA1,ABC transporters in lipid homeostasis,0.03334879539321947,1,0,1,0.03766104321074538
1062,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03115238999264778,0,0,1,0.03518062622044942
1063,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03334879539321947,1,0,1,0.03766104321074538
1064,APOA1,Amyloid fiber formation,0.03115238999264778,0,0,1,0.03518062622044942
1065,APOA1,Amyloid fiber formation,0.03334879539321947,1,0,1,0.03766104321074538
1066,APOA1,Post-translational protein phosphorylation,0.03115238999264778,0,0,1,0.03518062622044942
1067,APOA1,Post-translational protein phosphorylation,0.03334879539321947,1,0,1,0.03766104321074538
1068,APOE,Nuclear signaling by ERBB4,0.005760138481491595,0,0,1,0.006504967321711396
1069,APOE,Nuclear signaling by ERBB4,0.006102973584264536,1,0,1,0.006892133558675904
1070,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.005760138481491595,0,0,1,0.006504967321711396
1071,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.006102973584264536,1,0,1,0.006892133558675904
1072,APOE,Chylomicron assembly,0.005760138481491595,0,0,1,0.006504967321711396
1073,APOE,Chylomicron assembly,0.006102973584264536,1,0,1,0.006892133558675904
1074,APOE,Chylomicron remodeling,0.005760138481491595,0,0,1,0.006504967321711396
1075,APOE,Chylomicron remodeling,0.006102973584264536,1,0,1,0.006892133558675904
1076,APOE,HDL remodeling,0.005760138481491595,0,0,1,0.006504967321711396
1077,APOE,HDL remodeling,0.006102973584264536,1,0,1,0.006892133558675904
1078,APOE,Chylomicron clearance,0.005760138481491595,0,0,1,0.006504967321711396
1079,APOE,Chylomicron clearance,0.006102973584264536,1,0,1,0.006892133558675904
1080,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.005760138481491595,0,0,1,0.006504967321711396
1081,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.006102973584264536,1,0,1,0.006892133558675904
1082,APOE,Scavenging by Class A Receptors,0.005760138481491595,0,0,1,0.006504967321711396
1083,APOE,Scavenging by Class A Receptors,0.006102973584264536,1,0,1,0.006892133558675904
1084,APOE,Retinoid metabolism and transport,0.005760138481491595,0,0,1,0.006504967321711396
1085,APOE,Retinoid metabolism and transport,0.006102973584264536,1,0,1,0.006892133558675904
1086,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005760138481491595,0,0,1,0.006504967321711396
1087,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006102973584264536,1,0,1,0.006892133558675904
1088,APOE,Amyloid fiber formation,0.005760138481491595,0,0,1,0.006504967321711396
1089,APOE,Amyloid fiber formation,0.006102973584264536,1,0,1,0.006892133558675904
1090,APOE,Post-translational protein phosphorylation,0.005760138481491595,0,0,1,0.006504967321711396
1091,APOE,Post-translational protein phosphorylation,0.006102973584264536,1,0,1,0.006892133558675904
1092,APOA2,PPARA activates gene expression,0.002085910425217099,0,0,1,0.0023556341910274175
1093,APOA2,PPARA activates gene expression,0.0016112501330999155,1,0,1,0.0018195967851460382
1094,APOA2,Chylomicron assembly,0.002085910425217099,0,0,1,0.0023556341910274175
1095,APOA2,Chylomicron assembly,0.0016112501330999155,1,0,1,0.0018195967851460382
1096,APOA2,Chylomicron remodeling,0.002085910425217099,0,0,1,0.0023556341910274175
1097,APOA2,Chylomicron remodeling,0.0016112501330999155,1,0,1,0.0018195967851460382
1098,APOA2,Retinoid metabolism and transport,0.002085910425217099,0,0,1,0.0023556341910274175
1099,APOA2,Retinoid metabolism and transport,0.0016112501330999155,1,0,1,0.0018195967851460382
1100,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002085910425217099,0,0,1,0.0023556341910274175
1101,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0016112501330999155,1,0,1,0.0018195967851460382
1102,APOA2,Post-translational protein phosphorylation,0.002085910425217099,0,0,1,0.0023556341910274175
1103,APOA2,Post-translational protein phosphorylation,0.0016112501330999155,1,0,1,0.0018195967851460382
1104,APOC1,VLDL assembly,0.005892452015050275,0,0,1,0.006654389981389623
1105,APOC1,VLDL assembly,0.006229009910486343,1,0,1,0.00703446732131994
1106,APOC1,VLDL clearance,0.005892452015050275,0,0,1,0.006654389981389623
1107,APOC1,VLDL clearance,0.006229009910486343,1,0,1,0.00703446732131994
1108,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.005892452015050275,0,0,1,0.006654389981389623
1109,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.006229009910486343,1,0,1,0.00703446732131994
1110,APOC2,Chylomicron assembly,0.00596342675884545,0,0,1,0.0067345422885846575
1111,APOC2,Chylomicron assembly,0.0021059004847934766,1,0,1,0.002378209114307687
1112,APOC2,Assembly of active LPL and LIPC lipase complexes,0.00596342675884545,0,0,1,0.0067345422885846575
1113,APOC2,Assembly of active LPL and LIPC lipase complexes,0.0021059004847934766,1,0,1,0.002378209114307687
1114,APOC2,Chylomicron remodeling,0.00596342675884545,0,0,1,0.0067345422885846575
1115,APOC2,Chylomicron remodeling,0.0021059004847934766,1,0,1,0.002378209114307687
1116,APOC2,HDL remodeling,0.00596342675884545,0,0,1,0.0067345422885846575
1117,APOC2,HDL remodeling,0.0021059004847934766,1,0,1,0.002378209114307687
1118,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.00596342675884545,0,0,1,0.0067345422885846575
1119,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0021059004847934766,1,0,1,0.002378209114307687
1120,APOC2,Retinoid metabolism and transport,0.00596342675884545,0,0,1,0.0067345422885846575
1121,APOC2,Retinoid metabolism and transport,0.0021059004847934766,1,0,1,0.002378209114307687
1122,APOC3,Chylomicron assembly,0.005620334915616455,0,0,1,0.006347086112709453
1123,APOC3,Chylomicron assembly,0.00538853626277081,1,0,1,0.006085314166284444
1124,APOC3,Chylomicron remodeling,0.005620334915616455,0,0,1,0.006347086112709453
1125,APOC3,Chylomicron remodeling,0.00538853626277081,1,0,1,0.006085314166284444
1126,APOC3,HDL remodeling,0.005620334915616455,0,0,1,0.006347086112709453
1127,APOC3,HDL remodeling,0.00538853626277081,1,0,1,0.006085314166284444
1128,APOC3,Retinoid metabolism and transport,0.005620334915616455,0,0,1,0.006347086112709453
1129,APOC3,Retinoid metabolism and transport,0.00538853626277081,1,0,1,0.006085314166284444
1130,FIBA,Antigen processing-Cross presentation,0.008569389214004368,0,0,1,0.009677475113356936
1131,FIBA,Antigen processing-Cross presentation,0.006403849860066773,1,0,1,0.007231915379592292
1132,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.008569389214004368,0,0,1,0.009677475113356936
1133,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.006403849860066773,1,0,1,0.007231915379592292
1134,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.008569389214004368,0,0,1,0.009677475113356936
1135,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.006403849860066773,1,0,1,0.007231915379592292
1136,FIBA,Regulation of TLR by endogenous ligand,0.008569389214004368,0,0,1,0.009677475113356936
1137,FIBA,Regulation of TLR by endogenous ligand,0.006403849860066773,1,0,1,0.007231915379592292
1138,FIBA,MyD88 deficiency (TLR2/4),0.008569389214004368,0,0,1,0.009677475113356936
1139,FIBA,MyD88 deficiency (TLR2/4),0.006403849860066773,1,0,1,0.007231915379592292
1140,FIBA,IRAK4 deficiency (TLR2/4),0.008569389214004368,0,0,1,0.009677475113356936
1141,FIBA,IRAK4 deficiency (TLR2/4),0.006403849860066773,1,0,1,0.007231915379592292
1142,FIBA,RAF/MAP kinase cascade,0.008569389214004368,0,0,1,0.009677475113356936
1143,FIBA,RAF/MAP kinase cascade,0.006403849860066773,1,0,1,0.007231915379592292
1144,FIBA,Signaling by RAS mutants,0.008569389214004368,0,0,1,0.009677475113356936
1145,FIBA,Signaling by RAS mutants,0.006403849860066773,1,0,1,0.007231915379592292
1146,FIBA,Signaling by moderate kinase activity BRAF mutants,0.008569389214004368,0,0,1,0.009677475113356936
1147,FIBA,Signaling by moderate kinase activity BRAF mutants,0.006403849860066773,1,0,1,0.007231915379592292
1148,FIBA,Signaling by high-kinase activity BRAF mutants,0.008569389214004368,0,0,1,0.009677475113356936
1149,FIBA,Signaling by high-kinase activity BRAF mutants,0.006403849860066773,1,0,1,0.007231915379592292
1150,FIBA,Signaling by BRAF and RAF1 fusions,0.008569389214004368,0,0,1,0.009677475113356936
1151,FIBA,Signaling by BRAF and RAF1 fusions,0.006403849860066773,1,0,1,0.007231915379592292
1152,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.008569389214004368,0,0,1,0.009677475113356936
1153,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.006403849860066773,1,0,1,0.007231915379592292
1154,FIBA,Signaling by RAF1 mutants,0.008569389214004368,0,0,1,0.009677475113356936
1155,FIBA,Signaling by RAF1 mutants,0.006403849860066773,1,0,1,0.007231915379592292
1156,FIBA,Platelet degranulation ,0.008569389214004368,0,0,1,0.009677475113356936
1157,FIBA,Platelet degranulation ,0.006403849860066773,1,0,1,0.007231915379592292
1158,FIBA,Common Pathway of Fibrin Clot Formation,0.008569389214004368,0,0,1,0.009677475113356936
1159,FIBA,Common Pathway of Fibrin Clot Formation,0.006403849860066773,1,0,1,0.007231915379592292
1160,FIBA,Integrin cell surface interactions,0.008569389214004368,0,0,1,0.009677475113356936
1161,FIBA,Integrin cell surface interactions,0.006403849860066773,1,0,1,0.007231915379592292
1162,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.008569389214004368,0,0,1,0.009677475113356936
1163,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.006403849860066773,1,0,1,0.007231915379592292
1164,FIBA,p130Cas linkage to MAPK signaling for integrins,0.008569389214004368,0,0,1,0.009677475113356936
1165,FIBA,p130Cas linkage to MAPK signaling for integrins,0.006403849860066773,1,0,1,0.007231915379592292
1166,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008569389214004368,0,0,1,0.009677475113356936
1167,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006403849860066773,1,0,1,0.007231915379592292
1168,FIBA,Amyloid fiber formation,0.008569389214004368,0,0,1,0.009677475113356936
1169,FIBA,Amyloid fiber formation,0.006403849860066773,1,0,1,0.007231915379592292
1170,FIBA,Post-translational protein phosphorylation,0.008569389214004368,0,0,1,0.009677475113356936
1171,FIBA,Post-translational protein phosphorylation,0.006403849860066773,1,0,1,0.007231915379592292
1172,FIBB,Antigen processing-Cross presentation,0.0018643573158225464,0,0,1,0.0021054326131893244
1173,FIBB,Antigen processing-Cross presentation,0.0006078739888379215,1,0,1,0.000686476626528099
1174,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.0018643573158225464,0,0,1,0.0021054326131893244
1175,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.0006078739888379215,1,0,1,0.000686476626528099
1176,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.0018643573158225464,0,0,1,0.0021054326131893244
1177,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.0006078739888379215,1,0,1,0.000686476626528099
1178,FIBB,Regulation of TLR by endogenous ligand,0.0018643573158225464,0,0,1,0.0021054326131893244
1179,FIBB,Regulation of TLR by endogenous ligand,0.0006078739888379215,1,0,1,0.000686476626528099
1180,FIBB,MyD88 deficiency (TLR2/4),0.0018643573158225464,0,0,1,0.0021054326131893244
1181,FIBB,MyD88 deficiency (TLR2/4),0.0006078739888379215,1,0,1,0.000686476626528099
1182,FIBB,IRAK4 deficiency (TLR2/4),0.0018643573158225464,0,0,1,0.0021054326131893244
1183,FIBB,IRAK4 deficiency (TLR2/4),0.0006078739888379215,1,0,1,0.000686476626528099
1184,FIBB,RAF/MAP kinase cascade,0.0018643573158225464,0,0,1,0.0021054326131893244
1185,FIBB,RAF/MAP kinase cascade,0.0006078739888379215,1,0,1,0.000686476626528099
1186,FIBB,Signaling by RAS mutants,0.0018643573158225464,0,0,1,0.0021054326131893244
1187,FIBB,Signaling by RAS mutants,0.0006078739888379215,1,0,1,0.000686476626528099
1188,FIBB,Signaling by moderate kinase activity BRAF mutants,0.0018643573158225464,0,0,1,0.0021054326131893244
1189,FIBB,Signaling by moderate kinase activity BRAF mutants,0.0006078739888379215,1,0,1,0.000686476626528099
1190,FIBB,Signaling by high-kinase activity BRAF mutants,0.0018643573158225464,0,0,1,0.0021054326131893244
1191,FIBB,Signaling by high-kinase activity BRAF mutants,0.0006078739888379215,1,0,1,0.000686476626528099
1192,FIBB,Signaling by BRAF and RAF1 fusions,0.0018643573158225464,0,0,1,0.0021054326131893244
1193,FIBB,Signaling by BRAF and RAF1 fusions,0.0006078739888379215,1,0,1,0.000686476626528099
1194,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0018643573158225464,0,0,1,0.0021054326131893244
1195,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0006078739888379215,1,0,1,0.000686476626528099
1196,FIBB,Signaling by RAF1 mutants,0.0018643573158225464,0,0,1,0.0021054326131893244
1197,FIBB,Signaling by RAF1 mutants,0.0006078739888379215,1,0,1,0.000686476626528099
1198,FIBB,Platelet degranulation ,0.0018643573158225464,0,0,1,0.0021054326131893244
1199,FIBB,Platelet degranulation ,0.0006078739888379215,1,0,1,0.000686476626528099
1200,FIBB,Common Pathway of Fibrin Clot Formation,0.0018643573158225464,0,0,1,0.0021054326131893244
1201,FIBB,Common Pathway of Fibrin Clot Formation,0.0006078739888379215,1,0,1,0.000686476626528099
1202,FIBB,Integrin cell surface interactions,0.0018643573158225464,0,0,1,0.0021054326131893244
1203,FIBB,Integrin cell surface interactions,0.0006078739888379215,1,0,1,0.000686476626528099
1204,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0018643573158225464,0,0,1,0.0021054326131893244
1205,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0006078739888379215,1,0,1,0.000686476626528099
1206,FIBB,p130Cas linkage to MAPK signaling for integrins,0.0018643573158225464,0,0,1,0.0021054326131893244
1207,FIBB,p130Cas linkage to MAPK signaling for integrins,0.0006078739888379215,1,0,1,0.000686476626528099
1208,FIBG,Antigen processing-Cross presentation,0.004253961182460762,0,0,1,0.004804030071264947
1209,FIBG,Antigen processing-Cross presentation,0.0009888534599469246,1,0,1,0.0011167195829726475
1210,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.004253961182460762,0,0,1,0.004804030071264947
1211,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.0009888534599469246,1,0,1,0.0011167195829726475
1212,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.004253961182460762,0,0,1,0.004804030071264947
1213,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.0009888534599469246,1,0,1,0.0011167195829726475
1214,FIBG,Regulation of TLR by endogenous ligand,0.004253961182460762,0,0,1,0.004804030071264947
1215,FIBG,Regulation of TLR by endogenous ligand,0.0009888534599469246,1,0,1,0.0011167195829726475
1216,FIBG,MyD88 deficiency (TLR2/4),0.004253961182460762,0,0,1,0.004804030071264947
1217,FIBG,MyD88 deficiency (TLR2/4),0.0009888534599469246,1,0,1,0.0011167195829726475
1218,FIBG,IRAK4 deficiency (TLR2/4),0.004253961182460762,0,0,1,0.004804030071264947
1219,FIBG,IRAK4 deficiency (TLR2/4),0.0009888534599469246,1,0,1,0.0011167195829726475
1220,FIBG,RAF/MAP kinase cascade,0.004253961182460762,0,0,1,0.004804030071264947
1221,FIBG,RAF/MAP kinase cascade,0.0009888534599469246,1,0,1,0.0011167195829726475
1222,FIBG,Signaling by RAS mutants,0.004253961182460762,0,0,1,0.004804030071264947
1223,FIBG,Signaling by RAS mutants,0.0009888534599469246,1,0,1,0.0011167195829726475
1224,FIBG,Signaling by moderate kinase activity BRAF mutants,0.004253961182460762,0,0,1,0.004804030071264947
1225,FIBG,Signaling by moderate kinase activity BRAF mutants,0.0009888534599469246,1,0,1,0.0011167195829726475
1226,FIBG,Signaling by high-kinase activity BRAF mutants,0.004253961182460762,0,0,1,0.004804030071264947
1227,FIBG,Signaling by high-kinase activity BRAF mutants,0.0009888534599469246,1,0,1,0.0011167195829726475
1228,FIBG,Signaling by BRAF and RAF1 fusions,0.004253961182460762,0,0,1,0.004804030071264947
1229,FIBG,Signaling by BRAF and RAF1 fusions,0.0009888534599469246,1,0,1,0.0011167195829726475
1230,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.004253961182460762,0,0,1,0.004804030071264947
1231,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0009888534599469246,1,0,1,0.0011167195829726475
1232,FIBG,Signaling by RAF1 mutants,0.004253961182460762,0,0,1,0.004804030071264947
1233,FIBG,Signaling by RAF1 mutants,0.0009888534599469246,1,0,1,0.0011167195829726475
1234,FIBG,Platelet degranulation ,0.004253961182460762,0,0,1,0.004804030071264947
1235,FIBG,Platelet degranulation ,0.0009888534599469246,1,0,1,0.0011167195829726475
1236,FIBG,Common Pathway of Fibrin Clot Formation,0.004253961182460762,0,0,1,0.004804030071264947
1237,FIBG,Common Pathway of Fibrin Clot Formation,0.0009888534599469246,1,0,1,0.0011167195829726475
1238,FIBG,Integrin cell surface interactions,0.004253961182460762,0,0,1,0.004804030071264947
1239,FIBG,Integrin cell surface interactions,0.0009888534599469246,1,0,1,0.0011167195829726475
1240,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.004253961182460762,0,0,1,0.004804030071264947
1241,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0009888534599469246,1,0,1,0.0011167195829726475
1242,FIBG,p130Cas linkage to MAPK signaling for integrins,0.004253961182460762,0,0,1,0.004804030071264947
1243,FIBG,p130Cas linkage to MAPK signaling for integrins,0.0009888534599469246,1,0,1,0.0011167195829726475
1244,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004253961182460762,0,0,1,0.004804030071264947
1245,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0009888534599469246,1,0,1,0.0011167195829726475
1246,FIBG,Post-translational protein phosphorylation,0.004253961182460762,0,0,1,0.004804030071264947
1247,FIBG,Post-translational protein phosphorylation,0.0009888534599469246,1,0,1,0.0011167195829726475
1248,B3AT,Bicarbonate transporters,0.0022409786018164745,0,0,1,0.002530753838698649
1249,B3AT,Bicarbonate transporters,0.003648248701450902,1,0,1,0.00411999445163839
1250,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0022409786018164745,0,0,1,0.002530753838698649
1251,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.003648248701450902,1,0,1,0.00411999445163839
1252,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.0022409786018164745,0,0,1,0.002530753838698649
1253,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.003648248701450902,1,0,1,0.00411999445163839
1254,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.0022409786018164745,0,0,1,0.002530753838698649
1255,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.003648248701450902,1,0,1,0.00411999445163839
1256,CRP,Initial triggering of complement,0.0001750633228595855,0,0,1,0.00019770031538146745
1257,CRP,Initial triggering of complement,0.00012315390873270885,1,0,1,0.00013907862708881433
1258,SAMP,Amyloid fiber formation,0.0009644414163021746,0,0,1,0.0010891508801236548
1259,SAMP,Amyloid fiber formation,0.0007372108994569699,1,0,1,0.0008325377637336326
1260,C1QA,Initial triggering of complement,0.0005195449240174067,0,0,1,0.000586725955244587
1261,C1QA,Initial triggering of complement,0.0004202199105838176,1,0,1,0.0004745574772314104
1262,C1QA,Regulation of Complement cascade,0.0005195449240174067,0,0,1,0.000586725955244587
1263,C1QA,Regulation of Complement cascade,0.0004202199105838176,1,0,1,0.0004745574772314104
1264,C1QB,Initial triggering of complement,4.3753791694178645e-05,0,0,1,4.941148308953462e-05
1265,C1QB,Initial triggering of complement,5.9359213817712774e-05,1,0,1,6.703480261236921e-05
1266,C1QB,Regulation of Complement cascade,4.3753791694178645e-05,0,0,1,4.941148308953462e-05
1267,C1QB,Regulation of Complement cascade,5.9359213817712774e-05,1,0,1,6.703480261236921e-05
1268,C1QC,Initial triggering of complement,0.0008997609529447791,0,0,1,0.001016106750742922
1269,C1QC,Initial triggering of complement,0.0007018739701042651,1,0,1,0.0007926315060234108
1270,C1QC,Regulation of Complement cascade,0.0008997609529447791,0,0,1,0.001016106750742922
1271,C1QC,Regulation of Complement cascade,0.0007018739701042651,1,0,1,0.0007926315060234108
1272,CO9,Terminal pathway of complement,0.0006089419893004593,0,0,1,0.0006876827274110385
1273,CO9,Terminal pathway of complement,0.0007274782806604063,1,0,1,0.000821546644782283
1274,CO9,Regulation of Complement cascade,0.0006089419893004593,0,0,1,0.0006876827274110385
1275,CO9,Regulation of Complement cascade,0.0007274782806604063,1,0,1,0.000821546644782283
1276,APOH,Platelet degranulation ,0.0004992021184519674,0,0,1,0.000563752673289594
1277,APOH,Platelet degranulation ,0.0006804232351236453,1,0,1,0.000768407031121639
1278,A2GL,Neutrophil degranulation,0.0011321415907027562,0,0,1,0.0012785359370673897
1279,A2GL,Neutrophil degranulation,0.000665902262187328,1,0,1,0.0007520083881491284
1280,FINC,G alpha (s) signalling events,0.005016312884394497,0,0,1,0.005664959530628544
1281,FINC,G alpha (s) signalling events,0.0017558595159590106,1,0,1,0.001982905239089263
1282,FINC,Interleukin-4 and Interleukin-13 signaling,0.005016312884394497,0,0,1,0.005664959530628544
1283,FINC,Interleukin-4 and Interleukin-13 signaling,0.0017558595159590106,1,0,1,0.001982905239089263
1284,FINC,RAF/MAP kinase cascade,0.005016312884394497,0,0,1,0.005664959530628544
1285,FINC,RAF/MAP kinase cascade,0.0017558595159590106,1,0,1,0.001982905239089263
1286,FINC,Signaling by RAS mutants,0.005016312884394497,0,0,1,0.005664959530628544
1287,FINC,Signaling by RAS mutants,0.0017558595159590106,1,0,1,0.001982905239089263
1288,FINC,Signaling by moderate kinase activity BRAF mutants,0.005016312884394497,0,0,1,0.005664959530628544
1289,FINC,Signaling by moderate kinase activity BRAF mutants,0.0017558595159590106,1,0,1,0.001982905239089263
1290,FINC,Signaling by high-kinase activity BRAF mutants,0.005016312884394497,0,0,1,0.005664959530628544
1291,FINC,Signaling by high-kinase activity BRAF mutants,0.0017558595159590106,1,0,1,0.001982905239089263
1292,FINC,Signaling by BRAF and RAF1 fusions,0.005016312884394497,0,0,1,0.005664959530628544
1293,FINC,Signaling by BRAF and RAF1 fusions,0.0017558595159590106,1,0,1,0.001982905239089263
1294,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005016312884394497,0,0,1,0.005664959530628544
1295,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0017558595159590106,1,0,1,0.001982905239089263
1296,FINC,Signaling by RAF1 mutants,0.005016312884394497,0,0,1,0.005664959530628544
1297,FINC,Signaling by RAF1 mutants,0.0017558595159590106,1,0,1,0.001982905239089263
1298,FINC,MET promotes cell motility,0.005016312884394497,0,0,1,0.005664959530628544
1299,FINC,MET promotes cell motility,0.0017558595159590106,1,0,1,0.001982905239089263
1300,FINC,Platelet degranulation ,0.005016312884394497,0,0,1,0.005664959530628544
1301,FINC,Platelet degranulation ,0.0017558595159590106,1,0,1,0.001982905239089263
1302,FINC,ALK mutants bind TKIs,0.005016312884394497,0,0,1,0.005664959530628544
1303,FINC,ALK mutants bind TKIs,0.0017558595159590106,1,0,1,0.001982905239089263
1304,FINC,Signaling by ALK fusions and activated point mutants,0.005016312884394497,0,0,1,0.005664959530628544
1305,FINC,Signaling by ALK fusions and activated point mutants,0.0017558595159590106,1,0,1,0.001982905239089263
1306,FINC,Fibronectin matrix formation,0.005016312884394497,0,0,1,0.005664959530628544
1307,FINC,Fibronectin matrix formation,0.0017558595159590106,1,0,1,0.001982905239089263
1308,FINC,Integrin cell surface interactions,0.005016312884394497,0,0,1,0.005664959530628544
1309,FINC,Integrin cell surface interactions,0.0017558595159590106,1,0,1,0.001982905239089263
1310,FINC,ECM proteoglycans,0.005016312884394497,0,0,1,0.005664959530628544
1311,FINC,ECM proteoglycans,0.0017558595159590106,1,0,1,0.001982905239089263
1312,FINC,Molecules associated with elastic fibres,0.005016312884394497,0,0,1,0.005664959530628544
1313,FINC,Molecules associated with elastic fibres,0.0017558595159590106,1,0,1,0.001982905239089263
1314,FINC,Syndecan interactions,0.005016312884394497,0,0,1,0.005664959530628544
1315,FINC,Syndecan interactions,0.0017558595159590106,1,0,1,0.001982905239089263
1316,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.005016312884394497,0,0,1,0.005664959530628544
1317,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0017558595159590106,1,0,1,0.001982905239089263
1318,FINC,p130Cas linkage to MAPK signaling for integrins,0.005016312884394497,0,0,1,0.005664959530628544
1319,FINC,p130Cas linkage to MAPK signaling for integrins,0.0017558595159590106,1,0,1,0.001982905239089263
1320,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005016312884394497,0,0,1,0.005664959530628544
1321,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0017558595159590106,1,0,1,0.001982905239089263
1322,FINC,Post-translational protein phosphorylation,0.005016312884394497,0,0,1,0.005664959530628544
1323,FINC,Post-translational protein phosphorylation,0.0017558595159590106,1,0,1,0.001982905239089263
1324,RET4,Retinoid cycle disease events,0.006724295962557413,0,0,1,0.007593797551656255
1325,RET4,Retinoid cycle disease events,0.007470950714576497,1,0,1,0.008437000328480285
1326,RET4,Retinoid metabolism disease events,0.006724295962557413,0,0,1,0.007593797551656255
1327,RET4,Retinoid metabolism disease events,0.007470950714576497,1,0,1,0.008437000328480285
1328,RET4,The canonical retinoid cycle in rods (twilight vision),0.006724295962557413,0,0,1,0.007593797551656255
1329,RET4,The canonical retinoid cycle in rods (twilight vision),0.007470950714576497,1,0,1,0.008437000328480285
1330,RET4,Retinoid metabolism and transport,0.006724295962557413,0,0,1,0.007593797551656255
1331,RET4,Retinoid metabolism and transport,0.007470950714576497,1,0,1,0.008437000328480285
1332,AMBP,Scavenging of heme from plasma,4.947852948524936e-05,0,0,1,5.5876472147686255e-05
1333,AMBP,Scavenging of heme from plasma,0.00010088868717320559,1,0,1,0.00011393434642253983
1334,A1AG1,Platelet degranulation ,0.00033537877470504274,0,0,1,0.00037874575009991365
1335,A1AG1,Platelet degranulation ,7.369954225898571e-05,1,0,1,8.32294424101494e-05
1336,A1AG1,Neutrophil degranulation,0.00033537877470504274,0,0,1,0.00037874575009991365
1337,A1AG1,Neutrophil degranulation,7.369954225898571e-05,1,0,1,8.32294424101494e-05
1338,FETUA,Platelet degranulation ,0.0011166734014879814,0,0,1,0.0012610675956913151
1339,FETUA,Platelet degranulation ,0.0010330242034266343,1,0,1,0.0011666019328214316
1340,FETUA,Neutrophil degranulation,0.0011166734014879814,0,0,1,0.0012610675956913151
1341,FETUA,Neutrophil degranulation,0.0010330242034266343,1,0,1,0.0011666019328214316
1342,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0011166734014879814,0,0,1,0.0012610675956913151
1343,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0010330242034266343,1,0,1,0.0011666019328214316
1344,FETUA,Post-translational protein phosphorylation,0.0011166734014879814,0,0,1,0.0012610675956913151
1345,FETUA,Post-translational protein phosphorylation,0.0010330242034266343,1,0,1,0.0011666019328214316
1346,TTHY,Retinoid cycle disease events,0.004969687887257217,0,0,1,0.005612305573830902
1347,TTHY,Retinoid cycle disease events,0.008617288305383693,1,0,1,0.009731567914278883
1348,TTHY,Neutrophil degranulation,0.004969687887257217,0,0,1,0.005612305573830902
1349,TTHY,Neutrophil degranulation,0.008617288305383693,1,0,1,0.009731567914278883
1350,TTHY,The canonical retinoid cycle in rods (twilight vision),0.004969687887257217,0,0,1,0.005612305573830902
1351,TTHY,The canonical retinoid cycle in rods (twilight vision),0.008617288305383693,1,0,1,0.009731567914278883
1352,TTHY,Retinoid metabolism and transport,0.004969687887257217,0,0,1,0.005612305573830902
1353,TTHY,Retinoid metabolism and transport,0.008617288305383693,1,0,1,0.009731567914278883
1354,TTHY,Amyloid fiber formation,0.004969687887257217,0,0,1,0.005612305573830902
1355,TTHY,Amyloid fiber formation,0.008617288305383693,1,0,1,0.009731567914278883
1356,ALBU,Bile acid and bile salt metabolism,0.0018852231329718255,0,0,1,0.0021289965360243393
1357,ALBU,Bile acid and bile salt metabolism,0.002811590262349386,1,0,1,0.003175149840128269
1358,ALBU,Platelet degranulation ,0.0018852231329718255,0,0,1,0.0021289965360243393
1359,ALBU,Platelet degranulation ,0.002811590262349386,1,0,1,0.003175149840128269
1360,ALBU,HDL remodeling,0.0018852231329718255,0,0,1,0.0021289965360243393
1361,ALBU,HDL remodeling,0.002811590262349386,1,0,1,0.003175149840128269
1362,ALBU,Cytoprotection by HMOX1,0.0018852231329718255,0,0,1,0.0021289965360243393
1363,ALBU,Cytoprotection by HMOX1,0.002811590262349386,1,0,1,0.003175149840128269
1364,ALBU,Heme biosynthesis,0.0018852231329718255,0,0,1,0.0021289965360243393
1365,ALBU,Heme biosynthesis,0.002811590262349386,1,0,1,0.003175149840128269
1366,ALBU,Heme degradation,0.0018852231329718255,0,0,1,0.0021289965360243393
1367,ALBU,Heme degradation,0.002811590262349386,1,0,1,0.003175149840128269
1368,ALBU,Scavenging of heme from plasma,0.0018852231329718255,0,0,1,0.0021289965360243393
1369,ALBU,Scavenging of heme from plasma,0.002811590262349386,1,0,1,0.003175149840128269
1370,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0018852231329718255,0,0,1,0.0021289965360243393
1371,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002811590262349386,1,0,1,0.003175149840128269
1372,ALBU,Post-translational protein phosphorylation,0.0018852231329718255,0,0,1,0.0021289965360243393
1373,ALBU,Post-translational protein phosphorylation,0.002811590262349386,1,0,1,0.003175149840128269
1374,ALBU,Aspirin ADME,0.0018852231329718255,0,0,1,0.0021289965360243393
1375,ALBU,Aspirin ADME,0.002811590262349386,1,0,1,0.003175149840128269
1376,VTDB,Vitamin D (calciferol) metabolism,0.0005483589156765124,0,0,1,0.0006192658107971588
1377,VTDB,Vitamin D (calciferol) metabolism,0.00018424262144876386,1,0,1,0.00020806656569831303
1378,CXCL7,Class A/1 (Rhodopsin-like receptors),0.0006548351560997916,0,0,1,0.0007395102227531647
1379,CXCL7,Class A/1 (Rhodopsin-like receptors),0.0006853385934569297,1,0,1,0.0007739579819252101
1380,CXCL7,G alpha (i) signalling events,0.0006548351560997916,0,0,1,0.0007395102227531647
1381,CXCL7,G alpha (i) signalling events,0.0006853385934569297,1,0,1,0.0007739579819252101
1382,CXCL7,Platelet degranulation ,0.0006548351560997916,0,0,1,0.0007395102227531647
1383,CXCL7,Platelet degranulation ,0.0006853385934569297,1,0,1,0.0007739579819252101
1384,CXCL7,Neutrophil degranulation,0.0006548351560997916,0,0,1,0.0007395102227531647
1385,CXCL7,Neutrophil degranulation,0.0006853385934569297,1,0,1,0.0007739579819252101
1386,PLF4,Transcriptional regulation by RUNX1,0.0006228763371410506,0,0,1,0.000703418890290396
1387,PLF4,Transcriptional regulation by RUNX1,0.0002601255434531417,1,0,1,0.0002937617151292743
1388,PLF4,Class A/1 (Rhodopsin-like receptors),0.0006228763371410506,0,0,1,0.000703418890290396
1389,PLF4,Class A/1 (Rhodopsin-like receptors),0.0002601255434531417,1,0,1,0.0002937617151292743
1390,PLF4,G alpha (i) signalling events,0.0006228763371410506,0,0,1,0.000703418890290396
1391,PLF4,G alpha (i) signalling events,0.0002601255434531417,1,0,1,0.0002937617151292743
1392,PLF4,Platelet degranulation ,0.0006228763371410506,0,0,1,0.000703418890290396
1393,PLF4,Platelet degranulation ,0.0002601255434531417,1,0,1,0.0002937617151292743
1394,PLF4,Common Pathway of Fibrin Clot Formation,0.0006228763371410506,0,0,1,0.000703418890290396
1395,PLF4,Common Pathway of Fibrin Clot Formation,0.0002601255434531417,1,0,1,0.0002937617151292743
1396,TFR1,RHO GTPase cycle,0.0016246597533332017,0,0,1,0.0018347403692272838
1397,TFR1,RHO GTPase cycle,0.0017641185893503438,1,0,1,0.001992232272231064
1398,TFR1,Golgi Associated Vesicle Biogenesis,0.0016246597533332017,0,0,1,0.0018347403692272838
1399,TFR1,Golgi Associated Vesicle Biogenesis,0.0017641185893503438,1,0,1,0.001992232272231064
1400,TFR1,Cargo recognition for clathrin-mediated endocytosis,0.0016246597533332017,0,0,1,0.0018347403692272838
1401,TFR1,Cargo recognition for clathrin-mediated endocytosis,0.0017641185893503438,1,0,1,0.001992232272231064
1402,TFR1,Transferrin endocytosis and recycling,0.0016246597533332017,0,0,1,0.0018347403692272838
1403,TFR1,Transferrin endocytosis and recycling,0.0017641185893503438,1,0,1,0.001992232272231064
1404,TRFE,Platelet degranulation ,0.0004755828308923829,0,0,1,0.0005370792357965746
1405,TRFE,Platelet degranulation ,0.00038385318030063144,1,0,1,0.00043348825765452976
1406,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.0004755828308923829,0,0,1,0.0005370792357965746
1407,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.00038385318030063144,1,0,1,0.00043348825765452976
1408,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0004755828308923829,0,0,1,0.0005370792357965746
1409,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00038385318030063144,1,0,1,0.00043348825765452976
1410,TRFE,Post-translational protein phosphorylation,0.0004755828308923829,0,0,1,0.0005370792357965746
1411,TRFE,Post-translational protein phosphorylation,0.00038385318030063144,1,0,1,0.00043348825765452976
1412,TRFE,Transferrin endocytosis and recycling,0.0004755828308923829,0,0,1,0.0005370792357965746
1413,TRFE,Transferrin endocytosis and recycling,0.00038385318030063144,1,0,1,0.00043348825765452976
1414,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.004052874967243126,0,0,1,0.004576941909575711
1415,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.0027231062422057397,1,0,1,0.0030752241766433485
1416,TRFL,Metal sequestration by antimicrobial proteins,0.004052874967243126,0,0,1,0.004576941909575711
1417,TRFL,Metal sequestration by antimicrobial proteins,0.0027231062422057397,1,0,1,0.0030752241766433485
1418,TRFL,Neutrophil degranulation,0.004052874967243126,0,0,1,0.004576941909575711
1419,TRFL,Neutrophil degranulation,0.0027231062422057397,1,0,1,0.0030752241766433485
1420,TRFL,Amyloid fiber formation,0.004052874967243126,0,0,1,0.004576941909575711
1421,TRFL,Amyloid fiber formation,0.0027231062422057397,1,0,1,0.0030752241766433485
1422,HEMO,Scavenging of heme from plasma,5.315557529540172e-05,0,0,1,6.00289873888273e-05
1423,HEMO,Scavenging of heme from plasma,0.00010824057366164075,1,0,1,0.0001222368866329652
1424,ANGI,Adherens junctions interactions,0.0012142281929240206,0,0,1,0.0013712369488078878
1425,ANGI,Adherens junctions interactions,0.0003260691920645675,1,0,1,0.0003682323690328353
1426,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0012142281929240206,0,0,1,0.0013712369488078878
1427,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0003260691920645675,1,0,1,0.0003682323690328353
1428,FA11,Defective factor IX causes hemophilia B,0.0002049180339634007,0,0,1,0.00023141546316019981
1429,FA11,Defective factor IX causes hemophilia B,4.014243010047236e-05,1,0,1,4.533314552361906e-05
1430,FA11,Intrinsic Pathway of Fibrin Clot Formation,0.0002049180339634007,0,0,1,0.00023141546316019981
1431,FA11,Intrinsic Pathway of Fibrin Clot Formation,4.014243010047236e-05,1,0,1,4.533314552361906e-05
1432,KLKB1,Defective factor XII causes hereditary angioedema,0.0007731865498176076,0,0,1,0.0008731653338389721
1433,KLKB1,Defective factor XII causes hereditary angioedema,0.0012074266920526358,1,0,1,0.0013635559631772277
1434,KLKB1,Defective SERPING1 causes hereditary angioedema,0.0007731865498176076,0,0,1,0.0008731653338389721
1435,KLKB1,Defective SERPING1 causes hereditary angioedema,0.0012074266920526358,1,0,1,0.0013635559631772277
1436,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.0007731865498176076,0,0,1,0.0008731653338389721
1437,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.0012074266920526358,1,0,1,0.0013635559631772277
1438,KLKB1,Activation of Matrix Metalloproteinases,0.0007731865498176076,0,0,1,0.0008731653338389721
1439,KLKB1,Activation of Matrix Metalloproteinases,0.0012074266920526358,1,0,1,0.0013635559631772277
1440,C4BPA,Regulation of Complement cascade,0.00017655203615769317,0,0,1,0.00019938153040549927
1441,C4BPA,Regulation of Complement cascade,0.0001410915061150572,1,0,1,0.00015933568951485112
1442,VTNC,Regulation of Complement cascade,0.00242173234610025,0,0,1,0.0027348803894093644
1443,VTNC,Regulation of Complement cascade,0.0019790539684708614,1,0,1,0.002234960397943862
1444,VTNC,Integrin cell surface interactions,0.00242173234610025,0,0,1,0.0027348803894093644
1445,VTNC,Integrin cell surface interactions,0.0019790539684708614,1,0,1,0.002234960397943862
1446,VTNC,ECM proteoglycans,0.00242173234610025,0,0,1,0.0027348803894093644
1447,VTNC,ECM proteoglycans,0.0019790539684708614,1,0,1,0.002234960397943862
1448,VTNC,Molecules associated with elastic fibres,0.00242173234610025,0,0,1,0.0027348803894093644
1449,VTNC,Molecules associated with elastic fibres,0.0019790539684708614,1,0,1,0.002234960397943862
1450,VTNC,Syndecan interactions,0.00242173234610025,0,0,1,0.0027348803894093644
1451,VTNC,Syndecan interactions,0.0019790539684708614,1,0,1,0.002234960397943862
1452,CATA,FOXO-mediated transcription,0.002200361585296539,0,0,1,0.0024848847391940876
1453,CATA,FOXO-mediated transcription,0.0014151494603173874,1,0,1,0.0015981388336896976
1454,CATA,Detoxification of Reactive Oxygen Species,0.002200361585296539,0,0,1,0.0024848847391940876
1455,CATA,Detoxification of Reactive Oxygen Species,0.0014151494603173874,1,0,1,0.0015981388336896976
1456,CATA,Neutrophil degranulation,0.002200361585296539,0,0,1,0.0024848847391940876
1457,CATA,Neutrophil degranulation,0.0014151494603173874,1,0,1,0.0015981388336896976
1458,FUCO,Neutrophil degranulation,0.001375315498163555,0,0,1,0.001553154043317458
1459,FUCO,Neutrophil degranulation,0.0008065818620167275,1,0,1,0.0009108789088253449
1460,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0027076319361116347,0,0,1,0.003057748927429852
1461,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0025973580377929113,1,0,1,0.0029332157921057745
1462,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.0027076319361116347,0,0,1,0.003057748927429852
1463,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.0025973580377929113,1,0,1,0.0029332157921057745
1464,PROC,Common Pathway of Fibrin Clot Formation,0.0027076319361116347,0,0,1,0.003057748927429852
1465,PROC,Common Pathway of Fibrin Clot Formation,0.0025973580377929113,1,0,1,0.0029332157921057745
1466,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0027076319361116347,0,0,1,0.003057748927429852
1467,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0025973580377929113,1,0,1,0.0029332157921057745
1468,PROC,Post-translational protein phosphorylation,0.0027076319361116347,0,0,1,0.003057748927429852
1469,PROC,Post-translational protein phosphorylation,0.0025973580377929113,1,0,1,0.0029332157921057745
1470,ALDOA,Glycolysis,0.0002918839570594141,0,0,1,0.00032962672833373123
1471,ALDOA,Glycolysis,0.00015162655260095572,1,0,1,0.00017123299603685236
1472,ALDOA,Gluconeogenesis,0.0002918839570594141,0,0,1,0.00032962672833373123
1473,ALDOA,Gluconeogenesis,0.00015162655260095572,1,0,1,0.00017123299603685236
1474,ALDOA,Platelet degranulation ,0.0002918839570594141,0,0,1,0.00032962672833373123
1475,ALDOA,Platelet degranulation ,0.00015162655260095572,1,0,1,0.00017123299603685236
1476,ALDOA,Neutrophil degranulation,0.0002918839570594141,0,0,1,0.00032962672833373123
1477,ALDOA,Neutrophil degranulation,0.00015162655260095572,1,0,1,0.00017123299603685236
1478,APOB,Regulation of TLR by endogenous ligand,0.04256688294146886,0,0,1,0.04807109818819262
1479,APOB,Regulation of TLR by endogenous ligand,0.04455405408099913,1,0,1,0.05031522536791714
1480,APOB,Cargo recognition for clathrin-mediated endocytosis,0.04256688294146886,0,0,1,0.04807109818819262
1481,APOB,Cargo recognition for clathrin-mediated endocytosis,0.04455405408099913,1,0,1,0.05031522536791714
1482,APOB,VLDL assembly,0.04256688294146886,0,0,1,0.04807109818819262
1483,APOB,VLDL assembly,0.04455405408099913,1,0,1,0.05031522536791714
1484,APOB,Chylomicron assembly,0.04256688294146886,0,0,1,0.04807109818819262
1485,APOB,Chylomicron assembly,0.04455405408099913,1,0,1,0.05031522536791714
1486,APOB,Chylomicron remodeling,0.04256688294146886,0,0,1,0.04807109818819262
1487,APOB,Chylomicron remodeling,0.04455405408099913,1,0,1,0.05031522536791714
1488,APOB,LDL remodeling,0.04256688294146886,0,0,1,0.04807109818819262
1489,APOB,LDL remodeling,0.04455405408099913,1,0,1,0.05031522536791714
1490,APOB,Chylomicron clearance,0.04256688294146886,0,0,1,0.04807109818819262
1491,APOB,Chylomicron clearance,0.04455405408099913,1,0,1,0.05031522536791714
1492,APOB,LDL clearance,0.04256688294146886,0,0,1,0.04807109818819262
1493,APOB,LDL clearance,0.04455405408099913,1,0,1,0.05031522536791714
1494,APOB,VLDL clearance,0.04256688294146886,0,0,1,0.04807109818819262
1495,APOB,VLDL clearance,0.04455405408099913,1,0,1,0.05031522536791714
1496,APOB,Scavenging by Class B Receptors,0.04256688294146886,0,0,1,0.04807109818819262
1497,APOB,Scavenging by Class B Receptors,0.04455405408099913,1,0,1,0.05031522536791714
1498,APOB,Scavenging by Class A Receptors,0.04256688294146886,0,0,1,0.04807109818819262
1499,APOB,Scavenging by Class A Receptors,0.04455405408099913,1,0,1,0.05031522536791714
1500,APOB,Scavenging by Class F Receptors,0.04256688294146886,0,0,1,0.04807109818819262
1501,APOB,Scavenging by Class F Receptors,0.04455405408099913,1,0,1,0.05031522536791714
1502,APOB,Scavenging by Class H Receptors,0.04256688294146886,0,0,1,0.04807109818819262
1503,APOB,Scavenging by Class H Receptors,0.04455405408099913,1,0,1,0.05031522536791714
1504,APOB,Retinoid metabolism and transport,0.04256688294146886,0,0,1,0.04807109818819262
1505,APOB,Retinoid metabolism and transport,0.04455405408099913,1,0,1,0.05031522536791714
1506,APOB,Heme signaling,0.04256688294146886,0,0,1,0.04807109818819262
1507,APOB,Heme signaling,0.04455405408099913,1,0,1,0.05031522536791714
1508,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.04256688294146886,0,0,1,0.04807109818819262
1509,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.04455405408099913,1,0,1,0.05031522536791714
1510,APOB,Platelet sensitization by LDL,0.04256688294146886,0,0,1,0.04807109818819262
1511,APOB,Platelet sensitization by LDL,0.04455405408099913,1,0,1,0.05031522536791714
1512,APOB,Post-translational protein phosphorylation,0.04256688294146886,0,0,1,0.04807109818819262
1513,APOB,Post-translational protein phosphorylation,0.04455405408099913,1,0,1,0.05031522536791714
1514,SODM,FOXO-mediated transcription,0.0008926782815399235,0,0,1,0.0010081082371330417
1515,SODM,FOXO-mediated transcription,0.0012658408031619253,1,0,1,0.0014295234542564266
1516,SODM,Interleukin-12 family signaling,0.0008926782815399235,0,0,1,0.0010081082371330417
1517,SODM,Interleukin-12 family signaling,0.0012658408031619253,1,0,1,0.0014295234542564266
1518,SODM,Neurodegenerative Diseases,0.0008926782815399235,0,0,1,0.0010081082371330417
1519,SODM,Neurodegenerative Diseases,0.0012658408031619253,1,0,1,0.0014295234542564266
1520,SODM,Detoxification of Reactive Oxygen Species,0.0008926782815399235,0,0,1,0.0010081082371330417
1521,SODM,Detoxification of Reactive Oxygen Species,0.0012658408031619253,1,0,1,0.0014295234542564266
1522,SODM,Transcriptional activation of mitochondrial biogenesis,0.0008926782815399235,0,0,1,0.0010081082371330417
1523,SODM,Transcriptional activation of mitochondrial biogenesis,0.0012658408031619253,1,0,1,0.0014295234542564266
1524,LCAT,HDL remodeling,0.0002187297205108536,0,0,1,0.0002470131037269309
1525,LCAT,HDL remodeling,0.00024174663291895058,1,0,1,0.0002730062744714289
1526,HRG,Platelet degranulation ,0.0008578543341006715,0,0,1,0.000968781293721315
1527,HRG,Platelet degranulation ,0.00036276895779277773,1,0,1,0.0004096776880201406
1528,HRG,Dissolution of Fibrin Clot,0.0008578543341006715,0,0,1,0.000968781293721315
1529,HRG,Dissolution of Fibrin Clot,0.00036276895779277773,1,0,1,0.0004096776880201406
1530,LV743,Initial triggering of complement,0.004295746792453668,0,0,1,0.004851218872088924
1531,LV743,Initial triggering of complement,0.003541684838750703,1,0,1,0.003999651087191945
1532,LV743,Regulation of Complement cascade,0.004295746792453668,0,0,1,0.004851218872088924
1533,LV743,Regulation of Complement cascade,0.003541684838750703,1,0,1,0.003999651087191945
1534,LV743,FCGR activation,0.004295746792453668,0,0,1,0.004851218872088924
1535,LV743,FCGR activation,0.003541684838750703,1,0,1,0.003999651087191945
1536,LV743,Regulation of actin dynamics for phagocytic cup formation,0.004295746792453668,0,0,1,0.004851218872088924
1537,LV743,Regulation of actin dynamics for phagocytic cup formation,0.003541684838750703,1,0,1,0.003999651087191945
1538,LV743,Role of phospholipids in phagocytosis,0.004295746792453668,0,0,1,0.004851218872088924
1539,LV743,Role of phospholipids in phagocytosis,0.003541684838750703,1,0,1,0.003999651087191945
1540,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.004295746792453668,0,0,1,0.004851218872088924
1541,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.003541684838750703,1,0,1,0.003999651087191945
1542,LV743,FCERI mediated MAPK activation,0.004295746792453668,0,0,1,0.004851218872088924
1543,LV743,FCERI mediated MAPK activation,0.003541684838750703,1,0,1,0.003999651087191945
1544,LV743,FCERI mediated Ca+2 mobilization,0.004295746792453668,0,0,1,0.004851218872088924
1545,LV743,FCERI mediated Ca+2 mobilization,0.003541684838750703,1,0,1,0.003999651087191945
1546,LV743,FCERI mediated NF-kB activation,0.004295746792453668,0,0,1,0.004851218872088924
1547,LV743,FCERI mediated NF-kB activation,0.003541684838750703,1,0,1,0.003999651087191945
1548,LV743,Parasite infection,0.004295746792453668,0,0,1,0.004851218872088924
1549,LV743,Parasite infection,0.003541684838750703,1,0,1,0.003999651087191945
1550,LV743,Leishmania parasite growth and survival,0.004295746792453668,0,0,1,0.004851218872088924
1551,LV743,Leishmania parasite growth and survival,0.003541684838750703,1,0,1,0.003999651087191945
1552,LV743,Potential therapeutics for SARS,0.004295746792453668,0,0,1,0.004851218872088924
1553,LV743,Potential therapeutics for SARS,0.003541684838750703,1,0,1,0.003999651087191945
1554,LV743,CD22 mediated BCR regulation,0.004295746792453668,0,0,1,0.004851218872088924
1555,LV743,CD22 mediated BCR regulation,0.003541684838750703,1,0,1,0.003999651087191945
1556,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004295746792453668,0,0,1,0.004851218872088924
1557,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003541684838750703,1,0,1,0.003999651087191945
1558,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004295746792453668,0,0,1,0.004851218872088924
1559,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003541684838750703,1,0,1,0.003999651087191945
1560,LV743,Scavenging of heme from plasma,0.004295746792453668,0,0,1,0.004851218872088924
1561,LV743,Scavenging of heme from plasma,0.003541684838750703,1,0,1,0.003999651087191945
1562,A1BG,Platelet degranulation ,0.0011572218438582957,0,0,1,0.0013068592538975758
1563,A1BG,Platelet degranulation ,0.0005532159370193572,1,0,1,0.000624750881202598
1564,A1BG,Neutrophil degranulation,0.0011572218438582957,0,0,1,0.0013068592538975758
1565,A1BG,Neutrophil degranulation,0.0005532159370193572,1,0,1,0.000624750881202598
1566,K2C6B,Formation of the cornified envelope,0.0002707634006823318,0,0,1,0.00030577512658999905
1567,K2C6B,Formation of the cornified envelope,0.0005339644966380515,1,0,1,0.0006030100860847972
1568,K2C1,Neutrophil degranulation,0.0007897147189179505,0,0,1,0.0008918307184006309
1569,K2C1,Neutrophil degranulation,0.0005361011372022099,1,0,1,0.0006054230101998602
1570,K2C1,Formation of the cornified envelope,0.0007897147189179505,0,0,1,0.0008918307184006309
1571,K2C1,Formation of the cornified envelope,0.0005361011372022099,1,0,1,0.0006054230101998602
1572,VWF,RAF/MAP kinase cascade,0.0008057275319811658,0,0,1,0.0009099141075482327
1573,VWF,RAF/MAP kinase cascade,0.0006647274274454674,1,0,1,0.0007506816385182349
1574,VWF,Signaling by RAS mutants,0.0008057275319811658,0,0,1,0.0009099141075482327
1575,VWF,Signaling by RAS mutants,0.0006647274274454674,1,0,1,0.0007506816385182349
1576,VWF,Signaling by moderate kinase activity BRAF mutants,0.0008057275319811658,0,0,1,0.0009099141075482327
1577,VWF,Signaling by moderate kinase activity BRAF mutants,0.0006647274274454674,1,0,1,0.0007506816385182349
1578,VWF,Signaling by high-kinase activity BRAF mutants,0.0008057275319811658,0,0,1,0.0009099141075482327
1579,VWF,Signaling by high-kinase activity BRAF mutants,0.0006647274274454674,1,0,1,0.0007506816385182349
1580,VWF,Signaling by BRAF and RAF1 fusions,0.0008057275319811658,0,0,1,0.0009099141075482327
1581,VWF,Signaling by BRAF and RAF1 fusions,0.0006647274274454674,1,0,1,0.0007506816385182349
1582,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0008057275319811658,0,0,1,0.0009099141075482327
1583,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0006647274274454674,1,0,1,0.0007506816385182349
1584,VWF,Signaling by RAF1 mutants,0.0008057275319811658,0,0,1,0.0009099141075482327
1585,VWF,Signaling by RAF1 mutants,0.0006647274274454674,1,0,1,0.0007506816385182349
1586,VWF,Platelet degranulation ,0.0008057275319811658,0,0,1,0.0009099141075482327
1587,VWF,Platelet degranulation ,0.0006647274274454674,1,0,1,0.0007506816385182349
1588,VWF,Defective factor VIII causes hemophilia A,0.0008057275319811658,0,0,1,0.0009099141075482327
1589,VWF,Defective factor VIII causes hemophilia A,0.0006647274274454674,1,0,1,0.0007506816385182349
1590,VWF,Platelet Adhesion to exposed collagen,0.0008057275319811658,0,0,1,0.0009099141075482327
1591,VWF,Platelet Adhesion to exposed collagen,0.0006647274274454674,1,0,1,0.0007506816385182349
1592,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.0008057275319811658,0,0,1,0.0009099141075482327
1593,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.0006647274274454674,1,0,1,0.0007506816385182349
1594,VWF,Integrin cell surface interactions,0.0008057275319811658,0,0,1,0.0009099141075482327
1595,VWF,Integrin cell surface interactions,0.0006647274274454674,1,0,1,0.0007506816385182349
1596,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0008057275319811658,0,0,1,0.0009099141075482327
1597,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0006647274274454674,1,0,1,0.0007506816385182349
1598,VWF,p130Cas linkage to MAPK signaling for integrins,0.0008057275319811658,0,0,1,0.0009099141075482327
1599,VWF,p130Cas linkage to MAPK signaling for integrins,0.0006647274274454674,1,0,1,0.0007506816385182349
1600,VWF,GP1b-IX-V activation signalling,0.0008057275319811658,0,0,1,0.0009099141075482327
1601,VWF,GP1b-IX-V activation signalling,0.0006647274274454674,1,0,1,0.0007506816385182349
1602,G3P,Glycolysis,0.0002445258170030633,0,0,1,0.00027614482777292733
1603,G3P,Glycolysis,0.0005298543339985219,1,0,1,0.0005983684487799011
1604,G3P,Gluconeogenesis,0.0002445258170030633,0,0,1,0.00027614482777292733
1605,G3P,Gluconeogenesis,0.0005298543339985219,1,0,1,0.0005983684487799011
1606,ARLY,Urea cycle,0.00031456409262577167,0,0,1,0.00035523957448060656
1607,ARLY,Urea cycle,6.976400490788975e-05,1,0,1,7.878501074509253e-05
1608,KV116,Initial triggering of complement,0.0026625706375086665,0,0,1,0.0030068608670424076
1609,KV116,Initial triggering of complement,0.0023801813234884893,1,0,1,0.0026879565098634683
1610,KV116,Regulation of Complement cascade,0.0026625706375086665,0,0,1,0.0030068608670424076
1611,KV116,Regulation of Complement cascade,0.0023801813234884893,1,0,1,0.0026879565098634683
1612,KV116,FCGR activation,0.0026625706375086665,0,0,1,0.0030068608670424076
1613,KV116,FCGR activation,0.0023801813234884893,1,0,1,0.0026879565098634683
1614,KV116,Regulation of actin dynamics for phagocytic cup formation,0.0026625706375086665,0,0,1,0.0030068608670424076
1615,KV116,Regulation of actin dynamics for phagocytic cup formation,0.0023801813234884893,1,0,1,0.0026879565098634683
1616,KV116,Role of phospholipids in phagocytosis,0.0026625706375086665,0,0,1,0.0030068608670424076
1617,KV116,Role of phospholipids in phagocytosis,0.0023801813234884893,1,0,1,0.0026879565098634683
1618,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.0026625706375086665,0,0,1,0.0030068608670424076
1619,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.0023801813234884893,1,0,1,0.0026879565098634683
1620,KV116,FCERI mediated MAPK activation,0.0026625706375086665,0,0,1,0.0030068608670424076
1621,KV116,FCERI mediated MAPK activation,0.0023801813234884893,1,0,1,0.0026879565098634683
1622,KV116,FCERI mediated Ca+2 mobilization,0.0026625706375086665,0,0,1,0.0030068608670424076
1623,KV116,FCERI mediated Ca+2 mobilization,0.0023801813234884893,1,0,1,0.0026879565098634683
1624,KV116,FCERI mediated NF-kB activation,0.0026625706375086665,0,0,1,0.0030068608670424076
1625,KV116,FCERI mediated NF-kB activation,0.0023801813234884893,1,0,1,0.0026879565098634683
1626,KV116,Parasite infection,0.0026625706375086665,0,0,1,0.0030068608670424076
1627,KV116,Parasite infection,0.0023801813234884893,1,0,1,0.0026879565098634683
1628,KV116,Leishmania parasite growth and survival,0.0026625706375086665,0,0,1,0.0030068608670424076
1629,KV116,Leishmania parasite growth and survival,0.0023801813234884893,1,0,1,0.0026879565098634683
1630,KV116,Potential therapeutics for SARS,0.0026625706375086665,0,0,1,0.0030068608670424076
1631,KV116,Potential therapeutics for SARS,0.0023801813234884893,1,0,1,0.0026879565098634683
1632,KV116,CD22 mediated BCR regulation,0.0026625706375086665,0,0,1,0.0030068608670424076
1633,KV116,CD22 mediated BCR regulation,0.0023801813234884893,1,0,1,0.0026879565098634683
1634,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0026625706375086665,0,0,1,0.0030068608670424076
1635,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0023801813234884893,1,0,1,0.0026879565098634683
1636,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0026625706375086665,0,0,1,0.0030068608670424076
1637,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0023801813234884893,1,0,1,0.0026879565098634683
1638,KV116,Scavenging of heme from plasma,0.0026625706375086665,0,0,1,0.0030068608670424076
1639,KV116,Scavenging of heme from plasma,0.0023801813234884893,1,0,1,0.0026879565098634683
1640,KV311,Initial triggering of complement,0.00019854576583922036,0,0,1,0.00022421921327034607
1641,KV311,Initial triggering of complement,0.000880641991356413,1,0,1,0.00099451556491345
1642,KV311,Regulation of Complement cascade,0.00019854576583922036,0,0,1,0.00022421921327034607
1643,KV311,Regulation of Complement cascade,0.000880641991356413,1,0,1,0.00099451556491345
1644,KV311,FCGR activation,0.00019854576583922036,0,0,1,0.00022421921327034607
1645,KV311,FCGR activation,0.000880641991356413,1,0,1,0.00099451556491345
1646,KV311,Regulation of actin dynamics for phagocytic cup formation,0.00019854576583922036,0,0,1,0.00022421921327034607
1647,KV311,Regulation of actin dynamics for phagocytic cup formation,0.000880641991356413,1,0,1,0.00099451556491345
1648,KV311,Role of phospholipids in phagocytosis,0.00019854576583922036,0,0,1,0.00022421921327034607
1649,KV311,Role of phospholipids in phagocytosis,0.000880641991356413,1,0,1,0.00099451556491345
1650,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.00019854576583922036,0,0,1,0.00022421921327034607
1651,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.000880641991356413,1,0,1,0.00099451556491345
1652,KV311,FCERI mediated MAPK activation,0.00019854576583922036,0,0,1,0.00022421921327034607
1653,KV311,FCERI mediated MAPK activation,0.000880641991356413,1,0,1,0.00099451556491345
1654,KV311,FCERI mediated Ca+2 mobilization,0.00019854576583922036,0,0,1,0.00022421921327034607
1655,KV311,FCERI mediated Ca+2 mobilization,0.000880641991356413,1,0,1,0.00099451556491345
1656,KV311,FCERI mediated NF-kB activation,0.00019854576583922036,0,0,1,0.00022421921327034607
1657,KV311,FCERI mediated NF-kB activation,0.000880641991356413,1,0,1,0.00099451556491345
1658,KV311,Parasite infection,0.00019854576583922036,0,0,1,0.00022421921327034607
1659,KV311,Parasite infection,0.000880641991356413,1,0,1,0.00099451556491345
1660,KV311,Leishmania parasite growth and survival,0.00019854576583922036,0,0,1,0.00022421921327034607
1661,KV311,Leishmania parasite growth and survival,0.000880641991356413,1,0,1,0.00099451556491345
1662,KV311,Potential therapeutics for SARS,0.00019854576583922036,0,0,1,0.00022421921327034607
1663,KV311,Potential therapeutics for SARS,0.000880641991356413,1,0,1,0.00099451556491345
1664,KV311,CD22 mediated BCR regulation,0.00019854576583922036,0,0,1,0.00022421921327034607
1665,KV311,CD22 mediated BCR regulation,0.000880641991356413,1,0,1,0.00099451556491345
1666,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00019854576583922036,0,0,1,0.00022421921327034607
1667,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.000880641991356413,1,0,1,0.00099451556491345
1668,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00019854576583922036,0,0,1,0.00022421921327034607
1669,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.000880641991356413,1,0,1,0.00099451556491345
1670,KV311,Scavenging of heme from plasma,0.00019854576583922036,0,0,1,0.00022421921327034607
1671,KV311,Scavenging of heme from plasma,0.000880641991356413,1,0,1,0.00099451556491345
1672,MT1A,Metallothioneins bind metals,2.959406540447227e-05,0,0,1,3.342079864767966e-05
1673,MT1A,Metallothioneins bind metals,7.808381916834266e-05,1,0,1,8.81806390031375e-05
1674,MT1E,Metallothioneins bind metals,0.001978733942921978,0,0,1,0.0022345989907061213
1675,MT1E,Metallothioneins bind metals,0.006015921912160773,1,0,1,0.006793825456508769
1676,H2A1B,Packaging Of Telomere Ends,0.007783984693315656,0,0,1,0.008790511933943672
1677,H2A1B,Packaging Of Telomere Ends,0.0034822109769935233,1,0,1,0.00393248681180698
1678,H2A1B,Inhibition of DNA recombination at telomere,0.007783984693315656,0,0,1,0.008790511933943672
1679,H2A1B,Inhibition of DNA recombination at telomere,0.0034822109769935233,1,0,1,0.00393248681180698
1680,H2A1B,Pre-NOTCH Transcription and Translation,0.007783984693315656,0,0,1,0.008790511933943672
1681,H2A1B,Pre-NOTCH Transcription and Translation,0.0034822109769935233,1,0,1,0.00393248681180698
1682,H2A1B,RHO GTPase Effectors,0.007783984693315656,0,0,1,0.008790511933943672
1683,H2A1B,RHO GTPase Effectors,0.0034822109769935233,1,0,1,0.00393248681180698
1684,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.007783984693315656,0,0,1,0.008790511933943672
1685,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.0034822109769935233,1,0,1,0.00393248681180698
1686,H2A1B,Transcriptional regulation by RUNX1,0.007783984693315656,0,0,1,0.008790511933943672
1687,H2A1B,Transcriptional regulation by RUNX1,0.0034822109769935233,1,0,1,0.00393248681180698
1688,H2A1B,Oxidative Stress Induced Senescence,0.007783984693315656,0,0,1,0.008790511933943672
1689,H2A1B,Oxidative Stress Induced Senescence,0.0034822109769935233,1,0,1,0.00393248681180698
1690,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.007783984693315656,0,0,1,0.008790511933943672
1691,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.0034822109769935233,1,0,1,0.00393248681180698
1692,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.007783984693315656,0,0,1,0.008790511933943672
1693,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.0034822109769935233,1,0,1,0.00393248681180698
1694,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.007783984693315656,0,0,1,0.008790511933943672
1695,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0034822109769935233,1,0,1,0.00393248681180698
1696,H2A1B,B-WICH complex positively regulates rRNA expression,0.007783984693315656,0,0,1,0.008790511933943672
1697,H2A1B,B-WICH complex positively regulates rRNA expression,0.0034822109769935233,1,0,1,0.00393248681180698
1698,H2A1B,SIRT1 negatively regulates rRNA expression,0.007783984693315656,0,0,1,0.008790511933943672
1699,H2A1B,SIRT1 negatively regulates rRNA expression,0.0034822109769935233,1,0,1,0.00393248681180698
1700,H2A1B,NoRC negatively regulates rRNA expression,0.007783984693315656,0,0,1,0.008790511933943672
1701,H2A1B,NoRC negatively regulates rRNA expression,0.0034822109769935233,1,0,1,0.00393248681180698
1702,H2A1B,UCH proteinases,0.007783984693315656,0,0,1,0.008790511933943672
1703,H2A1B,UCH proteinases,0.0034822109769935233,1,0,1,0.00393248681180698
1704,H2A1B,Ub-specific processing proteases,0.007783984693315656,0,0,1,0.008790511933943672
1705,H2A1B,Ub-specific processing proteases,0.0034822109769935233,1,0,1,0.00393248681180698
1706,H2A1B,Metalloprotease DUBs,0.007783984693315656,0,0,1,0.008790511933943672
1707,H2A1B,Metalloprotease DUBs,0.0034822109769935233,1,0,1,0.00393248681180698
1708,H2A1B,Assembly of the ORC complex at the origin of replication,0.007783984693315656,0,0,1,0.008790511933943672
1709,H2A1B,Assembly of the ORC complex at the origin of replication,0.0034822109769935233,1,0,1,0.00393248681180698
1710,H2A1B,Mitotic Prophase,0.007783984693315656,0,0,1,0.008790511933943672
1711,H2A1B,Mitotic Prophase,0.0034822109769935233,1,0,1,0.00393248681180698
1712,H2A1B,RNA Polymerase I Promoter Opening,0.007783984693315656,0,0,1,0.008790511933943672
1713,H2A1B,RNA Polymerase I Promoter Opening,0.0034822109769935233,1,0,1,0.00393248681180698
1714,H2A1B,RNA Polymerase I Promoter Escape,0.007783984693315656,0,0,1,0.008790511933943672
1715,H2A1B,RNA Polymerase I Promoter Escape,0.0034822109769935233,1,0,1,0.00393248681180698
1716,H2A1B,Depurination,0.007783984693315656,0,0,1,0.008790511933943672
1717,H2A1B,Depurination,0.0034822109769935233,1,0,1,0.00393248681180698
1718,H2A1B,Depyrimidination,0.007783984693315656,0,0,1,0.008790511933943672
1719,H2A1B,Depyrimidination,0.0034822109769935233,1,0,1,0.00393248681180698
1720,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.007783984693315656,0,0,1,0.008790511933943672
1721,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.0034822109769935233,1,0,1,0.00393248681180698
1722,H2A1B,Estrogen-dependent gene expression,0.007783984693315656,0,0,1,0.008790511933943672
1723,H2A1B,Estrogen-dependent gene expression,0.0034822109769935233,1,0,1,0.00393248681180698
1724,H2A1B,HCMV Early Events,0.007783984693315656,0,0,1,0.008790511933943672
1725,H2A1B,HCMV Early Events,0.0034822109769935233,1,0,1,0.00393248681180698
1726,H2A1B,HCMV Late Events,0.007783984693315656,0,0,1,0.008790511933943672
1727,H2A1B,HCMV Late Events,0.0034822109769935233,1,0,1,0.00393248681180698
1728,H2A1B,Transcriptional regulation of granulopoiesis,0.007783984693315656,0,0,1,0.008790511933943672
1729,H2A1B,Transcriptional regulation of granulopoiesis,0.0034822109769935233,1,0,1,0.00393248681180698
1730,H2A1B,Meiotic synapsis,0.007783984693315656,0,0,1,0.008790511933943672
1731,H2A1B,Meiotic synapsis,0.0034822109769935233,1,0,1,0.00393248681180698
1732,H2A1B,Meiotic recombination,0.007783984693315656,0,0,1,0.008790511933943672
1733,H2A1B,Meiotic recombination,0.0034822109769935233,1,0,1,0.00393248681180698
1734,H2A1B,Transcriptional regulation by small RNAs,0.007783984693315656,0,0,1,0.008790511933943672
1735,H2A1B,Transcriptional regulation by small RNAs,0.0034822109769935233,1,0,1,0.00393248681180698
1736,H2A1B,PRC2 methylates histones and DNA,0.007783984693315656,0,0,1,0.008790511933943672
1737,H2A1B,PRC2 methylates histones and DNA,0.0034822109769935233,1,0,1,0.00393248681180698
1738,H2A1B,DNA methylation,0.007783984693315656,0,0,1,0.008790511933943672
1739,H2A1B,DNA methylation,0.0034822109769935233,1,0,1,0.00393248681180698
1740,H2A1B,HDACs deacetylate histones,0.007783984693315656,0,0,1,0.008790511933943672
1741,H2A1B,HDACs deacetylate histones,0.0034822109769935233,1,0,1,0.00393248681180698
1742,H2A1B,HATs acetylate histones,0.007783984693315656,0,0,1,0.008790511933943672
1743,H2A1B,HATs acetylate histones,0.0034822109769935233,1,0,1,0.00393248681180698
1744,H2A1B,RMTs methylate histone arginines,0.007783984693315656,0,0,1,0.008790511933943672
1745,H2A1B,RMTs methylate histone arginines,0.0034822109769935233,1,0,1,0.00393248681180698
1746,H2A1B,Amyloid fiber formation,0.007783984693315656,0,0,1,0.008790511933943672
1747,H2A1B,Amyloid fiber formation,0.0034822109769935233,1,0,1,0.00393248681180698
1748,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.007783984693315656,0,0,1,0.008790511933943672
1749,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0034822109769935233,1,0,1,0.00393248681180698
1750,H2A1B,Defective pyroptosis,0.007783984693315656,0,0,1,0.008790511933943672
1751,H2A1B,Defective pyroptosis,0.0034822109769935233,1,0,1,0.00393248681180698
1752,IGF1,IGF1R signaling cascade,0.004122268832832348,0,0,1,0.004655308919229312
1753,IGF1,IGF1R signaling cascade,0.00530731090141205,1,0,1,0.005993585760269436
1754,IGF1,Platelet degranulation ,0.004122268832832348,0,0,1,0.004655308919229312
1755,IGF1,Platelet degranulation ,0.00530731090141205,1,0,1,0.005993585760269436
1756,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.004122268832832348,0,0,1,0.004655308919229312
1757,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.00530731090141205,1,0,1,0.005993585760269436
1758,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004122268832832348,0,0,1,0.004655308919229312
1759,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00530731090141205,1,0,1,0.005993585760269436
1760,ALDOB,Fructose catabolism,0.0039839459216355275,0,0,1,0.004499099824592005
1761,ALDOB,Fructose catabolism,0.005047283737264576,1,0,1,0.0056999351456233464
1762,ALDOB,Hereditary fructose intolerance,0.0039839459216355275,0,0,1,0.004499099824592005
1763,ALDOB,Hereditary fructose intolerance,0.005047283737264576,1,0,1,0.0056999351456233464
1764,ALDOB,Glycolysis,0.0039839459216355275,0,0,1,0.004499099824592005
1765,ALDOB,Glycolysis,0.005047283737264576,1,0,1,0.0056999351456233464
1766,ALDOB,Gluconeogenesis,0.0039839459216355275,0,0,1,0.004499099824592005
1767,ALDOB,Gluconeogenesis,0.005047283737264576,1,0,1,0.0056999351456233464
1768,APOD,Transport of fatty acids,0.003171964714508669,0,0,1,0.0035821233950884867
1769,APOD,Transport of fatty acids,0.0007588651704577272,1,0,1,0.0008569920933800499
1770,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.003171964714508669,0,0,1,0.0035821233950884867
1771,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0007588651704577272,1,0,1,0.0008569920933800499
1772,ALDH2,Serotonin clearance from the synaptic cleft,0.0007128173869214291,0,0,1,0.0008049899882043957
1773,ALDH2,Serotonin clearance from the synaptic cleft,9.841538381584603e-05,1,0,1,0.00011114122650571854
1774,ALDH2,Ethanol oxidation,0.0007128173869214291,0,0,1,0.0008049899882043957
1775,ALDH2,Ethanol oxidation,9.841538381584603e-05,1,0,1,0.00011114122650571854
1776,ALDH2,Smooth Muscle Contraction,0.0007128173869214291,0,0,1,0.0008049899882043957
1777,ALDH2,Smooth Muscle Contraction,9.841538381584603e-05,1,0,1,0.00011114122650571854
1778,ITB3,TGF-beta receptor signaling activates SMADs,0.015862229339267852,0,0,1,0.01791333382573637
1779,ITB3,TGF-beta receptor signaling activates SMADs,0.009908331001442172,1,0,1,0.011189552054031694
1780,ITB3,VEGFA-VEGFR2 Pathway,0.015862229339267852,0,0,1,0.01791333382573637
1781,ITB3,VEGFA-VEGFR2 Pathway,0.009908331001442172,1,0,1,0.011189552054031694
1782,ITB3,L1CAM interactions,0.015862229339267852,0,0,1,0.01791333382573637
1783,ITB3,L1CAM interactions,0.009908331001442172,1,0,1,0.011189552054031694
1784,ITB3,RAF/MAP kinase cascade,0.015862229339267852,0,0,1,0.01791333382573637
1785,ITB3,RAF/MAP kinase cascade,0.009908331001442172,1,0,1,0.011189552054031694
1786,ITB3,Signaling by RAS mutants,0.015862229339267852,0,0,1,0.01791333382573637
1787,ITB3,Signaling by RAS mutants,0.009908331001442172,1,0,1,0.011189552054031694
1788,ITB3,Signaling by moderate kinase activity BRAF mutants,0.015862229339267852,0,0,1,0.01791333382573637
1789,ITB3,Signaling by moderate kinase activity BRAF mutants,0.009908331001442172,1,0,1,0.011189552054031694
1790,ITB3,Signaling by high-kinase activity BRAF mutants,0.015862229339267852,0,0,1,0.01791333382573637
1791,ITB3,Signaling by high-kinase activity BRAF mutants,0.009908331001442172,1,0,1,0.011189552054031694
1792,ITB3,Signaling by BRAF and RAF1 fusions,0.015862229339267852,0,0,1,0.01791333382573637
1793,ITB3,Signaling by BRAF and RAF1 fusions,0.009908331001442172,1,0,1,0.011189552054031694
1794,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.015862229339267852,0,0,1,0.01791333382573637
1795,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.009908331001442172,1,0,1,0.011189552054031694
1796,ITB3,Signaling by RAF1 mutants,0.015862229339267852,0,0,1,0.01791333382573637
1797,ITB3,Signaling by RAF1 mutants,0.009908331001442172,1,0,1,0.011189552054031694
1798,ITB3,Platelet degranulation ,0.015862229339267852,0,0,1,0.01791333382573637
1799,ITB3,Platelet degranulation ,0.009908331001442172,1,0,1,0.011189552054031694
1800,ITB3,Integrin cell surface interactions,0.015862229339267852,0,0,1,0.01791333382573637
1801,ITB3,Integrin cell surface interactions,0.009908331001442172,1,0,1,0.011189552054031694
1802,ITB3,ECM proteoglycans,0.015862229339267852,0,0,1,0.01791333382573637
1803,ITB3,ECM proteoglycans,0.009908331001442172,1,0,1,0.011189552054031694
1804,ITB3,Molecules associated with elastic fibres,0.015862229339267852,0,0,1,0.01791333382573637
1805,ITB3,Molecules associated with elastic fibres,0.009908331001442172,1,0,1,0.011189552054031694
1806,ITB3,PECAM1 interactions,0.015862229339267852,0,0,1,0.01791333382573637
1807,ITB3,PECAM1 interactions,0.009908331001442172,1,0,1,0.011189552054031694
1808,ITB3,Syndecan interactions,0.015862229339267852,0,0,1,0.01791333382573637
1809,ITB3,Syndecan interactions,0.009908331001442172,1,0,1,0.011189552054031694
1810,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.015862229339267852,0,0,1,0.01791333382573637
1811,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.009908331001442172,1,0,1,0.011189552054031694
1812,ITB3,p130Cas linkage to MAPK signaling for integrins,0.015862229339267852,0,0,1,0.01791333382573637
1813,ITB3,p130Cas linkage to MAPK signaling for integrins,0.009908331001442172,1,0,1,0.011189552054031694
1814,S10A8,Antigen processing-Cross presentation,0.004265848355644635,0,0,1,0.0048174543445453685
1815,S10A8,Antigen processing-Cross presentation,0.0045674964615311075,1,0,1,0.005158107798928903
1816,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.004265848355644635,0,0,1,0.0048174543445453685
1817,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.0045674964615311075,1,0,1,0.005158107798928903
1818,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.004265848355644635,0,0,1,0.0048174543445453685
1819,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.0045674964615311075,1,0,1,0.005158107798928903
1820,S10A8,Regulation of TLR by endogenous ligand,0.004265848355644635,0,0,1,0.0048174543445453685
1821,S10A8,Regulation of TLR by endogenous ligand,0.0045674964615311075,1,0,1,0.005158107798928903
1822,S10A8,RHO GTPase Effectors,0.004265848355644635,0,0,1,0.0048174543445453685
1823,S10A8,RHO GTPase Effectors,0.0045674964615311075,1,0,1,0.005158107798928903
1824,S10A8,MyD88 deficiency (TLR2/4),0.004265848355644635,0,0,1,0.0048174543445453685
1825,S10A8,MyD88 deficiency (TLR2/4),0.0045674964615311075,1,0,1,0.005158107798928903
1826,S10A8,IRAK4 deficiency (TLR2/4),0.004265848355644635,0,0,1,0.0048174543445453685
1827,S10A8,IRAK4 deficiency (TLR2/4),0.0045674964615311075,1,0,1,0.005158107798928903
1828,S10A8,Metal sequestration by antimicrobial proteins,0.004265848355644635,0,0,1,0.0048174543445453685
1829,S10A8,Metal sequestration by antimicrobial proteins,0.0045674964615311075,1,0,1,0.005158107798928903
1830,S10A8,Neutrophil degranulation,0.004265848355644635,0,0,1,0.0048174543445453685
1831,S10A8,Neutrophil degranulation,0.0045674964615311075,1,0,1,0.005158107798928903
1832,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.000906269268478967,0,0,1,0.001023456639986959
1833,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.005038656009512429,1,0,1,0.005690191788364025
1834,PAI1,Platelet degranulation ,0.000906269268478967,0,0,1,0.001023456639986959
1835,PAI1,Platelet degranulation ,0.005038656009512429,1,0,1,0.005690191788364025
1836,PAI1,Dissolution of Fibrin Clot,0.000906269268478967,0,0,1,0.001023456639986959
1837,PAI1,Dissolution of Fibrin Clot,0.005038656009512429,1,0,1,0.005690191788364025
1838,PAI1,ECM proteoglycans,0.000906269268478967,0,0,1,0.001023456639986959
1839,PAI1,ECM proteoglycans,0.005038656009512429,1,0,1,0.005690191788364025
1840,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.000906269268478967,0,0,1,0.001023456639986959
1841,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.005038656009512429,1,0,1,0.005690191788364025
1842,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.0002990142385659582,0,0,1,0.0003376790083863215
1843,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.00015765403840152875,1,0,1,0.00017803988067873928
1844,IPSP,Common Pathway of Fibrin Clot Formation,0.0002990142385659582,0,0,1,0.0003376790083863215
1845,IPSP,Common Pathway of Fibrin Clot Formation,0.00015765403840152875,1,0,1,0.00017803988067873928
1846,IC1,Regulation of Complement cascade,0.003540905224148963,0,0,1,0.003998770662611157
1847,IC1,Regulation of Complement cascade,0.004647524558298165,1,0,1,0.005248484125116405
1848,IC1,Platelet degranulation ,0.003540905224148963,0,0,1,0.003998770662611157
1849,IC1,Platelet degranulation ,0.004647524558298165,1,0,1,0.005248484125116405
1850,IC1,Defective SERPING1 causes hereditary angioedema,0.003540905224148963,0,0,1,0.003998770662611157
1851,IC1,Defective SERPING1 causes hereditary angioedema,0.004647524558298165,1,0,1,0.005248484125116405
1852,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.003540905224148963,0,0,1,0.003998770662611157
1853,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.004647524558298165,1,0,1,0.005248484125116405
1854,CFAI,Regulation of Complement cascade,0.00030233113922247874,0,0,1,0.00034142480902103853
1855,CFAI,Regulation of Complement cascade,0.00023946342800049218,1,0,1,0.0002704278341386026
1856,F13B,Common Pathway of Fibrin Clot Formation,0.0001171645521080179,0,0,1,0.00013231480200945594
1857,F13B,Common Pathway of Fibrin Clot Formation,7.210008073465832e-05,1,0,1,8.142315858875938e-05
1858,PERM,Events associated with phagocytolytic activity of PMN cells,0.005445336988597616,0,0,1,0.006149459649338385
1859,PERM,Events associated with phagocytolytic activity of PMN cells,0.004949976389324718,1,0,1,0.005590045232291391
1860,PERM,Neutrophil degranulation,0.005445336988597616,0,0,1,0.006149459649338385
1861,PERM,Neutrophil degranulation,0.004949976389324718,1,0,1,0.005590045232291391
1862,ICAM1,Interleukin-10 signaling,0.005732642474983462,0,0,1,0.006473915876613734
1863,ICAM1,Interleukin-10 signaling,0.0033479578491936862,1,0,1,0.003780873753894988
1864,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.005732642474983462,0,0,1,0.006473915876613734
1865,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.0033479578491936862,1,0,1,0.003780873753894988
1866,ICAM1,Interferon gamma signaling,0.005732642474983462,0,0,1,0.006473915876613734
1867,ICAM1,Interferon gamma signaling,0.0033479578491936862,1,0,1,0.003780873753894988
1868,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005732642474983462,0,0,1,0.006473915876613734
1869,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0033479578491936862,1,0,1,0.003780873753894988
1870,ICAM1,Integrin cell surface interactions,0.005732642474983462,0,0,1,0.006473915876613734
1871,ICAM1,Integrin cell surface interactions,0.0033479578491936862,1,0,1,0.003780873753894988
1872,TETN,Platelet degranulation ,4.864337840911221e-05,0,0,1,5.4933329812407274e-05
1873,TETN,Platelet degranulation ,6.654489940961026e-05,1,0,1,7.51496509115166e-05
1874,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.0014020841600289123,0,0,1,0.0015833840926885976
1875,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.0006482393008611076,1,0,1,0.0007320614742683423
1876,HEP2,Common Pathway of Fibrin Clot Formation,0.0014020841600289123,0,0,1,0.0015833840926885976
1877,HEP2,Common Pathway of Fibrin Clot Formation,0.0006482393008611076,1,0,1,0.0007320614742683423
1878,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0014020841600289123,0,0,1,0.0015833840926885976
1879,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006482393008611076,1,0,1,0.0007320614742683423
1880,HEP2,Post-translational protein phosphorylation,0.0014020841600289123,0,0,1,0.0015833840926885976
1881,HEP2,Post-translational protein phosphorylation,0.0006482393008611076,1,0,1,0.0007320614742683423
1882,K2C8,Formation of the cornified envelope,1.0542210268075107e-05,0,0,1,1.190539663461023e-05
1883,K2C8,Formation of the cornified envelope,2.341191876430319e-05,1,0,1,2.643925436683554e-05
1884,CHLE,Glycerophospholipid biosynthesis,0.0008324006777639176,0,0,1,0.000940036289895334
1885,CHLE,Glycerophospholipid biosynthesis,0.0013391449469986928,1,0,1,0.0015123063702811685
1886,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",0.0008324006777639176,0,0,1,0.000940036289895334
1887,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",0.0013391449469986928,1,0,1,0.0015123063702811685
1888,CHLE,Aspirin ADME,0.0008324006777639176,0,0,1,0.000940036289895334
1889,CHLE,Aspirin ADME,0.0013391449469986928,1,0,1,0.0015123063702811685
1890,KV230,Initial triggering of complement,0.0004664044250224612,0,0,1,0.0005267139936342397
1891,KV230,Initial triggering of complement,0.0008794397164016801,1,0,1,0.0009931578268456277
1892,KV230,Regulation of Complement cascade,0.0004664044250224612,0,0,1,0.0005267139936342397
1893,KV230,Regulation of Complement cascade,0.0008794397164016801,1,0,1,0.0009931578268456277
1894,KV230,FCGR activation,0.0004664044250224612,0,0,1,0.0005267139936342397
1895,KV230,FCGR activation,0.0008794397164016801,1,0,1,0.0009931578268456277
1896,KV230,Regulation of actin dynamics for phagocytic cup formation,0.0004664044250224612,0,0,1,0.0005267139936342397
1897,KV230,Regulation of actin dynamics for phagocytic cup formation,0.0008794397164016801,1,0,1,0.0009931578268456277
1898,KV230,Role of phospholipids in phagocytosis,0.0004664044250224612,0,0,1,0.0005267139936342397
1899,KV230,Role of phospholipids in phagocytosis,0.0008794397164016801,1,0,1,0.0009931578268456277
1900,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.0004664044250224612,0,0,1,0.0005267139936342397
1901,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.0008794397164016801,1,0,1,0.0009931578268456277
1902,KV230,FCERI mediated MAPK activation,0.0004664044250224612,0,0,1,0.0005267139936342397
1903,KV230,FCERI mediated MAPK activation,0.0008794397164016801,1,0,1,0.0009931578268456277
1904,KV230,FCERI mediated Ca+2 mobilization,0.0004664044250224612,0,0,1,0.0005267139936342397
1905,KV230,FCERI mediated Ca+2 mobilization,0.0008794397164016801,1,0,1,0.0009931578268456277
1906,KV230,FCERI mediated NF-kB activation,0.0004664044250224612,0,0,1,0.0005267139936342397
1907,KV230,FCERI mediated NF-kB activation,0.0008794397164016801,1,0,1,0.0009931578268456277
1908,KV230,Parasite infection,0.0004664044250224612,0,0,1,0.0005267139936342397
1909,KV230,Parasite infection,0.0008794397164016801,1,0,1,0.0009931578268456277
1910,KV230,Leishmania parasite growth and survival,0.0004664044250224612,0,0,1,0.0005267139936342397
1911,KV230,Leishmania parasite growth and survival,0.0008794397164016801,1,0,1,0.0009931578268456277
1912,KV230,Potential therapeutics for SARS,0.0004664044250224612,0,0,1,0.0005267139936342397
1913,KV230,Potential therapeutics for SARS,0.0008794397164016801,1,0,1,0.0009931578268456277
1914,KV230,CD22 mediated BCR regulation,0.0004664044250224612,0,0,1,0.0005267139936342397
1915,KV230,CD22 mediated BCR regulation,0.0008794397164016801,1,0,1,0.0009931578268456277
1916,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0004664044250224612,0,0,1,0.0005267139936342397
1917,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0008794397164016801,1,0,1,0.0009931578268456277
1918,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004664044250224612,0,0,1,0.0005267139936342397
1919,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008794397164016801,1,0,1,0.0009931578268456277
1920,KV230,Scavenging of heme from plasma,0.0004664044250224612,0,0,1,0.0005267139936342397
1921,KV230,Scavenging of heme from plasma,0.0008794397164016801,1,0,1,0.0009931578268456277
1922,KV401,Initial triggering of complement,0.005784109184819984,0,0,1,0.006532037615651488
1923,KV401,Initial triggering of complement,0.003846181152879913,1,0,1,0.004343521044373802
1924,KV401,Regulation of Complement cascade,0.005784109184819984,0,0,1,0.006532037615651488
1925,KV401,Regulation of Complement cascade,0.003846181152879913,1,0,1,0.004343521044373802
1926,KV401,FCGR activation,0.005784109184819984,0,0,1,0.006532037615651488
1927,KV401,FCGR activation,0.003846181152879913,1,0,1,0.004343521044373802
1928,KV401,Regulation of actin dynamics for phagocytic cup formation,0.005784109184819984,0,0,1,0.006532037615651488
1929,KV401,Regulation of actin dynamics for phagocytic cup formation,0.003846181152879913,1,0,1,0.004343521044373802
1930,KV401,Role of phospholipids in phagocytosis,0.005784109184819984,0,0,1,0.006532037615651488
1931,KV401,Role of phospholipids in phagocytosis,0.003846181152879913,1,0,1,0.004343521044373802
1932,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.005784109184819984,0,0,1,0.006532037615651488
1933,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.003846181152879913,1,0,1,0.004343521044373802
1934,KV401,FCERI mediated MAPK activation,0.005784109184819984,0,0,1,0.006532037615651488
1935,KV401,FCERI mediated MAPK activation,0.003846181152879913,1,0,1,0.004343521044373802
1936,KV401,FCERI mediated Ca+2 mobilization,0.005784109184819984,0,0,1,0.006532037615651488
1937,KV401,FCERI mediated Ca+2 mobilization,0.003846181152879913,1,0,1,0.004343521044373802
1938,KV401,FCERI mediated NF-kB activation,0.005784109184819984,0,0,1,0.006532037615651488
1939,KV401,FCERI mediated NF-kB activation,0.003846181152879913,1,0,1,0.004343521044373802
1940,KV401,Parasite infection,0.005784109184819984,0,0,1,0.006532037615651488
1941,KV401,Parasite infection,0.003846181152879913,1,0,1,0.004343521044373802
1942,KV401,Leishmania parasite growth and survival,0.005784109184819984,0,0,1,0.006532037615651488
1943,KV401,Leishmania parasite growth and survival,0.003846181152879913,1,0,1,0.004343521044373802
1944,KV401,Potential therapeutics for SARS,0.005784109184819984,0,0,1,0.006532037615651488
1945,KV401,Potential therapeutics for SARS,0.003846181152879913,1,0,1,0.004343521044373802
1946,KV401,CD22 mediated BCR regulation,0.005784109184819984,0,0,1,0.006532037615651488
1947,KV401,CD22 mediated BCR regulation,0.003846181152879913,1,0,1,0.004343521044373802
1948,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005784109184819984,0,0,1,0.006532037615651488
1949,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003846181152879913,1,0,1,0.004343521044373802
1950,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005784109184819984,0,0,1,0.006532037615651488
1951,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003846181152879913,1,0,1,0.004343521044373802
1952,KV401,Scavenging of heme from plasma,0.005784109184819984,0,0,1,0.006532037615651488
1953,KV401,Scavenging of heme from plasma,0.003846181152879913,1,0,1,0.004343521044373802
1954,HV434,Initial triggering of complement,0.0026596851526606807,0,0,1,0.0030036022674959292
1955,HV434,Initial triggering of complement,0.0016962106567496513,1,0,1,0.001915543337777166
1956,HV434,Regulation of Complement cascade,0.0026596851526606807,0,0,1,0.0030036022674959292
1957,HV434,Regulation of Complement cascade,0.0016962106567496513,1,0,1,0.001915543337777166
1958,HV434,FCGR activation,0.0026596851526606807,0,0,1,0.0030036022674959292
1959,HV434,FCGR activation,0.0016962106567496513,1,0,1,0.001915543337777166
1960,HV434,Regulation of actin dynamics for phagocytic cup formation,0.0026596851526606807,0,0,1,0.0030036022674959292
1961,HV434,Regulation of actin dynamics for phagocytic cup formation,0.0016962106567496513,1,0,1,0.001915543337777166
1962,HV434,Role of phospholipids in phagocytosis,0.0026596851526606807,0,0,1,0.0030036022674959292
1963,HV434,Role of phospholipids in phagocytosis,0.0016962106567496513,1,0,1,0.001915543337777166
1964,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.0026596851526606807,0,0,1,0.0030036022674959292
1965,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.0016962106567496513,1,0,1,0.001915543337777166
1966,HV434,FCERI mediated MAPK activation,0.0026596851526606807,0,0,1,0.0030036022674959292
1967,HV434,FCERI mediated MAPK activation,0.0016962106567496513,1,0,1,0.001915543337777166
1968,HV434,FCERI mediated Ca+2 mobilization,0.0026596851526606807,0,0,1,0.0030036022674959292
1969,HV434,FCERI mediated Ca+2 mobilization,0.0016962106567496513,1,0,1,0.001915543337777166
1970,HV434,FCERI mediated NF-kB activation,0.0026596851526606807,0,0,1,0.0030036022674959292
1971,HV434,FCERI mediated NF-kB activation,0.0016962106567496513,1,0,1,0.001915543337777166
1972,HV434,Parasite infection,0.0026596851526606807,0,0,1,0.0030036022674959292
1973,HV434,Parasite infection,0.0016962106567496513,1,0,1,0.001915543337777166
1974,HV434,Leishmania parasite growth and survival,0.0026596851526606807,0,0,1,0.0030036022674959292
1975,HV434,Leishmania parasite growth and survival,0.0016962106567496513,1,0,1,0.001915543337777166
1976,HV434,Potential therapeutics for SARS,0.0026596851526606807,0,0,1,0.0030036022674959292
1977,HV434,Potential therapeutics for SARS,0.0016962106567496513,1,0,1,0.001915543337777166
1978,HV434,CD22 mediated BCR regulation,0.0026596851526606807,0,0,1,0.0030036022674959292
1979,HV434,CD22 mediated BCR regulation,0.0016962106567496513,1,0,1,0.001915543337777166
1980,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0026596851526606807,0,0,1,0.0030036022674959292
1981,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0016962106567496513,1,0,1,0.001915543337777166
1982,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0026596851526606807,0,0,1,0.0030036022674959292
1983,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0016962106567496513,1,0,1,0.001915543337777166
1984,HV434,Scavenging of heme from plasma,0.0026596851526606807,0,0,1,0.0030036022674959292
1985,HV434,Scavenging of heme from plasma,0.0016962106567496513,1,0,1,0.001915543337777166
1986,GELS,Apoptotic cleavage of cellular proteins,0.0005137630272688996,0,0,1,0.0005801964161497546
1987,GELS,Apoptotic cleavage of cellular proteins,0.000979850480966496,1,0,1,0.0011065524517042034
1988,GELS,Neutrophil degranulation,0.0005137630272688996,0,0,1,0.0005801964161497546
1989,GELS,Neutrophil degranulation,0.000979850480966496,1,0,1,0.0011065524517042034
1990,GELS,Amyloid fiber formation,0.0005137630272688996,0,0,1,0.0005801964161497546
1991,GELS,Amyloid fiber formation,0.000979850480966496,1,0,1,0.0011065524517042034
1992,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.0005137630272688996,0,0,1,0.0005801964161497546
1993,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.000979850480966496,1,0,1,0.0011065524517042034
1994,CO2,Initial triggering of complement,0.0011119097337536844,0,0,1,0.0012556879502118427
1995,CO2,Initial triggering of complement,0.0004872149095943979,1,0,1,0.000550215428977227
1996,CO2,Activation of C3 and C5,0.0011119097337536844,0,0,1,0.0012556879502118427
1997,CO2,Activation of C3 and C5,0.0004872149095943979,1,0,1,0.000550215428977227
1998,CO2,Regulation of Complement cascade,0.0011119097337536844,0,0,1,0.0012556879502118427
1999,CO2,Regulation of Complement cascade,0.0004872149095943979,1,0,1,0.000550215428977227
2000,S10A9,Antigen processing-Cross presentation,0.00082517044652631,0,0,1,0.0009318711358664546
2001,S10A9,Antigen processing-Cross presentation,0.0007216088186997847,1,0,1,0.0008149182176407215
2002,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.00082517044652631,0,0,1,0.0009318711358664546
2003,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.0007216088186997847,1,0,1,0.0008149182176407215
2004,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.00082517044652631,0,0,1,0.0009318711358664546
2005,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.0007216088186997847,1,0,1,0.0008149182176407215
2006,S10A9,Regulation of TLR by endogenous ligand,0.00082517044652631,0,0,1,0.0009318711358664546
2007,S10A9,Regulation of TLR by endogenous ligand,0.0007216088186997847,1,0,1,0.0008149182176407215
2008,S10A9,RHO GTPase Effectors,0.00082517044652631,0,0,1,0.0009318711358664546
2009,S10A9,RHO GTPase Effectors,0.0007216088186997847,1,0,1,0.0008149182176407215
2010,S10A9,MyD88 deficiency (TLR2/4),0.00082517044652631,0,0,1,0.0009318711358664546
2011,S10A9,MyD88 deficiency (TLR2/4),0.0007216088186997847,1,0,1,0.0008149182176407215
2012,S10A9,IRAK4 deficiency (TLR2/4),0.00082517044652631,0,0,1,0.0009318711358664546
2013,S10A9,IRAK4 deficiency (TLR2/4),0.0007216088186997847,1,0,1,0.0008149182176407215
2014,S10A9,Metal sequestration by antimicrobial proteins,0.00082517044652631,0,0,1,0.0009318711358664546
2015,S10A9,Metal sequestration by antimicrobial proteins,0.0007216088186997847,1,0,1,0.0008149182176407215
2016,S10A9,Neutrophil degranulation,0.00082517044652631,0,0,1,0.0009318711358664546
2017,S10A9,Neutrophil degranulation,0.0007216088186997847,1,0,1,0.0008149182176407215
2018,APOA4,Chylomicron assembly,0.012319721768463627,0,0,1,0.013912753621103955
2019,APOA4,Chylomicron assembly,0.01135756298446196,1,0,1,0.012826180534651408
2020,APOA4,Assembly of active LPL and LIPC lipase complexes,0.012319721768463627,0,0,1,0.013912753621103955
2021,APOA4,Assembly of active LPL and LIPC lipase complexes,0.01135756298446196,1,0,1,0.012826180534651408
2022,APOA4,Chylomicron remodeling,0.012319721768463627,0,0,1,0.013912753621103955
2023,APOA4,Chylomicron remodeling,0.01135756298446196,1,0,1,0.012826180534651408
2024,APOA4,Retinoid metabolism and transport,0.012319721768463627,0,0,1,0.013912753621103955
2025,APOA4,Retinoid metabolism and transport,0.01135756298446196,1,0,1,0.012826180534651408
2026,APOA4,Amyloid fiber formation,0.012319721768463627,0,0,1,0.013912753621103955
2027,APOA4,Amyloid fiber formation,0.01135756298446196,1,0,1,0.012826180534651408
2028,ENOA,Glycolysis,0.00021457153781028206,0,0,1,0.00024231723700917114
2029,ENOA,Glycolysis,0.0006250011190112567,1,0,1,0.0007058184222939871
2030,ENOA,Gluconeogenesis,0.00021457153781028206,0,0,1,0.00024231723700917114
2031,ENOA,Gluconeogenesis,0.0006250011190112567,1,0,1,0.0007058184222939871
2032,ENOA,Response of Mtb to phagocytosis,0.00021457153781028206,0,0,1,0.00024231723700917114
2033,ENOA,Response of Mtb to phagocytosis,0.0006250011190112567,1,0,1,0.0007058184222939871
2034,PYGL,Glycogen breakdown (glycogenolysis),0.000570158648142428,0,0,1,0.0006438844111604111
2035,PYGL,Glycogen breakdown (glycogenolysis),0.00016961478309100952,1,0,1,0.00019154723880882683
2036,PYGL,Neutrophil degranulation,0.000570158648142428,0,0,1,0.0006438844111604111
2037,PYGL,Neutrophil degranulation,0.00016961478309100952,1,0,1,0.00019154723880882683
2038,G6PI,Transcriptional Regulation by TP53,0.00043876172785900134,0,0,1,0.000495496889686123
2039,G6PI,Transcriptional Regulation by TP53,0.00012079473764905682,1,0,1,0.000136414397599403
2040,G6PI,Glycolysis,0.00043876172785900134,0,0,1,0.000495496889686123
2041,G6PI,Glycolysis,0.00012079473764905682,1,0,1,0.000136414397599403
2042,G6PI,Gluconeogenesis,0.00043876172785900134,0,0,1,0.000495496889686123
2043,G6PI,Gluconeogenesis,0.00012079473764905682,1,0,1,0.000136414397599403
2044,G6PI,Neutrophil degranulation,0.00043876172785900134,0,0,1,0.000495496889686123
2045,G6PI,Neutrophil degranulation,0.00012079473764905682,1,0,1,0.000136414397599403
2046,TPM3,RHO GTPase cycle,0.0016135413019130772,0,0,1,0.0018221842191645137
2047,TPM3,RHO GTPase cycle,0.0037018243125332565,1,0,1,0.00418049778857226
2048,TPM3,Signaling by ALK fusions and activated point mutants,0.0016135413019130772,0,0,1,0.0018221842191645137
2049,TPM3,Signaling by ALK fusions and activated point mutants,0.0037018243125332565,1,0,1,0.00418049778857226
2050,TPM3,Striated Muscle Contraction,0.0016135413019130772,0,0,1,0.0018221842191645137
2051,TPM3,Striated Muscle Contraction,0.0037018243125332565,1,0,1,0.00418049778857226
2052,TPM3,Smooth Muscle Contraction,0.0016135413019130772,0,0,1,0.0018221842191645137
2053,TPM3,Smooth Muscle Contraction,0.0037018243125332565,1,0,1,0.00418049778857226
2054,FABPL,PPARA activates gene expression,0.005367243088673101,0,0,1,0.006061267626062162
2055,FABPL,PPARA activates gene expression,0.004015237530858876,1,0,1,0.004534437672127389
2056,FABPL,Triglyceride catabolism,0.005367243088673101,0,0,1,0.006061267626062162
2057,FABPL,Triglyceride catabolism,0.004015237530858876,1,0,1,0.004534437672127389
2058,FABPL,Cytoprotection by HMOX1,0.005367243088673101,0,0,1,0.006061267626062162
2059,FABPL,Cytoprotection by HMOX1,0.004015237530858876,1,0,1,0.004534437672127389
2060,FABPL,Heme degradation,0.005367243088673101,0,0,1,0.006061267626062162
2061,FABPL,Heme degradation,0.004015237530858876,1,0,1,0.004534437672127389
2062,LDHB,Pyruvate metabolism,0.0003673472034685529,0,0,1,0.0004148479349868371
2063,LDHB,Pyruvate metabolism,0.0016489719101803434,1,0,1,0.0018621962691712074
2064,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.003234442823899196,0,0,1,0.003652680389718665
2065,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.002531445534758153,1,0,1,0.002858780311134095
2066,PROS,Regulation of Complement cascade,0.003234442823899196,0,0,1,0.003652680389718665
2067,PROS,Regulation of Complement cascade,0.002531445534758153,1,0,1,0.002858780311134095
2068,PROS,Platelet degranulation ,0.003234442823899196,0,0,1,0.003652680389718665
2069,PROS,Platelet degranulation ,0.002531445534758153,1,0,1,0.002858780311134095
2070,PROS,Intrinsic Pathway of Fibrin Clot Formation,0.003234442823899196,0,0,1,0.003652680389718665
2071,PROS,Intrinsic Pathway of Fibrin Clot Formation,0.002531445534758153,1,0,1,0.002858780311134095
2072,PROS,Common Pathway of Fibrin Clot Formation,0.003234442823899196,0,0,1,0.003652680389718665
2073,PROS,Common Pathway of Fibrin Clot Formation,0.002531445534758153,1,0,1,0.002858780311134095
2074,PDIA1,Interleukin-12 family signaling,0.003577308676697238,0,0,1,0.004039881352915721
2075,PDIA1,Interleukin-12 family signaling,0.003825015869454911,1,0,1,0.00431961893204147
2076,PDIA1,VLDL assembly,0.003577308676697238,0,0,1,0.004039881352915721
2077,PDIA1,VLDL assembly,0.003825015869454911,1,0,1,0.00431961893204147
2078,PDIA1,Chylomicron assembly,0.003577308676697238,0,0,1,0.004039881352915721
2079,PDIA1,Chylomicron assembly,0.003825015869454911,1,0,1,0.00431961893204147
2080,PDIA1,LDL remodeling,0.003577308676697238,0,0,1,0.004039881352915721
2081,PDIA1,LDL remodeling,0.003825015869454911,1,0,1,0.00431961893204147
2082,PDIA1,Detoxification of Reactive Oxygen Species,0.003577308676697238,0,0,1,0.004039881352915721
2083,PDIA1,Detoxification of Reactive Oxygen Species,0.003825015869454911,1,0,1,0.00431961893204147
2084,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003577308676697238,0,0,1,0.004039881352915721
2085,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003825015869454911,1,0,1,0.00431961893204147
2086,PDIA1,Hedgehog ligand biogenesis,0.003577308676697238,0,0,1,0.004039881352915721
2087,PDIA1,Hedgehog ligand biogenesis,0.003825015869454911,1,0,1,0.00431961893204147
2088,PDIA1,Post-translational protein phosphorylation,0.003577308676697238,0,0,1,0.004039881352915721
2089,PDIA1,Post-translational protein phosphorylation,0.003825015869454911,1,0,1,0.00431961893204147
2090,ADH1A,Ethanol oxidation,0.003330653143909566,0,0,1,0.0037613314212328916
2091,ADH1A,Ethanol oxidation,0.0012867033886687764,1,0,1,0.001453083727573559
2092,ADH1A,RA biosynthesis pathway,0.003330653143909566,0,0,1,0.0037613314212328916
2093,ADH1A,RA biosynthesis pathway,0.0012867033886687764,1,0,1,0.001453083727573559
2094,ADH1A,Abacavir metabolism,0.003330653143909566,0,0,1,0.0037613314212328916
2095,ADH1A,Abacavir metabolism,0.0012867033886687764,1,0,1,0.001453083727573559
2096,CSF1R,Transcriptional Regulation by VENTX,0.0019328872404926396,0,0,1,0.002182823967923363
2097,CSF1R,Transcriptional Regulation by VENTX,0.0025461315446850008,1,0,1,0.0028753653316101542
2098,CSF1R,Other interleukin signaling,0.0019328872404926396,0,0,1,0.002182823967923363
2099,CSF1R,Other interleukin signaling,0.0025461315446850008,1,0,1,0.0028753653316101542
2100,CATD,Estrogen-dependent gene expression,0.0015531673547377464,0,0,1,0.00175400347060783
2101,CATD,Estrogen-dependent gene expression,0.0007960339339545587,1,0,1,0.0008989670550432457
2102,CATD,MHC class II antigen presentation,0.0015531673547377464,0,0,1,0.00175400347060783
2103,CATD,MHC class II antigen presentation,0.0007960339339545587,1,0,1,0.0008989670550432457
2104,CATD,Collagen degradation,0.0015531673547377464,0,0,1,0.00175400347060783
2105,CATD,Collagen degradation,0.0007960339339545587,1,0,1,0.0008989670550432457
2106,CATD,Neutrophil degranulation,0.0015531673547377464,0,0,1,0.00175400347060783
2107,CATD,Neutrophil degranulation,0.0007960339339545587,1,0,1,0.0008989670550432457
2108,CATD,Metabolism of Angiotensinogen to Angiotensins,0.0015531673547377464,0,0,1,0.00175400347060783
2109,CATD,Metabolism of Angiotensinogen to Angiotensins,0.0007960339339545587,1,0,1,0.0008989670550432457
2110,CO8A,Terminal pathway of complement,0.0008557949587540242,0,0,1,0.000966455625792302
2111,CO8A,Terminal pathway of complement,0.0008007486083876899,1,0,1,0.0009042913720225287
2112,CO8A,Regulation of Complement cascade,0.0008557949587540242,0,0,1,0.000966455625792302
2113,CO8A,Regulation of Complement cascade,0.0008007486083876899,1,0,1,0.0009042913720225287
2114,CO8B,Terminal pathway of complement,0.0006313149200567413,0,0,1,0.0007129486448760714
2115,CO8B,Terminal pathway of complement,0.000995088771994376,1,0,1,0.0011237611673442166
2116,CO8B,Regulation of Complement cascade,0.0006313149200567413,0,0,1,0.0007129486448760714
2117,CO8B,Regulation of Complement cascade,0.000995088771994376,1,0,1,0.0011237611673442166
2118,GP1BA,Transcriptional regulation by RUNX1,0.00025214988078099904,0,0,1,0.00028475473982512387
2119,GP1BA,Transcriptional regulation by RUNX1,0.00036014224322191226,1,0,1,0.0004067113196764201
2120,GP1BA,Defective factor IX causes hemophilia B,0.00025214988078099904,0,0,1,0.00028475473982512387
2121,GP1BA,Defective factor IX causes hemophilia B,0.00036014224322191226,1,0,1,0.0004067113196764201
2122,GP1BA,Platelet Adhesion to exposed collagen,0.00025214988078099904,0,0,1,0.00028475473982512387
2123,GP1BA,Platelet Adhesion to exposed collagen,0.00036014224322191226,1,0,1,0.0004067113196764201
2124,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.00025214988078099904,0,0,1,0.00028475473982512387
2125,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.00036014224322191226,1,0,1,0.0004067113196764201
2126,GP1BA,GP1b-IX-V activation signalling,0.00025214988078099904,0,0,1,0.00028475473982512387
2127,GP1BA,GP1b-IX-V activation signalling,0.00036014224322191226,1,0,1,0.0004067113196764201
2128,CO8G,Terminal pathway of complement,0.00040447834900876996,0,0,1,0.0004567804144112338
2129,CO8G,Terminal pathway of complement,0.0007224751954321259,1,0,1,0.0008158966233422996
2130,CO8G,Regulation of Complement cascade,0.00040447834900876996,0,0,1,0.0004567804144112338
2131,CO8G,Regulation of Complement cascade,0.0007224751954321259,1,0,1,0.0008158966233422996
2132,TBB5,G2/M Transition,0.0009490908256514462,0,0,1,0.0010718153436825065
2133,TBB5,G2/M Transition,0.0008460130567779424,1,0,1,0.0009554088509789787
2134,TBB5,Mitotic Prometaphase,0.0009490908256514462,0,0,1,0.0010718153436825065
2135,TBB5,Mitotic Prometaphase,0.0008460130567779424,1,0,1,0.0009554088509789787
2136,TBB5,Potential therapeutics for SARS,0.0009490908256514462,0,0,1,0.0010718153436825065
2137,TBB5,Potential therapeutics for SARS,0.0008460130567779424,1,0,1,0.0009554088509789787
2138,TBB5,Neutrophil degranulation,0.0009490908256514462,0,0,1,0.0010718153436825065
2139,TBB5,Neutrophil degranulation,0.0008460130567779424,1,0,1,0.0009554088509789787
2140,TBB5,Anchoring of the basal body to the plasma membrane,0.0009490908256514462,0,0,1,0.0010718153436825065
2141,TBB5,Anchoring of the basal body to the plasma membrane,0.0008460130567779424,1,0,1,0.0009554088509789787
2142,CAH3,Reversible hydration of carbon dioxide,0.0010050686895031822,0,0,1,0.0011350315625746016
2143,CAH3,Reversible hydration of carbon dioxide,0.0016417287495152713,1,0,1,0.00185401651384352
2144,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0006095116633277109,0,0,1,0.0006883260645362148
2145,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.00038367074880752257,1,0,1,0.0004332822364095654
2146,TRY1,Activation of Matrix Metalloproteinases,0.0006095116633277109,0,0,1,0.0006883260645362148
2147,TRY1,Activation of Matrix Metalloproteinases,0.00038367074880752257,1,0,1,0.0004332822364095654
2148,TRY2,Defensins,0.005137059415057112,0,0,1,0.005801319487718836
2149,TRY2,Defensins,0.0033502587026249865,1,0,1,0.0037834721248249134
2150,TRY2,Collagen degradation,0.005137059415057112,0,0,1,0.005801319487718836
2151,TRY2,Collagen degradation,0.0033502587026249865,1,0,1,0.0037834721248249134
2152,TRY2,Activation of Matrix Metalloproteinases,0.005137059415057112,0,0,1,0.005801319487718836
2153,TRY2,Activation of Matrix Metalloproteinases,0.0033502587026249865,1,0,1,0.0037834721248249134
2154,TRY2,Neutrophil degranulation,0.005137059415057112,0,0,1,0.005801319487718836
2155,TRY2,Neutrophil degranulation,0.0033502587026249865,1,0,1,0.0037834721248249134
2156,SAP,Class A/1 (Rhodopsin-like receptors),0.0008995032798071028,0,0,1,0.001015815758547916
2157,SAP,Class A/1 (Rhodopsin-like receptors),0.0022422003956880363,1,0,1,0.0025321336196247354
2158,SAP,G alpha (i) signalling events,0.0008995032798071028,0,0,1,0.001015815758547916
2159,SAP,G alpha (i) signalling events,0.0022422003956880363,1,0,1,0.0025321336196247354
2160,SAP,Glycosphingolipid metabolism,0.0008995032798071028,0,0,1,0.001015815758547916
2161,SAP,Glycosphingolipid metabolism,0.0022422003956880363,1,0,1,0.0025321336196247354
2162,SAP,Platelet degranulation ,0.0008995032798071028,0,0,1,0.001015815758547916
2163,SAP,Platelet degranulation ,0.0022422003956880363,1,0,1,0.0025321336196247354
2164,SAP,Neutrophil degranulation,0.0008995032798071028,0,0,1,0.001015815758547916
2165,SAP,Neutrophil degranulation,0.0022422003956880363,1,0,1,0.0025321336196247354
2166,PROF1,RHO GTPase Effectors,0.0004398360142797432,0,0,1,0.0004967100893485162
2167,PROF1,RHO GTPase Effectors,0.0005448384371572552,1,0,1,0.0006152901081646374
2168,PROF1,Signaling by ROBO receptors,0.0004398360142797432,0,0,1,0.0004967100893485162
2169,PROF1,Signaling by ROBO receptors,0.0005448384371572552,1,0,1,0.0006152901081646374
2170,PROF1,PCP/CE pathway,0.0004398360142797432,0,0,1,0.0004967100893485162
2171,PROF1,PCP/CE pathway,0.0005448384371572552,1,0,1,0.0006152901081646374
2172,PROF1,Platelet degranulation ,0.0004398360142797432,0,0,1,0.0004967100893485162
2173,PROF1,Platelet degranulation ,0.0005448384371572552,1,0,1,0.0006152901081646374
2174,CATB,Trafficking and processing of endosomal TLR,0.003142566476572721,0,0,1,0.0035489237458606574
2175,CATB,Trafficking and processing of endosomal TLR,0.00261476475980043,1,0,1,0.0029528733330140104
2176,CATB,MHC class II antigen presentation,0.003142566476572721,0,0,1,0.0035489237458606574
2177,CATB,MHC class II antigen presentation,0.00261476475980043,1,0,1,0.0029528733330140104
2178,CATB,Collagen degradation,0.003142566476572721,0,0,1,0.0035489237458606574
2179,CATB,Collagen degradation,0.00261476475980043,1,0,1,0.0029528733330140104
2180,CATB,Neutrophil degranulation,0.003142566476572721,0,0,1,0.0035489237458606574
2181,CATB,Neutrophil degranulation,0.00261476475980043,1,0,1,0.0029528733330140104
2182,HS90A,Downregulation of ERBB2 signaling,0.00544921116995611,0,0,1,0.0061538347912236625
2183,HS90A,Downregulation of ERBB2 signaling,0.001475380940983225,1,0,1,0.0016661586937553028
2184,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.00544921116995611,0,0,1,0.0061538347912236625
2185,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.001475380940983225,1,0,1,0.0016661586937553028
2186,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.00544921116995611,0,0,1,0.0061538347912236625
2187,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.001475380940983225,1,0,1,0.0016661586937553028
2188,HS90A,Signaling by ERBB2 KD Mutants,0.00544921116995611,0,0,1,0.0061538347912236625
2189,HS90A,Signaling by ERBB2 KD Mutants,0.001475380940983225,1,0,1,0.0016661586937553028
2190,HS90A,Drug resistance in ERBB2 KD mutants,0.00544921116995611,0,0,1,0.0061538347912236625
2191,HS90A,Drug resistance in ERBB2 KD mutants,0.001475380940983225,1,0,1,0.0016661586937553028
2192,HS90A,Signaling by ERBB2 ECD mutants,0.00544921116995611,0,0,1,0.0061538347912236625
2193,HS90A,Signaling by ERBB2 ECD mutants,0.001475380940983225,1,0,1,0.0016661586937553028
2194,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.00544921116995611,0,0,1,0.0061538347912236625
2195,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.001475380940983225,1,0,1,0.0016661586937553028
2196,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.00544921116995611,0,0,1,0.0061538347912236625
2197,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.001475380940983225,1,0,1,0.0016661586937553028
2198,HS90A,Signaling by EGFRvIII in Cancer,0.00544921116995611,0,0,1,0.0061538347912236625
2199,HS90A,Signaling by EGFRvIII in Cancer,0.001475380940983225,1,0,1,0.0016661586937553028
2200,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.00544921116995611,0,0,1,0.0061538347912236625
2201,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.001475380940983225,1,0,1,0.0016661586937553028
2202,HS90A,Influenza Viral RNA Transcription and Replication,0.00544921116995611,0,0,1,0.0061538347912236625
2203,HS90A,Influenza Viral RNA Transcription and Replication,0.001475380940983225,1,0,1,0.0016661586937553028
2204,HS90A,VEGFA-VEGFR2 Pathway,0.00544921116995611,0,0,1,0.0061538347912236625
2205,HS90A,VEGFA-VEGFR2 Pathway,0.001475380940983225,1,0,1,0.0016661586937553028
2206,HS90A,RHO GTPase cycle,0.00544921116995611,0,0,1,0.0061538347912236625
2207,HS90A,RHO GTPase cycle,0.001475380940983225,1,0,1,0.0016661586937553028
2208,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.00544921116995611,0,0,1,0.0061538347912236625
2209,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.001475380940983225,1,0,1,0.0016661586937553028
2210,HS90A,HSF1 activation,0.00544921116995611,0,0,1,0.0061538347912236625
2211,HS90A,HSF1 activation,0.001475380940983225,1,0,1,0.0016661586937553028
2212,HS90A,HSF1-dependent transactivation,0.00544921116995611,0,0,1,0.0061538347912236625
2213,HS90A,HSF1-dependent transactivation,0.001475380940983225,1,0,1,0.0016661586937553028
2214,HS90A,Semaphorin interactions,0.00544921116995611,0,0,1,0.0061538347912236625
2215,HS90A,Semaphorin interactions,0.001475380940983225,1,0,1,0.0016661586937553028
2216,HS90A,Interleukin-4 and Interleukin-13 signaling,0.00544921116995611,0,0,1,0.0061538347912236625
2217,HS90A,Interleukin-4 and Interleukin-13 signaling,0.001475380940983225,1,0,1,0.0016661586937553028
2218,HS90A,G2/M Transition,0.00544921116995611,0,0,1,0.0061538347912236625
2219,HS90A,G2/M Transition,0.001475380940983225,1,0,1,0.0016661586937553028
2220,HS90A,Regulation of necroptotic cell death,0.00544921116995611,0,0,1,0.0061538347912236625
2221,HS90A,Regulation of necroptotic cell death,0.001475380940983225,1,0,1,0.0016661586937553028
2222,HS90A,Uptake and function of diphtheria toxin,0.00544921116995611,0,0,1,0.0061538347912236625
2223,HS90A,Uptake and function of diphtheria toxin,0.001475380940983225,1,0,1,0.0016661586937553028
2224,HS90A,Mitotic Prometaphase,0.00544921116995611,0,0,1,0.0061538347912236625
2225,HS90A,Mitotic Prometaphase,0.001475380940983225,1,0,1,0.0016661586937553028
2226,HS90A,Extra-nuclear estrogen signaling,0.00544921116995611,0,0,1,0.0061538347912236625
2227,HS90A,Extra-nuclear estrogen signaling,0.001475380940983225,1,0,1,0.0016661586937553028
2228,HS90A,Estrogen-dependent gene expression,0.00544921116995611,0,0,1,0.0061538347912236625
2229,HS90A,Estrogen-dependent gene expression,0.001475380940983225,1,0,1,0.0016661586937553028
2230,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.00544921116995611,0,0,1,0.0061538347912236625
2231,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.001475380940983225,1,0,1,0.0016661586937553028
2232,HS90A,Aggrephagy,0.00544921116995611,0,0,1,0.0061538347912236625
2233,HS90A,Aggrephagy,0.001475380940983225,1,0,1,0.0016661586937553028
2234,HS90A,Potential therapeutics for SARS,0.00544921116995611,0,0,1,0.0061538347912236625
2235,HS90A,Potential therapeutics for SARS,0.001475380940983225,1,0,1,0.0016661586937553028
2236,HS90A,SARS-CoV-2 Infection,0.00544921116995611,0,0,1,0.0061538347912236625
2237,HS90A,SARS-CoV-2 Infection,0.001475380940983225,1,0,1,0.0016661586937553028
2238,HS90A,Neutrophil degranulation,0.00544921116995611,0,0,1,0.0061538347912236625
2239,HS90A,Neutrophil degranulation,0.001475380940983225,1,0,1,0.0016661586937553028
2240,HS90A,eNOS activation,0.00544921116995611,0,0,1,0.0061538347912236625
2241,HS90A,eNOS activation,0.001475380940983225,1,0,1,0.0016661586937553028
2242,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.00544921116995611,0,0,1,0.0061538347912236625
2243,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.001475380940983225,1,0,1,0.0016661586937553028
2244,HS90A,Scavenging by Class F Receptors,0.00544921116995611,0,0,1,0.0061538347912236625
2245,HS90A,Scavenging by Class F Receptors,0.001475380940983225,1,0,1,0.0016661586937553028
2246,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00544921116995611,0,0,1,0.0061538347912236625
2247,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.001475380940983225,1,0,1,0.0016661586937553028
2248,HS90A,Anchoring of the basal body to the plasma membrane,0.00544921116995611,0,0,1,0.0061538347912236625
2249,HS90A,Anchoring of the basal body to the plasma membrane,0.001475380940983225,1,0,1,0.0016661586937553028
2250,HS90A,Chaperone Mediated Autophagy,0.00544921116995611,0,0,1,0.0061538347912236625
2251,HS90A,Chaperone Mediated Autophagy,0.001475380940983225,1,0,1,0.0016661586937553028
2252,FUMH,Citric acid cycle (TCA cycle),0.00046345450273339124,0,0,1,0.0005233826244052451
2253,FUMH,Citric acid cycle (TCA cycle),0.00016612607642915454,1,0,1,0.00018760741637168863
2254,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.006054555039928498,0,0,1,0.006837454135658072
2255,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.008270253161403356,1,0,1,0.009339658539472858
2256,PSPB,Defective CSF2RB causes SMDP5,0.006054555039928498,0,0,1,0.006837454135658072
2257,PSPB,Defective CSF2RB causes SMDP5,0.008270253161403356,1,0,1,0.009339658539472858
2258,PSPB,Defective CSF2RA causes SMDP4,0.006054555039928498,0,0,1,0.006837454135658072
2259,PSPB,Defective CSF2RA causes SMDP4,0.008270253161403356,1,0,1,0.009339658539472858
2260,PSPB,Surfactant metabolism,0.006054555039928498,0,0,1,0.006837454135658072
2261,PSPB,Surfactant metabolism,0.008270253161403356,1,0,1,0.009339658539472858
2262,TSP1,Transcriptional regulation by RUNX1,0.0022769964155204755,0,0,1,0.0025714290241819235
2263,TSP1,Transcriptional regulation by RUNX1,0.00235065721016197,1,0,1,0.0026546147086188255
2264,TSP1,Diseases associated with O-glycosylation of proteins,0.0022769964155204755,0,0,1,0.0025714290241819235
2265,TSP1,Diseases associated with O-glycosylation of proteins,0.00235065721016197,1,0,1,0.0026546147086188255
2266,TSP1,O-glycosylation of TSR domain-containing proteins,0.0022769964155204755,0,0,1,0.0025714290241819235
2267,TSP1,O-glycosylation of TSR domain-containing proteins,0.00235065721016197,1,0,1,0.0026546147086188255
2268,TSP1,Platelet degranulation ,0.0022769964155204755,0,0,1,0.0025714290241819235
2269,TSP1,Platelet degranulation ,0.00235065721016197,1,0,1,0.0026546147086188255
2270,TSP1,Integrin cell surface interactions,0.0022769964155204755,0,0,1,0.0025714290241819235
2271,TSP1,Integrin cell surface interactions,0.00235065721016197,1,0,1,0.0026546147086188255
2272,TSP1,Syndecan interactions,0.0022769964155204755,0,0,1,0.0025714290241819235
2273,TSP1,Syndecan interactions,0.00235065721016197,1,0,1,0.0026546147086188255
2274,TSP1,Signaling by PDGF,0.0022769964155204755,0,0,1,0.0025714290241819235
2275,TSP1,Signaling by PDGF,0.00235065721016197,1,0,1,0.0026546147086188255
2276,RNAS1,Chaperone Mediated Autophagy,0.016421323152983485,0,0,1,0.018544722636904227
2277,RNAS1,Chaperone Mediated Autophagy,0.013963684773836096,1,0,1,0.015769293296740566
2278,RNAS1,Late endosomal microautophagy,0.016421323152983485,0,0,1,0.018544722636904227
2279,RNAS1,Late endosomal microautophagy,0.013963684773836096,1,0,1,0.015769293296740566
2280,CO1A2,Collagen chain trimerization,0.010408882552824045,0,0,1,0.01175482865198735
2281,CO1A2,Collagen chain trimerization,0.005946349033490201,1,0,1,0.006715256286048085
2282,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.010408882552824045,0,0,1,0.01175482865198735
2283,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.005946349033490201,1,0,1,0.006715256286048085
2284,CO1A2,Anchoring fibril formation,0.010408882552824045,0,0,1,0.01175482865198735
2285,CO1A2,Anchoring fibril formation,0.005946349033490201,1,0,1,0.006715256286048085
2286,CO1A2,Crosslinking of collagen fibrils,0.010408882552824045,0,0,1,0.01175482865198735
2287,CO1A2,Crosslinking of collagen fibrils,0.005946349033490201,1,0,1,0.006715256286048085
2288,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.010408882552824045,0,0,1,0.01175482865198735
2289,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.005946349033490201,1,0,1,0.006715256286048085
2290,CO1A2,MET promotes cell motility,0.010408882552824045,0,0,1,0.01175482865198735
2291,CO1A2,MET promotes cell motility,0.005946349033490201,1,0,1,0.006715256286048085
2292,CO1A2,Platelet Adhesion to exposed collagen,0.010408882552824045,0,0,1,0.01175482865198735
2293,CO1A2,Platelet Adhesion to exposed collagen,0.005946349033490201,1,0,1,0.006715256286048085
2294,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010408882552824045,0,0,1,0.01175482865198735
2295,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005946349033490201,1,0,1,0.006715256286048085
2296,CO1A2,Collagen degradation,0.010408882552824045,0,0,1,0.01175482865198735
2297,CO1A2,Collagen degradation,0.005946349033490201,1,0,1,0.006715256286048085
2298,CO1A2,Integrin cell surface interactions,0.010408882552824045,0,0,1,0.01175482865198735
2299,CO1A2,Integrin cell surface interactions,0.005946349033490201,1,0,1,0.006715256286048085
2300,CO1A2,ECM proteoglycans,0.010408882552824045,0,0,1,0.01175482865198735
2301,CO1A2,ECM proteoglycans,0.005946349033490201,1,0,1,0.006715256286048085
2302,CO1A2,Scavenging by Class A Receptors,0.010408882552824045,0,0,1,0.01175482865198735
2303,CO1A2,Scavenging by Class A Receptors,0.005946349033490201,1,0,1,0.006715256286048085
2304,CO1A2,Syndecan interactions,0.010408882552824045,0,0,1,0.01175482865198735
2305,CO1A2,Syndecan interactions,0.005946349033490201,1,0,1,0.006715256286048085
2306,CO1A2,GPVI-mediated activation cascade,0.010408882552824045,0,0,1,0.01175482865198735
2307,CO1A2,GPVI-mediated activation cascade,0.005946349033490201,1,0,1,0.006715256286048085
2308,CO1A2,GP1b-IX-V activation signalling,0.010408882552824045,0,0,1,0.01175482865198735
2309,CO1A2,GP1b-IX-V activation signalling,0.005946349033490201,1,0,1,0.006715256286048085
2310,CBG,Metabolism of steroid hormones,0.001344686608582746,0,0,1,0.0015185646100141332
2311,CBG,Metabolism of steroid hormones,0.0014682872799571,1,0,1,0.001658147769484209
2312,4F2,Amino acid transport across the plasma membrane,0.0015148401365563426,0,0,1,0.0017107202574345288
2313,4F2,Amino acid transport across the plasma membrane,4.1846298700542794e-05,1,0,1,4.7257337033868694e-05
2314,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0015148401365563426,0,0,1,0.0017107202574345288
2315,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),4.1846298700542794e-05,1,0,1,4.7257337033868694e-05
2316,4F2,Basigin interactions,0.0015148401365563426,0,0,1,0.0017107202574345288
2317,4F2,Basigin interactions,4.1846298700542794e-05,1,0,1,4.7257337033868694e-05
2318,4F2,Tryptophan catabolism,0.0015148401365563426,0,0,1,0.0017107202574345288
2319,4F2,Tryptophan catabolism,4.1846298700542794e-05,1,0,1,4.7257337033868694e-05
2320,HS90B,Inflammasomes,0.012608092295970333,0,0,1,0.01423841260725563
2321,HS90B,Inflammasomes,0.013395051025137834,1,0,1,0.015127130965888651
2322,HS90B,RHO GTPase cycle,0.012608092295970333,0,0,1,0.01423841260725563
2323,HS90B,RHO GTPase cycle,0.013395051025137834,1,0,1,0.015127130965888651
2324,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.012608092295970333,0,0,1,0.01423841260725563
2325,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.013395051025137834,1,0,1,0.015127130965888651
2326,HS90B,Aryl hydrocarbon receptor signalling,0.012608092295970333,0,0,1,0.01423841260725563
2327,HS90B,Aryl hydrocarbon receptor signalling,0.013395051025137834,1,0,1,0.015127130965888651
2328,HS90B,HSF1 activation,0.012608092295970333,0,0,1,0.01423841260725563
2329,HS90B,HSF1 activation,0.013395051025137834,1,0,1,0.015127130965888651
2330,HS90B,HSF1-dependent transactivation,0.012608092295970333,0,0,1,0.01423841260725563
2331,HS90B,HSF1-dependent transactivation,0.013395051025137834,1,0,1,0.015127130965888651
2332,HS90B,Semaphorin interactions,0.012608092295970333,0,0,1,0.01423841260725563
2333,HS90B,Semaphorin interactions,0.013395051025137834,1,0,1,0.015127130965888651
2334,HS90B,G2/M Transition,0.012608092295970333,0,0,1,0.01423841260725563
2335,HS90B,G2/M Transition,0.013395051025137834,1,0,1,0.015127130965888651
2336,HS90B,Uptake and function of diphtheria toxin,0.012608092295970333,0,0,1,0.01423841260725563
2337,HS90B,Uptake and function of diphtheria toxin,0.013395051025137834,1,0,1,0.015127130965888651
2338,HS90B,Estrogen-dependent gene expression,0.012608092295970333,0,0,1,0.01423841260725563
2339,HS90B,Estrogen-dependent gene expression,0.013395051025137834,1,0,1,0.015127130965888651
2340,HS90B,Cell recruitment (pro-inflammatory response),0.012608092295970333,0,0,1,0.01423841260725563
2341,HS90B,Cell recruitment (pro-inflammatory response),0.013395051025137834,1,0,1,0.015127130965888651
2342,HS90B,Potential therapeutics for SARS,0.012608092295970333,0,0,1,0.01423841260725563
2343,HS90B,Potential therapeutics for SARS,0.013395051025137834,1,0,1,0.015127130965888651
2344,HS90B,SARS-CoV-2 Infection,0.012608092295970333,0,0,1,0.01423841260725563
2345,HS90B,SARS-CoV-2 Infection,0.013395051025137834,1,0,1,0.015127130965888651
2346,HS90B,Neutrophil degranulation,0.012608092295970333,0,0,1,0.01423841260725563
2347,HS90B,Neutrophil degranulation,0.013395051025137834,1,0,1,0.015127130965888651
2348,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.012608092295970333,0,0,1,0.01423841260725563
2349,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.013395051025137834,1,0,1,0.015127130965888651
2350,HS90B,Chaperone Mediated Autophagy,0.012608092295970333,0,0,1,0.01423841260725563
2351,HS90B,Chaperone Mediated Autophagy,0.013395051025137834,1,0,1,0.015127130965888651
2352,SODE,Detoxification of Reactive Oxygen Species,0.0003402077700971272,0,0,1,0.000384199170590261
2353,SODE,Detoxification of Reactive Oxygen Species,0.00012680547193041016,1,0,1,0.00014320236462577368
2354,ITA2B,Transcriptional regulation by RUNX1,0.0005960062700553281,0,0,1,0.0006730743232480501
2355,ITA2B,Transcriptional regulation by RUNX1,0.0009973578089741792,1,0,1,0.0011263236077183156
2356,ITA2B,L1CAM interactions,0.0005960062700553281,0,0,1,0.0006730743232480501
2357,ITA2B,L1CAM interactions,0.0009973578089741792,1,0,1,0.0011263236077183156
2358,ITA2B,RAF/MAP kinase cascade,0.0005960062700553281,0,0,1,0.0006730743232480501
2359,ITA2B,RAF/MAP kinase cascade,0.0009973578089741792,1,0,1,0.0011263236077183156
2360,ITA2B,Signaling by RAS mutants,0.0005960062700553281,0,0,1,0.0006730743232480501
2361,ITA2B,Signaling by RAS mutants,0.0009973578089741792,1,0,1,0.0011263236077183156
2362,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.0005960062700553281,0,0,1,0.0006730743232480501
2363,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.0009973578089741792,1,0,1,0.0011263236077183156
2364,ITA2B,Signaling by high-kinase activity BRAF mutants,0.0005960062700553281,0,0,1,0.0006730743232480501
2365,ITA2B,Signaling by high-kinase activity BRAF mutants,0.0009973578089741792,1,0,1,0.0011263236077183156
2366,ITA2B,Signaling by BRAF and RAF1 fusions,0.0005960062700553281,0,0,1,0.0006730743232480501
2367,ITA2B,Signaling by BRAF and RAF1 fusions,0.0009973578089741792,1,0,1,0.0011263236077183156
2368,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0005960062700553281,0,0,1,0.0006730743232480501
2369,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0009973578089741792,1,0,1,0.0011263236077183156
2370,ITA2B,Signaling by RAF1 mutants,0.0005960062700553281,0,0,1,0.0006730743232480501
2371,ITA2B,Signaling by RAF1 mutants,0.0009973578089741792,1,0,1,0.0011263236077183156
2372,ITA2B,Platelet degranulation ,0.0005960062700553281,0,0,1,0.0006730743232480501
2373,ITA2B,Platelet degranulation ,0.0009973578089741792,1,0,1,0.0011263236077183156
2374,ITA2B,Integrin cell surface interactions,0.0005960062700553281,0,0,1,0.0006730743232480501
2375,ITA2B,Integrin cell surface interactions,0.0009973578089741792,1,0,1,0.0011263236077183156
2376,ITA2B,ECM proteoglycans,0.0005960062700553281,0,0,1,0.0006730743232480501
2377,ITA2B,ECM proteoglycans,0.0009973578089741792,1,0,1,0.0011263236077183156
2378,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0005960062700553281,0,0,1,0.0006730743232480501
2379,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0009973578089741792,1,0,1,0.0011263236077183156
2380,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.0005960062700553281,0,0,1,0.0006730743232480501
2381,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.0009973578089741792,1,0,1,0.0011263236077183156
2382,APOA,LDL remodeling,0.0013031268748862406,0,0,1,0.0014716308929753044
2383,APOA,LDL remodeling,0.00123025675004544,1,0,1,0.0013893381178377716
2384,PLEK,Platelet degranulation ,0.00020617555953880777,0,0,1,0.0002328355961657732
2385,PLEK,Platelet degranulation ,0.00028314529928475675,1,0,1,0.0003197580969731454
2386,CD14,Antigen processing-Cross presentation,0.018722137328128562,0,0,1,0.02114304923456155
2387,CD14,Antigen processing-Cross presentation,0.018031869752144648,1,0,1,0.020363524915929274
2388,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.018722137328128562,0,0,1,0.02114304923456155
2389,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.018031869752144648,1,0,1,0.020363524915929274
2390,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.018722137328128562,0,0,1,0.02114304923456155
2391,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.018031869752144648,1,0,1,0.020363524915929274
2392,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.018722137328128562,0,0,1,0.02114304923456155
2393,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.018031869752144648,1,0,1,0.020363524915929274
2394,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.018722137328128562,0,0,1,0.02114304923456155
2395,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.018031869752144648,1,0,1,0.020363524915929274
2396,CD14,Regulation of TLR by endogenous ligand,0.018722137328128562,0,0,1,0.02114304923456155
2397,CD14,Regulation of TLR by endogenous ligand,0.018031869752144648,1,0,1,0.020363524915929274
2398,CD14,Caspase activation via Death Receptors in the presence of ligand,0.018722137328128562,0,0,1,0.02114304923456155
2399,CD14,Caspase activation via Death Receptors in the presence of ligand,0.018031869752144648,1,0,1,0.020363524915929274
2400,CD14,MyD88 deficiency (TLR2/4),0.018722137328128562,0,0,1,0.02114304923456155
2401,CD14,MyD88 deficiency (TLR2/4),0.018031869752144648,1,0,1,0.020363524915929274
2402,CD14,IRAK4 deficiency (TLR2/4),0.018722137328128562,0,0,1,0.02114304923456155
2403,CD14,IRAK4 deficiency (TLR2/4),0.018031869752144648,1,0,1,0.020363524915929274
2404,CD14,Neutrophil degranulation,0.018722137328128562,0,0,1,0.02114304923456155
2405,CD14,Neutrophil degranulation,0.018031869752144648,1,0,1,0.020363524915929274
2406,CFAH,Regulation of Complement cascade,0.0007409875066031912,0,0,1,0.0008368027143337004
2407,CFAH,Regulation of Complement cascade,0.0005922449864616274,1,0,1,0.0006688266776500616
2408,FCG3A,FCGR activation,0.0007739555233878916,0,0,1,0.0008740337414236213
2409,FCG3A,FCGR activation,0.0004715959390146546,1,0,1,0.0005325768090818087
2410,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.0007739555233878916,0,0,1,0.0008740337414236213
2411,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.0004715959390146546,1,0,1,0.0005325768090818087
2412,FCG3A,Role of phospholipids in phagocytosis,0.0007739555233878916,0,0,1,0.0008740337414236213
2413,FCG3A,Role of phospholipids in phagocytosis,0.0004715959390146546,1,0,1,0.0005325768090818087
2414,FCG3A,Parasite infection,0.0007739555233878916,0,0,1,0.0008740337414236213
2415,FCG3A,Parasite infection,0.0004715959390146546,1,0,1,0.0005325768090818087
2416,FCG3A,Leishmania parasite growth and survival,0.0007739555233878916,0,0,1,0.0008740337414236213
2417,FCG3A,Leishmania parasite growth and survival,0.0004715959390146546,1,0,1,0.0005325768090818087
2418,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007739555233878916,0,0,1,0.0008740337414236213
2419,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004715959390146546,1,0,1,0.0005325768090818087
2420,A2AP,Platelet degranulation ,0.004804995410983613,0,0,1,0.005426317132800556
2421,A2AP,Platelet degranulation ,0.0032644583014854074,1,0,1,0.0036865770922842787
2422,A2AP,Dissolution of Fibrin Clot,0.004804995410983613,0,0,1,0.005426317132800556
2423,A2AP,Dissolution of Fibrin Clot,0.0032644583014854074,1,0,1,0.0036865770922842787
2424,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0019076290361785334,0,0,1,0.002154299689523406
2425,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.005103129986165523,1,0,1,0.0057630027307704924
2426,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.0019076290361785334,0,0,1,0.002154299689523406
2427,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.005103129986165523,1,0,1,0.0057630027307704924
2428,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0019076290361785334,0,0,1,0.002154299689523406
2429,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.005103129986165523,1,0,1,0.0057630027307704924
2430,K1C16,Formation of the cornified envelope,8.180366515765217e-05,0,0,1,9.238148880562205e-05
2431,K1C16,Formation of the cornified envelope,0.00016752832187951288,1,0,1,0.00018919098261074851
2432,ENOG,Glycolysis,9.870613201958338e-05,0,0,1,0.00011146957061936006
2433,ENOG,Glycolysis,0.00023287800568741566,1,0,1,0.00026299086763443294
2434,ENOG,Gluconeogenesis,9.870613201958338e-05,0,0,1,0.00011146957061936006
2435,ENOG,Gluconeogenesis,0.00023287800568741566,1,0,1,0.00026299086763443294
2436,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,0.0015686361986652093,0,0,1,0.001771472551355823
2437,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,0.0027580715835255187,1,0,1,0.003114710797218267
2438,THIK,Peroxisomal lipid metabolism,0.0015686361986652093,0,0,1,0.001771472551355823
2439,THIK,Peroxisomal lipid metabolism,0.0027580715835255187,1,0,1,0.003114710797218267
2440,THIK,Neutrophil degranulation,0.0015686361986652093,0,0,1,0.001771472551355823
2441,THIK,Neutrophil degranulation,0.0027580715835255187,1,0,1,0.003114710797218267
2442,THIK,TYSND1 cleaves peroxisomal proteins,0.0015686361986652093,0,0,1,0.001771472551355823
2443,THIK,TYSND1 cleaves peroxisomal proteins,0.0027580715835255187,1,0,1,0.003114710797218267
2444,DOPO,Catecholamine biosynthesis,0.0002423695834553895,0,0,1,0.00027370977715553943
2445,DOPO,Catecholamine biosynthesis,0.00020330410286637028,1,0,1,0.00022959283874250387
2446,F16P1,Gluconeogenesis,7.536289924793457e-06,0,0,1,8.51078838559965e-06
2447,F16P1,Gluconeogenesis,5.436140665625515e-05,1,0,1,6.139074173259008e-05
2448,C1S,Initial triggering of complement,0.00028280009244843795,0,0,1,0.00031936825231980925
2449,C1S,Initial triggering of complement,0.00018852689821855867,1,0,1,0.0002129048313883188
2450,C1S,Regulation of Complement cascade,0.00028280009244843795,0,0,1,0.00031936825231980925
2451,C1S,Regulation of Complement cascade,0.00018852689821855867,1,0,1,0.0002129048313883188
2452,LKHA4,Arachidonic acid metabolism,0.000287852212401732,0,0,1,0.0003250736490402426
2453,LKHA4,Arachidonic acid metabolism,0.00041058024456378455,1,0,1,0.00046367133054344236
2454,LKHA4,Biosynthesis of DHA-derived SPMs,0.000287852212401732,0,0,1,0.0003250736490402426
2455,LKHA4,Biosynthesis of DHA-derived SPMs,0.00041058024456378455,1,0,1,0.00046367133054344236
2456,LKHA4,Biosynthesis of EPA-derived SPMs,0.000287852212401732,0,0,1,0.0003250736490402426
2457,LKHA4,Biosynthesis of EPA-derived SPMs,0.00041058024456378455,1,0,1,0.00046367133054344236
2458,LKHA4,Neutrophil degranulation,0.000287852212401732,0,0,1,0.0003250736490402426
2459,LKHA4,Neutrophil degranulation,0.00041058024456378455,1,0,1,0.00046367133054344236
2460,CO4A,Initial triggering of complement,0.0005528939029690071,0,0,1,0.0006243872057491802
2461,CO4A,Initial triggering of complement,0.0008362971070277228,1,0,1,0.000944436556505912
2462,CO4A,Activation of C3 and C5,0.0005528939029690071,0,0,1,0.0006243872057491802
2463,CO4A,Activation of C3 and C5,0.0008362971070277228,1,0,1,0.000944436556505912
2464,CO4A,Regulation of Complement cascade,0.0005528939029690071,0,0,1,0.0006243872057491802
2465,CO4A,Regulation of Complement cascade,0.0008362971070277228,1,0,1,0.000944436556505912
2466,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005528939029690071,0,0,1,0.0006243872057491802
2467,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0008362971070277228,1,0,1,0.000944436556505912
2468,CO4A,Post-translational protein phosphorylation,0.0005528939029690071,0,0,1,0.0006243872057491802
2469,CO4A,Post-translational protein phosphorylation,0.0008362971070277228,1,0,1,0.000944436556505912
2470,CO4B,Initial triggering of complement,0.0003270048850197615,0,0,1,0.000369289054061546
2471,CO4B,Initial triggering of complement,0.00014471756793483768,1,0,1,0.00016343062815564387
2472,CO4B,Activation of C3 and C5,0.0003270048850197615,0,0,1,0.000369289054061546
2473,CO4B,Activation of C3 and C5,0.00014471756793483768,1,0,1,0.00016343062815564387
2474,CO4B,Regulation of Complement cascade,0.0003270048850197615,0,0,1,0.000369289054061546
2475,CO4B,Regulation of Complement cascade,0.00014471756793483768,1,0,1,0.00016343062815564387
2476,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.0027480134438907402,0,0,1,0.003103352065157974
2477,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.0009117150132227336,1,0,1,0.001029606560117249
2478,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.0027480134438907402,0,0,1,0.003103352065157974
2479,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.0009117150132227336,1,0,1,0.001029606560117249
2480,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.0027480134438907402,0,0,1,0.003103352065157974
2481,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.0009117150132227336,1,0,1,0.001029606560117249
2482,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.0027480134438907402,0,0,1,0.003103352065157974
2483,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.0009117150132227336,1,0,1,0.001029606560117249
2484,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.0027480134438907402,0,0,1,0.003103352065157974
2485,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.0009117150132227336,1,0,1,0.001029606560117249
2486,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0027480134438907402,0,0,1,0.003103352065157974
2487,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0009117150132227336,1,0,1,0.001029606560117249
2488,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.0027480134438907402,0,0,1,0.003103352065157974
2489,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.0009117150132227336,1,0,1,0.001029606560117249
2490,SAA1,TRAF6 mediated NF-kB activation,0.0027480134438907402,0,0,1,0.003103352065157974
2491,SAA1,TRAF6 mediated NF-kB activation,0.0009117150132227336,1,0,1,0.001029606560117249
2492,SAA1,Class A/1 (Rhodopsin-like receptors),0.0027480134438907402,0,0,1,0.003103352065157974
2493,SAA1,Class A/1 (Rhodopsin-like receptors),0.0009117150132227336,1,0,1,0.001029606560117249
2494,SAA1,G alpha (q) signalling events,0.0027480134438907402,0,0,1,0.003103352065157974
2495,SAA1,G alpha (q) signalling events,0.0009117150132227336,1,0,1,0.001029606560117249
2496,SAA1,G alpha (i) signalling events,0.0027480134438907402,0,0,1,0.003103352065157974
2497,SAA1,G alpha (i) signalling events,0.0009117150132227336,1,0,1,0.001029606560117249
2498,SAA1,Interleukin-1 family signaling,0.0027480134438907402,0,0,1,0.003103352065157974
2499,SAA1,Interleukin-1 family signaling,0.0009117150132227336,1,0,1,0.001029606560117249
2500,SAA1,Interleukin-4 and Interleukin-13 signaling,0.0027480134438907402,0,0,1,0.003103352065157974
2501,SAA1,Interleukin-4 and Interleukin-13 signaling,0.0009117150132227336,1,0,1,0.001029606560117249
2502,SAA1,Advanced glycosylation endproduct receptor signaling,0.0027480134438907402,0,0,1,0.003103352065157974
2503,SAA1,Advanced glycosylation endproduct receptor signaling,0.0009117150132227336,1,0,1,0.001029606560117249
2504,SAA1,Scavenging by Class B Receptors,0.0027480134438907402,0,0,1,0.003103352065157974
2505,SAA1,Scavenging by Class B Receptors,0.0009117150132227336,1,0,1,0.001029606560117249
2506,SAA1,Amyloid fiber formation,0.0027480134438907402,0,0,1,0.003103352065157974
2507,SAA1,Amyloid fiber formation,0.0009117150132227336,1,0,1,0.001029606560117249
2508,OSTP,Transcriptional regulation by RUNX3,0.005116341814048929,0,0,1,0.0057779229464767256
2509,OSTP,Transcriptional regulation by RUNX3,0.004221309758226392,1,0,1,0.004767156574501911
2510,OSTP,Integrin cell surface interactions,0.005116341814048929,0,0,1,0.0057779229464767256
2511,OSTP,Integrin cell surface interactions,0.004221309758226392,1,0,1,0.004767156574501911
2512,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005116341814048929,0,0,1,0.0057779229464767256
2513,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004221309758226392,1,0,1,0.004767156574501911
2514,OSTP,Post-translational protein phosphorylation,0.005116341814048929,0,0,1,0.0057779229464767256
2515,OSTP,Post-translational protein phosphorylation,0.004221309758226392,1,0,1,0.004767156574501911
2516,OSTP,Signaling by PDGF,0.005116341814048929,0,0,1,0.0057779229464767256
2517,OSTP,Signaling by PDGF,0.004221309758226392,1,0,1,0.004767156574501911
2518,CO7,Terminal pathway of complement,0.0010812307345305515,0,0,1,0.001221041927715937
2519,CO7,Terminal pathway of complement,0.0010632053641081815,1,0,1,0.0012006857425415666
2520,CO7,Regulation of Complement cascade,0.0010812307345305515,0,0,1,0.001221041927715937
2521,CO7,Regulation of Complement cascade,0.0010632053641081815,1,0,1,0.0012006857425415666
2522,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.0004194920180582023,0,0,1,0.0004737354627767128
2523,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.0005752796984553487,1,0,1,0.0006496676514497596
2524,CH60,Mitochondrial protein import,0.0004194920180582023,0,0,1,0.0004737354627767128
2525,CH60,Mitochondrial protein import,0.0005752796984553487,1,0,1,0.0006496676514497596
2526,CLUS,Terminal pathway of complement,0.00024163218456592467,0,0,1,0.0002728770270932887
2527,CLUS,Terminal pathway of complement,0.00029424551422250616,1,0,1,0.0003322936524404394
2528,CLUS,Regulation of Complement cascade,0.00024163218456592467,0,0,1,0.0002728770270932887
2529,CLUS,Regulation of Complement cascade,0.00029424551422250616,1,0,1,0.0003322936524404394
2530,CLUS,Platelet degranulation ,0.00024163218456592467,0,0,1,0.0002728770270932887
2531,CLUS,Platelet degranulation ,0.00029424551422250616,1,0,1,0.0003322936524404394
2532,BIP,Regulation of HSF1-mediated heat shock response,0.0013120996307933346,0,0,1,0.001481763893101757
2533,BIP,Regulation of HSF1-mediated heat shock response,0.00035452253581817533,1,0,1,0.00040036494221755344
2534,BIP,ATF6 (ATF6-alpha) activates chaperones,0.0013120996307933346,0,0,1,0.001481763893101757
2535,BIP,ATF6 (ATF6-alpha) activates chaperones,0.00035452253581817533,1,0,1,0.00040036494221755344
2536,BIP,IRE1alpha activates chaperones,0.0013120996307933346,0,0,1,0.001481763893101757
2537,BIP,IRE1alpha activates chaperones,0.00035452253581817533,1,0,1,0.00040036494221755344
2538,BIP,PERK regulates gene expression,0.0013120996307933346,0,0,1,0.001481763893101757
2539,BIP,PERK regulates gene expression,0.00035452253581817533,1,0,1,0.00040036494221755344
2540,BIP,Platelet degranulation ,0.0013120996307933346,0,0,1,0.001481763893101757
2541,BIP,Platelet degranulation ,0.00035452253581817533,1,0,1,0.00040036494221755344
2542,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0013120996307933346,0,0,1,0.001481763893101757
2543,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.00035452253581817533,1,0,1,0.00040036494221755344
2544,LAMC1,L1CAM interactions,0.0037939255149458265,0,0,1,0.004284508362955006
2545,LAMC1,L1CAM interactions,0.005170133236682203,1,0,1,0.005838670001003651
2546,LAMC1,MET promotes cell motility,0.0037939255149458265,0,0,1,0.004284508362955006
2547,LAMC1,MET promotes cell motility,0.005170133236682203,1,0,1,0.005838670001003651
2548,LAMC1,Laminin interactions,0.0037939255149458265,0,0,1,0.004284508362955006
2549,LAMC1,Laminin interactions,0.005170133236682203,1,0,1,0.005838670001003651
2550,LAMC1,ECM proteoglycans,0.0037939255149458265,0,0,1,0.004284508362955006
2551,LAMC1,ECM proteoglycans,0.005170133236682203,1,0,1,0.005838670001003651
2552,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0037939255149458265,0,0,1,0.004284508362955006
2553,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005170133236682203,1,0,1,0.005838670001003651
2554,LAMC1,Post-translational protein phosphorylation,0.0037939255149458265,0,0,1,0.004284508362955006
2555,LAMC1,Post-translational protein phosphorylation,0.005170133236682203,1,0,1,0.005838670001003651
2556,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0037939255149458265,0,0,1,0.004284508362955006
2557,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.005170133236682203,1,0,1,0.005838670001003651
2558,HSP7C,"GABA synthesis, release, reuptake and degradation",0.007554027704559834,0,0,1,0.008530819792502583
2559,HSP7C,"GABA synthesis, release, reuptake and degradation",0.008490101872768423,1,0,1,0.009587935327912116
2560,HSP7C,Lysosome Vesicle Biogenesis,0.007554027704559834,0,0,1,0.008530819792502583
2561,HSP7C,Lysosome Vesicle Biogenesis,0.008490101872768423,1,0,1,0.009587935327912116
2562,HSP7C,Golgi Associated Vesicle Biogenesis,0.007554027704559834,0,0,1,0.008530819792502583
2563,HSP7C,Golgi Associated Vesicle Biogenesis,0.008490101872768423,1,0,1,0.009587935327912116
2564,HSP7C,Regulation of HSF1-mediated heat shock response,0.007554027704559834,0,0,1,0.008530819792502583
2565,HSP7C,Regulation of HSF1-mediated heat shock response,0.008490101872768423,1,0,1,0.009587935327912116
2566,HSP7C,HSF1-dependent transactivation,0.007554027704559834,0,0,1,0.008530819792502583
2567,HSP7C,HSF1-dependent transactivation,0.008490101872768423,1,0,1,0.009587935327912116
2568,HSP7C,L1CAM interactions,0.007554027704559834,0,0,1,0.008530819792502583
2569,HSP7C,L1CAM interactions,0.008490101872768423,1,0,1,0.009587935327912116
2570,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.007554027704559834,0,0,1,0.008530819792502583
2571,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.008490101872768423,1,0,1,0.009587935327912116
2572,HSP7C,mRNA Splicing - Major Pathway,0.007554027704559834,0,0,1,0.008530819792502583
2573,HSP7C,mRNA Splicing - Major Pathway,0.008490101872768423,1,0,1,0.009587935327912116
2574,HSP7C,Lipophagy,0.007554027704559834,0,0,1,0.008530819792502583
2575,HSP7C,Lipophagy,0.008490101872768423,1,0,1,0.009587935327912116
2576,HSP7C,Neutrophil degranulation,0.007554027704559834,0,0,1,0.008530819792502583
2577,HSP7C,Neutrophil degranulation,0.008490101872768423,1,0,1,0.009587935327912116
2578,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.007554027704559834,0,0,1,0.008530819792502583
2579,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.008490101872768423,1,0,1,0.009587935327912116
2580,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.007554027704559834,0,0,1,0.008530819792502583
2581,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.008490101872768423,1,0,1,0.009587935327912116
2582,HSP7C,Protein methylation,0.007554027704559834,0,0,1,0.008530819792502583
2583,HSP7C,Protein methylation,0.008490101872768423,1,0,1,0.009587935327912116
2584,HSP7C,Chaperone Mediated Autophagy,0.007554027704559834,0,0,1,0.008530819792502583
2585,HSP7C,Chaperone Mediated Autophagy,0.008490101872768423,1,0,1,0.009587935327912116
2586,HSP7C,Late endosomal microautophagy,0.007554027704559834,0,0,1,0.008530819792502583
2587,HSP7C,Late endosomal microautophagy,0.008490101872768423,1,0,1,0.009587935327912116
2588,PYGB,Glycogen breakdown (glycogenolysis),0.0011165674694879973,0,0,1,0.0012609479658941436
2589,PYGB,Glycogen breakdown (glycogenolysis),0.00036458377074125237,1,0,1,0.0004117271698099932
2590,PYGB,Neutrophil degranulation,0.0011165674694879973,0,0,1,0.0012609479658941436
2591,PYGB,Neutrophil degranulation,0.00036458377074125237,1,0,1,0.0004117271698099932
2592,C1TC,Metabolism of folate and pterines,0.0003256485285747118,0,0,1,0.00036775731061822577
2593,C1TC,Metabolism of folate and pterines,0.0007905095798225818,1,0,1,0.000892728360744916
2594,CO6A1,Collagen chain trimerization,0.006982891952446402,0,0,1,0.007885831930544639
2595,CO6A1,Collagen chain trimerization,0.00527109706836846,1,0,1,0.005952689208684888
2596,CO6A1,NCAM signaling for neurite out-growth,0.006982891952446402,0,0,1,0.007885831930544639
2597,CO6A1,NCAM signaling for neurite out-growth,0.00527109706836846,1,0,1,0.005952689208684888
2598,CO6A1,Collagen degradation,0.006982891952446402,0,0,1,0.007885831930544639
2599,CO6A1,Collagen degradation,0.00527109706836846,1,0,1,0.005952689208684888
2600,CO6A1,Integrin cell surface interactions,0.006982891952446402,0,0,1,0.007885831930544639
2601,CO6A1,Integrin cell surface interactions,0.00527109706836846,1,0,1,0.005952689208684888
2602,CO6A1,ECM proteoglycans,0.006982891952446402,0,0,1,0.007885831930544639
2603,CO6A1,ECM proteoglycans,0.00527109706836846,1,0,1,0.005952689208684888
2604,CO6A1,Signaling by PDGF,0.006982891952446402,0,0,1,0.007885831930544639
2605,CO6A1,Signaling by PDGF,0.00527109706836846,1,0,1,0.005952689208684888
2606,CO6A3,Collagen chain trimerization,0.00805385907294068,0,0,1,0.009095283082427123
2607,CO6A3,Collagen chain trimerization,0.004855699187763943,1,0,1,0.00548357728585125
2608,CO6A3,NCAM signaling for neurite out-growth,0.00805385907294068,0,0,1,0.009095283082427123
2609,CO6A3,NCAM signaling for neurite out-growth,0.004855699187763943,1,0,1,0.00548357728585125
2610,CO6A3,Collagen degradation,0.00805385907294068,0,0,1,0.009095283082427123
2611,CO6A3,Collagen degradation,0.004855699187763943,1,0,1,0.00548357728585125
2612,CO6A3,Integrin cell surface interactions,0.00805385907294068,0,0,1,0.009095283082427123
2613,CO6A3,Integrin cell surface interactions,0.004855699187763943,1,0,1,0.00548357728585125
2614,CO6A3,ECM proteoglycans,0.00805385907294068,0,0,1,0.009095283082427123
2615,CO6A3,ECM proteoglycans,0.004855699187763943,1,0,1,0.00548357728585125
2616,CO6A3,Signaling by PDGF,0.00805385907294068,0,0,1,0.009095283082427123
2617,CO6A3,Signaling by PDGF,0.004855699187763943,1,0,1,0.00548357728585125
2618,FA5,COPII-mediated vesicle transport,0.007737356997054329,0,0,1,0.008737854929005124
2619,FA5,COPII-mediated vesicle transport,0.008081629977029391,1,0,1,0.009126644971411548
2620,FA5,Cargo concentration in the ER,0.007737356997054329,0,0,1,0.008737854929005124
2621,FA5,Cargo concentration in the ER,0.008081629977029391,1,0,1,0.009126644971411548
2622,FA5,Platelet degranulation ,0.007737356997054329,0,0,1,0.008737854929005124
2623,FA5,Platelet degranulation ,0.008081629977029391,1,0,1,0.009126644971411548
2624,FA5,Common Pathway of Fibrin Clot Formation,0.007737356997054329,0,0,1,0.008737854929005124
2625,FA5,Common Pathway of Fibrin Clot Formation,0.008081629977029391,1,0,1,0.009126644971411548
2626,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007737356997054329,0,0,1,0.008737854929005124
2627,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008081629977029391,1,0,1,0.009126644971411548
2628,FA5,Post-translational protein phosphorylation,0.007737356997054329,0,0,1,0.008737854929005124
2629,FA5,Post-translational protein phosphorylation,0.008081629977029391,1,0,1,0.009126644971411548
2630,ACTN1,RHO GTPase cycle,0.0016657905862903042,0,0,1,0.001881189725464191
2631,ACTN1,RHO GTPase cycle,0.012106205733861718,1,0,1,0.013671628371735443
2632,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.0016657905862903042,0,0,1,0.001881189725464191
2633,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.012106205733861718,1,0,1,0.013671628371735443
2634,ACTN1,Platelet degranulation ,0.0016657905862903042,0,0,1,0.001881189725464191
2635,ACTN1,Platelet degranulation ,0.012106205733861718,1,0,1,0.013671628371735443
2636,ACTN1,Nephrin family interactions,0.0016657905862903042,0,0,1,0.001881189725464191
2637,ACTN1,Nephrin family interactions,0.012106205733861718,1,0,1,0.013671628371735443
2638,ACTN1,Syndecan interactions,0.0016657905862903042,0,0,1,0.001881189725464191
2639,ACTN1,Syndecan interactions,0.012106205733861718,1,0,1,0.013671628371735443
2640,ICAM2,CD209 (DC-SIGN) signaling,0.001415677412370513,0,0,1,0.0015987350538785084
2641,ICAM2,CD209 (DC-SIGN) signaling,0.00058986969671991,1,0,1,0.0006661442452399528
2642,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001415677412370513,0,0,1,0.0015987350538785084
2643,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00058986969671991,1,0,1,0.0006661442452399528
2644,ICAM2,Integrin cell surface interactions,0.001415677412370513,0,0,1,0.0015987350538785084
2645,ICAM2,Integrin cell surface interactions,0.00058986969671991,1,0,1,0.0006661442452399528
2646,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.011786126549388778,0,0,1,0.013310160562923782
2647,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.009226835166165596,1,0,1,0.01041993372756247
2648,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.011786126549388778,0,0,1,0.013310160562923782
2649,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.009226835166165596,1,0,1,0.01041993372756247
2650,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.011786126549388778,0,0,1,0.013310160562923782
2651,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.009226835166165596,1,0,1,0.01041993372756247
2652,CSPG2,ECM proteoglycans,0.011786126549388778,0,0,1,0.013310160562923782
2653,CSPG2,ECM proteoglycans,0.009226835166165596,1,0,1,0.01041993372756247
2654,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.011786126549388778,0,0,1,0.013310160562923782
2655,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009226835166165596,1,0,1,0.01041993372756247
2656,CSPG2,Post-translational protein phosphorylation,0.011786126549388778,0,0,1,0.013310160562923782
2657,CSPG2,Post-translational protein phosphorylation,0.009226835166165596,1,0,1,0.01041993372756247
2658,K1C10,Formation of the cornified envelope,1.2735696877388324e-05,0,0,1,1.4382517412182082e-05
2659,K1C10,Formation of the cornified envelope,2.5476590056687685e-05,1,0,1,2.877090304684417e-05
2660,K2C5,Type I hemidesmosome assembly,0.0006318988712221741,0,0,1,0.0007136081052798137
2661,K2C5,Type I hemidesmosome assembly,0.0023365829439554835,1,0,1,0.0026387205348859474
2662,K2C5,Formation of the cornified envelope,0.0006318988712221741,0,0,1,0.0007136081052798137
2663,K2C5,Formation of the cornified envelope,0.0023365829439554835,1,0,1,0.0026387205348859474
2664,CO6,Terminal pathway of complement,3.209415961673128e-05,0,0,1,3.6244173676630925e-05
2665,CO6,Terminal pathway of complement,2.8241039578019006e-05,1,0,1,3.1892816496766004e-05
2666,CO6,Regulation of Complement cascade,3.209415961673128e-05,0,0,1,3.6244173676630925e-05
2667,CO6,Regulation of Complement cascade,2.8241039578019006e-05,1,0,1,3.1892816496766004e-05
2668,PRG2,Neutrophil degranulation,4.358999560078382e-06,0,0,1,4.922650694037069e-06
2669,PRG2,Neutrophil degranulation,2.5554144725865073e-06,1,0,1,2.8858486112818377e-06
2670,PLSL,Interleukin-12 family signaling,0.0003893671676162215,0,0,1,0.0004397152446298423
2671,PLSL,Interleukin-12 family signaling,7.80172282326577e-05,1,0,1,8.810543736311709e-05
2672,CD59,Regulation of Complement cascade,0.0036377248240735518,0,0,1,0.004108109758473924
2673,CD59,Regulation of Complement cascade,0.003950396956331368,1,0,1,0.0044612127280088225
2674,CD59,COPII-mediated vesicle transport,0.0036377248240735518,0,0,1,0.004108109758473924
2675,CD59,COPII-mediated vesicle transport,0.003950396956331368,1,0,1,0.0044612127280088225
2676,CD59,Cargo concentration in the ER,0.0036377248240735518,0,0,1,0.004108109758473924
2677,CD59,Cargo concentration in the ER,0.003950396956331368,1,0,1,0.0044612127280088225
2678,CD59,COPI-mediated anterograde transport,0.0036377248240735518,0,0,1,0.004108109758473924
2679,CD59,COPI-mediated anterograde transport,0.003950396956331368,1,0,1,0.0044612127280088225
2680,CD59,Neutrophil degranulation,0.0036377248240735518,0,0,1,0.004108109758473924
2681,CD59,Neutrophil degranulation,0.003950396956331368,1,0,1,0.0044612127280088225
2682,GFAP,Nuclear signaling by ERBB4,0.0008887183980937384,0,0,1,0.0010036363112413311
2683,GFAP,Nuclear signaling by ERBB4,0.0019056040870184126,1,0,1,0.0021520128993434413
2684,GFAP,Chaperone Mediated Autophagy,0.0008887183980937384,0,0,1,0.0010036363112413311
2685,GFAP,Chaperone Mediated Autophagy,0.0019056040870184126,1,0,1,0.0021520128993434413
2686,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001032840015859435,0,0,1,0.0011663939284289077
2687,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006139436658310939,1,0,1,0.0006933311579982705
2688,LYAM1,Neutrophil degranulation,0.001032840015859435,0,0,1,0.0011663939284289077
2689,LYAM1,Neutrophil degranulation,0.0006139436658310939,1,0,1,0.0006933311579982705
2690,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0025313265717985477,0,0,1,0.002858645965377094
2691,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0033020977939001574,1,0,1,0.0037290836516231693
2692,GLU2B,SARS-CoV-1 Infection,0.0025313265717985477,0,0,1,0.002858645965377094
2693,GLU2B,SARS-CoV-1 Infection,0.0033020977939001574,1,0,1,0.0037290836516231693
2694,GLU2B,SARS-CoV-2 Infection,0.0025313265717985477,0,0,1,0.002858645965377094
2695,GLU2B,SARS-CoV-2 Infection,0.0033020977939001574,1,0,1,0.0037290836516231693
2696,GLU2B,Advanced glycosylation endproduct receptor signaling,0.0025313265717985477,0,0,1,0.002858645965377094
2697,GLU2B,Advanced glycosylation endproduct receptor signaling,0.0033020977939001574,1,0,1,0.0037290836516231693
2698,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0025313265717985477,0,0,1,0.002858645965377094
2699,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0033020977939001574,1,0,1,0.0037290836516231693
2700,GLU2B,Post-translational protein phosphorylation,0.0025313265717985477,0,0,1,0.002858645965377094
2701,GLU2B,Post-translational protein phosphorylation,0.0033020977939001574,1,0,1,0.0037290836516231693
2702,NID1,Laminin interactions,0.00023410953376015885,0,0,1,0.00026438164146646935
2703,NID1,Laminin interactions,0.00045248553141192795,1,0,1,0.0005109952833320786
2704,PA2GA,Glycerophospholipid biosynthesis,0.0009354522904123506,0,0,1,0.001056413244178928
2705,PA2GA,Glycerophospholipid biosynthesis,0.0010462954389534153,1,0,1,0.0011815892380221378
2706,KPYM,Neutrophil degranulation,0.00031902016706937254,0,0,1,0.00036027185256417633
2707,KPYM,Neutrophil degranulation,0.00018742706443905253,1,0,1,0.00021166278090324966
2708,ENPL,Trafficking and processing of endosomal TLR,0.0006785976299055952,0,0,1,0.0007663453615413122
2709,ENPL,Trafficking and processing of endosomal TLR,0.00040770915162459365,1,0,1,0.00046042898388683965
2710,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.0006785976299055952,0,0,1,0.0007663453615413122
2711,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.00040770915162459365,1,0,1,0.00046042898388683965
2712,ENPL,Interleukin-4 and Interleukin-13 signaling,0.0006785976299055952,0,0,1,0.0007663453615413122
2713,ENPL,Interleukin-4 and Interleukin-13 signaling,0.00040770915162459365,1,0,1,0.00046042898388683965
2714,ENPL,Scavenging by Class A Receptors,0.0006785976299055952,0,0,1,0.0007663453615413122
2715,ENPL,Scavenging by Class A Receptors,0.00040770915162459365,1,0,1,0.00046042898388683965
2716,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006785976299055952,0,0,1,0.0007663453615413122
2717,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00040770915162459365,1,0,1,0.00046042898388683965
2718,ENPL,Post-translational protein phosphorylation,0.0006785976299055952,0,0,1,0.0007663453615413122
2719,ENPL,Post-translational protein phosphorylation,0.00040770915162459365,1,0,1,0.00046042898388683965
2720,GPIX,Defective factor IX causes hemophilia B,2.8884072758653052e-05,0,0,1,3.2618998660656874e-05
2721,GPIX,Defective factor IX causes hemophilia B,0.00020918340658515497,1,0,1,0.00023623238025491679
2722,GPIX,Platelet Adhesion to exposed collagen,2.8884072758653052e-05,0,0,1,3.2618998660656874e-05
2723,GPIX,Platelet Adhesion to exposed collagen,0.00020918340658515497,1,0,1,0.00023623238025491679
2724,GPIX,Intrinsic Pathway of Fibrin Clot Formation,2.8884072758653052e-05,0,0,1,3.2618998660656874e-05
2725,GPIX,Intrinsic Pathway of Fibrin Clot Formation,0.00020918340658515497,1,0,1,0.00023623238025491679
2726,GPIX,GP1b-IX-V activation signalling,2.8884072758653052e-05,0,0,1,3.2618998660656874e-05
2727,GPIX,GP1b-IX-V activation signalling,0.00020918340658515497,1,0,1,0.00023623238025491679
2728,MMP9,EPH-Ephrin signaling,0.0034221148940966214,0,0,1,0.003864619857451054
2729,MMP9,EPH-Ephrin signaling,0.000497171779117827,1,0,1,0.0005614597959459319
2730,MMP9,Interleukin-4 and Interleukin-13 signaling,0.0034221148940966214,0,0,1,0.003864619857451054
2731,MMP9,Interleukin-4 and Interleukin-13 signaling,0.000497171779117827,1,0,1,0.0005614597959459319
2732,MMP9,Extra-nuclear estrogen signaling,0.0034221148940966214,0,0,1,0.003864619857451054
2733,MMP9,Extra-nuclear estrogen signaling,0.000497171779117827,1,0,1,0.0005614597959459319
2734,MMP9,Collagen degradation,0.0034221148940966214,0,0,1,0.003864619857451054
2735,MMP9,Collagen degradation,0.000497171779117827,1,0,1,0.0005614597959459319
2736,MMP9,Activation of Matrix Metalloproteinases,0.0034221148940966214,0,0,1,0.003864619857451054
2737,MMP9,Activation of Matrix Metalloproteinases,0.000497171779117827,1,0,1,0.0005614597959459319
2738,MMP9,Neutrophil degranulation,0.0034221148940966214,0,0,1,0.003864619857451054
2739,MMP9,Neutrophil degranulation,0.000497171779117827,1,0,1,0.0005614597959459319
2740,MMP9,Signaling by SCF-KIT,0.0034221148940966214,0,0,1,0.003864619857451054
2741,MMP9,Signaling by SCF-KIT,0.000497171779117827,1,0,1,0.0005614597959459319
2742,AMPN,Neutrophil degranulation,0.0005278559615881992,0,0,1,0.0005961116719215792
2743,AMPN,Neutrophil degranulation,0.0007659446526599707,1,0,1,0.0008649870053996488
2744,AMPN,Metabolism of Angiotensinogen to Angiotensins,0.0005278559615881992,0,0,1,0.0005961116719215792
2745,AMPN,Metabolism of Angiotensinogen to Angiotensins,0.0007659446526599707,1,0,1,0.0008649870053996488
2746,PVR,Adherens junctions interactions,4.0400575554534316e-05,0,0,1,4.56246711090398e-05
2747,PVR,Adherens junctions interactions,0.0002414283536211026,1,0,1,0.00027264683928799867
2748,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,4.0400575554534316e-05,0,0,1,4.56246711090398e-05
2749,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002414283536211026,1,0,1,0.00027264683928799867
2750,CBPN,Regulation of Complement cascade,0.0007285946210058359,0,0,1,0.0008228073362552851
2751,CBPN,Regulation of Complement cascade,0.0005847425250552074,1,0,1,0.00066035409206241
2752,B4GT1,Keratan sulfate/keratin metabolism,0.013347528191340371,0,0,1,0.015073463075458428
2753,B4GT1,Keratan sulfate/keratin metabolism,0.008641000161236116,1,0,1,0.009758345889834985
2754,B4GT1,Pre-NOTCH Processing in Golgi,0.013347528191340371,0,0,1,0.015073463075458428
2755,B4GT1,Pre-NOTCH Processing in Golgi,0.008641000161236116,1,0,1,0.009758345889834985
2756,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.013347528191340371,0,0,1,0.015073463075458428
2757,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.008641000161236116,1,0,1,0.009758345889834985
2758,B4GT1,Diseases associated with N-glycosylation of proteins,0.013347528191340371,0,0,1,0.015073463075458428
2759,B4GT1,Diseases associated with N-glycosylation of proteins,0.008641000161236116,1,0,1,0.009758345889834985
2760,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.013347528191340371,0,0,1,0.015073463075458428
2761,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.008641000161236116,1,0,1,0.009758345889834985
2762,B4GT1,Neutrophil degranulation,0.013347528191340371,0,0,1,0.015073463075458428
2763,B4GT1,Neutrophil degranulation,0.008641000161236116,1,0,1,0.009758345889834985
2764,B4GT1,Lactose synthesis,0.013347528191340371,0,0,1,0.015073463075458428
2765,B4GT1,Lactose synthesis,0.008641000161236116,1,0,1,0.009758345889834985
2766,EZRI,L1CAM interactions,0.00020434428566419265,0,0,1,0.0002307675249293347
2767,EZRI,L1CAM interactions,0.0009450725884610892,1,0,1,0.0010672775184725493
2768,EZRI,Netrin-1 signaling,0.00020434428566419265,0,0,1,0.0002307675249293347
2769,EZRI,Netrin-1 signaling,0.0009450725884610892,1,0,1,0.0010672775184725493
2770,EZRI,Sensory processing of sound by inner hair cells of the cochlea,0.00020434428566419265,0,0,1,0.0002307675249293347
2771,EZRI,Sensory processing of sound by inner hair cells of the cochlea,0.0009450725884610892,1,0,1,0.0010672775184725493
2772,EZRI,Sensory processing of sound by outer hair cells of the cochlea,0.00020434428566419265,0,0,1,0.0002307675249293347
2773,EZRI,Sensory processing of sound by outer hair cells of the cochlea,0.0009450725884610892,1,0,1,0.0010672775184725493
2774,TIMP2,Activation of Matrix Metalloproteinases,0.0010847602669518384,0,0,1,0.0012250278549875062
2775,TIMP2,Activation of Matrix Metalloproteinases,0.0006471953581844878,1,0,1,0.0007308825420223602
2776,TIMP2,Neutrophil degranulation,0.0010847602669518384,0,0,1,0.0012250278549875062
2777,TIMP2,Neutrophil degranulation,0.0006471953581844878,1,0,1,0.0007308825420223602
2778,CD44,Hyaluronan metabolism,0.005505356655066401,0,0,1,0.00621724030605245
2779,CD44,Hyaluronan metabolism,0.0036819432984353845,1,0,1,0.004158046011163663
2780,CD44,Interferon gamma signaling,0.005505356655066401,0,0,1,0.00621724030605245
2781,CD44,Interferon gamma signaling,0.0036819432984353845,1,0,1,0.004158046011163663
2782,CD44,Integrin cell surface interactions,0.005505356655066401,0,0,1,0.00621724030605245
2783,CD44,Integrin cell surface interactions,0.0036819432984353845,1,0,1,0.004158046011163663
2784,CD44,Neutrophil degranulation,0.005505356655066401,0,0,1,0.00621724030605245
2785,CD44,Neutrophil degranulation,0.0036819432984353845,1,0,1,0.004158046011163663
2786,CD36,Antigen processing-Cross presentation,0.0002947746121245117,0,0,1,0.00033289116664493134
2787,CD36,Antigen processing-Cross presentation,0.00015156055536206243,1,0,1,0.00017115846486304406
2788,CD36,Toll Like Receptor 4 (TLR4) Cascade,0.0002947746121245117,0,0,1,0.00033289116664493134
2789,CD36,Toll Like Receptor 4 (TLR4) Cascade,0.00015156055536206243,1,0,1,0.00017115846486304406
2790,CD36,Toll Like Receptor 2 (TLR2) Cascade,0.0002947746121245117,0,0,1,0.00033289116664493134
2791,CD36,Toll Like Receptor 2 (TLR2) Cascade,0.00015156055536206243,1,0,1,0.00017115846486304406
2792,CD36,Regulation of TLR by endogenous ligand,0.0002947746121245117,0,0,1,0.00033289116664493134
2793,CD36,Regulation of TLR by endogenous ligand,0.00015156055536206243,1,0,1,0.00017115846486304406
2794,CD36,PPARA activates gene expression,0.0002947746121245117,0,0,1,0.00033289116664493134
2795,CD36,PPARA activates gene expression,0.00015156055536206243,1,0,1,0.00017115846486304406
2796,CD36,Free fatty acids regulate insulin secretion,0.0002947746121245117,0,0,1,0.00033289116664493134
2797,CD36,Free fatty acids regulate insulin secretion,0.00015156055536206243,1,0,1,0.00017115846486304406
2798,CD36,Interleukin-4 and Interleukin-13 signaling,0.0002947746121245117,0,0,1,0.00033289116664493134
2799,CD36,Interleukin-4 and Interleukin-13 signaling,0.00015156055536206243,1,0,1,0.00017115846486304406
2800,CD36,MyD88 deficiency (TLR2/4),0.0002947746121245117,0,0,1,0.00033289116664493134
2801,CD36,MyD88 deficiency (TLR2/4),0.00015156055536206243,1,0,1,0.00017115846486304406
2802,CD36,IRAK4 deficiency (TLR2/4),0.0002947746121245117,0,0,1,0.00033289116664493134
2803,CD36,IRAK4 deficiency (TLR2/4),0.00015156055536206243,1,0,1,0.00017115846486304406
2804,CD36,Platelet degranulation ,0.0002947746121245117,0,0,1,0.00033289116664493134
2805,CD36,Platelet degranulation ,0.00015156055536206243,1,0,1,0.00017115846486304406
2806,CD36,Transcriptional regulation of white adipocyte differentiation,0.0002947746121245117,0,0,1,0.00033289116664493134
2807,CD36,Transcriptional regulation of white adipocyte differentiation,0.00015156055536206243,1,0,1,0.00017115846486304406
2808,CD36,Neutrophil degranulation,0.0002947746121245117,0,0,1,0.00033289116664493134
2809,CD36,Neutrophil degranulation,0.00015156055536206243,1,0,1,0.00017115846486304406
2810,CD36,Scavenging by Class B Receptors,0.0002947746121245117,0,0,1,0.00033289116664493134
2811,CD36,Scavenging by Class B Receptors,0.00015156055536206243,1,0,1,0.00017115846486304406
2812,FAAA,Tyrosine catabolism,0.00010234595134848112,0,0,1,0.00011558004571774384
2813,FAAA,Tyrosine catabolism,2.8687639117518804e-05,1,0,1,3.2397164685559076e-05
2814,HSP76,Regulation of HSF1-mediated heat shock response,0.00017378869944339957,0,0,1,0.00019626087365685971
2815,HSP76,Regulation of HSF1-mediated heat shock response,0.00012053053058126389,1,0,1,0.00013611602658841418
2816,HSP76,Neutrophil degranulation,0.00017378869944339957,0,0,1,0.00019626087365685971
2817,HSP76,Neutrophil degranulation,0.00012053053058126389,1,0,1,0.00013611602658841418
2818,AATC,Methionine salvage pathway,0.00022902773309332528,0,0,1,0.00025864272609500363
2819,AATC,Methionine salvage pathway,0.0011078246015532953,1,0,1,0.001251074579968438
2820,AATC,Gluconeogenesis,0.00022902773309332528,0,0,1,0.00025864272609500363
2821,AATC,Gluconeogenesis,0.0011078246015532953,1,0,1,0.001251074579968438
2822,AATC,Aspartate and asparagine metabolism,0.00022902773309332528,0,0,1,0.00025864272609500363
2823,AATC,Aspartate and asparagine metabolism,0.0011078246015532953,1,0,1,0.001251074579968438
2824,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0008889713514741596,0,0,1,0.0010039219733792891
2825,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.000917981805319444,1,0,1,0.0010366836951430903
2826,CTRB1,Activation of Matrix Metalloproteinases,0.0008889713514741596,0,0,1,0.0010039219733792891
2827,CTRB1,Activation of Matrix Metalloproteinases,0.000917981805319444,1,0,1,0.0010366836951430903
2828,IBP3,Transcriptional Regulation by TP53,0.0010155886572686674,0,0,1,0.0011469118405852473
2829,IBP3,Transcriptional Regulation by TP53,0.0015071598303768438,1,0,1,0.0017020468304190309
2830,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0010155886572686674,0,0,1,0.0011469118405852473
2831,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0015071598303768438,1,0,1,0.0017020468304190309
2832,IBP3,Post-translational protein phosphorylation,0.0010155886572686674,0,0,1,0.0011469118405852473
2833,IBP3,Post-translational protein phosphorylation,0.0015071598303768438,1,0,1,0.0017020468304190309
2834,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0010301533829942162,0,0,1,0.0011633598939087587
2835,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0011641998915245513,1,0,1,0.0013147396151396173
2836,VINC,RAF/MAP kinase cascade,0.005085698606063456,0,0,1,0.005743317343292287
2837,VINC,RAF/MAP kinase cascade,0.00812375717820023,1,0,1,0.009174219533698893
2838,VINC,Signaling by RAS mutants,0.005085698606063456,0,0,1,0.005743317343292287
2839,VINC,Signaling by RAS mutants,0.00812375717820023,1,0,1,0.009174219533698893
2840,VINC,Signaling by moderate kinase activity BRAF mutants,0.005085698606063456,0,0,1,0.005743317343292287
2841,VINC,Signaling by moderate kinase activity BRAF mutants,0.00812375717820023,1,0,1,0.009174219533698893
2842,VINC,Signaling by high-kinase activity BRAF mutants,0.005085698606063456,0,0,1,0.005743317343292287
2843,VINC,Signaling by high-kinase activity BRAF mutants,0.00812375717820023,1,0,1,0.009174219533698893
2844,VINC,Signaling by BRAF and RAF1 fusions,0.005085698606063456,0,0,1,0.005743317343292287
2845,VINC,Signaling by BRAF and RAF1 fusions,0.00812375717820023,1,0,1,0.009174219533698893
2846,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005085698606063456,0,0,1,0.005743317343292287
2847,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00812375717820023,1,0,1,0.009174219533698893
2848,VINC,Signaling by RAF1 mutants,0.005085698606063456,0,0,1,0.005743317343292287
2849,VINC,Signaling by RAF1 mutants,0.00812375717820023,1,0,1,0.009174219533698893
2850,VINC,Platelet degranulation ,0.005085698606063456,0,0,1,0.005743317343292287
2851,VINC,Platelet degranulation ,0.00812375717820023,1,0,1,0.009174219533698893
2852,VINC,Signaling by ALK fusions and activated point mutants,0.005085698606063456,0,0,1,0.005743317343292287
2853,VINC,Signaling by ALK fusions and activated point mutants,0.00812375717820023,1,0,1,0.009174219533698893
2854,VINC,Neutrophil degranulation,0.005085698606063456,0,0,1,0.005743317343292287
2855,VINC,Neutrophil degranulation,0.00812375717820023,1,0,1,0.009174219533698893
2856,VINC,Smooth Muscle Contraction,0.005085698606063456,0,0,1,0.005743317343292287
2857,VINC,Smooth Muscle Contraction,0.00812375717820023,1,0,1,0.009174219533698893
2858,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.0011338938447483697,0,0,1,0.0012805147706219436
2859,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.0005997310759015688,1,0,1,0.0006772807742539366
2860,LBP,Regulation of TLR by endogenous ligand,0.0011338938447483697,0,0,1,0.0012805147706219436
2861,LBP,Regulation of TLR by endogenous ligand,0.0005997310759015688,1,0,1,0.0006772807742539366
2862,LBP,Interleukin-4 and Interleukin-13 signaling,0.0011338938447483697,0,0,1,0.0012805147706219436
2863,LBP,Interleukin-4 and Interleukin-13 signaling,0.0005997310759015688,1,0,1,0.0006772807742539366
2864,ML12A,EPH-Ephrin signaling,0.0007428321485090907,0,0,1,0.0008388858821875102
2865,ML12A,EPH-Ephrin signaling,0.0019558666759704802,1,0,1,0.002208774815691179
2866,ML12A,Smooth Muscle Contraction,0.0007428321485090907,0,0,1,0.0008388858821875102
2867,ML12A,Smooth Muscle Contraction,0.0019558666759704802,1,0,1,0.002208774815691179
2868,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.002831021524549113,0,0,1,0.0031970937093659577
2869,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.0011278415995190335,1,0,1,0.001273679924972604
2870,VCAM1,Interferon gamma signaling,0.002831021524549113,0,0,1,0.0031970937093659577
2871,VCAM1,Interferon gamma signaling,0.0011278415995190335,1,0,1,0.001273679924972604
2872,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002831021524549113,0,0,1,0.0031970937093659577
2873,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0011278415995190335,1,0,1,0.001273679924972604
2874,VCAM1,Integrin cell surface interactions,0.002831021524549113,0,0,1,0.0031970937093659577
2875,VCAM1,Integrin cell surface interactions,0.0011278415995190335,1,0,1,0.001273679924972604
2876,A1AG2,Platelet degranulation ,0.0006134902869742632,0,0,1,0.0006928191538758845
2877,A1AG2,Platelet degranulation ,0.0004926258357637538,1,0,1,0.0005563260282319064
2878,A1AG2,Neutrophil degranulation,0.0006134902869742632,0,0,1,0.0006928191538758845
2879,A1AG2,Neutrophil degranulation,0.0004926258357637538,1,0,1,0.0005563260282319064
2880,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0038109094650331677,0,0,1,0.004303688464382553
2881,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004293930643028122,1,0,1,0.004849167881005551
2882,ITIH2,Post-translational protein phosphorylation,0.0038109094650331677,0,0,1,0.004303688464382553
2883,ITIH2,Post-translational protein phosphorylation,0.004293930643028122,1,0,1,0.004849167881005551
2884,TYPH,Pyrimidine catabolism,0.0001452199977251356,0,0,1,0.00016399802586280734
2885,TYPH,Pyrimidine catabolism,0.001041598399308614,1,0,1,0.0011762848361407611
2886,TYPH,Pyrimidine salvage,0.0001452199977251356,0,0,1,0.00016399802586280734
2887,TYPH,Pyrimidine salvage,0.001041598399308614,1,0,1,0.0011762848361407611
2888,C4BPB,Regulation of Complement cascade,0.000610726007568567,0,0,1,0.0006896974325388173
2889,C4BPB,Regulation of Complement cascade,0.0004886317242056142,1,0,1,0.0005518154482782384
2890,FLNA,Antiviral mechanism by IFN-stimulated genes,0.00041209765378123406,0,0,1,0.0004653849520830788
2891,FLNA,Antiviral mechanism by IFN-stimulated genes,0.0001826653742867207,1,0,1,0.0002062853687218306
2892,FLNA,RHO GTPase Effectors,0.00041209765378123406,0,0,1,0.0004653849520830788
2893,FLNA,RHO GTPase Effectors,0.0001826653742867207,1,0,1,0.0002062853687218306
2894,FLNA,Platelet degranulation ,0.00041209765378123406,0,0,1,0.0004653849520830788
2895,FLNA,Platelet degranulation ,0.0001826653742867207,1,0,1,0.0002062853687218306
2896,FLNA,GP1b-IX-V activation signalling,0.00041209765378123406,0,0,1,0.0004653849520830788
2897,FLNA,GP1b-IX-V activation signalling,0.0001826653742867207,1,0,1,0.0002062853687218306
2898,TENX,ECM proteoglycans,0.0022822926645309,0,0,1,0.002577410117666248
2899,TENX,ECM proteoglycans,0.0011101041858138866,1,0,1,0.0012536489314653476
2900,GPX3,Detoxification of Reactive Oxygen Species,0.0024142592498585867,0,0,1,0.0027264409661211532
2901,GPX3,Detoxification of Reactive Oxygen Species,0.0009107981005575215,1,0,1,0.0010285710838099983
2902,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00032777283441937284,0,0,1,0.0003701563050426207
2903,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00048177009491240743,1,0,1,0.0005440665591726331
2904,IBP4,Post-translational protein phosphorylation,0.00032777283441937284,0,0,1,0.0003701563050426207
2905,IBP4,Post-translational protein phosphorylation,0.00048177009491240743,1,0,1,0.0005440665591726331
2906,CPN2,Regulation of Complement cascade,0.0002533329477472102,0,0,1,0.00028609078616833726
2907,CPN2,Regulation of Complement cascade,0.0002038955498909243,1,0,1,0.00023026076427582384
2908,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.00044720230459742785,0,0,1,0.0005050288959106753
2909,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0004081696059150778,1,0,1,0.000460948978349189
2910,MMP8,Collagen degradation,0.0019875264164890033,0,0,1,0.0022445283966421575
2911,MMP8,Collagen degradation,0.0012366367843200637,1,0,1,0.001396543138099208
2912,MMP8,Activation of Matrix Metalloproteinases,0.0019875264164890033,0,0,1,0.0022445283966421575
2913,MMP8,Activation of Matrix Metalloproteinases,0.0012366367843200637,1,0,1,0.001396543138099208
2914,MMP8,Neutrophil degranulation,0.0019875264164890033,0,0,1,0.0022445283966421575
2915,MMP8,Neutrophil degranulation,0.0012366367843200637,1,0,1,0.001396543138099208
2916,MRC1,Antigen processing-Cross presentation,0.0005024609482890884,0,0,1,0.0005674328941151184
2917,MRC1,Antigen processing-Cross presentation,0.000526910072099772,1,0,1,0.000595043471871886
2918,MRC1,Modulation by Mtb of host immune system,0.0005024609482890884,0,0,1,0.0005674328941151184
2919,MRC1,Modulation by Mtb of host immune system,0.000526910072099772,1,0,1,0.000595043471871886
2920,HV102,Initial triggering of complement,0.0007272459399977896,0,0,1,0.0008212842607401835
2921,HV102,Initial triggering of complement,0.000195230077723157,1,0,1,0.00022047478196660528
2922,HV102,Regulation of Complement cascade,0.0007272459399977896,0,0,1,0.0008212842607401835
2923,HV102,Regulation of Complement cascade,0.000195230077723157,1,0,1,0.00022047478196660528
2924,HV102,FCGR activation,0.0007272459399977896,0,0,1,0.0008212842607401835
2925,HV102,FCGR activation,0.000195230077723157,1,0,1,0.00022047478196660528
2926,HV102,Regulation of actin dynamics for phagocytic cup formation,0.0007272459399977896,0,0,1,0.0008212842607401835
2927,HV102,Regulation of actin dynamics for phagocytic cup formation,0.000195230077723157,1,0,1,0.00022047478196660528
2928,HV102,Role of phospholipids in phagocytosis,0.0007272459399977896,0,0,1,0.0008212842607401835
2929,HV102,Role of phospholipids in phagocytosis,0.000195230077723157,1,0,1,0.00022047478196660528
2930,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007272459399977896,0,0,1,0.0008212842607401835
2931,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.000195230077723157,1,0,1,0.00022047478196660528
2932,HV102,FCERI mediated MAPK activation,0.0007272459399977896,0,0,1,0.0008212842607401835
2933,HV102,FCERI mediated MAPK activation,0.000195230077723157,1,0,1,0.00022047478196660528
2934,HV102,FCERI mediated Ca+2 mobilization,0.0007272459399977896,0,0,1,0.0008212842607401835
2935,HV102,FCERI mediated Ca+2 mobilization,0.000195230077723157,1,0,1,0.00022047478196660528
2936,HV102,FCERI mediated NF-kB activation,0.0007272459399977896,0,0,1,0.0008212842607401835
2937,HV102,FCERI mediated NF-kB activation,0.000195230077723157,1,0,1,0.00022047478196660528
2938,HV102,Parasite infection,0.0007272459399977896,0,0,1,0.0008212842607401835
2939,HV102,Parasite infection,0.000195230077723157,1,0,1,0.00022047478196660528
2940,HV102,Leishmania parasite growth and survival,0.0007272459399977896,0,0,1,0.0008212842607401835
2941,HV102,Leishmania parasite growth and survival,0.000195230077723157,1,0,1,0.00022047478196660528
2942,HV102,Potential therapeutics for SARS,0.0007272459399977896,0,0,1,0.0008212842607401835
2943,HV102,Potential therapeutics for SARS,0.000195230077723157,1,0,1,0.00022047478196660528
2944,HV102,CD22 mediated BCR regulation,0.0007272459399977896,0,0,1,0.0008212842607401835
2945,HV102,CD22 mediated BCR regulation,0.000195230077723157,1,0,1,0.00022047478196660528
2946,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007272459399977896,0,0,1,0.0008212842607401835
2947,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.000195230077723157,1,0,1,0.00022047478196660528
2948,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007272459399977896,0,0,1,0.0008212842607401835
2949,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.000195230077723157,1,0,1,0.00022047478196660528
2950,HV102,Scavenging of heme from plasma,0.0007272459399977896,0,0,1,0.0008212842607401835
2951,HV102,Scavenging of heme from plasma,0.000195230077723157,1,0,1,0.00022047478196660528
2952,EST1,Metabolism of Angiotensinogen to Angiotensins,0.003961748149846373,0,0,1,0.004474031715454139
2953,EST1,Metabolism of Angiotensinogen to Angiotensins,0.0055900497343107525,1,0,1,0.006312884831723117
2954,EST1,Physiological factors,0.003961748149846373,0,0,1,0.004474031715454139
2955,EST1,Physiological factors,0.0055900497343107525,1,0,1,0.006312884831723117
2956,EST1,Aspirin ADME,0.003961748149846373,0,0,1,0.004474031715454139
2957,EST1,Aspirin ADME,0.0055900497343107525,1,0,1,0.006312884831723117
2958,FBLN1,Molecules associated with elastic fibres,0.0002061919190173354,0,0,1,0.00023285407104681367
2959,FBLN1,Molecules associated with elastic fibres,0.00019867019438588336,1,0,1,0.0002243597313555504
2960,SAHH,Methylation,0.0010134440636661774,0,0,1,0.0011444899350447164
2961,SAHH,Methylation,0.0017593769713536585,1,0,1,0.0019868775276846292
2962,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0010134440636661774,0,0,1,0.0011444899350447164
2963,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0017593769713536585,1,0,1,0.0019868775276846292
2964,SAHH,Defective AHCY causes HMAHCHD,0.0010134440636661774,0,0,1,0.0011444899350447164
2965,SAHH,Defective AHCY causes HMAHCHD,0.0017593769713536585,1,0,1,0.0019868775276846292
2966,PRTN3,Other interleukin signaling,0.003399843095499059,0,0,1,0.003839468149286675
2967,PRTN3,Other interleukin signaling,0.0011286563768214185,1,0,1,0.001274600059053324
2968,PRTN3,Common Pathway of Fibrin Clot Formation,0.003399843095499059,0,0,1,0.003839468149286675
2969,PRTN3,Common Pathway of Fibrin Clot Formation,0.0011286563768214185,1,0,1,0.001274600059053324
2970,PRTN3,Neutrophil degranulation,0.003399843095499059,0,0,1,0.003839468149286675
2971,PRTN3,Neutrophil degranulation,0.0011286563768214185,1,0,1,0.001274600059053324
2972,ALAT1,Alanine metabolism,0.00016811446947003373,0,0,1,0.00018985292345371425
2973,ALAT1,Alanine metabolism,0.0005876475904192445,1,0,1,0.0006636348040316132
2974,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00104533354985926,0,0,1,0.001180502969498439
2975,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0011735731037185873,1,0,1,0.0013253248535358099
2976,THIL,Utilization of Ketone Bodies,0.00010440839688875733,0,0,1,0.00011790918083930639
2977,THIL,Utilization of Ketone Bodies,0.0007336736250601397,1,0,1,0.0008285430933913758
2978,THIL,Synthesis of Ketone Bodies,0.00010440839688875733,0,0,1,0.00011790918083930639
2979,THIL,Synthesis of Ketone Bodies,0.0007336736250601397,1,0,1,0.0008285430933913758
2980,THIL,Branched-chain amino acid catabolism,0.00010440839688875733,0,0,1,0.00011790918083930639
2981,THIL,Branched-chain amino acid catabolism,0.0007336736250601397,1,0,1,0.0008285430933913758
2982,TENA,Integrin cell surface interactions,0.001228294522550798,0,0,1,0.0013871221597021428
2983,TENA,Integrin cell surface interactions,0.0011012514795798354,1,0,1,0.0012436515043294809
2984,TENA,ECM proteoglycans,0.001228294522550798,0,0,1,0.0013871221597021428
2985,TENA,ECM proteoglycans,0.0011012514795798354,1,0,1,0.0012436515043294809
2986,TENA,Syndecan interactions,0.001228294522550798,0,0,1,0.0013871221597021428
2987,TENA,Syndecan interactions,0.0011012514795798354,1,0,1,0.0012436515043294809
2988,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001228294522550798,0,0,1,0.0013871221597021428
2989,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0011012514795798354,1,0,1,0.0012436515043294809
2990,TENA,Post-translational protein phosphorylation,0.001228294522550798,0,0,1,0.0013871221597021428
2991,TENA,Post-translational protein phosphorylation,0.0011012514795798354,1,0,1,0.0012436515043294809
2992,ZA2G,Miscellaneous transport and binding events,0.001645770443346134,0,0,1,0.00185858082881244
2993,ZA2G,Miscellaneous transport and binding events,0.0008792083548920567,1,0,1,0.000992896548568302
2994,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.01101867929881032,0,0,1,0.012443476662494813
2995,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.00562814600188947,1,0,1,0.00635590723065936
2996,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.01101867929881032,0,0,1,0.012443476662494813
2997,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00562814600188947,1,0,1,0.00635590723065936
2998,PSA1,Antigen processing-Cross presentation,0.01101867929881032,0,0,1,0.012443476662494813
2999,PSA1,Antigen processing-Cross presentation,0.00562814600188947,1,0,1,0.00635590723065936
3000,PSA1,PTEN Regulation,0.01101867929881032,0,0,1,0.012443476662494813
3001,PSA1,PTEN Regulation,0.00562814600188947,1,0,1,0.00635590723065936
3002,PSA1,Host Interactions of HIV factors,0.01101867929881032,0,0,1,0.012443476662494813
3003,PSA1,Host Interactions of HIV factors,0.00562814600188947,1,0,1,0.00635590723065936
3004,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.01101867929881032,0,0,1,0.012443476662494813
3005,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.00562814600188947,1,0,1,0.00635590723065936
3006,PSA1,APC/C-mediated degradation of cell cycle proteins,0.01101867929881032,0,0,1,0.012443476662494813
3007,PSA1,APC/C-mediated degradation of cell cycle proteins,0.00562814600188947,1,0,1,0.00635590723065936
3008,PSA1,Degradation of AXIN,0.01101867929881032,0,0,1,0.012443476662494813
3009,PSA1,Degradation of AXIN,0.00562814600188947,1,0,1,0.00635590723065936
3010,PSA1,Degradation of DVL,0.01101867929881032,0,0,1,0.012443476662494813
3011,PSA1,Degradation of DVL,0.00562814600188947,1,0,1,0.00635590723065936
3012,PSA1,Downstream TCR signaling,0.01101867929881032,0,0,1,0.012443476662494813
3013,PSA1,Downstream TCR signaling,0.00562814600188947,1,0,1,0.00635590723065936
3014,PSA1,Transcriptional regulation by RUNX3,0.01101867929881032,0,0,1,0.012443476662494813
3015,PSA1,Transcriptional regulation by RUNX3,0.00562814600188947,1,0,1,0.00635590723065936
3016,PSA1,Transcriptional regulation by RUNX2,0.01101867929881032,0,0,1,0.012443476662494813
3017,PSA1,Transcriptional regulation by RUNX2,0.00562814600188947,1,0,1,0.00635590723065936
3018,PSA1,Transcriptional regulation by RUNX1,0.01101867929881032,0,0,1,0.012443476662494813
3019,PSA1,Transcriptional regulation by RUNX1,0.00562814600188947,1,0,1,0.00635590723065936
3020,PSA1,FCERI mediated NF-kB activation,0.01101867929881032,0,0,1,0.012443476662494813
3021,PSA1,FCERI mediated NF-kB activation,0.00562814600188947,1,0,1,0.00635590723065936
3022,PSA1,Mitotic Metaphase and Anaphase,0.01101867929881032,0,0,1,0.012443476662494813
3023,PSA1,Mitotic Metaphase and Anaphase,0.00562814600188947,1,0,1,0.00635590723065936
3024,PSA1,Regulation of ornithine decarboxylase (ODC),0.01101867929881032,0,0,1,0.012443476662494813
3025,PSA1,Regulation of ornithine decarboxylase (ODC),0.00562814600188947,1,0,1,0.00635590723065936
3026,PSA1,Signaling by ROBO receptors,0.01101867929881032,0,0,1,0.012443476662494813
3027,PSA1,Signaling by ROBO receptors,0.00562814600188947,1,0,1,0.00635590723065936
3028,PSA1,PCP/CE pathway,0.01101867929881032,0,0,1,0.012443476662494813
3029,PSA1,PCP/CE pathway,0.00562814600188947,1,0,1,0.00635590723065936
3030,PSA1,Interleukin-1 family signaling,0.01101867929881032,0,0,1,0.012443476662494813
3031,PSA1,Interleukin-1 family signaling,0.00562814600188947,1,0,1,0.00635590723065936
3032,PSA1,G2/M Transition,0.01101867929881032,0,0,1,0.012443476662494813
3033,PSA1,G2/M Transition,0.00562814600188947,1,0,1,0.00635590723065936
3034,PSA1,G1/S Transition,0.01101867929881032,0,0,1,0.012443476662494813
3035,PSA1,G1/S Transition,0.00562814600188947,1,0,1,0.00635590723065936
3036,PSA1,Hh mutants are degraded by ERAD,0.01101867929881032,0,0,1,0.012443476662494813
3037,PSA1,Hh mutants are degraded by ERAD,0.00562814600188947,1,0,1,0.00635590723065936
3038,PSA1,CLEC7A (Dectin-1) signaling,0.01101867929881032,0,0,1,0.012443476662494813
3039,PSA1,CLEC7A (Dectin-1) signaling,0.00562814600188947,1,0,1,0.00635590723065936
3040,PSA1,Degradation of GLI1 by the proteasome,0.01101867929881032,0,0,1,0.012443476662494813
3041,PSA1,Degradation of GLI1 by the proteasome,0.00562814600188947,1,0,1,0.00635590723065936
3042,PSA1,Degradation of GLI2 by the proteasome,0.01101867929881032,0,0,1,0.012443476662494813
3043,PSA1,Degradation of GLI2 by the proteasome,0.00562814600188947,1,0,1,0.00635590723065936
3044,PSA1,GLI3 is processed to GLI3R by the proteasome,0.01101867929881032,0,0,1,0.012443476662494813
3045,PSA1,GLI3 is processed to GLI3R by the proteasome,0.00562814600188947,1,0,1,0.00635590723065936
3046,PSA1,Defective CFTR causes cystic fibrosis,0.01101867929881032,0,0,1,0.012443476662494813
3047,PSA1,Defective CFTR causes cystic fibrosis,0.00562814600188947,1,0,1,0.00635590723065936
3048,PSA1,NIK-->noncanonical NF-kB signaling,0.01101867929881032,0,0,1,0.012443476662494813
3049,PSA1,NIK-->noncanonical NF-kB signaling,0.00562814600188947,1,0,1,0.00635590723065936
3050,PSA1,RAF/MAP kinase cascade,0.01101867929881032,0,0,1,0.012443476662494813
3051,PSA1,RAF/MAP kinase cascade,0.00562814600188947,1,0,1,0.00635590723065936
3052,PSA1,UCH proteinases,0.01101867929881032,0,0,1,0.012443476662494813
3053,PSA1,UCH proteinases,0.00562814600188947,1,0,1,0.00635590723065936
3054,PSA1,Ub-specific processing proteases,0.01101867929881032,0,0,1,0.012443476662494813
3055,PSA1,Ub-specific processing proteases,0.00562814600188947,1,0,1,0.00635590723065936
3056,PSA1,Orc1 removal from chromatin,0.01101867929881032,0,0,1,0.012443476662494813
3057,PSA1,Orc1 removal from chromatin,0.00562814600188947,1,0,1,0.00635590723065936
3058,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.01101867929881032,0,0,1,0.012443476662494813
3059,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.00562814600188947,1,0,1,0.00635590723065936
3060,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.01101867929881032,0,0,1,0.012443476662494813
3061,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.00562814600188947,1,0,1,0.00635590723065936
3062,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.01101867929881032,0,0,1,0.012443476662494813
3063,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.00562814600188947,1,0,1,0.00635590723065936
3064,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.01101867929881032,0,0,1,0.012443476662494813
3065,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.00562814600188947,1,0,1,0.00635590723065936
3066,PSA1,p53-Independent G1/S DNA damage checkpoint,0.01101867929881032,0,0,1,0.012443476662494813
3067,PSA1,p53-Independent G1/S DNA damage checkpoint,0.00562814600188947,1,0,1,0.00635590723065936
3068,PSA1,Negative regulation of NOTCH4 signaling,0.01101867929881032,0,0,1,0.012443476662494813
3069,PSA1,Negative regulation of NOTCH4 signaling,0.00562814600188947,1,0,1,0.00635590723065936
3070,PSA1,KEAP1-NFE2L2 pathway,0.01101867929881032,0,0,1,0.012443476662494813
3071,PSA1,KEAP1-NFE2L2 pathway,0.00562814600188947,1,0,1,0.00635590723065936
3072,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.01101867929881032,0,0,1,0.012443476662494813
3073,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.00562814600188947,1,0,1,0.00635590723065936
3074,PSA1,Degradation of beta-catenin by the destruction complex,0.01101867929881032,0,0,1,0.012443476662494813
3075,PSA1,Degradation of beta-catenin by the destruction complex,0.00562814600188947,1,0,1,0.00635590723065936
3076,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.01101867929881032,0,0,1,0.012443476662494813
3077,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00562814600188947,1,0,1,0.00635590723065936
3078,PSA1,Hedgehog ligand biogenesis,0.01101867929881032,0,0,1,0.012443476662494813
3079,PSA1,Hedgehog ligand biogenesis,0.00562814600188947,1,0,1,0.00635590723065936
3080,PSA1,Hedgehog 'on' state,0.01101867929881032,0,0,1,0.012443476662494813
3081,PSA1,Hedgehog 'on' state,0.00562814600188947,1,0,1,0.00635590723065936
3082,PSA1,MAPK6/MAPK4 signaling,0.01101867929881032,0,0,1,0.012443476662494813
3083,PSA1,MAPK6/MAPK4 signaling,0.00562814600188947,1,0,1,0.00635590723065936
3084,PSA1,Neddylation,0.01101867929881032,0,0,1,0.012443476662494813
3085,PSA1,Neddylation,0.00562814600188947,1,0,1,0.00635590723065936
3086,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.003112727018583774,0,0,1,0.0035152258235382383
3087,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.004088976221906049,1,0,1,0.004617711325555844
3088,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.003112727018583774,0,0,1,0.0035152258235382383
3089,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.004088976221906049,1,0,1,0.004617711325555844
3090,PSA3,Antigen processing-Cross presentation,0.003112727018583774,0,0,1,0.0035152258235382383
3091,PSA3,Antigen processing-Cross presentation,0.004088976221906049,1,0,1,0.004617711325555844
3092,PSA3,PTEN Regulation,0.003112727018583774,0,0,1,0.0035152258235382383
3093,PSA3,PTEN Regulation,0.004088976221906049,1,0,1,0.004617711325555844
3094,PSA3,Host Interactions of HIV factors,0.003112727018583774,0,0,1,0.0035152258235382383
3095,PSA3,Host Interactions of HIV factors,0.004088976221906049,1,0,1,0.004617711325555844
3096,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.003112727018583774,0,0,1,0.0035152258235382383
3097,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.004088976221906049,1,0,1,0.004617711325555844
3098,PSA3,APC/C-mediated degradation of cell cycle proteins,0.003112727018583774,0,0,1,0.0035152258235382383
3099,PSA3,APC/C-mediated degradation of cell cycle proteins,0.004088976221906049,1,0,1,0.004617711325555844
3100,PSA3,Degradation of AXIN,0.003112727018583774,0,0,1,0.0035152258235382383
3101,PSA3,Degradation of AXIN,0.004088976221906049,1,0,1,0.004617711325555844
3102,PSA3,Degradation of DVL,0.003112727018583774,0,0,1,0.0035152258235382383
3103,PSA3,Degradation of DVL,0.004088976221906049,1,0,1,0.004617711325555844
3104,PSA3,Downstream TCR signaling,0.003112727018583774,0,0,1,0.0035152258235382383
3105,PSA3,Downstream TCR signaling,0.004088976221906049,1,0,1,0.004617711325555844
3106,PSA3,Transcriptional regulation by RUNX3,0.003112727018583774,0,0,1,0.0035152258235382383
3107,PSA3,Transcriptional regulation by RUNX3,0.004088976221906049,1,0,1,0.004617711325555844
3108,PSA3,Transcriptional regulation by RUNX2,0.003112727018583774,0,0,1,0.0035152258235382383
3109,PSA3,Transcriptional regulation by RUNX2,0.004088976221906049,1,0,1,0.004617711325555844
3110,PSA3,Transcriptional regulation by RUNX1,0.003112727018583774,0,0,1,0.0035152258235382383
3111,PSA3,Transcriptional regulation by RUNX1,0.004088976221906049,1,0,1,0.004617711325555844
3112,PSA3,FCERI mediated NF-kB activation,0.003112727018583774,0,0,1,0.0035152258235382383
3113,PSA3,FCERI mediated NF-kB activation,0.004088976221906049,1,0,1,0.004617711325555844
3114,PSA3,Mitotic Metaphase and Anaphase,0.003112727018583774,0,0,1,0.0035152258235382383
3115,PSA3,Mitotic Metaphase and Anaphase,0.004088976221906049,1,0,1,0.004617711325555844
3116,PSA3,Regulation of ornithine decarboxylase (ODC),0.003112727018583774,0,0,1,0.0035152258235382383
3117,PSA3,Regulation of ornithine decarboxylase (ODC),0.004088976221906049,1,0,1,0.004617711325555844
3118,PSA3,Signaling by ROBO receptors,0.003112727018583774,0,0,1,0.0035152258235382383
3119,PSA3,Signaling by ROBO receptors,0.004088976221906049,1,0,1,0.004617711325555844
3120,PSA3,PCP/CE pathway,0.003112727018583774,0,0,1,0.0035152258235382383
3121,PSA3,PCP/CE pathway,0.004088976221906049,1,0,1,0.004617711325555844
3122,PSA3,Interleukin-1 family signaling,0.003112727018583774,0,0,1,0.0035152258235382383
3123,PSA3,Interleukin-1 family signaling,0.004088976221906049,1,0,1,0.004617711325555844
3124,PSA3,G2/M Transition,0.003112727018583774,0,0,1,0.0035152258235382383
3125,PSA3,G2/M Transition,0.004088976221906049,1,0,1,0.004617711325555844
3126,PSA3,G1/S Transition,0.003112727018583774,0,0,1,0.0035152258235382383
3127,PSA3,G1/S Transition,0.004088976221906049,1,0,1,0.004617711325555844
3128,PSA3,Hh mutants are degraded by ERAD,0.003112727018583774,0,0,1,0.0035152258235382383
3129,PSA3,Hh mutants are degraded by ERAD,0.004088976221906049,1,0,1,0.004617711325555844
3130,PSA3,CLEC7A (Dectin-1) signaling,0.003112727018583774,0,0,1,0.0035152258235382383
3131,PSA3,CLEC7A (Dectin-1) signaling,0.004088976221906049,1,0,1,0.004617711325555844
3132,PSA3,Degradation of GLI1 by the proteasome,0.003112727018583774,0,0,1,0.0035152258235382383
3133,PSA3,Degradation of GLI1 by the proteasome,0.004088976221906049,1,0,1,0.004617711325555844
3134,PSA3,Degradation of GLI2 by the proteasome,0.003112727018583774,0,0,1,0.0035152258235382383
3135,PSA3,Degradation of GLI2 by the proteasome,0.004088976221906049,1,0,1,0.004617711325555844
3136,PSA3,GLI3 is processed to GLI3R by the proteasome,0.003112727018583774,0,0,1,0.0035152258235382383
3137,PSA3,GLI3 is processed to GLI3R by the proteasome,0.004088976221906049,1,0,1,0.004617711325555844
3138,PSA3,Defective CFTR causes cystic fibrosis,0.003112727018583774,0,0,1,0.0035152258235382383
3139,PSA3,Defective CFTR causes cystic fibrosis,0.004088976221906049,1,0,1,0.004617711325555844
3140,PSA3,NIK-->noncanonical NF-kB signaling,0.003112727018583774,0,0,1,0.0035152258235382383
3141,PSA3,NIK-->noncanonical NF-kB signaling,0.004088976221906049,1,0,1,0.004617711325555844
3142,PSA3,RAF/MAP kinase cascade,0.003112727018583774,0,0,1,0.0035152258235382383
3143,PSA3,RAF/MAP kinase cascade,0.004088976221906049,1,0,1,0.004617711325555844
3144,PSA3,UCH proteinases,0.003112727018583774,0,0,1,0.0035152258235382383
3145,PSA3,UCH proteinases,0.004088976221906049,1,0,1,0.004617711325555844
3146,PSA3,Ub-specific processing proteases,0.003112727018583774,0,0,1,0.0035152258235382383
3147,PSA3,Ub-specific processing proteases,0.004088976221906049,1,0,1,0.004617711325555844
3148,PSA3,Orc1 removal from chromatin,0.003112727018583774,0,0,1,0.0035152258235382383
3149,PSA3,Orc1 removal from chromatin,0.004088976221906049,1,0,1,0.004617711325555844
3150,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.003112727018583774,0,0,1,0.0035152258235382383
3151,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.004088976221906049,1,0,1,0.004617711325555844
3152,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.003112727018583774,0,0,1,0.0035152258235382383
3153,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.004088976221906049,1,0,1,0.004617711325555844
3154,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.003112727018583774,0,0,1,0.0035152258235382383
3155,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.004088976221906049,1,0,1,0.004617711325555844
3156,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.003112727018583774,0,0,1,0.0035152258235382383
3157,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.004088976221906049,1,0,1,0.004617711325555844
3158,PSA3,p53-Independent G1/S DNA damage checkpoint,0.003112727018583774,0,0,1,0.0035152258235382383
3159,PSA3,p53-Independent G1/S DNA damage checkpoint,0.004088976221906049,1,0,1,0.004617711325555844
3160,PSA3,Negative regulation of NOTCH4 signaling,0.003112727018583774,0,0,1,0.0035152258235382383
3161,PSA3,Negative regulation of NOTCH4 signaling,0.004088976221906049,1,0,1,0.004617711325555844
3162,PSA3,KEAP1-NFE2L2 pathway,0.003112727018583774,0,0,1,0.0035152258235382383
3163,PSA3,KEAP1-NFE2L2 pathway,0.004088976221906049,1,0,1,0.004617711325555844
3164,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.003112727018583774,0,0,1,0.0035152258235382383
3165,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.004088976221906049,1,0,1,0.004617711325555844
3166,PSA3,Degradation of beta-catenin by the destruction complex,0.003112727018583774,0,0,1,0.0035152258235382383
3167,PSA3,Degradation of beta-catenin by the destruction complex,0.004088976221906049,1,0,1,0.004617711325555844
3168,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.003112727018583774,0,0,1,0.0035152258235382383
3169,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.004088976221906049,1,0,1,0.004617711325555844
3170,PSA3,Hedgehog ligand biogenesis,0.003112727018583774,0,0,1,0.0035152258235382383
3171,PSA3,Hedgehog ligand biogenesis,0.004088976221906049,1,0,1,0.004617711325555844
3172,PSA3,Hedgehog 'on' state,0.003112727018583774,0,0,1,0.0035152258235382383
3173,PSA3,Hedgehog 'on' state,0.004088976221906049,1,0,1,0.004617711325555844
3174,PSA3,MAPK6/MAPK4 signaling,0.003112727018583774,0,0,1,0.0035152258235382383
3175,PSA3,MAPK6/MAPK4 signaling,0.004088976221906049,1,0,1,0.004617711325555844
3176,PSA3,Neddylation,0.003112727018583774,0,0,1,0.0035152258235382383
3177,PSA3,Neddylation,0.004088976221906049,1,0,1,0.004617711325555844
3178,PTX3,Neutrophil degranulation,0.0002303475388922601,0,0,1,0.0002601331926212273
3179,PTX3,Neutrophil degranulation,0.00013551386153008694,1,0,1,0.00015303681391074295
3180,HGFL,Signaling by MST1,0.0004861685552638851,0,0,1,0.0005490337732325278
3181,HGFL,Signaling by MST1,0.0002695095720943944,1,0,1,0.00030435916861993163
3182,STOM,RHO GTPase cycle,0.0001889487068580409,0,0,1,0.00021338118302893715
3183,STOM,RHO GTPase cycle,0.00032664830374636635,1,0,1,0.00036888636417163747
3184,STOM,Neutrophil degranulation,0.0001889487068580409,0,0,1,0.00021338118302893715
3185,STOM,Neutrophil degranulation,0.00032664830374636635,1,0,1,0.00036888636417163747
3186,STOM,Stimuli-sensing channels,0.0001889487068580409,0,0,1,0.00021338118302893715
3187,STOM,Stimuli-sensing channels,0.00032664830374636635,1,0,1,0.00036888636417163747
3188,PON1,Arachidonic acid metabolism,0.0059464324845320505,0,0,1,0.006715350527931667
3189,PON1,Arachidonic acid metabolism,0.0018708450095680765,1,0,1,0.002112759214093721
3190,PON1,Atorvastatin ADME,0.0059464324845320505,0,0,1,0.006715350527931667
3191,PON1,Atorvastatin ADME,0.0018708450095680765,1,0,1,0.002112759214093721
3192,1433T,Activation of BH3-only proteins,0.0003841175651447381,0,0,1,0.00043378682942963475
3193,1433T,Activation of BH3-only proteins,0.0008270386795925218,1,0,1,0.0009339809453934473
3194,1433T,RHO GTPase Effectors,0.0003841175651447381,0,0,1,0.00043378682942963475
3195,1433T,RHO GTPase Effectors,0.0008270386795925218,1,0,1,0.0009339809453934473
3196,1433T,Transcriptional Regulation by TP53,0.0003841175651447381,0,0,1,0.00043378682942963475
3197,1433T,Transcriptional Regulation by TP53,0.0008270386795925218,1,0,1,0.0009339809453934473
3198,1433T,FOXO-mediated transcription,0.0003841175651447381,0,0,1,0.00043378682942963475
3199,1433T,FOXO-mediated transcription,0.0008270386795925218,1,0,1,0.0009339809453934473
3200,1433T,G2/M DNA damage checkpoint,0.0003841175651447381,0,0,1,0.00043378682942963475
3201,1433T,G2/M DNA damage checkpoint,0.0008270386795925218,1,0,1,0.0009339809453934473
3202,1433T,SARS-CoV-2 Infection,0.0003841175651447381,0,0,1,0.00043378682942963475
3203,1433T,SARS-CoV-2 Infection,0.0008270386795925218,1,0,1,0.0009339809453934473
3204,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0003841175651447381,0,0,1,0.00043378682942963475
3205,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0008270386795925218,1,0,1,0.0009339809453934473
3206,CALR,Antigen processing-Cross presentation,0.013188046736519802,0,0,1,0.014893359479796581
3207,CALR,Antigen processing-Cross presentation,0.013102824166228022,1,0,1,0.014797116995939366
3208,CALR,Virus Assembly and Release,0.013188046736519802,0,0,1,0.014893359479796581
3209,CALR,Virus Assembly and Release,0.013102824166228022,1,0,1,0.014797116995939366
3210,CALR,ATF6 (ATF6-alpha) activates chaperones,0.013188046736519802,0,0,1,0.014893359479796581
3211,CALR,ATF6 (ATF6-alpha) activates chaperones,0.013102824166228022,1,0,1,0.014797116995939366
3212,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.013188046736519802,0,0,1,0.014893359479796581
3213,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.013102824166228022,1,0,1,0.014797116995939366
3214,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.013188046736519802,0,0,1,0.014893359479796581
3215,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.013102824166228022,1,0,1,0.014797116995939366
3216,CALR,Scavenging by Class A Receptors,0.013188046736519802,0,0,1,0.014893359479796581
3217,CALR,Scavenging by Class A Receptors,0.013102824166228022,1,0,1,0.014797116995939366
3218,CALR,Scavenging by Class F Receptors,0.013188046736519802,0,0,1,0.014893359479796581
3219,CALR,Scavenging by Class F Receptors,0.013102824166228022,1,0,1,0.014797116995939366
3220,PROP,Initial triggering of complement,0.003719414617135875,0,0,1,0.0042003626506735186
3221,PROP,Initial triggering of complement,0.003998815379238322,1,0,1,0.004515892013895883
3222,PROP,Activation of C3 and C5,0.003719414617135875,0,0,1,0.0042003626506735186
3223,PROP,Activation of C3 and C5,0.003998815379238322,1,0,1,0.004515892013895883
3224,PROP,Regulation of Complement cascade,0.003719414617135875,0,0,1,0.0042003626506735186
3225,PROP,Regulation of Complement cascade,0.003998815379238322,1,0,1,0.004515892013895883
3226,PROP,Diseases associated with O-glycosylation of proteins,0.003719414617135875,0,0,1,0.0042003626506735186
3227,PROP,Diseases associated with O-glycosylation of proteins,0.003998815379238322,1,0,1,0.004515892013895883
3228,PROP,O-glycosylation of TSR domain-containing proteins,0.003719414617135875,0,0,1,0.0042003626506735186
3229,PROP,O-glycosylation of TSR domain-containing proteins,0.003998815379238322,1,0,1,0.004515892013895883
3230,PROP,Neutrophil degranulation,0.003719414617135875,0,0,1,0.0042003626506735186
3231,PROP,Neutrophil degranulation,0.003998815379238322,1,0,1,0.004515892013895883
3232,IL1R2,Interleukin-1 family signaling,0.0005322498952137273,0,0,1,0.0006010737739161182
3233,IL1R2,Interleukin-1 family signaling,0.0002508721957424937,1,0,1,0.00028331184058761027
3234,IL1R2,Interleukin-10 signaling,0.0005322498952137273,0,0,1,0.0006010737739161182
3235,IL1R2,Interleukin-10 signaling,0.0002508721957424937,1,0,1,0.00028331184058761027
3236,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.003906117464406274,0,0,1,0.004411207567730083
3237,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.002658109347865477,1,0,1,0.0030018226993950695
3238,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.003906117464406274,0,0,1,0.004411207567730083
3239,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.002658109347865477,1,0,1,0.0030018226993950695
3240,PSA5,Antigen processing-Cross presentation,0.003906117464406274,0,0,1,0.004411207567730083
3241,PSA5,Antigen processing-Cross presentation,0.002658109347865477,1,0,1,0.0030018226993950695
3242,PSA5,PTEN Regulation,0.003906117464406274,0,0,1,0.004411207567730083
3243,PSA5,PTEN Regulation,0.002658109347865477,1,0,1,0.0030018226993950695
3244,PSA5,Host Interactions of HIV factors,0.003906117464406274,0,0,1,0.004411207567730083
3245,PSA5,Host Interactions of HIV factors,0.002658109347865477,1,0,1,0.0030018226993950695
3246,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.003906117464406274,0,0,1,0.004411207567730083
3247,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.002658109347865477,1,0,1,0.0030018226993950695
3248,PSA5,APC/C-mediated degradation of cell cycle proteins,0.003906117464406274,0,0,1,0.004411207567730083
3249,PSA5,APC/C-mediated degradation of cell cycle proteins,0.002658109347865477,1,0,1,0.0030018226993950695
3250,PSA5,Degradation of AXIN,0.003906117464406274,0,0,1,0.004411207567730083
3251,PSA5,Degradation of AXIN,0.002658109347865477,1,0,1,0.0030018226993950695
3252,PSA5,Degradation of DVL,0.003906117464406274,0,0,1,0.004411207567730083
3253,PSA5,Degradation of DVL,0.002658109347865477,1,0,1,0.0030018226993950695
3254,PSA5,Downstream TCR signaling,0.003906117464406274,0,0,1,0.004411207567730083
3255,PSA5,Downstream TCR signaling,0.002658109347865477,1,0,1,0.0030018226993950695
3256,PSA5,Transcriptional regulation by RUNX3,0.003906117464406274,0,0,1,0.004411207567730083
3257,PSA5,Transcriptional regulation by RUNX3,0.002658109347865477,1,0,1,0.0030018226993950695
3258,PSA5,Transcriptional regulation by RUNX2,0.003906117464406274,0,0,1,0.004411207567730083
3259,PSA5,Transcriptional regulation by RUNX2,0.002658109347865477,1,0,1,0.0030018226993950695
3260,PSA5,Transcriptional regulation by RUNX1,0.003906117464406274,0,0,1,0.004411207567730083
3261,PSA5,Transcriptional regulation by RUNX1,0.002658109347865477,1,0,1,0.0030018226993950695
3262,PSA5,FCERI mediated NF-kB activation,0.003906117464406274,0,0,1,0.004411207567730083
3263,PSA5,FCERI mediated NF-kB activation,0.002658109347865477,1,0,1,0.0030018226993950695
3264,PSA5,Mitotic Metaphase and Anaphase,0.003906117464406274,0,0,1,0.004411207567730083
3265,PSA5,Mitotic Metaphase and Anaphase,0.002658109347865477,1,0,1,0.0030018226993950695
3266,PSA5,Regulation of ornithine decarboxylase (ODC),0.003906117464406274,0,0,1,0.004411207567730083
3267,PSA5,Regulation of ornithine decarboxylase (ODC),0.002658109347865477,1,0,1,0.0030018226993950695
3268,PSA5,Signaling by ROBO receptors,0.003906117464406274,0,0,1,0.004411207567730083
3269,PSA5,Signaling by ROBO receptors,0.002658109347865477,1,0,1,0.0030018226993950695
3270,PSA5,PCP/CE pathway,0.003906117464406274,0,0,1,0.004411207567730083
3271,PSA5,PCP/CE pathway,0.002658109347865477,1,0,1,0.0030018226993950695
3272,PSA5,Interleukin-1 family signaling,0.003906117464406274,0,0,1,0.004411207567730083
3273,PSA5,Interleukin-1 family signaling,0.002658109347865477,1,0,1,0.0030018226993950695
3274,PSA5,G2/M Transition,0.003906117464406274,0,0,1,0.004411207567730083
3275,PSA5,G2/M Transition,0.002658109347865477,1,0,1,0.0030018226993950695
3276,PSA5,G1/S Transition,0.003906117464406274,0,0,1,0.004411207567730083
3277,PSA5,G1/S Transition,0.002658109347865477,1,0,1,0.0030018226993950695
3278,PSA5,Hh mutants are degraded by ERAD,0.003906117464406274,0,0,1,0.004411207567730083
3279,PSA5,Hh mutants are degraded by ERAD,0.002658109347865477,1,0,1,0.0030018226993950695
3280,PSA5,CLEC7A (Dectin-1) signaling,0.003906117464406274,0,0,1,0.004411207567730083
3281,PSA5,CLEC7A (Dectin-1) signaling,0.002658109347865477,1,0,1,0.0030018226993950695
3282,PSA5,Degradation of GLI1 by the proteasome,0.003906117464406274,0,0,1,0.004411207567730083
3283,PSA5,Degradation of GLI1 by the proteasome,0.002658109347865477,1,0,1,0.0030018226993950695
3284,PSA5,Degradation of GLI2 by the proteasome,0.003906117464406274,0,0,1,0.004411207567730083
3285,PSA5,Degradation of GLI2 by the proteasome,0.002658109347865477,1,0,1,0.0030018226993950695
3286,PSA5,GLI3 is processed to GLI3R by the proteasome,0.003906117464406274,0,0,1,0.004411207567730083
3287,PSA5,GLI3 is processed to GLI3R by the proteasome,0.002658109347865477,1,0,1,0.0030018226993950695
3288,PSA5,Defective CFTR causes cystic fibrosis,0.003906117464406274,0,0,1,0.004411207567730083
3289,PSA5,Defective CFTR causes cystic fibrosis,0.002658109347865477,1,0,1,0.0030018226993950695
3290,PSA5,NIK-->noncanonical NF-kB signaling,0.003906117464406274,0,0,1,0.004411207567730083
3291,PSA5,NIK-->noncanonical NF-kB signaling,0.002658109347865477,1,0,1,0.0030018226993950695
3292,PSA5,RAF/MAP kinase cascade,0.003906117464406274,0,0,1,0.004411207567730083
3293,PSA5,RAF/MAP kinase cascade,0.002658109347865477,1,0,1,0.0030018226993950695
3294,PSA5,UCH proteinases,0.003906117464406274,0,0,1,0.004411207567730083
3295,PSA5,UCH proteinases,0.002658109347865477,1,0,1,0.0030018226993950695
3296,PSA5,Ub-specific processing proteases,0.003906117464406274,0,0,1,0.004411207567730083
3297,PSA5,Ub-specific processing proteases,0.002658109347865477,1,0,1,0.0030018226993950695
3298,PSA5,Orc1 removal from chromatin,0.003906117464406274,0,0,1,0.004411207567730083
3299,PSA5,Orc1 removal from chromatin,0.002658109347865477,1,0,1,0.0030018226993950695
3300,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.003906117464406274,0,0,1,0.004411207567730083
3301,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.002658109347865477,1,0,1,0.0030018226993950695
3302,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.003906117464406274,0,0,1,0.004411207567730083
3303,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.002658109347865477,1,0,1,0.0030018226993950695
3304,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.003906117464406274,0,0,1,0.004411207567730083
3305,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.002658109347865477,1,0,1,0.0030018226993950695
3306,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.003906117464406274,0,0,1,0.004411207567730083
3307,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.002658109347865477,1,0,1,0.0030018226993950695
3308,PSA5,p53-Independent G1/S DNA damage checkpoint,0.003906117464406274,0,0,1,0.004411207567730083
3309,PSA5,p53-Independent G1/S DNA damage checkpoint,0.002658109347865477,1,0,1,0.0030018226993950695
3310,PSA5,Negative regulation of NOTCH4 signaling,0.003906117464406274,0,0,1,0.004411207567730083
3311,PSA5,Negative regulation of NOTCH4 signaling,0.002658109347865477,1,0,1,0.0030018226993950695
3312,PSA5,KEAP1-NFE2L2 pathway,0.003906117464406274,0,0,1,0.004411207567730083
3313,PSA5,KEAP1-NFE2L2 pathway,0.002658109347865477,1,0,1,0.0030018226993950695
3314,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.003906117464406274,0,0,1,0.004411207567730083
3315,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.002658109347865477,1,0,1,0.0030018226993950695
3316,PSA5,Neutrophil degranulation,0.003906117464406274,0,0,1,0.004411207567730083
3317,PSA5,Neutrophil degranulation,0.002658109347865477,1,0,1,0.0030018226993950695
3318,PSA5,Degradation of beta-catenin by the destruction complex,0.003906117464406274,0,0,1,0.004411207567730083
3319,PSA5,Degradation of beta-catenin by the destruction complex,0.002658109347865477,1,0,1,0.0030018226993950695
3320,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.003906117464406274,0,0,1,0.004411207567730083
3321,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.002658109347865477,1,0,1,0.0030018226993950695
3322,PSA5,Hedgehog ligand biogenesis,0.003906117464406274,0,0,1,0.004411207567730083
3323,PSA5,Hedgehog ligand biogenesis,0.002658109347865477,1,0,1,0.0030018226993950695
3324,PSA5,Hedgehog 'on' state,0.003906117464406274,0,0,1,0.004411207567730083
3325,PSA5,Hedgehog 'on' state,0.002658109347865477,1,0,1,0.0030018226993950695
3326,PSA5,MAPK6/MAPK4 signaling,0.003906117464406274,0,0,1,0.004411207567730083
3327,PSA5,MAPK6/MAPK4 signaling,0.002658109347865477,1,0,1,0.0030018226993950695
3328,PSA5,Neddylation,0.003906117464406274,0,0,1,0.004411207567730083
3329,PSA5,Neddylation,0.002658109347865477,1,0,1,0.0030018226993950695
3330,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.006892859269179366,0,0,1,0.007784157350251146
3331,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.0048749673305561545,1,0,1,0.005505336943126182
3332,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.006892859269179366,0,0,1,0.007784157350251146
3333,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0048749673305561545,1,0,1,0.005505336943126182
3334,PSB6,Antigen processing-Cross presentation,0.006892859269179366,0,0,1,0.007784157350251146
3335,PSB6,Antigen processing-Cross presentation,0.0048749673305561545,1,0,1,0.005505336943126182
3336,PSB6,PTEN Regulation,0.006892859269179366,0,0,1,0.007784157350251146
3337,PSB6,PTEN Regulation,0.0048749673305561545,1,0,1,0.005505336943126182
3338,PSB6,Host Interactions of HIV factors,0.006892859269179366,0,0,1,0.007784157350251146
3339,PSB6,Host Interactions of HIV factors,0.0048749673305561545,1,0,1,0.005505336943126182
3340,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.006892859269179366,0,0,1,0.007784157350251146
3341,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0048749673305561545,1,0,1,0.005505336943126182
3342,PSB6,APC/C-mediated degradation of cell cycle proteins,0.006892859269179366,0,0,1,0.007784157350251146
3343,PSB6,APC/C-mediated degradation of cell cycle proteins,0.0048749673305561545,1,0,1,0.005505336943126182
3344,PSB6,Degradation of AXIN,0.006892859269179366,0,0,1,0.007784157350251146
3345,PSB6,Degradation of AXIN,0.0048749673305561545,1,0,1,0.005505336943126182
3346,PSB6,Degradation of DVL,0.006892859269179366,0,0,1,0.007784157350251146
3347,PSB6,Degradation of DVL,0.0048749673305561545,1,0,1,0.005505336943126182
3348,PSB6,Downstream TCR signaling,0.006892859269179366,0,0,1,0.007784157350251146
3349,PSB6,Downstream TCR signaling,0.0048749673305561545,1,0,1,0.005505336943126182
3350,PSB6,Transcriptional regulation by RUNX3,0.006892859269179366,0,0,1,0.007784157350251146
3351,PSB6,Transcriptional regulation by RUNX3,0.0048749673305561545,1,0,1,0.005505336943126182
3352,PSB6,Transcriptional regulation by RUNX2,0.006892859269179366,0,0,1,0.007784157350251146
3353,PSB6,Transcriptional regulation by RUNX2,0.0048749673305561545,1,0,1,0.005505336943126182
3354,PSB6,Transcriptional regulation by RUNX1,0.006892859269179366,0,0,1,0.007784157350251146
3355,PSB6,Transcriptional regulation by RUNX1,0.0048749673305561545,1,0,1,0.005505336943126182
3356,PSB6,FCERI mediated NF-kB activation,0.006892859269179366,0,0,1,0.007784157350251146
3357,PSB6,FCERI mediated NF-kB activation,0.0048749673305561545,1,0,1,0.005505336943126182
3358,PSB6,Mitotic Metaphase and Anaphase,0.006892859269179366,0,0,1,0.007784157350251146
3359,PSB6,Mitotic Metaphase and Anaphase,0.0048749673305561545,1,0,1,0.005505336943126182
3360,PSB6,Regulation of ornithine decarboxylase (ODC),0.006892859269179366,0,0,1,0.007784157350251146
3361,PSB6,Regulation of ornithine decarboxylase (ODC),0.0048749673305561545,1,0,1,0.005505336943126182
3362,PSB6,Signaling by ROBO receptors,0.006892859269179366,0,0,1,0.007784157350251146
3363,PSB6,Signaling by ROBO receptors,0.0048749673305561545,1,0,1,0.005505336943126182
3364,PSB6,PCP/CE pathway,0.006892859269179366,0,0,1,0.007784157350251146
3365,PSB6,PCP/CE pathway,0.0048749673305561545,1,0,1,0.005505336943126182
3366,PSB6,Interleukin-1 family signaling,0.006892859269179366,0,0,1,0.007784157350251146
3367,PSB6,Interleukin-1 family signaling,0.0048749673305561545,1,0,1,0.005505336943126182
3368,PSB6,G2/M Transition,0.006892859269179366,0,0,1,0.007784157350251146
3369,PSB6,G2/M Transition,0.0048749673305561545,1,0,1,0.005505336943126182
3370,PSB6,G1/S Transition,0.006892859269179366,0,0,1,0.007784157350251146
3371,PSB6,G1/S Transition,0.0048749673305561545,1,0,1,0.005505336943126182
3372,PSB6,Hh mutants are degraded by ERAD,0.006892859269179366,0,0,1,0.007784157350251146
3373,PSB6,Hh mutants are degraded by ERAD,0.0048749673305561545,1,0,1,0.005505336943126182
3374,PSB6,CLEC7A (Dectin-1) signaling,0.006892859269179366,0,0,1,0.007784157350251146
3375,PSB6,CLEC7A (Dectin-1) signaling,0.0048749673305561545,1,0,1,0.005505336943126182
3376,PSB6,Degradation of GLI1 by the proteasome,0.006892859269179366,0,0,1,0.007784157350251146
3377,PSB6,Degradation of GLI1 by the proteasome,0.0048749673305561545,1,0,1,0.005505336943126182
3378,PSB6,Degradation of GLI2 by the proteasome,0.006892859269179366,0,0,1,0.007784157350251146
3379,PSB6,Degradation of GLI2 by the proteasome,0.0048749673305561545,1,0,1,0.005505336943126182
3380,PSB6,GLI3 is processed to GLI3R by the proteasome,0.006892859269179366,0,0,1,0.007784157350251146
3381,PSB6,GLI3 is processed to GLI3R by the proteasome,0.0048749673305561545,1,0,1,0.005505336943126182
3382,PSB6,Defective CFTR causes cystic fibrosis,0.006892859269179366,0,0,1,0.007784157350251146
3383,PSB6,Defective CFTR causes cystic fibrosis,0.0048749673305561545,1,0,1,0.005505336943126182
3384,PSB6,NIK-->noncanonical NF-kB signaling,0.006892859269179366,0,0,1,0.007784157350251146
3385,PSB6,NIK-->noncanonical NF-kB signaling,0.0048749673305561545,1,0,1,0.005505336943126182
3386,PSB6,RAF/MAP kinase cascade,0.006892859269179366,0,0,1,0.007784157350251146
3387,PSB6,RAF/MAP kinase cascade,0.0048749673305561545,1,0,1,0.005505336943126182
3388,PSB6,UCH proteinases,0.006892859269179366,0,0,1,0.007784157350251146
3389,PSB6,UCH proteinases,0.0048749673305561545,1,0,1,0.005505336943126182
3390,PSB6,Ub-specific processing proteases,0.006892859269179366,0,0,1,0.007784157350251146
3391,PSB6,Ub-specific processing proteases,0.0048749673305561545,1,0,1,0.005505336943126182
3392,PSB6,Orc1 removal from chromatin,0.006892859269179366,0,0,1,0.007784157350251146
3393,PSB6,Orc1 removal from chromatin,0.0048749673305561545,1,0,1,0.005505336943126182
3394,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.006892859269179366,0,0,1,0.007784157350251146
3395,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.0048749673305561545,1,0,1,0.005505336943126182
3396,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.006892859269179366,0,0,1,0.007784157350251146
3397,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.0048749673305561545,1,0,1,0.005505336943126182
3398,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.006892859269179366,0,0,1,0.007784157350251146
3399,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.0048749673305561545,1,0,1,0.005505336943126182
3400,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.006892859269179366,0,0,1,0.007784157350251146
3401,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.0048749673305561545,1,0,1,0.005505336943126182
3402,PSB6,p53-Independent G1/S DNA damage checkpoint,0.006892859269179366,0,0,1,0.007784157350251146
3403,PSB6,p53-Independent G1/S DNA damage checkpoint,0.0048749673305561545,1,0,1,0.005505336943126182
3404,PSB6,Negative regulation of NOTCH4 signaling,0.006892859269179366,0,0,1,0.007784157350251146
3405,PSB6,Negative regulation of NOTCH4 signaling,0.0048749673305561545,1,0,1,0.005505336943126182
3406,PSB6,KEAP1-NFE2L2 pathway,0.006892859269179366,0,0,1,0.007784157350251146
3407,PSB6,KEAP1-NFE2L2 pathway,0.0048749673305561545,1,0,1,0.005505336943126182
3408,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.006892859269179366,0,0,1,0.007784157350251146
3409,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.0048749673305561545,1,0,1,0.005505336943126182
3410,PSB6,Degradation of beta-catenin by the destruction complex,0.006892859269179366,0,0,1,0.007784157350251146
3411,PSB6,Degradation of beta-catenin by the destruction complex,0.0048749673305561545,1,0,1,0.005505336943126182
3412,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.006892859269179366,0,0,1,0.007784157350251146
3413,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0048749673305561545,1,0,1,0.005505336943126182
3414,PSB6,Hedgehog ligand biogenesis,0.006892859269179366,0,0,1,0.007784157350251146
3415,PSB6,Hedgehog ligand biogenesis,0.0048749673305561545,1,0,1,0.005505336943126182
3416,PSB6,Hedgehog 'on' state,0.006892859269179366,0,0,1,0.007784157350251146
3417,PSB6,Hedgehog 'on' state,0.0048749673305561545,1,0,1,0.005505336943126182
3418,PSB6,MAPK6/MAPK4 signaling,0.006892859269179366,0,0,1,0.007784157350251146
3419,PSB6,MAPK6/MAPK4 signaling,0.0048749673305561545,1,0,1,0.005505336943126182
3420,PSB6,Neddylation,0.006892859269179366,0,0,1,0.007784157350251146
3421,PSB6,Neddylation,0.0048749673305561545,1,0,1,0.005505336943126182
3422,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.004410010212937815,0,0,1,0.004980257404531266
3423,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.005728338690247708,1,0,1,0.006469055580432363
3424,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.004410010212937815,0,0,1,0.004980257404531266
3425,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.005728338690247708,1,0,1,0.006469055580432363
3426,PSB5,Antigen processing-Cross presentation,0.004410010212937815,0,0,1,0.004980257404531266
3427,PSB5,Antigen processing-Cross presentation,0.005728338690247708,1,0,1,0.006469055580432363
3428,PSB5,PTEN Regulation,0.004410010212937815,0,0,1,0.004980257404531266
3429,PSB5,PTEN Regulation,0.005728338690247708,1,0,1,0.006469055580432363
3430,PSB5,Host Interactions of HIV factors,0.004410010212937815,0,0,1,0.004980257404531266
3431,PSB5,Host Interactions of HIV factors,0.005728338690247708,1,0,1,0.006469055580432363
3432,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.004410010212937815,0,0,1,0.004980257404531266
3433,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.005728338690247708,1,0,1,0.006469055580432363
3434,PSB5,APC/C-mediated degradation of cell cycle proteins,0.004410010212937815,0,0,1,0.004980257404531266
3435,PSB5,APC/C-mediated degradation of cell cycle proteins,0.005728338690247708,1,0,1,0.006469055580432363
3436,PSB5,Degradation of AXIN,0.004410010212937815,0,0,1,0.004980257404531266
3437,PSB5,Degradation of AXIN,0.005728338690247708,1,0,1,0.006469055580432363
3438,PSB5,Degradation of DVL,0.004410010212937815,0,0,1,0.004980257404531266
3439,PSB5,Degradation of DVL,0.005728338690247708,1,0,1,0.006469055580432363
3440,PSB5,Downstream TCR signaling,0.004410010212937815,0,0,1,0.004980257404531266
3441,PSB5,Downstream TCR signaling,0.005728338690247708,1,0,1,0.006469055580432363
3442,PSB5,Transcriptional regulation by RUNX3,0.004410010212937815,0,0,1,0.004980257404531266
3443,PSB5,Transcriptional regulation by RUNX3,0.005728338690247708,1,0,1,0.006469055580432363
3444,PSB5,Transcriptional regulation by RUNX2,0.004410010212937815,0,0,1,0.004980257404531266
3445,PSB5,Transcriptional regulation by RUNX2,0.005728338690247708,1,0,1,0.006469055580432363
3446,PSB5,Transcriptional regulation by RUNX1,0.004410010212937815,0,0,1,0.004980257404531266
3447,PSB5,Transcriptional regulation by RUNX1,0.005728338690247708,1,0,1,0.006469055580432363
3448,PSB5,FCERI mediated NF-kB activation,0.004410010212937815,0,0,1,0.004980257404531266
3449,PSB5,FCERI mediated NF-kB activation,0.005728338690247708,1,0,1,0.006469055580432363
3450,PSB5,Mitotic Metaphase and Anaphase,0.004410010212937815,0,0,1,0.004980257404531266
3451,PSB5,Mitotic Metaphase and Anaphase,0.005728338690247708,1,0,1,0.006469055580432363
3452,PSB5,Regulation of ornithine decarboxylase (ODC),0.004410010212937815,0,0,1,0.004980257404531266
3453,PSB5,Regulation of ornithine decarboxylase (ODC),0.005728338690247708,1,0,1,0.006469055580432363
3454,PSB5,Signaling by ROBO receptors,0.004410010212937815,0,0,1,0.004980257404531266
3455,PSB5,Signaling by ROBO receptors,0.005728338690247708,1,0,1,0.006469055580432363
3456,PSB5,PCP/CE pathway,0.004410010212937815,0,0,1,0.004980257404531266
3457,PSB5,PCP/CE pathway,0.005728338690247708,1,0,1,0.006469055580432363
3458,PSB5,Interleukin-1 family signaling,0.004410010212937815,0,0,1,0.004980257404531266
3459,PSB5,Interleukin-1 family signaling,0.005728338690247708,1,0,1,0.006469055580432363
3460,PSB5,G2/M Transition,0.004410010212937815,0,0,1,0.004980257404531266
3461,PSB5,G2/M Transition,0.005728338690247708,1,0,1,0.006469055580432363
3462,PSB5,G1/S Transition,0.004410010212937815,0,0,1,0.004980257404531266
3463,PSB5,G1/S Transition,0.005728338690247708,1,0,1,0.006469055580432363
3464,PSB5,Hh mutants are degraded by ERAD,0.004410010212937815,0,0,1,0.004980257404531266
3465,PSB5,Hh mutants are degraded by ERAD,0.005728338690247708,1,0,1,0.006469055580432363
3466,PSB5,CLEC7A (Dectin-1) signaling,0.004410010212937815,0,0,1,0.004980257404531266
3467,PSB5,CLEC7A (Dectin-1) signaling,0.005728338690247708,1,0,1,0.006469055580432363
3468,PSB5,Degradation of GLI1 by the proteasome,0.004410010212937815,0,0,1,0.004980257404531266
3469,PSB5,Degradation of GLI1 by the proteasome,0.005728338690247708,1,0,1,0.006469055580432363
3470,PSB5,Degradation of GLI2 by the proteasome,0.004410010212937815,0,0,1,0.004980257404531266
3471,PSB5,Degradation of GLI2 by the proteasome,0.005728338690247708,1,0,1,0.006469055580432363
3472,PSB5,GLI3 is processed to GLI3R by the proteasome,0.004410010212937815,0,0,1,0.004980257404531266
3473,PSB5,GLI3 is processed to GLI3R by the proteasome,0.005728338690247708,1,0,1,0.006469055580432363
3474,PSB5,Defective CFTR causes cystic fibrosis,0.004410010212937815,0,0,1,0.004980257404531266
3475,PSB5,Defective CFTR causes cystic fibrosis,0.005728338690247708,1,0,1,0.006469055580432363
3476,PSB5,NIK-->noncanonical NF-kB signaling,0.004410010212937815,0,0,1,0.004980257404531266
3477,PSB5,NIK-->noncanonical NF-kB signaling,0.005728338690247708,1,0,1,0.006469055580432363
3478,PSB5,RAF/MAP kinase cascade,0.004410010212937815,0,0,1,0.004980257404531266
3479,PSB5,RAF/MAP kinase cascade,0.005728338690247708,1,0,1,0.006469055580432363
3480,PSB5,UCH proteinases,0.004410010212937815,0,0,1,0.004980257404531266
3481,PSB5,UCH proteinases,0.005728338690247708,1,0,1,0.006469055580432363
3482,PSB5,Ub-specific processing proteases,0.004410010212937815,0,0,1,0.004980257404531266
3483,PSB5,Ub-specific processing proteases,0.005728338690247708,1,0,1,0.006469055580432363
3484,PSB5,Orc1 removal from chromatin,0.004410010212937815,0,0,1,0.004980257404531266
3485,PSB5,Orc1 removal from chromatin,0.005728338690247708,1,0,1,0.006469055580432363
3486,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.004410010212937815,0,0,1,0.004980257404531266
3487,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.005728338690247708,1,0,1,0.006469055580432363
3488,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.004410010212937815,0,0,1,0.004980257404531266
3489,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.005728338690247708,1,0,1,0.006469055580432363
3490,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.004410010212937815,0,0,1,0.004980257404531266
3491,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.005728338690247708,1,0,1,0.006469055580432363
3492,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.004410010212937815,0,0,1,0.004980257404531266
3493,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.005728338690247708,1,0,1,0.006469055580432363
3494,PSB5,p53-Independent G1/S DNA damage checkpoint,0.004410010212937815,0,0,1,0.004980257404531266
3495,PSB5,p53-Independent G1/S DNA damage checkpoint,0.005728338690247708,1,0,1,0.006469055580432363
3496,PSB5,Negative regulation of NOTCH4 signaling,0.004410010212937815,0,0,1,0.004980257404531266
3497,PSB5,Negative regulation of NOTCH4 signaling,0.005728338690247708,1,0,1,0.006469055580432363
3498,PSB5,KEAP1-NFE2L2 pathway,0.004410010212937815,0,0,1,0.004980257404531266
3499,PSB5,KEAP1-NFE2L2 pathway,0.005728338690247708,1,0,1,0.006469055580432363
3500,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.004410010212937815,0,0,1,0.004980257404531266
3501,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.005728338690247708,1,0,1,0.006469055580432363
3502,PSB5,Degradation of beta-catenin by the destruction complex,0.004410010212937815,0,0,1,0.004980257404531266
3503,PSB5,Degradation of beta-catenin by the destruction complex,0.005728338690247708,1,0,1,0.006469055580432363
3504,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.004410010212937815,0,0,1,0.004980257404531266
3505,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.005728338690247708,1,0,1,0.006469055580432363
3506,PSB5,Hedgehog ligand biogenesis,0.004410010212937815,0,0,1,0.004980257404531266
3507,PSB5,Hedgehog ligand biogenesis,0.005728338690247708,1,0,1,0.006469055580432363
3508,PSB5,Hedgehog 'on' state,0.004410010212937815,0,0,1,0.004980257404531266
3509,PSB5,Hedgehog 'on' state,0.005728338690247708,1,0,1,0.006469055580432363
3510,PSB5,MAPK6/MAPK4 signaling,0.004410010212937815,0,0,1,0.004980257404531266
3511,PSB5,MAPK6/MAPK4 signaling,0.005728338690247708,1,0,1,0.006469055580432363
3512,PSB5,Neddylation,0.004410010212937815,0,0,1,0.004980257404531266
3513,PSB5,Neddylation,0.005728338690247708,1,0,1,0.006469055580432363
3514,GRN,Neutrophil degranulation,0.0008272260902000374,0,0,1,0.0009341925895894242
3515,GRN,Neutrophil degranulation,0.00048368392056771635,1,0,1,0.0005462278567503285
3516,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0006868022199729599,0,0,1,0.0007756108662592517
3517,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0006923711595573429,1,0,1,0.0007818999112413118
3518,CCN2,Transcriptional regulation by RUNX3,0.0006868022199729599,0,0,1,0.0007756108662592517
3519,CCN2,Transcriptional regulation by RUNX3,0.0006923711595573429,1,0,1,0.0007818999112413118
3520,TKT,KEAP1-NFE2L2 pathway,0.002274706350464544,0,0,1,0.002568842836644715
3521,TKT,KEAP1-NFE2L2 pathway,0.002959242316026732,1,0,1,0.0033418944049058152
3522,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.002274706350464544,0,0,1,0.002568842836644715
3523,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.002959242316026732,1,0,1,0.0033418944049058152
3524,TKT,Pentose phosphate pathway,0.002274706350464544,0,0,1,0.002568842836644715
3525,TKT,Pentose phosphate pathway,0.002959242316026732,1,0,1,0.0033418944049058152
3526,KAIN,Platelet degranulation ,3.788050545394323e-05,0,0,1,4.2778737160500084e-05
3527,KAIN,Platelet degranulation ,5.183051154464001e-05,1,0,1,5.8532583018414106e-05
3528,PRDX6,Detoxification of Reactive Oxygen Species,0.00016735131784887669,0,0,1,0.00018899109063960938
3529,PRDX6,Detoxification of Reactive Oxygen Species,7.801448384436972e-05,1,0,1,8.810233810496752e-05
3530,PRDX6,Neutrophil degranulation,0.00016735131784887669,0,0,1,0.00018899109063960938
3531,PRDX6,Neutrophil degranulation,7.801448384436972e-05,1,0,1,8.810233810496752e-05
3532,BLVRB,Cytoprotection by HMOX1,0.003671942321881463,0,0,1,0.004146751833796661
3533,BLVRB,Cytoprotection by HMOX1,0.001376731676961943,1,0,1,0.0015547533445903036
3534,BLVRB,Heme degradation,0.003671942321881463,0,0,1,0.004146751833796661
3535,BLVRB,Heme degradation,0.001376731676961943,1,0,1,0.0015547533445903036
3536,PEBP1,RAF/MAP kinase cascade,0.0001844712755092324,0,0,1,0.00020832478643312762
3537,PEBP1,RAF/MAP kinase cascade,0.0009082511493163231,1,0,1,0.0010256947927890056
3538,PEBP1,Signaling by RAS mutants,0.0001844712755092324,0,0,1,0.00020832478643312762
3539,PEBP1,Signaling by RAS mutants,0.0009082511493163231,1,0,1,0.0010256947927890056
3540,PEBP1,Signaling by moderate kinase activity BRAF mutants,0.0001844712755092324,0,0,1,0.00020832478643312762
3541,PEBP1,Signaling by moderate kinase activity BRAF mutants,0.0009082511493163231,1,0,1,0.0010256947927890056
3542,PEBP1,Signaling by high-kinase activity BRAF mutants,0.0001844712755092324,0,0,1,0.00020832478643312762
3543,PEBP1,Signaling by high-kinase activity BRAF mutants,0.0009082511493163231,1,0,1,0.0010256947927890056
3544,PEBP1,Signaling by BRAF and RAF1 fusions,0.0001844712755092324,0,0,1,0.00020832478643312762
3545,PEBP1,Signaling by BRAF and RAF1 fusions,0.0009082511493163231,1,0,1,0.0010256947927890056
3546,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0001844712755092324,0,0,1,0.00020832478643312762
3547,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0009082511493163231,1,0,1,0.0010256947927890056
3548,PDIA3,Antigen processing-Cross presentation,0.0004225034533520016,0,0,1,0.00047713629910045005
3549,PDIA3,Antigen processing-Cross presentation,0.0004503744295213211,1,0,1,0.000508611200231416
3550,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0004225034533520016,0,0,1,0.00047713629910045005
3551,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0004503744295213211,1,0,1,0.000508611200231416
3552,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0004225034533520016,0,0,1,0.00047713629910045005
3553,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0004503744295213211,1,0,1,0.000508611200231416
3554,P30443,Antigen processing-Cross presentation,0.0026155210517909435,0,0,1,0.0029537274191960994
3555,P30443,Antigen processing-Cross presentation,0.002519394641595557,1,0,1,0.0028451711476613754
3556,P30443,Interferon gamma signaling,0.0026155210517909435,0,0,1,0.0029537274191960994
3557,P30443,Interferon gamma signaling,0.002519394641595557,1,0,1,0.0028451711476613754
3558,P30443,Interferon alpha/beta signaling,0.0026155210517909435,0,0,1,0.0029537274191960994
3559,P30443,Interferon alpha/beta signaling,0.002519394641595557,1,0,1,0.0028451711476613754
3560,P30443,SARS-CoV-2 Infection,0.0026155210517909435,0,0,1,0.0029537274191960994
3561,P30443,SARS-CoV-2 Infection,0.002519394641595557,1,0,1,0.0028451711476613754
3562,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0026155210517909435,0,0,1,0.0029537274191960994
3563,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.002519394641595557,1,0,1,0.0028451711476613754
3564,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0026155210517909435,0,0,1,0.0029537274191960994
3565,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002519394641595557,1,0,1,0.0028451711476613754
3566,ILEU,Neutrophil degranulation,0.0005276479405899967,0,0,1,0.0005958767522577753
3567,ILEU,Neutrophil degranulation,0.00030726550796528955,1,0,1,0.00034699722842178646
3568,CPSM,Urea cycle,0.0004642494030971657,0,0,1,0.0005242803113110347
3569,CPSM,Urea cycle,4.725091216794589e-05,1,0,1,5.3360807307179654e-05
3570,1433B,Activation of BH3-only proteins,0.0012562775673867124,0,0,1,0.0014187236208136249
3571,1433B,Activation of BH3-only proteins,0.0008012286833689608,1,0,1,0.000904833524277231
3572,1433B,Signaling by NTRK1 (TRKA),0.0012562775673867124,0,0,1,0.0014187236208136249
3573,1433B,Signaling by NTRK1 (TRKA),0.0008012286833689608,1,0,1,0.000904833524277231
3574,1433B,RHO GTPase Effectors,0.0012562775673867124,0,0,1,0.0014187236208136249
3575,1433B,RHO GTPase Effectors,0.0008012286833689608,1,0,1,0.000904833524277231
3576,1433B,Transcriptional Regulation by TP53,0.0012562775673867124,0,0,1,0.0014187236208136249
3577,1433B,Transcriptional Regulation by TP53,0.0008012286833689608,1,0,1,0.000904833524277231
3578,1433B,FOXO-mediated transcription,0.0012562775673867124,0,0,1,0.0014187236208136249
3579,1433B,FOXO-mediated transcription,0.0008012286833689608,1,0,1,0.000904833524277231
3580,1433B,RAF/MAP kinase cascade,0.0012562775673867124,0,0,1,0.0014187236208136249
3581,1433B,RAF/MAP kinase cascade,0.0008012286833689608,1,0,1,0.000904833524277231
3582,1433B,Signaling by RAS mutants,0.0012562775673867124,0,0,1,0.0014187236208136249
3583,1433B,Signaling by RAS mutants,0.0008012286833689608,1,0,1,0.000904833524277231
3584,1433B,Signaling by moderate kinase activity BRAF mutants,0.0012562775673867124,0,0,1,0.0014187236208136249
3585,1433B,Signaling by moderate kinase activity BRAF mutants,0.0008012286833689608,1,0,1,0.000904833524277231
3586,1433B,Signaling by high-kinase activity BRAF mutants,0.0012562775673867124,0,0,1,0.0014187236208136249
3587,1433B,Signaling by high-kinase activity BRAF mutants,0.0008012286833689608,1,0,1,0.000904833524277231
3588,1433B,Signaling by BRAF and RAF1 fusions,0.0012562775673867124,0,0,1,0.0014187236208136249
3589,1433B,Signaling by BRAF and RAF1 fusions,0.0008012286833689608,1,0,1,0.000904833524277231
3590,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0012562775673867124,0,0,1,0.0014187236208136249
3591,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0008012286833689608,1,0,1,0.000904833524277231
3592,1433B,Signaling by RAF1 mutants,0.0012562775673867124,0,0,1,0.0014187236208136249
3593,1433B,Signaling by RAF1 mutants,0.0008012286833689608,1,0,1,0.000904833524277231
3594,1433B,Signaling by MRAS-complex mutants,0.0012562775673867124,0,0,1,0.0014187236208136249
3595,1433B,Signaling by MRAS-complex mutants,0.0008012286833689608,1,0,1,0.000904833524277231
3596,1433B,G2/M DNA damage checkpoint,0.0012562775673867124,0,0,1,0.0014187236208136249
3597,1433B,G2/M DNA damage checkpoint,0.0008012286833689608,1,0,1,0.000904833524277231
3598,1433B,SARS-CoV-2 Infection,0.0012562775673867124,0,0,1,0.0014187236208136249
3599,1433B,SARS-CoV-2 Infection,0.0008012286833689608,1,0,1,0.000904833524277231
3600,1433B,Rap1 signalling,0.0012562775673867124,0,0,1,0.0014187236208136249
3601,1433B,Rap1 signalling,0.0008012286833689608,1,0,1,0.000904833524277231
3602,1433B,Signaling by Hippo,0.0012562775673867124,0,0,1,0.0014187236208136249
3603,1433B,Signaling by Hippo,0.0008012286833689608,1,0,1,0.000904833524277231
3604,1433B,mTORC1-mediated signalling,0.0012562775673867124,0,0,1,0.0014187236208136249
3605,1433B,mTORC1-mediated signalling,0.0008012286833689608,1,0,1,0.000904833524277231
3606,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0012562775673867124,0,0,1,0.0014187236208136249
3607,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0008012286833689608,1,0,1,0.000904833524277231
3608,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0012562775673867124,0,0,1,0.0014187236208136249
3609,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0008012286833689608,1,0,1,0.000904833524277231
3610,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0012562775673867124,0,0,1,0.0014187236208136249
3611,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0008012286833689608,1,0,1,0.000904833524277231
3612,PRDX2,Transcriptional Regulation by TP53,0.001148977310803446,0,0,1,0.001297548641266145
3613,PRDX2,Transcriptional Regulation by TP53,0.002301664087897891,1,0,1,0.0025992864104641047
3614,PRDX2,Neurodegenerative Diseases,0.001148977310803446,0,0,1,0.001297548641266145
3615,PRDX2,Neurodegenerative Diseases,0.002301664087897891,1,0,1,0.0025992864104641047
3616,PRDX2,Detoxification of Reactive Oxygen Species,0.001148977310803446,0,0,1,0.001297548641266145
3617,PRDX2,Detoxification of Reactive Oxygen Species,0.002301664087897891,1,0,1,0.0025992864104641047
3618,HPPD,Tyrosine catabolism,0.001028578415238842,0,0,1,0.0011615812710832178
3619,HPPD,Tyrosine catabolism,0.0003528804189213842,1,0,1,0.00039851048736609814
3620,CADH5,VEGFA-VEGFR2 Pathway,0.0008403357897541955,0,0,1,0.0009489974710122004
3621,CADH5,VEGFA-VEGFR2 Pathway,0.002629824300641714,1,0,1,0.0029698801847359434
3622,CADH5,Adherens junctions interactions,0.0008403357897541955,0,0,1,0.0009489974710122004
3623,CADH5,Adherens junctions interactions,0.002629824300641714,1,0,1,0.0029698801847359434
3624,MA1A1,Intra-Golgi traffic,0.0007106086118371334,0,0,1,0.0008024956020380699
3625,MA1A1,Intra-Golgi traffic,0.001847049684989441,1,0,1,0.002085886976682953
3626,HS71L,Regulation of HSF1-mediated heat shock response,0.0010887571334393298,0,0,1,0.0012295415461034257
3627,HS71L,Regulation of HSF1-mediated heat shock response,0.0013174243767150125,1,0,1,0.0014877771683603689
3628,HS71L,HSF1-dependent transactivation,0.0010887571334393298,0,0,1,0.0012295415461034257
3629,HS71L,HSF1-dependent transactivation,0.0013174243767150125,1,0,1,0.0014877771683603689
3630,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0010887571334393298,0,0,1,0.0012295415461034257
3631,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0013174243767150125,1,0,1,0.0014877771683603689
3632,TRY3,Defensins,0.000684122546610829,0,0,1,0.000772584691157814
3633,TRY3,Defensins,0.0005636983605747012,1,0,1,0.0006365887602568865
3634,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.000684122546610829,0,0,1,0.000772584691157814
3635,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0005636983605747012,1,0,1,0.0006365887602568865
3636,TRY3,Neutrophil degranulation,0.000684122546610829,0,0,1,0.000772584691157814
3637,TRY3,Neutrophil degranulation,0.0005636983605747012,1,0,1,0.0006365887602568865
3638,CBS,Cysteine formation from homocysteine,0.00036934954244265247,0,0,1,0.0004171091913151978
3639,CBS,Cysteine formation from homocysteine,0.00027664144357830657,1,0,1,0.0003124132442458149
3640,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.00036934954244265247,0,0,1,0.0004171091913151978
3641,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.00027664144357830657,1,0,1,0.0003124132442458149
3642,K1C9,Formation of the cornified envelope,0.00014773080495408833,0,0,1,0.00016683349918136285
3643,K1C9,Formation of the cornified envelope,0.00030166620316670787,1,0,1,0.0003406738917769974
3644,FBN1,TGF-beta receptor signaling activates SMADs,0.006184575988835452,0,0,1,0.00698428776240078
3645,FBN1,TGF-beta receptor signaling activates SMADs,0.006140285814511897,1,0,1,0.006934270538409835
3646,FBN1,Integrin cell surface interactions,0.006184575988835452,0,0,1,0.00698428776240078
3647,FBN1,Integrin cell surface interactions,0.006140285814511897,1,0,1,0.006934270538409835
3648,FBN1,Molecules associated with elastic fibres,0.006184575988835452,0,0,1,0.00698428776240078
3649,FBN1,Molecules associated with elastic fibres,0.006140285814511897,1,0,1,0.006934270538409835
3650,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006184575988835452,0,0,1,0.00698428776240078
3651,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006140285814511897,1,0,1,0.006934270538409835
3652,FBN1,Post-translational protein phosphorylation,0.006184575988835452,0,0,1,0.00698428776240078
3653,FBN1,Post-translational protein phosphorylation,0.006140285814511897,1,0,1,0.006934270538409835
3654,MYH9,RHO GTPase Effectors,0.0031144968606295243,0,0,1,0.0035172245193524436
3655,MYH9,RHO GTPase Effectors,0.006895109656536337,1,0,1,0.007786698729467171
3656,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.0031144968606295243,0,0,1,0.0035172245193524436
3657,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.006895109656536337,1,0,1,0.007786698729467171
3658,MYH9,EPH-Ephrin signaling,0.0031144968606295243,0,0,1,0.0035172245193524436
3659,MYH9,EPH-Ephrin signaling,0.006895109656536337,1,0,1,0.007786698729467171
3660,MYH9,Semaphorin interactions,0.0031144968606295243,0,0,1,0.0035172245193524436
3661,MYH9,Semaphorin interactions,0.006895109656536337,1,0,1,0.007786698729467171
3662,MYH9,Parasite infection,0.0031144968606295243,0,0,1,0.0035172245193524436
3663,MYH9,Parasite infection,0.006895109656536337,1,0,1,0.007786698729467171
3664,MYH9,Leishmania parasite growth and survival,0.0031144968606295243,0,0,1,0.0035172245193524436
3665,MYH9,Leishmania parasite growth and survival,0.006895109656536337,1,0,1,0.007786698729467171
3666,MYH9,Signaling by ALK fusions and activated point mutants,0.0031144968606295243,0,0,1,0.0035172245193524436
3667,MYH9,Signaling by ALK fusions and activated point mutants,0.006895109656536337,1,0,1,0.007786698729467171
3668,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0031144968606295243,0,0,1,0.0035172245193524436
3669,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.006895109656536337,1,0,1,0.007786698729467171
3670,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.0031144968606295243,0,0,1,0.0035172245193524436
3671,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.006895109656536337,1,0,1,0.007786698729467171
3672,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.0031144968606295243,0,0,1,0.0035172245193524436
3673,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.006895109656536337,1,0,1,0.007786698729467171
3674,MYH10,RHO GTPase Effectors,9.326725257825056e-05,0,0,1,0.00010532740352628068
3675,MYH10,RHO GTPase Effectors,0.00015104280878242511,1,0,1,0.00017057376979151228
3676,MYH10,EPH-Ephrin signaling,9.326725257825056e-05,0,0,1,0.00010532740352628068
3677,MYH10,EPH-Ephrin signaling,0.00015104280878242511,1,0,1,0.00017057376979151228
3678,MYH10,Semaphorin interactions,9.326725257825056e-05,0,0,1,0.00010532740352628068
3679,MYH10,Semaphorin interactions,0.00015104280878242511,1,0,1,0.00017057376979151228
3680,MYH11,RHO GTPase Effectors,0.00011129724730681072,0,0,1,0.00012568881096410007
3681,MYH11,RHO GTPase Effectors,7.147288770768677e-05,1,0,1,8.071486482846793e-05
3682,MYH11,EPH-Ephrin signaling,0.00011129724730681072,0,0,1,0.00012568881096410007
3683,MYH11,EPH-Ephrin signaling,7.147288770768677e-05,1,0,1,8.071486482846793e-05
3684,MYH11,Semaphorin interactions,0.00011129724730681072,0,0,1,0.00012568881096410007
3685,MYH11,Semaphorin interactions,7.147288770768677e-05,1,0,1,8.071486482846793e-05
3686,MYH11,Smooth Muscle Contraction,0.00011129724730681072,0,0,1,0.00012568881096410007
3687,MYH11,Smooth Muscle Contraction,7.147288770768677e-05,1,0,1,8.071486482846793e-05
3688,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0017923922916941656,0,0,1,0.0020241619750327113
3689,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001996829165137814,1,0,1,0.00225503406003151
3690,K1C20,Formation of the cornified envelope,0.00017371326168986667,0,0,1,0.00019617568123950178
3691,K1C20,Formation of the cornified envelope,0.00034856542669825237,1,0,1,0.00039363753448569394
3692,K22E,Formation of the cornified envelope,6.654012715240832e-05,0,0,1,7.51442615658873e-05
3693,K22E,Formation of the cornified envelope,0.00013189368050939613,1,0,1,0.00014894851650019606
3694,CH3L1,Neutrophil degranulation,0.0007124029027255545,0,0,1,0.0008045219081125378
3695,CH3L1,Neutrophil degranulation,0.00041780611587307763,1,0,1,0.0004718315608727785
3696,PGM1,Diseases associated with glycosylation precursor biosynthesis,0.0009036979774399637,0,0,1,0.0010205528618508829
3697,PGM1,Diseases associated with glycosylation precursor biosynthesis,0.0005598945325556055,1,0,1,0.0006322930689221843
3698,PGM1,Glycogen synthesis,0.0009036979774399637,0,0,1,0.0010205528618508829
3699,PGM1,Glycogen synthesis,0.0005598945325556055,1,0,1,0.0006322930689221843
3700,PGM1,Glycogen breakdown (glycogenolysis),0.0009036979774399637,0,0,1,0.0010205528618508829
3701,PGM1,Glycogen breakdown (glycogenolysis),0.0005598945325556055,1,0,1,0.0006322930689221843
3702,PGM1,Neutrophil degranulation,0.0009036979774399637,0,0,1,0.0010205528618508829
3703,PGM1,Neutrophil degranulation,0.0005598945325556055,1,0,1,0.0006322930689221843
3704,PGM1,Galactose catabolism,0.0009036979774399637,0,0,1,0.0010205528618508829
3705,PGM1,Galactose catabolism,0.0005598945325556055,1,0,1,0.0006322930689221843
3706,FHR2,Regulation of Complement cascade,3.107685654232876e-05,0,0,1,3.509532573199761e-05
3707,FHR2,Regulation of Complement cascade,2.494679231138545e-05,1,0,1,2.8172598504100782e-05
3708,TAGL2,Platelet degranulation ,0.00032857844234044725,0,0,1,0.0003710660840726804
3709,TAGL2,Platelet degranulation ,0.00044829393215512923,1,0,1,0.0005062616790482933
3710,TALDO,Interleukin-12 family signaling,0.00017162019818942547,0,0,1,0.00019381196902730664
3711,TALDO,Interleukin-12 family signaling,0.0004185678646886833,1,0,1,0.00047269180948811794
3712,TALDO,Pentose phosphate pathway disease,0.00017162019818942547,0,0,1,0.00019381196902730664
3713,TALDO,Pentose phosphate pathway disease,0.0004185678646886833,1,0,1,0.00047269180948811794
3714,TALDO,KEAP1-NFE2L2 pathway,0.00017162019818942547,0,0,1,0.00019381196902730664
3715,TALDO,KEAP1-NFE2L2 pathway,0.0004185678646886833,1,0,1,0.00047269180948811794
3716,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.00017162019818942547,0,0,1,0.00019381196902730664
3717,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0004185678646886833,1,0,1,0.00047269180948811794
3718,TALDO,Pentose phosphate pathway,0.00017162019818942547,0,0,1,0.00019381196902730664
3719,TALDO,Pentose phosphate pathway,0.0004185678646886833,1,0,1,0.00047269180948811794
3720,GRP75,Regulation of HSF1-mediated heat shock response,0.0003703664743027402,0,0,1,0.00041825762004473854
3721,GRP75,Regulation of HSF1-mediated heat shock response,0.00028555278806072633,1,0,1,0.0003224768919926383
3722,GRP75,Interleukin-12 family signaling,0.0003703664743027402,0,0,1,0.00041825762004473854
3723,GRP75,Interleukin-12 family signaling,0.00028555278806072633,1,0,1,0.0003224768919926383
3724,GRP75,Cristae formation,0.0003703664743027402,0,0,1,0.00041825762004473854
3725,GRP75,Cristae formation,0.00028555278806072633,1,0,1,0.0003224768919926383
3726,GRP75,Mitochondrial protein import,0.0003703664743027402,0,0,1,0.00041825762004473854
3727,GRP75,Mitochondrial protein import,0.00028555278806072633,1,0,1,0.0003224768919926383
3728,COIA1,Collagen chain trimerization,0.005070344623985468,0,0,1,0.005725977976887057
3729,COIA1,Collagen chain trimerization,0.0033347269809429017,1,0,1,0.0037659320357599515
3730,COIA1,Collagen degradation,0.005070344623985468,0,0,1,0.005725977976887057
3731,COIA1,Collagen degradation,0.0033347269809429017,1,0,1,0.0037659320357599515
3732,COIA1,Activation of Matrix Metalloproteinases,0.005070344623985468,0,0,1,0.005725977976887057
3733,COIA1,Activation of Matrix Metalloproteinases,0.0033347269809429017,1,0,1,0.0037659320357599515
3734,COIA1,Integrin cell surface interactions,0.005070344623985468,0,0,1,0.005725977976887057
3735,COIA1,Integrin cell surface interactions,0.0033347269809429017,1,0,1,0.0037659320357599515
3736,COIA1,Laminin interactions,0.005070344623985468,0,0,1,0.005725977976887057
3737,COIA1,Laminin interactions,0.0033347269809429017,1,0,1,0.0037659320357599515
3738,MDHC,Gluconeogenesis,3.0149399792346058e-05,0,0,1,3.404794191122255e-05
3739,MDHC,Gluconeogenesis,0.0002515468547202831,1,0,1,0.00028407373799995913
3740,MDHM,Gluconeogenesis,0.00022070765995236142,0,0,1,0.000249246805481268
3741,MDHM,Gluconeogenesis,0.00024991260064327923,1,0,1,0.00028222816268949695
3742,MDHM,Citric acid cycle (TCA cycle),0.00022070765995236142,0,0,1,0.000249246805481268
3743,MDHM,Citric acid cycle (TCA cycle),0.00024991260064327923,1,0,1,0.00028222816268949695
3744,PTGDS,Arachidonic acid metabolism,0.006303457902952128,0,0,1,0.007118541994127381
3745,PTGDS,Arachidonic acid metabolism,0.0059091700120011475,1,0,1,0.006673269739957813
3746,PTGDS,Transcriptional regulation of testis differentiation,0.006303457902952128,0,0,1,0.007118541994127381
3747,PTGDS,Transcriptional regulation of testis differentiation,0.0059091700120011475,1,0,1,0.006673269739957813
3748,THIM,Mitochondrial Fatty Acid Beta-Oxidation,0.0006437110961332142,0,0,1,0.0007269477389170807
3749,THIM,Mitochondrial Fatty Acid Beta-Oxidation,0.001060507918423193,1,0,1,0.0011976394970234557
3750,MUC18,RHO GTPase cycle,0.000528364699828228,0,0,1,0.0005966861938080455
3751,MUC18,RHO GTPase cycle,0.0004989273008047768,1,0,1,0.000563442319672203
3752,BTD,Biotin transport and metabolism,0.0006696113342008322,0,0,1,0.0007561970708204297
3753,BTD,Biotin transport and metabolism,0.002577530782541844,1,0,1,0.0029108247249635785
3754,BTD,Defects in biotin (Btn) metabolism,0.0006696113342008322,0,0,1,0.0007561970708204297
3755,BTD,Defects in biotin (Btn) metabolism,0.002577530782541844,1,0,1,0.0029108247249635785
3756,GSHB,Glutathione conjugation,2.7936275548227473e-05,0,0,1,3.154864420629121e-05
3757,GSHB,Glutathione conjugation,0.0002244941824940766,1,0,1,0.00025352295361137384
3758,GSHB,Defective GSS causes GSS deficiency,2.7936275548227473e-05,0,0,1,3.154864420629121e-05
3759,GSHB,Defective GSS causes GSS deficiency,0.0002244941824940766,1,0,1,0.00025352295361137384
3760,MASP1,Initial triggering of complement,0.00043947574855097667,0,0,1,0.0004963032385756938
3761,MASP1,Initial triggering of complement,0.0005797355496537799,1,0,1,0.0006546996774208953
3762,MASP1,SARS-CoV-2 Infection,0.00043947574855097667,0,0,1,0.0004963032385756938
3763,MASP1,SARS-CoV-2 Infection,0.0005797355496537799,1,0,1,0.0006546996774208953
3764,MASP1,Scavenging by Class A Receptors,0.00043947574855097667,0,0,1,0.0004963032385756938
3765,MASP1,Scavenging by Class A Receptors,0.0005797355496537799,1,0,1,0.0006546996774208953
3766,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.0016367841947931313,0,0,1,0.001848432591340392
3767,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.002411244572571663,1,0,1,0.0027230364685904155
3768,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0016367841947931313,0,0,1,0.001848432591340392
3769,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.002411244572571663,1,0,1,0.0027230364685904155
3770,PSB2,Antigen processing-Cross presentation,0.0016367841947931313,0,0,1,0.001848432591340392
3771,PSB2,Antigen processing-Cross presentation,0.002411244572571663,1,0,1,0.0027230364685904155
3772,PSB2,PTEN Regulation,0.0016367841947931313,0,0,1,0.001848432591340392
3773,PSB2,PTEN Regulation,0.002411244572571663,1,0,1,0.0027230364685904155
3774,PSB2,Host Interactions of HIV factors,0.0016367841947931313,0,0,1,0.001848432591340392
3775,PSB2,Host Interactions of HIV factors,0.002411244572571663,1,0,1,0.0027230364685904155
3776,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0016367841947931313,0,0,1,0.001848432591340392
3777,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.002411244572571663,1,0,1,0.0027230364685904155
3778,PSB2,APC/C-mediated degradation of cell cycle proteins,0.0016367841947931313,0,0,1,0.001848432591340392
3779,PSB2,APC/C-mediated degradation of cell cycle proteins,0.002411244572571663,1,0,1,0.0027230364685904155
3780,PSB2,Degradation of AXIN,0.0016367841947931313,0,0,1,0.001848432591340392
3781,PSB2,Degradation of AXIN,0.002411244572571663,1,0,1,0.0027230364685904155
3782,PSB2,Degradation of DVL,0.0016367841947931313,0,0,1,0.001848432591340392
3783,PSB2,Degradation of DVL,0.002411244572571663,1,0,1,0.0027230364685904155
3784,PSB2,Downstream TCR signaling,0.0016367841947931313,0,0,1,0.001848432591340392
3785,PSB2,Downstream TCR signaling,0.002411244572571663,1,0,1,0.0027230364685904155
3786,PSB2,Transcriptional regulation by RUNX3,0.0016367841947931313,0,0,1,0.001848432591340392
3787,PSB2,Transcriptional regulation by RUNX3,0.002411244572571663,1,0,1,0.0027230364685904155
3788,PSB2,Transcriptional regulation by RUNX2,0.0016367841947931313,0,0,1,0.001848432591340392
3789,PSB2,Transcriptional regulation by RUNX2,0.002411244572571663,1,0,1,0.0027230364685904155
3790,PSB2,Transcriptional regulation by RUNX1,0.0016367841947931313,0,0,1,0.001848432591340392
3791,PSB2,Transcriptional regulation by RUNX1,0.002411244572571663,1,0,1,0.0027230364685904155
3792,PSB2,FCERI mediated NF-kB activation,0.0016367841947931313,0,0,1,0.001848432591340392
3793,PSB2,FCERI mediated NF-kB activation,0.002411244572571663,1,0,1,0.0027230364685904155
3794,PSB2,Mitotic Metaphase and Anaphase,0.0016367841947931313,0,0,1,0.001848432591340392
3795,PSB2,Mitotic Metaphase and Anaphase,0.002411244572571663,1,0,1,0.0027230364685904155
3796,PSB2,Regulation of ornithine decarboxylase (ODC),0.0016367841947931313,0,0,1,0.001848432591340392
3797,PSB2,Regulation of ornithine decarboxylase (ODC),0.002411244572571663,1,0,1,0.0027230364685904155
3798,PSB2,Signaling by ROBO receptors,0.0016367841947931313,0,0,1,0.001848432591340392
3799,PSB2,Signaling by ROBO receptors,0.002411244572571663,1,0,1,0.0027230364685904155
3800,PSB2,PCP/CE pathway,0.0016367841947931313,0,0,1,0.001848432591340392
3801,PSB2,PCP/CE pathway,0.002411244572571663,1,0,1,0.0027230364685904155
3802,PSB2,Interleukin-1 family signaling,0.0016367841947931313,0,0,1,0.001848432591340392
3803,PSB2,Interleukin-1 family signaling,0.002411244572571663,1,0,1,0.0027230364685904155
3804,PSB2,G2/M Transition,0.0016367841947931313,0,0,1,0.001848432591340392
3805,PSB2,G2/M Transition,0.002411244572571663,1,0,1,0.0027230364685904155
3806,PSB2,G1/S Transition,0.0016367841947931313,0,0,1,0.001848432591340392
3807,PSB2,G1/S Transition,0.002411244572571663,1,0,1,0.0027230364685904155
3808,PSB2,Hh mutants are degraded by ERAD,0.0016367841947931313,0,0,1,0.001848432591340392
3809,PSB2,Hh mutants are degraded by ERAD,0.002411244572571663,1,0,1,0.0027230364685904155
3810,PSB2,CLEC7A (Dectin-1) signaling,0.0016367841947931313,0,0,1,0.001848432591340392
3811,PSB2,CLEC7A (Dectin-1) signaling,0.002411244572571663,1,0,1,0.0027230364685904155
3812,PSB2,Degradation of GLI1 by the proteasome,0.0016367841947931313,0,0,1,0.001848432591340392
3813,PSB2,Degradation of GLI1 by the proteasome,0.002411244572571663,1,0,1,0.0027230364685904155
3814,PSB2,Degradation of GLI2 by the proteasome,0.0016367841947931313,0,0,1,0.001848432591340392
3815,PSB2,Degradation of GLI2 by the proteasome,0.002411244572571663,1,0,1,0.0027230364685904155
3816,PSB2,GLI3 is processed to GLI3R by the proteasome,0.0016367841947931313,0,0,1,0.001848432591340392
3817,PSB2,GLI3 is processed to GLI3R by the proteasome,0.002411244572571663,1,0,1,0.0027230364685904155
3818,PSB2,Defective CFTR causes cystic fibrosis,0.0016367841947931313,0,0,1,0.001848432591340392
3819,PSB2,Defective CFTR causes cystic fibrosis,0.002411244572571663,1,0,1,0.0027230364685904155
3820,PSB2,NIK-->noncanonical NF-kB signaling,0.0016367841947931313,0,0,1,0.001848432591340392
3821,PSB2,NIK-->noncanonical NF-kB signaling,0.002411244572571663,1,0,1,0.0027230364685904155
3822,PSB2,RAF/MAP kinase cascade,0.0016367841947931313,0,0,1,0.001848432591340392
3823,PSB2,RAF/MAP kinase cascade,0.002411244572571663,1,0,1,0.0027230364685904155
3824,PSB2,UCH proteinases,0.0016367841947931313,0,0,1,0.001848432591340392
3825,PSB2,UCH proteinases,0.002411244572571663,1,0,1,0.0027230364685904155
3826,PSB2,Ub-specific processing proteases,0.0016367841947931313,0,0,1,0.001848432591340392
3827,PSB2,Ub-specific processing proteases,0.002411244572571663,1,0,1,0.0027230364685904155
3828,PSB2,Orc1 removal from chromatin,0.0016367841947931313,0,0,1,0.001848432591340392
3829,PSB2,Orc1 removal from chromatin,0.002411244572571663,1,0,1,0.0027230364685904155
3830,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.0016367841947931313,0,0,1,0.001848432591340392
3831,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.002411244572571663,1,0,1,0.0027230364685904155
3832,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.0016367841947931313,0,0,1,0.001848432591340392
3833,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.002411244572571663,1,0,1,0.0027230364685904155
3834,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.0016367841947931313,0,0,1,0.001848432591340392
3835,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.002411244572571663,1,0,1,0.0027230364685904155
3836,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.0016367841947931313,0,0,1,0.001848432591340392
3837,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.002411244572571663,1,0,1,0.0027230364685904155
3838,PSB2,p53-Independent G1/S DNA damage checkpoint,0.0016367841947931313,0,0,1,0.001848432591340392
3839,PSB2,p53-Independent G1/S DNA damage checkpoint,0.002411244572571663,1,0,1,0.0027230364685904155
3840,PSB2,Negative regulation of NOTCH4 signaling,0.0016367841947931313,0,0,1,0.001848432591340392
3841,PSB2,Negative regulation of NOTCH4 signaling,0.002411244572571663,1,0,1,0.0027230364685904155
3842,PSB2,KEAP1-NFE2L2 pathway,0.0016367841947931313,0,0,1,0.001848432591340392
3843,PSB2,KEAP1-NFE2L2 pathway,0.002411244572571663,1,0,1,0.0027230364685904155
3844,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.0016367841947931313,0,0,1,0.001848432591340392
3845,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.002411244572571663,1,0,1,0.0027230364685904155
3846,PSB2,Degradation of beta-catenin by the destruction complex,0.0016367841947931313,0,0,1,0.001848432591340392
3847,PSB2,Degradation of beta-catenin by the destruction complex,0.002411244572571663,1,0,1,0.0027230364685904155
3848,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0016367841947931313,0,0,1,0.001848432591340392
3849,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.002411244572571663,1,0,1,0.0027230364685904155
3850,PSB2,Hedgehog ligand biogenesis,0.0016367841947931313,0,0,1,0.001848432591340392
3851,PSB2,Hedgehog ligand biogenesis,0.002411244572571663,1,0,1,0.0027230364685904155
3852,PSB2,Hedgehog 'on' state,0.0016367841947931313,0,0,1,0.001848432591340392
3853,PSB2,Hedgehog 'on' state,0.002411244572571663,1,0,1,0.0027230364685904155
3854,PSB2,MAPK6/MAPK4 signaling,0.0016367841947931313,0,0,1,0.001848432591340392
3855,PSB2,MAPK6/MAPK4 signaling,0.002411244572571663,1,0,1,0.0027230364685904155
3856,PSB2,Neddylation,0.0016367841947931313,0,0,1,0.001848432591340392
3857,PSB2,Neddylation,0.002411244572571663,1,0,1,0.0027230364685904155
3858,COMP,Integrin cell surface interactions,0.0014982286455947152,0,0,1,0.001691960776873862
3859,COMP,Integrin cell surface interactions,0.0006830392158469853,1,0,1,0.0007713612776513417
3860,COMP,ECM proteoglycans,0.0014982286455947152,0,0,1,0.001691960776873862
3861,COMP,ECM proteoglycans,0.0006830392158469853,1,0,1,0.0007713612776513417
3862,SEPP1,Platelet degranulation ,0.00012792832924627513,0,0,1,0.0001444704157620642
3863,SEPP1,Platelet degranulation ,0.00017262706641561632,1,0,1,0.0001949490328200759
3864,CAMP,Neutrophil degranulation,0.00031657005792606603,0,0,1,0.0003575049260461687
3865,CAMP,Neutrophil degranulation,0.00018594817128115177,1,0,1,0.00020999265583675024
3866,MMP14,Collagen degradation,0.003368583286233095,0,0,1,0.0038041662136801954
3867,MMP14,Collagen degradation,0.0020737682278906253,1,0,1,0.002341921917081874
3868,MMP14,Activation of Matrix Metalloproteinases,0.003368583286233095,0,0,1,0.0038041662136801954
3869,MMP14,Activation of Matrix Metalloproteinases,0.0020737682278906253,1,0,1,0.002341921917081874
3870,LUM,Keratan sulfate/keratin metabolism,0.0006467666692418244,0,0,1,0.0007303984204040755
3871,LUM,Keratan sulfate/keratin metabolism,0.0005824747262518827,1,0,1,0.0006577930499702374
3872,LUM,Diseases associated with glycosaminoglycan metabolism,0.0006467666692418244,0,0,1,0.0007303984204040755
3873,LUM,Diseases associated with glycosaminoglycan metabolism,0.0005824747262518827,1,0,1,0.0006577930499702374
3874,LUM,Integrin cell surface interactions,0.0006467666692418244,0,0,1,0.0007303984204040755
3875,LUM,Integrin cell surface interactions,0.0005824747262518827,1,0,1,0.0006577930499702374
3876,LUM,ECM proteoglycans,0.0006467666692418244,0,0,1,0.0007303984204040755
3877,LUM,ECM proteoglycans,0.0005824747262518827,1,0,1,0.0006577930499702374
3878,RIDA,Threonine catabolism,7.947300674011434e-05,0,0,1,8.974945888257941e-05
3879,RIDA,Threonine catabolism,9.594006873726934e-05,1,0,1,0.00010834583473713188
3880,CRIS3,Neutrophil degranulation,0.00017804903132753974,0,0,1,0.00020107209820901677
3881,CRIS3,Neutrophil degranulation,0.0001045219431330109,1,0,1,0.0001180374094592859
3882,HSP72,Regulation of HSF1-mediated heat shock response,0.0011829246970296596,0,0,1,0.0013358856775663298
3883,HSP72,Regulation of HSF1-mediated heat shock response,0.0036073197107785735,1,0,1,0.004073773037398157
3884,HSP72,HSF1-dependent transactivation,0.0011829246970296596,0,0,1,0.0013358856775663298
3885,HSP72,HSF1-dependent transactivation,0.0036073197107785735,1,0,1,0.004073773037398157
3886,HSP72,Meiotic synapsis,0.0011829246970296596,0,0,1,0.0013358856775663298
3887,HSP72,Meiotic synapsis,0.0036073197107785735,1,0,1,0.004073773037398157
3888,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0011829246970296596,0,0,1,0.0013358856775663298
3889,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0036073197107785735,1,0,1,0.004073773037398157
3890,MFAP4,Molecules associated with elastic fibres,0.00018807384663785637,0,0,1,0.00021239319686130388
3891,MFAP4,Molecules associated with elastic fibres,0.0001834990833203431,1,0,1,0.0002072268825477491
3892,CAD13,Adherens junctions interactions,0.0004319495818184214,0,0,1,0.00048780388238654434
3893,CAD13,Adherens junctions interactions,0.0017394751725779837,1,0,1,0.0019644022779844667
3894,DEF1,Defensins,0.0004766551739761455,0,0,1,0.0005382902408340322
3895,DEF1,Defensins,0.0011074770538856554,1,0,1,0.001250682091796843
3896,DEF1,Neutrophil degranulation,0.0004766551739761455,0,0,1,0.0005382902408340322
3897,DEF1,Neutrophil degranulation,0.0011074770538856554,1,0,1,0.001250682091796843
3898,TPIS,Glycolysis,0.00025597112671029516,0,0,1,0.00028907010133564386
3899,TPIS,Glycolysis,0.00039512814791709997,1,0,1,0.000446221162624462
3900,TPIS,Gluconeogenesis,0.00025597112671029516,0,0,1,0.00028907010133564386
3901,TPIS,Gluconeogenesis,0.00039512814791709997,1,0,1,0.000446221162624462
3902,MYL6,RHO GTPase Effectors,0.0003070789470624325,0,0,1,0.0003467865438036139
3903,MYL6,RHO GTPase Effectors,0.0021550038529247954,1,0,1,0.0024336619139420255
3904,MYL6,EPH-Ephrin signaling,0.0003070789470624325,0,0,1,0.0003467865438036139
3905,MYL6,EPH-Ephrin signaling,0.0021550038529247954,1,0,1,0.0024336619139420255
3906,MYL6,Semaphorin interactions,0.0003070789470624325,0,0,1,0.0003467865438036139
3907,MYL6,Semaphorin interactions,0.0021550038529247954,1,0,1,0.0024336619139420255
3908,MYL6,Smooth Muscle Contraction,0.0003070789470624325,0,0,1,0.0003467865438036139
3909,MYL6,Smooth Muscle Contraction,0.0021550038529247954,1,0,1,0.0024336619139420255
3910,ACTB,Gap junction trafficking,0.012453858947789422,0,0,1,0.014064235737539963
3911,ACTB,Gap junction trafficking,0.027922061993060916,1,0,1,0.0315325927324975
3912,ACTB,VEGFA-VEGFR2 Pathway,0.012453858947789422,0,0,1,0.014064235737539963
3913,ACTB,VEGFA-VEGFR2 Pathway,0.027922061993060916,1,0,1,0.0315325927324975
3914,ACTB,RHO GTPase Effectors,0.012453858947789422,0,0,1,0.014064235737539963
3915,ACTB,RHO GTPase Effectors,0.027922061993060916,1,0,1,0.0315325927324975
3916,ACTB,RHO GTPase cycle,0.012453858947789422,0,0,1,0.014064235737539963
3917,ACTB,RHO GTPase cycle,0.027922061993060916,1,0,1,0.0315325927324975
3918,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.012453858947789422,0,0,1,0.014064235737539963
3919,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.027922061993060916,1,0,1,0.0315325927324975
3920,ACTB,EPH-Ephrin signaling,0.012453858947789422,0,0,1,0.014064235737539963
3921,ACTB,EPH-Ephrin signaling,0.027922061993060916,1,0,1,0.0315325927324975
3922,ACTB,L1CAM interactions,0.012453858947789422,0,0,1,0.014064235737539963
3923,ACTB,L1CAM interactions,0.027922061993060916,1,0,1,0.0315325927324975
3924,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.012453858947789422,0,0,1,0.014064235737539963
3925,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.027922061993060916,1,0,1,0.0315325927324975
3926,ACTB,Adherens junctions interactions,0.012453858947789422,0,0,1,0.014064235737539963
3927,ACTB,Adherens junctions interactions,0.027922061993060916,1,0,1,0.0315325927324975
3928,ACTB,B-WICH complex positively regulates rRNA expression,0.012453858947789422,0,0,1,0.014064235737539963
3929,ACTB,B-WICH complex positively regulates rRNA expression,0.027922061993060916,1,0,1,0.0315325927324975
3930,ACTB,RAF/MAP kinase cascade,0.012453858947789422,0,0,1,0.014064235737539963
3931,ACTB,RAF/MAP kinase cascade,0.027922061993060916,1,0,1,0.0315325927324975
3932,ACTB,UCH proteinases,0.012453858947789422,0,0,1,0.014064235737539963
3933,ACTB,UCH proteinases,0.027922061993060916,1,0,1,0.0315325927324975
3934,ACTB,DNA Damage Recognition in GG-NER,0.012453858947789422,0,0,1,0.014064235737539963
3935,ACTB,DNA Damage Recognition in GG-NER,0.027922061993060916,1,0,1,0.0315325927324975
3936,ACTB,Signaling by RAS mutants,0.012453858947789422,0,0,1,0.014064235737539963
3937,ACTB,Signaling by RAS mutants,0.027922061993060916,1,0,1,0.0315325927324975
3938,ACTB,Signaling by moderate kinase activity BRAF mutants,0.012453858947789422,0,0,1,0.014064235737539963
3939,ACTB,Signaling by moderate kinase activity BRAF mutants,0.027922061993060916,1,0,1,0.0315325927324975
3940,ACTB,Signaling by high-kinase activity BRAF mutants,0.012453858947789422,0,0,1,0.014064235737539963
3941,ACTB,Signaling by high-kinase activity BRAF mutants,0.027922061993060916,1,0,1,0.0315325927324975
3942,ACTB,Signaling by BRAF and RAF1 fusions,0.012453858947789422,0,0,1,0.014064235737539963
3943,ACTB,Signaling by BRAF and RAF1 fusions,0.027922061993060916,1,0,1,0.0315325927324975
3944,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.012453858947789422,0,0,1,0.014064235737539963
3945,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.027922061993060916,1,0,1,0.0315325927324975
3946,ACTB,Signaling by RAF1 mutants,0.012453858947789422,0,0,1,0.014064235737539963
3947,ACTB,Signaling by RAF1 mutants,0.027922061993060916,1,0,1,0.0315325927324975
3948,ACTB,Parasite infection,0.012453858947789422,0,0,1,0.014064235737539963
3949,ACTB,Parasite infection,0.027922061993060916,1,0,1,0.0315325927324975
3950,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.012453858947789422,0,0,1,0.014064235737539963
3951,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.027922061993060916,1,0,1,0.0315325927324975
3952,ACTB,HATs acetylate histones,0.012453858947789422,0,0,1,0.014064235737539963
3953,ACTB,HATs acetylate histones,0.027922061993060916,1,0,1,0.0315325927324975
3954,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.012453858947789422,0,0,1,0.014064235737539963
3955,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.027922061993060916,1,0,1,0.0315325927324975
3956,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.012453858947789422,0,0,1,0.014064235737539963
3957,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.027922061993060916,1,0,1,0.0315325927324975
3958,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.0014613978442534533,0,0,1,0.0016503674783920324
3959,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.0008096274807912362,1,0,1,0.0009143183488086418
3960,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0014613978442534533,0,0,1,0.0016503674783920324
3961,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0008096274807912362,1,0,1,0.0009143183488086418
3962,PSA6,Antigen processing-Cross presentation,0.0014613978442534533,0,0,1,0.0016503674783920324
3963,PSA6,Antigen processing-Cross presentation,0.0008096274807912362,1,0,1,0.0009143183488086418
3964,PSA6,PTEN Regulation,0.0014613978442534533,0,0,1,0.0016503674783920324
3965,PSA6,PTEN Regulation,0.0008096274807912362,1,0,1,0.0009143183488086418
3966,PSA6,Host Interactions of HIV factors,0.0014613978442534533,0,0,1,0.0016503674783920324
3967,PSA6,Host Interactions of HIV factors,0.0008096274807912362,1,0,1,0.0009143183488086418
3968,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0014613978442534533,0,0,1,0.0016503674783920324
3969,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0008096274807912362,1,0,1,0.0009143183488086418
3970,PSA6,APC/C-mediated degradation of cell cycle proteins,0.0014613978442534533,0,0,1,0.0016503674783920324
3971,PSA6,APC/C-mediated degradation of cell cycle proteins,0.0008096274807912362,1,0,1,0.0009143183488086418
3972,PSA6,Degradation of AXIN,0.0014613978442534533,0,0,1,0.0016503674783920324
3973,PSA6,Degradation of AXIN,0.0008096274807912362,1,0,1,0.0009143183488086418
3974,PSA6,Degradation of DVL,0.0014613978442534533,0,0,1,0.0016503674783920324
3975,PSA6,Degradation of DVL,0.0008096274807912362,1,0,1,0.0009143183488086418
3976,PSA6,Downstream TCR signaling,0.0014613978442534533,0,0,1,0.0016503674783920324
3977,PSA6,Downstream TCR signaling,0.0008096274807912362,1,0,1,0.0009143183488086418
3978,PSA6,Transcriptional regulation by RUNX3,0.0014613978442534533,0,0,1,0.0016503674783920324
3979,PSA6,Transcriptional regulation by RUNX3,0.0008096274807912362,1,0,1,0.0009143183488086418
3980,PSA6,Transcriptional regulation by RUNX2,0.0014613978442534533,0,0,1,0.0016503674783920324
3981,PSA6,Transcriptional regulation by RUNX2,0.0008096274807912362,1,0,1,0.0009143183488086418
3982,PSA6,Transcriptional regulation by RUNX1,0.0014613978442534533,0,0,1,0.0016503674783920324
3983,PSA6,Transcriptional regulation by RUNX1,0.0008096274807912362,1,0,1,0.0009143183488086418
3984,PSA6,FCERI mediated NF-kB activation,0.0014613978442534533,0,0,1,0.0016503674783920324
3985,PSA6,FCERI mediated NF-kB activation,0.0008096274807912362,1,0,1,0.0009143183488086418
3986,PSA6,Mitotic Metaphase and Anaphase,0.0014613978442534533,0,0,1,0.0016503674783920324
3987,PSA6,Mitotic Metaphase and Anaphase,0.0008096274807912362,1,0,1,0.0009143183488086418
3988,PSA6,Regulation of ornithine decarboxylase (ODC),0.0014613978442534533,0,0,1,0.0016503674783920324
3989,PSA6,Regulation of ornithine decarboxylase (ODC),0.0008096274807912362,1,0,1,0.0009143183488086418
3990,PSA6,Signaling by ROBO receptors,0.0014613978442534533,0,0,1,0.0016503674783920324
3991,PSA6,Signaling by ROBO receptors,0.0008096274807912362,1,0,1,0.0009143183488086418
3992,PSA6,PCP/CE pathway,0.0014613978442534533,0,0,1,0.0016503674783920324
3993,PSA6,PCP/CE pathway,0.0008096274807912362,1,0,1,0.0009143183488086418
3994,PSA6,Interleukin-1 family signaling,0.0014613978442534533,0,0,1,0.0016503674783920324
3995,PSA6,Interleukin-1 family signaling,0.0008096274807912362,1,0,1,0.0009143183488086418
3996,PSA6,G2/M Transition,0.0014613978442534533,0,0,1,0.0016503674783920324
3997,PSA6,G2/M Transition,0.0008096274807912362,1,0,1,0.0009143183488086418
3998,PSA6,G1/S Transition,0.0014613978442534533,0,0,1,0.0016503674783920324
3999,PSA6,G1/S Transition,0.0008096274807912362,1,0,1,0.0009143183488086418
4000,PSA6,Hh mutants are degraded by ERAD,0.0014613978442534533,0,0,1,0.0016503674783920324
4001,PSA6,Hh mutants are degraded by ERAD,0.0008096274807912362,1,0,1,0.0009143183488086418
4002,PSA6,CLEC7A (Dectin-1) signaling,0.0014613978442534533,0,0,1,0.0016503674783920324
4003,PSA6,CLEC7A (Dectin-1) signaling,0.0008096274807912362,1,0,1,0.0009143183488086418
4004,PSA6,Degradation of GLI1 by the proteasome,0.0014613978442534533,0,0,1,0.0016503674783920324
4005,PSA6,Degradation of GLI1 by the proteasome,0.0008096274807912362,1,0,1,0.0009143183488086418
4006,PSA6,Degradation of GLI2 by the proteasome,0.0014613978442534533,0,0,1,0.0016503674783920324
4007,PSA6,Degradation of GLI2 by the proteasome,0.0008096274807912362,1,0,1,0.0009143183488086418
4008,PSA6,GLI3 is processed to GLI3R by the proteasome,0.0014613978442534533,0,0,1,0.0016503674783920324
4009,PSA6,GLI3 is processed to GLI3R by the proteasome,0.0008096274807912362,1,0,1,0.0009143183488086418
4010,PSA6,Defective CFTR causes cystic fibrosis,0.0014613978442534533,0,0,1,0.0016503674783920324
4011,PSA6,Defective CFTR causes cystic fibrosis,0.0008096274807912362,1,0,1,0.0009143183488086418
4012,PSA6,NIK-->noncanonical NF-kB signaling,0.0014613978442534533,0,0,1,0.0016503674783920324
4013,PSA6,NIK-->noncanonical NF-kB signaling,0.0008096274807912362,1,0,1,0.0009143183488086418
4014,PSA6,RAF/MAP kinase cascade,0.0014613978442534533,0,0,1,0.0016503674783920324
4015,PSA6,RAF/MAP kinase cascade,0.0008096274807912362,1,0,1,0.0009143183488086418
4016,PSA6,UCH proteinases,0.0014613978442534533,0,0,1,0.0016503674783920324
4017,PSA6,UCH proteinases,0.0008096274807912362,1,0,1,0.0009143183488086418
4018,PSA6,Ub-specific processing proteases,0.0014613978442534533,0,0,1,0.0016503674783920324
4019,PSA6,Ub-specific processing proteases,0.0008096274807912362,1,0,1,0.0009143183488086418
4020,PSA6,Orc1 removal from chromatin,0.0014613978442534533,0,0,1,0.0016503674783920324
4021,PSA6,Orc1 removal from chromatin,0.0008096274807912362,1,0,1,0.0009143183488086418
4022,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.0014613978442534533,0,0,1,0.0016503674783920324
4023,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.0008096274807912362,1,0,1,0.0009143183488086418
4024,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.0014613978442534533,0,0,1,0.0016503674783920324
4025,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.0008096274807912362,1,0,1,0.0009143183488086418
4026,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.0014613978442534533,0,0,1,0.0016503674783920324
4027,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.0008096274807912362,1,0,1,0.0009143183488086418
4028,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.0014613978442534533,0,0,1,0.0016503674783920324
4029,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.0008096274807912362,1,0,1,0.0009143183488086418
4030,PSA6,p53-Independent G1/S DNA damage checkpoint,0.0014613978442534533,0,0,1,0.0016503674783920324
4031,PSA6,p53-Independent G1/S DNA damage checkpoint,0.0008096274807912362,1,0,1,0.0009143183488086418
4032,PSA6,Negative regulation of NOTCH4 signaling,0.0014613978442534533,0,0,1,0.0016503674783920324
4033,PSA6,Negative regulation of NOTCH4 signaling,0.0008096274807912362,1,0,1,0.0009143183488086418
4034,PSA6,KEAP1-NFE2L2 pathway,0.0014613978442534533,0,0,1,0.0016503674783920324
4035,PSA6,KEAP1-NFE2L2 pathway,0.0008096274807912362,1,0,1,0.0009143183488086418
4036,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.0014613978442534533,0,0,1,0.0016503674783920324
4037,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.0008096274807912362,1,0,1,0.0009143183488086418
4038,PSA6,Degradation of beta-catenin by the destruction complex,0.0014613978442534533,0,0,1,0.0016503674783920324
4039,PSA6,Degradation of beta-catenin by the destruction complex,0.0008096274807912362,1,0,1,0.0009143183488086418
4040,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0014613978442534533,0,0,1,0.0016503674783920324
4041,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0008096274807912362,1,0,1,0.0009143183488086418
4042,PSA6,Hedgehog ligand biogenesis,0.0014613978442534533,0,0,1,0.0016503674783920324
4043,PSA6,Hedgehog ligand biogenesis,0.0008096274807912362,1,0,1,0.0009143183488086418
4044,PSA6,Hedgehog 'on' state,0.0014613978442534533,0,0,1,0.0016503674783920324
4045,PSA6,Hedgehog 'on' state,0.0008096274807912362,1,0,1,0.0009143183488086418
4046,PSA6,MAPK6/MAPK4 signaling,0.0014613978442534533,0,0,1,0.0016503674783920324
4047,PSA6,MAPK6/MAPK4 signaling,0.0008096274807912362,1,0,1,0.0009143183488086418
4048,PSA6,Neddylation,0.0014613978442534533,0,0,1,0.0016503674783920324
4049,PSA6,Neddylation,0.0008096274807912362,1,0,1,0.0009143183488086418
4050,RAB10,RAB GEFs exchange GTP for GDP on RABs,0.0011638948492360712,0,0,1,0.0013143951286095313
4051,RAB10,RAB GEFs exchange GTP for GDP on RABs,0.0007578648450556282,1,0,1,0.0008558624184472961
4052,RAB10,Neutrophil degranulation,0.0011638948492360712,0,0,1,0.0013143951286095313
4053,RAB10,Neutrophil degranulation,0.0007578648450556282,1,0,1,0.0008558624184472961
4054,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0011638948492360712,0,0,1,0.0013143951286095313
4055,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0007578648450556282,1,0,1,0.0008558624184472961
4056,RAB10,RAB geranylgeranylation,0.0011638948492360712,0,0,1,0.0013143951286095313
4057,RAB10,RAB geranylgeranylation,0.0007578648450556282,1,0,1,0.0008558624184472961
4058,LYSC,Neutrophil degranulation,0.003652620119153533,0,0,1,0.004124931126233374
4059,LYSC,Neutrophil degranulation,0.0027461593821000658,1,0,1,0.003101258259358075
4060,LYSC,Amyloid fiber formation,0.003652620119153533,0,0,1,0.004124931126233374
4061,LYSC,Amyloid fiber formation,0.0027461593821000658,1,0,1,0.003101258259358075
4062,B2MG,Antigen processing-Cross presentation,0.012011441280163421,0,0,1,0.013564610167824549
4063,B2MG,Antigen processing-Cross presentation,0.010523303855402007,1,0,1,0.011884045481855052
4064,B2MG,Host Interactions of HIV factors,0.012011441280163421,0,0,1,0.013564610167824549
4065,B2MG,Host Interactions of HIV factors,0.010523303855402007,1,0,1,0.011884045481855052
4066,B2MG,DAP12 signaling,0.012011441280163421,0,0,1,0.013564610167824549
4067,B2MG,DAP12 signaling,0.010523303855402007,1,0,1,0.011884045481855052
4068,B2MG,Interferon gamma signaling,0.012011441280163421,0,0,1,0.013564610167824549
4069,B2MG,Interferon gamma signaling,0.010523303855402007,1,0,1,0.011884045481855052
4070,B2MG,Modulation by Mtb of host immune system,0.012011441280163421,0,0,1,0.013564610167824549
4071,B2MG,Modulation by Mtb of host immune system,0.010523303855402007,1,0,1,0.011884045481855052
4072,B2MG,SARS-CoV-2 Infection,0.012011441280163421,0,0,1,0.013564610167824549
4073,B2MG,SARS-CoV-2 Infection,0.010523303855402007,1,0,1,0.011884045481855052
4074,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.012011441280163421,0,0,1,0.013564610167824549
4075,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.010523303855402007,1,0,1,0.011884045481855052
4076,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012011441280163421,0,0,1,0.013564610167824549
4077,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010523303855402007,1,0,1,0.011884045481855052
4078,B2MG,Neutrophil degranulation,0.012011441280163421,0,0,1,0.013564610167824549
4079,B2MG,Neutrophil degranulation,0.010523303855402007,1,0,1,0.011884045481855052
4080,B2MG,Amyloid fiber formation,0.012011441280163421,0,0,1,0.013564610167824549
4081,B2MG,Amyloid fiber formation,0.010523303855402007,1,0,1,0.011884045481855052
4082,NPC2,LDL clearance,0.0025824933188144817,0,0,1,0.0029164289541657134
4083,NPC2,LDL clearance,0.0020502599687220974,1,0,1,0.002315373864778451
4084,NPC2,Neutrophil degranulation,0.0025824933188144817,0,0,1,0.0029164289541657134
4085,NPC2,Neutrophil degranulation,0.0020502599687220974,1,0,1,0.002315373864778451
4086,1433G,Activation of BH3-only proteins,0.0007677235245701983,0,0,1,0.0008669958987071139
4087,1433G,Activation of BH3-only proteins,0.002738683995067468,1,0,1,0.003092816249062586
4088,1433G,RHO GTPase Effectors,0.0007677235245701983,0,0,1,0.0008669958987071139
4089,1433G,RHO GTPase Effectors,0.002738683995067468,1,0,1,0.003092816249062586
4090,1433G,Transcriptional Regulation by TP53,0.0007677235245701983,0,0,1,0.0008669958987071139
4091,1433G,Transcriptional Regulation by TP53,0.002738683995067468,1,0,1,0.003092816249062586
4092,1433G,FOXO-mediated transcription,0.0007677235245701983,0,0,1,0.0008669958987071139
4093,1433G,FOXO-mediated transcription,0.002738683995067468,1,0,1,0.003092816249062586
4094,1433G,G2/M Transition,0.0007677235245701983,0,0,1,0.0008669958987071139
4095,1433G,G2/M Transition,0.002738683995067468,1,0,1,0.003092816249062586
4096,1433G,Mitotic Prometaphase,0.0007677235245701983,0,0,1,0.0008669958987071139
4097,1433G,Mitotic Prometaphase,0.002738683995067468,1,0,1,0.003092816249062586
4098,1433G,G2/M DNA damage checkpoint,0.0007677235245701983,0,0,1,0.0008669958987071139
4099,1433G,G2/M DNA damage checkpoint,0.002738683995067468,1,0,1,0.003092816249062586
4100,1433G,SARS-CoV-2 Infection,0.0007677235245701983,0,0,1,0.0008669958987071139
4101,1433G,SARS-CoV-2 Infection,0.002738683995067468,1,0,1,0.003092816249062586
4102,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0007677235245701983,0,0,1,0.0008669958987071139
4103,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002738683995067468,1,0,1,0.003092816249062586
4104,1433G,Anchoring of the basal body to the plasma membrane,0.0007677235245701983,0,0,1,0.0008669958987071139
4105,1433G,Anchoring of the basal body to the plasma membrane,0.002738683995067468,1,0,1,0.003092816249062586
4106,1433E,Activation of BH3-only proteins,0.008167932948173227,0,0,1,0.009224107560004014
4107,1433E,Activation of BH3-only proteins,0.0016009235289760363,1,0,1,0.00180793487413714
4108,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.008167932948173227,0,0,1,0.009224107560004014
4109,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.0016009235289760363,1,0,1,0.00180793487413714
4110,1433E,RHO GTPase Effectors,0.008167932948173227,0,0,1,0.009224107560004014
4111,1433E,RHO GTPase Effectors,0.0016009235289760363,1,0,1,0.00180793487413714
4112,1433E,Transcriptional Regulation by TP53,0.008167932948173227,0,0,1,0.009224107560004014
4113,1433E,Transcriptional Regulation by TP53,0.0016009235289760363,1,0,1,0.00180793487413714
4114,1433E,Regulation of HSF1-mediated heat shock response,0.008167932948173227,0,0,1,0.009224107560004014
4115,1433E,Regulation of HSF1-mediated heat shock response,0.0016009235289760363,1,0,1,0.00180793487413714
4116,1433E,HSF1 activation,0.008167932948173227,0,0,1,0.009224107560004014
4117,1433E,HSF1 activation,0.0016009235289760363,1,0,1,0.00180793487413714
4118,1433E,G2/M Transition,0.008167932948173227,0,0,1,0.009224107560004014
4119,1433E,G2/M Transition,0.0016009235289760363,1,0,1,0.00180793487413714
4120,1433E,Mitotic Prometaphase,0.008167932948173227,0,0,1,0.009224107560004014
4121,1433E,Mitotic Prometaphase,0.0016009235289760363,1,0,1,0.00180793487413714
4122,1433E,G2/M DNA damage checkpoint,0.008167932948173227,0,0,1,0.009224107560004014
4123,1433E,G2/M DNA damage checkpoint,0.0016009235289760363,1,0,1,0.00180793487413714
4124,1433E,Neurodegenerative Diseases,0.008167932948173227,0,0,1,0.009224107560004014
4125,1433E,Neurodegenerative Diseases,0.0016009235289760363,1,0,1,0.00180793487413714
4126,1433E,RAB GEFs exchange GTP for GDP on RABs,0.008167932948173227,0,0,1,0.009224107560004014
4127,1433E,RAB GEFs exchange GTP for GDP on RABs,0.0016009235289760363,1,0,1,0.00180793487413714
4128,1433E,SARS-CoV-2 Infection,0.008167932948173227,0,0,1,0.009224107560004014
4129,1433E,SARS-CoV-2 Infection,0.0016009235289760363,1,0,1,0.00180793487413714
4130,1433E,Signaling by Hippo,0.008167932948173227,0,0,1,0.009224107560004014
4131,1433E,Signaling by Hippo,0.0016009235289760363,1,0,1,0.00180793487413714
4132,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.008167932948173227,0,0,1,0.009224107560004014
4133,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0016009235289760363,1,0,1,0.00180793487413714
4134,1433E,Anchoring of the basal body to the plasma membrane,0.008167932948173227,0,0,1,0.009224107560004014
4135,1433E,Anchoring of the basal body to the plasma membrane,0.0016009235289760363,1,0,1,0.00180793487413714
4136,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.0013538484746960665,0,0,1,0.0015289111737060554
4137,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.0015087205531599097,1,0,1,0.0017038093662911662
4138,ACTA,Smooth Muscle Contraction,0.0013538484746960665,0,0,1,0.0015289111737060554
4139,ACTA,Smooth Muscle Contraction,0.0015087205531599097,1,0,1,0.0017038093662911662
4140,H4,Packaging Of Telomere Ends,0.006344005798059398,0,0,1,0.007164333034305405
4141,H4,Packaging Of Telomere Ends,0.014630706645170142,1,0,1,0.016522566067844358
4142,H4,Inhibition of DNA recombination at telomere,0.006344005798059398,0,0,1,0.007164333034305405
4143,H4,Inhibition of DNA recombination at telomere,0.014630706645170142,1,0,1,0.016522566067844358
4144,H4,Pre-NOTCH Transcription and Translation,0.006344005798059398,0,0,1,0.007164333034305405
4145,H4,Pre-NOTCH Transcription and Translation,0.014630706645170142,1,0,1,0.016522566067844358
4146,H4,RHO GTPase Effectors,0.006344005798059398,0,0,1,0.007164333034305405
4147,H4,RHO GTPase Effectors,0.014630706645170142,1,0,1,0.016522566067844358
4148,H4,Formation of the beta-catenin:TCF transactivating complex,0.006344005798059398,0,0,1,0.007164333034305405
4149,H4,Formation of the beta-catenin:TCF transactivating complex,0.014630706645170142,1,0,1,0.016522566067844358
4150,H4,Transcriptional regulation by RUNX1,0.006344005798059398,0,0,1,0.007164333034305405
4151,H4,Transcriptional regulation by RUNX1,0.014630706645170142,1,0,1,0.016522566067844358
4152,H4,Oxidative Stress Induced Senescence,0.006344005798059398,0,0,1,0.007164333034305405
4153,H4,Oxidative Stress Induced Senescence,0.014630706645170142,1,0,1,0.016522566067844358
4154,H4,Senescence-Associated Secretory Phenotype (SASP),0.006344005798059398,0,0,1,0.007164333034305405
4155,H4,Senescence-Associated Secretory Phenotype (SASP),0.014630706645170142,1,0,1,0.016522566067844358
4156,H4,DNA Damage/Telomere Stress Induced Senescence,0.006344005798059398,0,0,1,0.007164333034305405
4157,H4,DNA Damage/Telomere Stress Induced Senescence,0.014630706645170142,1,0,1,0.016522566067844358
4158,H4,SUMO E3 ligases SUMOylate target proteins,0.006344005798059398,0,0,1,0.007164333034305405
4159,H4,SUMO E3 ligases SUMOylate target proteins,0.014630706645170142,1,0,1,0.016522566067844358
4160,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.006344005798059398,0,0,1,0.007164333034305405
4161,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.014630706645170142,1,0,1,0.016522566067844358
4162,H4,B-WICH complex positively regulates rRNA expression,0.006344005798059398,0,0,1,0.007164333034305405
4163,H4,B-WICH complex positively regulates rRNA expression,0.014630706645170142,1,0,1,0.016522566067844358
4164,H4,SIRT1 negatively regulates rRNA expression,0.006344005798059398,0,0,1,0.007164333034305405
4165,H4,SIRT1 negatively regulates rRNA expression,0.014630706645170142,1,0,1,0.016522566067844358
4166,H4,NoRC negatively regulates rRNA expression,0.006344005798059398,0,0,1,0.007164333034305405
4167,H4,NoRC negatively regulates rRNA expression,0.014630706645170142,1,0,1,0.016522566067844358
4168,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.006344005798059398,0,0,1,0.007164333034305405
4169,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.014630706645170142,1,0,1,0.016522566067844358
4170,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.006344005798059398,0,0,1,0.007164333034305405
4171,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.014630706645170142,1,0,1,0.016522566067844358
4172,H4,Assembly of the ORC complex at the origin of replication,0.006344005798059398,0,0,1,0.007164333034305405
4173,H4,Assembly of the ORC complex at the origin of replication,0.014630706645170142,1,0,1,0.016522566067844358
4174,H4,Mitotic Prophase,0.006344005798059398,0,0,1,0.007164333034305405
4175,H4,Mitotic Prophase,0.014630706645170142,1,0,1,0.016522566067844358
4176,H4,G2/M DNA damage checkpoint,0.006344005798059398,0,0,1,0.007164333034305405
4177,H4,G2/M DNA damage checkpoint,0.014630706645170142,1,0,1,0.016522566067844358
4178,H4,RNA Polymerase I Promoter Opening,0.006344005798059398,0,0,1,0.007164333034305405
4179,H4,RNA Polymerase I Promoter Opening,0.014630706645170142,1,0,1,0.016522566067844358
4180,H4,RNA Polymerase I Promoter Escape,0.006344005798059398,0,0,1,0.007164333034305405
4181,H4,RNA Polymerase I Promoter Escape,0.014630706645170142,1,0,1,0.016522566067844358
4182,H4,Depurination,0.006344005798059398,0,0,1,0.007164333034305405
4183,H4,Depurination,0.014630706645170142,1,0,1,0.016522566067844358
4184,H4,Depyrimidination,0.006344005798059398,0,0,1,0.007164333034305405
4185,H4,Depyrimidination,0.014630706645170142,1,0,1,0.016522566067844358
4186,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.006344005798059398,0,0,1,0.007164333034305405
4187,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.014630706645170142,1,0,1,0.016522566067844358
4188,H4,Estrogen-dependent gene expression,0.006344005798059398,0,0,1,0.007164333034305405
4189,H4,Estrogen-dependent gene expression,0.014630706645170142,1,0,1,0.016522566067844358
4190,H4,HCMV Early Events,0.006344005798059398,0,0,1,0.007164333034305405
4191,H4,HCMV Early Events,0.014630706645170142,1,0,1,0.016522566067844358
4192,H4,HCMV Late Events,0.006344005798059398,0,0,1,0.007164333034305405
4193,H4,HCMV Late Events,0.014630706645170142,1,0,1,0.016522566067844358
4194,H4,Transcriptional regulation of granulopoiesis,0.006344005798059398,0,0,1,0.007164333034305405
4195,H4,Transcriptional regulation of granulopoiesis,0.014630706645170142,1,0,1,0.016522566067844358
4196,H4,Meiotic synapsis,0.006344005798059398,0,0,1,0.007164333034305405
4197,H4,Meiotic synapsis,0.014630706645170142,1,0,1,0.016522566067844358
4198,H4,Meiotic recombination,0.006344005798059398,0,0,1,0.007164333034305405
4199,H4,Meiotic recombination,0.014630706645170142,1,0,1,0.016522566067844358
4200,H4,Transcriptional regulation by small RNAs,0.006344005798059398,0,0,1,0.007164333034305405
4201,H4,Transcriptional regulation by small RNAs,0.014630706645170142,1,0,1,0.016522566067844358
4202,H4,PRC2 methylates histones and DNA,0.006344005798059398,0,0,1,0.007164333034305405
4203,H4,PRC2 methylates histones and DNA,0.014630706645170142,1,0,1,0.016522566067844358
4204,H4,DNA methylation,0.006344005798059398,0,0,1,0.007164333034305405
4205,H4,DNA methylation,0.014630706645170142,1,0,1,0.016522566067844358
4206,H4,HDACs deacetylate histones,0.006344005798059398,0,0,1,0.007164333034305405
4207,H4,HDACs deacetylate histones,0.014630706645170142,1,0,1,0.016522566067844358
4208,H4,PKMTs methylate histone lysines,0.006344005798059398,0,0,1,0.007164333034305405
4209,H4,PKMTs methylate histone lysines,0.014630706645170142,1,0,1,0.016522566067844358
4210,H4,HDMs demethylate histones,0.006344005798059398,0,0,1,0.007164333034305405
4211,H4,HDMs demethylate histones,0.014630706645170142,1,0,1,0.016522566067844358
4212,H4,HATs acetylate histones,0.006344005798059398,0,0,1,0.007164333034305405
4213,H4,HATs acetylate histones,0.014630706645170142,1,0,1,0.016522566067844358
4214,H4,RMTs methylate histone arginines,0.006344005798059398,0,0,1,0.007164333034305405
4215,H4,RMTs methylate histone arginines,0.014630706645170142,1,0,1,0.016522566067844358
4216,H4,Amyloid fiber formation,0.006344005798059398,0,0,1,0.007164333034305405
4217,H4,Amyloid fiber formation,0.014630706645170142,1,0,1,0.016522566067844358
4218,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.006344005798059398,0,0,1,0.007164333034305405
4219,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.014630706645170142,1,0,1,0.016522566067844358
4220,H4,Nonhomologous End-Joining (NHEJ),0.006344005798059398,0,0,1,0.007164333034305405
4221,H4,Nonhomologous End-Joining (NHEJ),0.014630706645170142,1,0,1,0.016522566067844358
4222,H4,Defective pyroptosis,0.006344005798059398,0,0,1,0.007164333034305405
4223,H4,Defective pyroptosis,0.014630706645170142,1,0,1,0.016522566067844358
4224,RAP1A,Signaling by NTRK1 (TRKA),0.00656896075682932,0,0,1,0.007418376345999598
4225,RAP1A,Signaling by NTRK1 (TRKA),0.0008781466181916664,1,0,1,0.000991697521398644
4226,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.00656896075682932,0,0,1,0.007418376345999598
4227,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.0008781466181916664,1,0,1,0.000991697521398644
4228,RAP1A,RAF/MAP kinase cascade,0.00656896075682932,0,0,1,0.007418376345999598
4229,RAP1A,RAF/MAP kinase cascade,0.0008781466181916664,1,0,1,0.000991697521398644
4230,RAP1A,Signaling by RAS mutants,0.00656896075682932,0,0,1,0.007418376345999598
4231,RAP1A,Signaling by RAS mutants,0.0008781466181916664,1,0,1,0.000991697521398644
4232,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.00656896075682932,0,0,1,0.007418376345999598
4233,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.0008781466181916664,1,0,1,0.000991697521398644
4234,RAP1A,Signaling by high-kinase activity BRAF mutants,0.00656896075682932,0,0,1,0.007418376345999598
4235,RAP1A,Signaling by high-kinase activity BRAF mutants,0.0008781466181916664,1,0,1,0.000991697521398644
4236,RAP1A,Signaling by BRAF and RAF1 fusions,0.00656896075682932,0,0,1,0.007418376345999598
4237,RAP1A,Signaling by BRAF and RAF1 fusions,0.0008781466181916664,1,0,1,0.000991697521398644
4238,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00656896075682932,0,0,1,0.007418376345999598
4239,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0008781466181916664,1,0,1,0.000991697521398644
4240,RAP1A,Signaling by RAF1 mutants,0.00656896075682932,0,0,1,0.007418376345999598
4241,RAP1A,Signaling by RAF1 mutants,0.0008781466181916664,1,0,1,0.000991697521398644
4242,RAP1A,MET promotes cell motility,0.00656896075682932,0,0,1,0.007418376345999598
4243,RAP1A,MET promotes cell motility,0.0008781466181916664,1,0,1,0.000991697521398644
4244,RAP1A,Rap1 signalling,0.00656896075682932,0,0,1,0.007418376345999598
4245,RAP1A,Rap1 signalling,0.0008781466181916664,1,0,1,0.000991697521398644
4246,RAP1A,Neutrophil degranulation,0.00656896075682932,0,0,1,0.007418376345999598
4247,RAP1A,Neutrophil degranulation,0.0008781466181916664,1,0,1,0.000991697521398644
4248,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00656896075682932,0,0,1,0.007418376345999598
4249,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0008781466181916664,1,0,1,0.000991697521398644
4250,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.00656896075682932,0,0,1,0.007418376345999598
4251,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.0008781466181916664,1,0,1,0.000991697521398644
4252,PPIA,Downstream signaling events of B Cell Receptor (BCR),0.0006197902479895678,0,0,1,0.0006999337468087266
4253,PPIA,Downstream signaling events of B Cell Receptor (BCR),0.0003948450209791559,1,0,1,0.0004459014252630877
4254,PPIA,HIV Life Cycle,0.0006197902479895678,0,0,1,0.0006999337468087266
4255,PPIA,HIV Life Cycle,0.0003948450209791559,1,0,1,0.0004459014252630877
4256,PPIA,Host Interactions of HIV factors,0.0006197902479895678,0,0,1,0.0006999337468087266
4257,PPIA,Host Interactions of HIV factors,0.0003948450209791559,1,0,1,0.0004459014252630877
4258,PPIA,Interleukin-12 family signaling,0.0006197902479895678,0,0,1,0.0006999337468087266
4259,PPIA,Interleukin-12 family signaling,0.0003948450209791559,1,0,1,0.0004459014252630877
4260,PPIA,Platelet degranulation ,0.0006197902479895678,0,0,1,0.0006999337468087266
4261,PPIA,Platelet degranulation ,0.0003948450209791559,1,0,1,0.0004459014252630877
4262,PPIA,Neutrophil degranulation,0.0006197902479895678,0,0,1,0.0006999337468087266
4263,PPIA,Neutrophil degranulation,0.0003948450209791559,1,0,1,0.0004459014252630877
4264,PPIA,Basigin interactions,0.0006197902479895678,0,0,1,0.0006999337468087266
4265,PPIA,Basigin interactions,0.0003948450209791559,1,0,1,0.0004459014252630877
4266,1433Z,Activation of BH3-only proteins,0.0018741533266283515,0,0,1,0.002116495321209218
4267,1433Z,Activation of BH3-only proteins,0.005852958193074837,1,0,1,0.006609789313856159
4268,1433Z,RHO GTPase Effectors,0.0018741533266283515,0,0,1,0.002116495321209218
4269,1433Z,RHO GTPase Effectors,0.005852958193074837,1,0,1,0.006609789313856159
4270,1433Z,Deactivation of the beta-catenin transactivating complex,0.0018741533266283515,0,0,1,0.002116495321209218
4271,1433Z,Deactivation of the beta-catenin transactivating complex,0.005852958193074837,1,0,1,0.006609789313856159
4272,1433Z,Transcriptional Regulation by TP53,0.0018741533266283515,0,0,1,0.002116495321209218
4273,1433Z,Transcriptional Regulation by TP53,0.005852958193074837,1,0,1,0.006609789313856159
4274,1433Z,FOXO-mediated transcription,0.0018741533266283515,0,0,1,0.002116495321209218
4275,1433Z,FOXO-mediated transcription,0.005852958193074837,1,0,1,0.006609789313856159
4276,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.0018741533266283515,0,0,1,0.002116495321209218
4277,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.005852958193074837,1,0,1,0.006609789313856159
4278,1433Z,G2/M DNA damage checkpoint,0.0018741533266283515,0,0,1,0.002116495321209218
4279,1433Z,G2/M DNA damage checkpoint,0.005852958193074837,1,0,1,0.006609789313856159
4280,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.0018741533266283515,0,0,1,0.002116495321209218
4281,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.005852958193074837,1,0,1,0.006609789313856159
4282,1433Z,Negative regulation of NOTCH4 signaling,0.0018741533266283515,0,0,1,0.002116495321209218
4283,1433Z,Negative regulation of NOTCH4 signaling,0.005852958193074837,1,0,1,0.006609789313856159
4284,1433Z,SARS-CoV-2 Infection,0.0018741533266283515,0,0,1,0.002116495321209218
4285,1433Z,SARS-CoV-2 Infection,0.005852958193074837,1,0,1,0.006609789313856159
4286,1433Z,Rap1 signalling,0.0018741533266283515,0,0,1,0.002116495321209218
4287,1433Z,Rap1 signalling,0.005852958193074837,1,0,1,0.006609789313856159
4288,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0018741533266283515,0,0,1,0.002116495321209218
4289,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.005852958193074837,1,0,1,0.006609789313856159
4290,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.0018741533266283515,0,0,1,0.002116495321209218
4291,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.005852958193074837,1,0,1,0.006609789313856159
4292,1433Z,GP1b-IX-V activation signalling,0.0018741533266283515,0,0,1,0.002116495321209218
4293,1433Z,GP1b-IX-V activation signalling,0.005852958193074837,1,0,1,0.006609789313856159
4294,TPM4,RHO GTPase cycle,0.004618157862524885,0,0,1,0.005215320096687986
4295,TPM4,RHO GTPase cycle,0.007684928487967416,1,0,1,0.008678647022904907
4296,TPM4,Signaling by ALK fusions and activated point mutants,0.004618157862524885,0,0,1,0.005215320096687986
4297,TPM4,Signaling by ALK fusions and activated point mutants,0.007684928487967416,1,0,1,0.008678647022904907
4298,TPM4,Striated Muscle Contraction,0.004618157862524885,0,0,1,0.005215320096687986
4299,TPM4,Striated Muscle Contraction,0.007684928487967416,1,0,1,0.008678647022904907
4300,TPM4,Smooth Muscle Contraction,0.004618157862524885,0,0,1,0.005215320096687986
4301,TPM4,Smooth Muscle Contraction,0.007684928487967416,1,0,1,0.008678647022904907
4302,TBA1B,Activation of NMDA receptors and postsynaptic events,0.003313323446232731,0,0,1,0.003741760864475416
4303,TBA1B,Activation of NMDA receptors and postsynaptic events,0.003481778701493129,1,0,1,0.003931998639862317
4304,TBA1B,Gap junction trafficking,0.003313323446232731,0,0,1,0.003741760864475416
4305,TBA1B,Gap junction trafficking,0.003481778701493129,1,0,1,0.003931998639862317
4306,TBA1B,RHO GTPase Effectors,0.003313323446232731,0,0,1,0.003741760864475416
4307,TBA1B,RHO GTPase Effectors,0.003481778701493129,1,0,1,0.003931998639862317
4308,TBA1B,RHO GTPase cycle,0.003313323446232731,0,0,1,0.003741760864475416
4309,TBA1B,RHO GTPase cycle,0.003481778701493129,1,0,1,0.003931998639862317
4310,TBA1B,COPI-mediated anterograde transport,0.003313323446232731,0,0,1,0.003741760864475416
4311,TBA1B,COPI-mediated anterograde transport,0.003481778701493129,1,0,1,0.003931998639862317
4312,TBA1B,Mitotic Metaphase and Anaphase,0.003313323446232731,0,0,1,0.003741760864475416
4313,TBA1B,Mitotic Metaphase and Anaphase,0.003481778701493129,1,0,1,0.003931998639862317
4314,TBA1B,L1CAM interactions,0.003313323446232731,0,0,1,0.003741760864475416
4315,TBA1B,L1CAM interactions,0.003481778701493129,1,0,1,0.003931998639862317
4316,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.003313323446232731,0,0,1,0.003741760864475416
4317,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.003481778701493129,1,0,1,0.003931998639862317
4318,TBA1B,G2/M Transition,0.003313323446232731,0,0,1,0.003741760864475416
4319,TBA1B,G2/M Transition,0.003481778701493129,1,0,1,0.003931998639862317
4320,TBA1B,Golgi-to-ER retrograde transport,0.003313323446232731,0,0,1,0.003741760864475416
4321,TBA1B,Golgi-to-ER retrograde transport,0.003481778701493129,1,0,1,0.003931998639862317
4322,TBA1B,Mitotic Prometaphase,0.003313323446232731,0,0,1,0.003741760864475416
4323,TBA1B,Mitotic Prometaphase,0.003481778701493129,1,0,1,0.003931998639862317
4324,TBA1B,HCMV Early Events,0.003313323446232731,0,0,1,0.003741760864475416
4325,TBA1B,HCMV Early Events,0.003481778701493129,1,0,1,0.003931998639862317
4326,TBA1B,Aggrephagy,0.003313323446232731,0,0,1,0.003741760864475416
4327,TBA1B,Aggrephagy,0.003481778701493129,1,0,1,0.003931998639862317
4328,TBA1B,MHC class II antigen presentation,0.003313323446232731,0,0,1,0.003741760864475416
4329,TBA1B,MHC class II antigen presentation,0.003481778701493129,1,0,1,0.003931998639862317
4330,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.003313323446232731,0,0,1,0.003741760864475416
4331,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.003481778701493129,1,0,1,0.003931998639862317
4332,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.003313323446232731,0,0,1,0.003741760864475416
4333,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.003481778701493129,1,0,1,0.003931998639862317
4334,TBA1B,Post-chaperonin tubulin folding pathway,0.003313323446232731,0,0,1,0.003741760864475416
4335,TBA1B,Post-chaperonin tubulin folding pathway,0.003481778701493129,1,0,1,0.003931998639862317
4336,TBA1B,Intraflagellar transport,0.003313323446232731,0,0,1,0.003741760864475416
4337,TBA1B,Intraflagellar transport,0.003481778701493129,1,0,1,0.003931998639862317
4338,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.003313323446232731,0,0,1,0.003741760864475416
4339,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.003481778701493129,1,0,1,0.003931998639862317
4340,TBA1B,Kinesins,0.003313323446232731,0,0,1,0.003741760864475416
4341,TBA1B,Kinesins,0.003481778701493129,1,0,1,0.003931998639862317
4342,TBA4A,Activation of NMDA receptors and postsynaptic events,0.001164580785892762,0,0,1,0.0013151697619887244
4343,TBA4A,Activation of NMDA receptors and postsynaptic events,0.00038483358567792647,1,0,1,0.0004345954367547938
4344,TBA4A,Gap junction trafficking,0.001164580785892762,0,0,1,0.0013151697619887244
4345,TBA4A,Gap junction trafficking,0.00038483358567792647,1,0,1,0.0004345954367547938
4346,TBA4A,RHO GTPase Effectors,0.001164580785892762,0,0,1,0.0013151697619887244
4347,TBA4A,RHO GTPase Effectors,0.00038483358567792647,1,0,1,0.0004345954367547938
4348,TBA4A,COPI-mediated anterograde transport,0.001164580785892762,0,0,1,0.0013151697619887244
4349,TBA4A,COPI-mediated anterograde transport,0.00038483358567792647,1,0,1,0.0004345954367547938
4350,TBA4A,Mitotic Metaphase and Anaphase,0.001164580785892762,0,0,1,0.0013151697619887244
4351,TBA4A,Mitotic Metaphase and Anaphase,0.00038483358567792647,1,0,1,0.0004345954367547938
4352,TBA4A,L1CAM interactions,0.001164580785892762,0,0,1,0.0013151697619887244
4353,TBA4A,L1CAM interactions,0.00038483358567792647,1,0,1,0.0004345954367547938
4354,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.001164580785892762,0,0,1,0.0013151697619887244
4355,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.00038483358567792647,1,0,1,0.0004345954367547938
4356,TBA4A,G2/M Transition,0.001164580785892762,0,0,1,0.0013151697619887244
4357,TBA4A,G2/M Transition,0.00038483358567792647,1,0,1,0.0004345954367547938
4358,TBA4A,Golgi-to-ER retrograde transport,0.001164580785892762,0,0,1,0.0013151697619887244
4359,TBA4A,Golgi-to-ER retrograde transport,0.00038483358567792647,1,0,1,0.0004345954367547938
4360,TBA4A,Mitotic Prometaphase,0.001164580785892762,0,0,1,0.0013151697619887244
4361,TBA4A,Mitotic Prometaphase,0.00038483358567792647,1,0,1,0.0004345954367547938
4362,TBA4A,Platelet degranulation ,0.001164580785892762,0,0,1,0.0013151697619887244
4363,TBA4A,Platelet degranulation ,0.00038483358567792647,1,0,1,0.0004345954367547938
4364,TBA4A,HCMV Early Events,0.001164580785892762,0,0,1,0.0013151697619887244
4365,TBA4A,HCMV Early Events,0.00038483358567792647,1,0,1,0.0004345954367547938
4366,TBA4A,Aggrephagy,0.001164580785892762,0,0,1,0.0013151697619887244
4367,TBA4A,Aggrephagy,0.00038483358567792647,1,0,1,0.0004345954367547938
4368,TBA4A,MHC class II antigen presentation,0.001164580785892762,0,0,1,0.0013151697619887244
4369,TBA4A,MHC class II antigen presentation,0.00038483358567792647,1,0,1,0.0004345954367547938
4370,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.001164580785892762,0,0,1,0.0013151697619887244
4371,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00038483358567792647,1,0,1,0.0004345954367547938
4372,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.001164580785892762,0,0,1,0.0013151697619887244
4373,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00038483358567792647,1,0,1,0.0004345954367547938
4374,TBA4A,Post-chaperonin tubulin folding pathway,0.001164580785892762,0,0,1,0.0013151697619887244
4375,TBA4A,Post-chaperonin tubulin folding pathway,0.00038483358567792647,1,0,1,0.0004345954367547938
4376,TBA4A,Anchoring of the basal body to the plasma membrane,0.001164580785892762,0,0,1,0.0013151697619887244
4377,TBA4A,Anchoring of the basal body to the plasma membrane,0.00038483358567792647,1,0,1,0.0004345954367547938
4378,TBA4A,Intraflagellar transport,0.001164580785892762,0,0,1,0.0013151697619887244
4379,TBA4A,Intraflagellar transport,0.00038483358567792647,1,0,1,0.0004345954367547938
4380,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.001164580785892762,0,0,1,0.0013151697619887244
4381,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.00038483358567792647,1,0,1,0.0004345954367547938
4382,TBA4A,Kinesins,0.001164580785892762,0,0,1,0.0013151697619887244
4383,TBA4A,Kinesins,0.00038483358567792647,1,0,1,0.0004345954367547938
4384,HBB,Cytoprotection by HMOX1,0.014910788012037365,0,0,1,0.016838864043100633
4385,HBB,Cytoprotection by HMOX1,0.012393148785630161,1,0,1,0.013995675298895869
4386,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.014910788012037365,0,0,1,0.016838864043100633
4387,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.012393148785630161,1,0,1,0.013995675298895869
4388,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.014910788012037365,0,0,1,0.016838864043100633
4389,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.012393148785630161,1,0,1,0.013995675298895869
4390,HBB,Neutrophil degranulation,0.014910788012037365,0,0,1,0.016838864043100633
4391,HBB,Neutrophil degranulation,0.012393148785630161,1,0,1,0.013995675298895869
4392,HBB,Scavenging of heme from plasma,0.014910788012037365,0,0,1,0.016838864043100633
4393,HBB,Scavenging of heme from plasma,0.012393148785630161,1,0,1,0.013995675298895869
4394,HBB,Heme signaling,0.014910788012037365,0,0,1,0.016838864043100633
4395,HBB,Heme signaling,0.012393148785630161,1,0,1,0.013995675298895869
4396,HBB,Chaperone Mediated Autophagy,0.014910788012037365,0,0,1,0.016838864043100633
4397,HBB,Chaperone Mediated Autophagy,0.012393148785630161,1,0,1,0.013995675298895869
4398,HBB,Late endosomal microautophagy,0.014910788012037365,0,0,1,0.016838864043100633
4399,HBB,Late endosomal microautophagy,0.012393148785630161,1,0,1,0.013995675298895869
4400,HBA,Cytoprotection by HMOX1,0.0011181257750315107,0,0,1,0.0012627077719596347
4401,HBA,Cytoprotection by HMOX1,0.00016429965709215734,1,0,1,0.00018554482740076658
4402,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.0011181257750315107,0,0,1,0.0012627077719596347
4403,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.00016429965709215734,1,0,1,0.00018554482740076658
4404,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.0011181257750315107,0,0,1,0.0012627077719596347
4405,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.00016429965709215734,1,0,1,0.00018554482740076658
4406,HBA,Scavenging of heme from plasma,0.0011181257750315107,0,0,1,0.0012627077719596347
4407,HBA,Scavenging of heme from plasma,0.00016429965709215734,1,0,1,0.00018554482740076658
4408,HBA,Heme signaling,0.0011181257750315107,0,0,1,0.0012627077719596347
4409,HBA,Heme signaling,0.00016429965709215734,1,0,1,0.00018554482740076658
4410,GSTO1,Methylation,0.000565630253413243,0,0,1,0.0006387704612392747
4411,GSTO1,Methylation,0.0002865339941835082,1,0,1,0.00032358497538074923
4412,GSTO1,Glutathione conjugation,0.000565630253413243,0,0,1,0.0006387704612392747
4413,GSTO1,Glutathione conjugation,0.0002865339941835082,1,0,1,0.00032358497538074923
4414,GSTO1,Vitamin C (ascorbate) metabolism,0.000565630253413243,0,0,1,0.0006387704612392747
4415,GSTO1,Vitamin C (ascorbate) metabolism,0.0002865339941835082,1,0,1,0.00032358497538074923
4416,GSTO1,Interleukin-12 family signaling,0.000565630253413243,0,0,1,0.0006387704612392747
4417,GSTO1,Interleukin-12 family signaling,0.0002865339941835082,1,0,1,0.00032358497538074923
4418,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.001525820777831698,0,0,1,0.0017231207774736105
4419,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0015471674356967694,1,0,1,0.00174722771731303
4420,NGAL,Interleukin-4 and Interleukin-13 signaling,0.0070935108023459275,0,0,1,0.008010754622260096
4421,NGAL,Interleukin-4 and Interleukin-13 signaling,0.005339975149447848,1,0,1,0.006030473739047009
4422,NGAL,Metal sequestration by antimicrobial proteins,0.0070935108023459275,0,0,1,0.008010754622260096
4423,NGAL,Metal sequestration by antimicrobial proteins,0.005339975149447848,1,0,1,0.006030473739047009
4424,NGAL,Neutrophil degranulation,0.0070935108023459275,0,0,1,0.008010754622260096
4425,NGAL,Neutrophil degranulation,0.005339975149447848,1,0,1,0.006030473739047009
4426,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.003755594307951497,0,0,1,0.004241220645185536
4427,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.0013179261455144545,1,0,1,0.0014883438196056319
4428,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.003755594307951497,0,0,1,0.004241220645185536
4429,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.0013179261455144545,1,0,1,0.0014883438196056319
4430,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.003755594307951497,0,0,1,0.004241220645185536
4431,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.0013179261455144545,1,0,1,0.0014883438196056319
4432,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.003755594307951497,0,0,1,0.004241220645185536
4433,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.0013179261455144545,1,0,1,0.0014883438196056319
4434,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.003755594307951497,0,0,1,0.004241220645185536
4435,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.0013179261455144545,1,0,1,0.0014883438196056319
4436,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.003755594307951497,0,0,1,0.004241220645185536
4437,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0013179261455144545,1,0,1,0.0014883438196056319
4438,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.003755594307951497,0,0,1,0.004241220645185536
4439,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.0013179261455144545,1,0,1,0.0014883438196056319
4440,S10AC,TRAF6 mediated NF-kB activation,0.003755594307951497,0,0,1,0.004241220645185536
4441,S10AC,TRAF6 mediated NF-kB activation,0.0013179261455144545,1,0,1,0.0014883438196056319
4442,S10AC,Interleukin-1 family signaling,0.003755594307951497,0,0,1,0.004241220645185536
4443,S10AC,Interleukin-1 family signaling,0.0013179261455144545,1,0,1,0.0014883438196056319
4444,S10AC,Neutrophil degranulation,0.003755594307951497,0,0,1,0.004241220645185536
4445,S10AC,Neutrophil degranulation,0.0013179261455144545,1,0,1,0.0014883438196056319
4446,S10AC,Advanced glycosylation endproduct receptor signaling,0.003755594307951497,0,0,1,0.004241220645185536
4447,S10AC,Advanced glycosylation endproduct receptor signaling,0.0013179261455144545,1,0,1,0.0014883438196056319
4448,BASP1,RHO GTPase cycle,0.0011007522859523158,0,0,1,0.0012430877612450647
4449,BASP1,RHO GTPase cycle,0.0009930433769270702,1,0,1,0.0011214512874488693
4450,LV321,Initial triggering of complement,0.003400568302111673,0,0,1,0.0038402871305198007
4451,LV321,Initial triggering of complement,0.0038802765178737215,1,0,1,0.0043820251941992265
4452,LV321,Regulation of Complement cascade,0.003400568302111673,0,0,1,0.0038402871305198007
4453,LV321,Regulation of Complement cascade,0.0038802765178737215,1,0,1,0.0043820251941992265
4454,LV321,FCGR activation,0.003400568302111673,0,0,1,0.0038402871305198007
4455,LV321,FCGR activation,0.0038802765178737215,1,0,1,0.0043820251941992265
4456,LV321,Regulation of actin dynamics for phagocytic cup formation,0.003400568302111673,0,0,1,0.0038402871305198007
4457,LV321,Regulation of actin dynamics for phagocytic cup formation,0.0038802765178737215,1,0,1,0.0043820251941992265
4458,LV321,Role of phospholipids in phagocytosis,0.003400568302111673,0,0,1,0.0038402871305198007
4459,LV321,Role of phospholipids in phagocytosis,0.0038802765178737215,1,0,1,0.0043820251941992265
4460,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.003400568302111673,0,0,1,0.0038402871305198007
4461,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.0038802765178737215,1,0,1,0.0043820251941992265
4462,LV321,FCERI mediated MAPK activation,0.003400568302111673,0,0,1,0.0038402871305198007
4463,LV321,FCERI mediated MAPK activation,0.0038802765178737215,1,0,1,0.0043820251941992265
4464,LV321,FCERI mediated Ca+2 mobilization,0.003400568302111673,0,0,1,0.0038402871305198007
4465,LV321,FCERI mediated Ca+2 mobilization,0.0038802765178737215,1,0,1,0.0043820251941992265
4466,LV321,FCERI mediated NF-kB activation,0.003400568302111673,0,0,1,0.0038402871305198007
4467,LV321,FCERI mediated NF-kB activation,0.0038802765178737215,1,0,1,0.0043820251941992265
4468,LV321,Parasite infection,0.003400568302111673,0,0,1,0.0038402871305198007
4469,LV321,Parasite infection,0.0038802765178737215,1,0,1,0.0043820251941992265
4470,LV321,Leishmania parasite growth and survival,0.003400568302111673,0,0,1,0.0038402871305198007
4471,LV321,Leishmania parasite growth and survival,0.0038802765178737215,1,0,1,0.0043820251941992265
4472,LV321,Potential therapeutics for SARS,0.003400568302111673,0,0,1,0.0038402871305198007
4473,LV321,Potential therapeutics for SARS,0.0038802765178737215,1,0,1,0.0043820251941992265
4474,LV321,CD22 mediated BCR regulation,0.003400568302111673,0,0,1,0.0038402871305198007
4475,LV321,CD22 mediated BCR regulation,0.0038802765178737215,1,0,1,0.0043820251941992265
4476,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003400568302111673,0,0,1,0.0038402871305198007
4477,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0038802765178737215,1,0,1,0.0043820251941992265
4478,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003400568302111673,0,0,1,0.0038402871305198007
4479,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0038802765178737215,1,0,1,0.0043820251941992265
4480,LV321,Scavenging of heme from plasma,0.003400568302111673,0,0,1,0.0038402871305198007
4481,LV321,Scavenging of heme from plasma,0.0038802765178737215,1,0,1,0.0043820251941992265
4482,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.0020901201606938953,0,0,1,0.002360388276679629
4483,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.0024186604756406605,1,0,1,0.0027314113032024328
4484,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.0020901201606938953,0,0,1,0.002360388276679629
4485,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.0024186604756406605,1,0,1,0.0027314113032024328
4486,PGBM,Diseases associated with glycosaminoglycan metabolism,0.0020901201606938953,0,0,1,0.002360388276679629
4487,PGBM,Diseases associated with glycosaminoglycan metabolism,0.0024186604756406605,1,0,1,0.0027314113032024328
4488,PGBM,SARS-CoV-2 Infection,0.0020901201606938953,0,0,1,0.002360388276679629
4489,PGBM,SARS-CoV-2 Infection,0.0024186604756406605,1,0,1,0.0027314113032024328
4490,PGBM,Integrin cell surface interactions,0.0020901201606938953,0,0,1,0.002360388276679629
4491,PGBM,Integrin cell surface interactions,0.0024186604756406605,1,0,1,0.0027314113032024328
4492,PGBM,Laminin interactions,0.0020901201606938953,0,0,1,0.002360388276679629
4493,PGBM,Laminin interactions,0.0024186604756406605,1,0,1,0.0027314113032024328
4494,PGBM,ECM proteoglycans,0.0020901201606938953,0,0,1,0.002360388276679629
4495,PGBM,ECM proteoglycans,0.0024186604756406605,1,0,1,0.0027314113032024328
4496,PGBM,Retinoid metabolism and transport,0.0020901201606938953,0,0,1,0.002360388276679629
4497,PGBM,Retinoid metabolism and transport,0.0024186604756406605,1,0,1,0.0027314113032024328
4498,PGBM,Amyloid fiber formation,0.0020901201606938953,0,0,1,0.002360388276679629
4499,PGBM,Amyloid fiber formation,0.0024186604756406605,1,0,1,0.0027314113032024328
4500,DHSO,Fructose biosynthesis,0.0016057660920205078,0,0,1,0.0018134036166784578
4501,DHSO,Fructose biosynthesis,0.0004487062113295749,1,0,1,0.0005067272689930157
4502,DHSO,Formation of xylulose-5-phosphate,0.0016057660920205078,0,0,1,0.0018134036166784578
4503,DHSO,Formation of xylulose-5-phosphate,0.0004487062113295749,1,0,1,0.0005067272689930157
4504,CAP1,Signaling by ROBO receptors,1.3013644487665113e-05,0,0,1,1.4696405720216317e-05
4505,CAP1,Signaling by ROBO receptors,5.545386716336819e-05,1,0,1,6.262446552618721e-05
4506,CAP1,Platelet degranulation ,1.3013644487665113e-05,0,0,1,1.4696405720216317e-05
4507,CAP1,Platelet degranulation ,5.545386716336819e-05,1,0,1,6.262446552618721e-05
4508,CAP1,Neutrophil degranulation,1.3013644487665113e-05,0,0,1,1.4696405720216317e-05
4509,CAP1,Neutrophil degranulation,5.545386716336819e-05,1,0,1,6.262446552618721e-05
4510,DSC2,Formation of the cornified envelope,6.866555257350547e-05,0,0,1,7.754452033629649e-05
4511,DSC2,Formation of the cornified envelope,0.00013264165535091415,1,0,1,0.00014979321006393086
4512,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003881637661958899,0,0,1,0.0004383562344360229
4513,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00030532219367208473,1,0,1,0.0003448026291055147
4514,NUCB1,Post-translational protein phosphorylation,0.0003881637661958899,0,0,1,0.0004383562344360229
4515,NUCB1,Post-translational protein phosphorylation,0.00030532219367208473,1,0,1,0.0003448026291055147
4516,FHR3,Regulation of Complement cascade,0.0008643625238840882,0,0,1,0.0009761310409540687
4517,FHR3,Regulation of Complement cascade,0.0006944630913309952,1,0,1,0.0007842623453860085
4518,ACY1,Defective ACY1 causes encephalopathy,0.0010368836044805446,0,0,1,0.0011709603831985768
4519,ACY1,Defective ACY1 causes encephalopathy,0.003674081519309923,1,0,1,0.004149167645397638
4520,ACY1,Aflatoxin activation and detoxification,0.0010368836044805446,0,0,1,0.0011709603831985768
4521,ACY1,Aflatoxin activation and detoxification,0.003674081519309923,1,0,1,0.004149167645397638
4522,ACY1,Paracetamol ADME,0.0010368836044805446,0,0,1,0.0011709603831985768
4523,ACY1,Paracetamol ADME,0.003674081519309923,1,0,1,0.004149167645397638
4524,FHR1,Regulation of Complement cascade,0.0002646753616077518,0,0,1,0.0002988998586844278
4525,FHR1,Regulation of Complement cascade,0.00021036737468820975,1,0,1,0.0002375694442586846
4526,HGFA,MET Receptor Activation,0.002742405061220096,0,0,1,0.003097018476804601
4527,HGFA,MET Receptor Activation,0.0016871381763193484,1,0,1,0.0019052977180033332
4528,AK1C1,Bile acid and bile salt metabolism,0.0007025344032991611,0,0,1,0.0007933773381531029
4529,AK1C1,Bile acid and bile salt metabolism,9.55456513223086e-05,1,0,1,0.00010790041621053265
4530,AK1C1,Retinoid metabolism and transport,0.0007025344032991611,0,0,1,0.0007933773381531029
4531,AK1C1,Retinoid metabolism and transport,9.55456513223086e-05,1,0,1,0.00010790041621053265
4532,1433F,Activation of BH3-only proteins,0.0003151402869740463,0,0,1,0.00035589027505291483
4533,1433F,Activation of BH3-only proteins,0.0005770778403624773,1,0,1,0.0006516983065083586
4534,1433F,RHO GTPase Effectors,0.0003151402869740463,0,0,1,0.00035589027505291483
4535,1433F,RHO GTPase Effectors,0.0005770778403624773,1,0,1,0.0006516983065083586
4536,1433F,Transcriptional Regulation by TP53,0.0003151402869740463,0,0,1,0.00035589027505291483
4537,1433F,Transcriptional Regulation by TP53,0.0005770778403624773,1,0,1,0.0006516983065083586
4538,1433F,G2/M DNA damage checkpoint,0.0003151402869740463,0,0,1,0.00035589027505291483
4539,1433F,G2/M DNA damage checkpoint,0.0005770778403624773,1,0,1,0.0006516983065083586
4540,1433F,SARS-CoV-2 Infection,0.0003151402869740463,0,0,1,0.00035589027505291483
4541,1433F,SARS-CoV-2 Infection,0.0005770778403624773,1,0,1,0.0006516983065083586
4542,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0003151402869740463,0,0,1,0.00035589027505291483
4543,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0005770778403624773,1,0,1,0.0006516983065083586
4544,EF1A2,Eukaryotic Translation Elongation,0.0007849012880183066,0,0,1,0.0008863948750076104
4545,EF1A2,Eukaryotic Translation Elongation,0.0033922878757052994,1,0,1,0.003830935983258954
4546,ITIH3,Platelet degranulation ,0.000502750029084054,0,0,1,0.0005677593552116056
4547,ITIH3,Platelet degranulation ,0.0006912840623035524,1,0,1,0.0007806722442096682
4548,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.0012188410961280723,0,0,1,0.0013764463347795952
4549,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.000481709219004677,1,0,1,0.00054399781155628
4550,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0012188410961280723,0,0,1,0.0013764463347795952
4551,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.000481709219004677,1,0,1,0.00054399781155628
4552,PSME1,Antigen processing-Cross presentation,0.0012188410961280723,0,0,1,0.0013764463347795952
4553,PSME1,Antigen processing-Cross presentation,0.000481709219004677,1,0,1,0.00054399781155628
4554,PSME1,PTEN Regulation,0.0012188410961280723,0,0,1,0.0013764463347795952
4555,PSME1,PTEN Regulation,0.000481709219004677,1,0,1,0.00054399781155628
4556,PSME1,Host Interactions of HIV factors,0.0012188410961280723,0,0,1,0.0013764463347795952
4557,PSME1,Host Interactions of HIV factors,0.000481709219004677,1,0,1,0.00054399781155628
4558,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0012188410961280723,0,0,1,0.0013764463347795952
4559,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.000481709219004677,1,0,1,0.00054399781155628
4560,PSME1,APC/C-mediated degradation of cell cycle proteins,0.0012188410961280723,0,0,1,0.0013764463347795952
4561,PSME1,APC/C-mediated degradation of cell cycle proteins,0.000481709219004677,1,0,1,0.00054399781155628
4562,PSME1,Degradation of AXIN,0.0012188410961280723,0,0,1,0.0013764463347795952
4563,PSME1,Degradation of AXIN,0.000481709219004677,1,0,1,0.00054399781155628
4564,PSME1,Degradation of DVL,0.0012188410961280723,0,0,1,0.0013764463347795952
4565,PSME1,Degradation of DVL,0.000481709219004677,1,0,1,0.00054399781155628
4566,PSME1,Downstream TCR signaling,0.0012188410961280723,0,0,1,0.0013764463347795952
4567,PSME1,Downstream TCR signaling,0.000481709219004677,1,0,1,0.00054399781155628
4568,PSME1,Transcriptional regulation by RUNX3,0.0012188410961280723,0,0,1,0.0013764463347795952
4569,PSME1,Transcriptional regulation by RUNX3,0.000481709219004677,1,0,1,0.00054399781155628
4570,PSME1,Transcriptional regulation by RUNX2,0.0012188410961280723,0,0,1,0.0013764463347795952
4571,PSME1,Transcriptional regulation by RUNX2,0.000481709219004677,1,0,1,0.00054399781155628
4572,PSME1,Transcriptional regulation by RUNX1,0.0012188410961280723,0,0,1,0.0013764463347795952
4573,PSME1,Transcriptional regulation by RUNX1,0.000481709219004677,1,0,1,0.00054399781155628
4574,PSME1,FCERI mediated NF-kB activation,0.0012188410961280723,0,0,1,0.0013764463347795952
4575,PSME1,FCERI mediated NF-kB activation,0.000481709219004677,1,0,1,0.00054399781155628
4576,PSME1,Mitotic Metaphase and Anaphase,0.0012188410961280723,0,0,1,0.0013764463347795952
4577,PSME1,Mitotic Metaphase and Anaphase,0.000481709219004677,1,0,1,0.00054399781155628
4578,PSME1,Regulation of ornithine decarboxylase (ODC),0.0012188410961280723,0,0,1,0.0013764463347795952
4579,PSME1,Regulation of ornithine decarboxylase (ODC),0.000481709219004677,1,0,1,0.00054399781155628
4580,PSME1,Signaling by ROBO receptors,0.0012188410961280723,0,0,1,0.0013764463347795952
4581,PSME1,Signaling by ROBO receptors,0.000481709219004677,1,0,1,0.00054399781155628
4582,PSME1,PCP/CE pathway,0.0012188410961280723,0,0,1,0.0013764463347795952
4583,PSME1,PCP/CE pathway,0.000481709219004677,1,0,1,0.00054399781155628
4584,PSME1,Interleukin-1 family signaling,0.0012188410961280723,0,0,1,0.0013764463347795952
4585,PSME1,Interleukin-1 family signaling,0.000481709219004677,1,0,1,0.00054399781155628
4586,PSME1,G2/M Transition,0.0012188410961280723,0,0,1,0.0013764463347795952
4587,PSME1,G2/M Transition,0.000481709219004677,1,0,1,0.00054399781155628
4588,PSME1,G1/S Transition,0.0012188410961280723,0,0,1,0.0013764463347795952
4589,PSME1,G1/S Transition,0.000481709219004677,1,0,1,0.00054399781155628
4590,PSME1,Hh mutants are degraded by ERAD,0.0012188410961280723,0,0,1,0.0013764463347795952
4591,PSME1,Hh mutants are degraded by ERAD,0.000481709219004677,1,0,1,0.00054399781155628
4592,PSME1,CLEC7A (Dectin-1) signaling,0.0012188410961280723,0,0,1,0.0013764463347795952
4593,PSME1,CLEC7A (Dectin-1) signaling,0.000481709219004677,1,0,1,0.00054399781155628
4594,PSME1,Degradation of GLI1 by the proteasome,0.0012188410961280723,0,0,1,0.0013764463347795952
4595,PSME1,Degradation of GLI1 by the proteasome,0.000481709219004677,1,0,1,0.00054399781155628
4596,PSME1,Degradation of GLI2 by the proteasome,0.0012188410961280723,0,0,1,0.0013764463347795952
4597,PSME1,Degradation of GLI2 by the proteasome,0.000481709219004677,1,0,1,0.00054399781155628
4598,PSME1,GLI3 is processed to GLI3R by the proteasome,0.0012188410961280723,0,0,1,0.0013764463347795952
4599,PSME1,GLI3 is processed to GLI3R by the proteasome,0.000481709219004677,1,0,1,0.00054399781155628
4600,PSME1,Defective CFTR causes cystic fibrosis,0.0012188410961280723,0,0,1,0.0013764463347795952
4601,PSME1,Defective CFTR causes cystic fibrosis,0.000481709219004677,1,0,1,0.00054399781155628
4602,PSME1,NIK-->noncanonical NF-kB signaling,0.0012188410961280723,0,0,1,0.0013764463347795952
4603,PSME1,NIK-->noncanonical NF-kB signaling,0.000481709219004677,1,0,1,0.00054399781155628
4604,PSME1,RAF/MAP kinase cascade,0.0012188410961280723,0,0,1,0.0013764463347795952
4605,PSME1,RAF/MAP kinase cascade,0.000481709219004677,1,0,1,0.00054399781155628
4606,PSME1,UCH proteinases,0.0012188410961280723,0,0,1,0.0013764463347795952
4607,PSME1,UCH proteinases,0.000481709219004677,1,0,1,0.00054399781155628
4608,PSME1,Ub-specific processing proteases,0.0012188410961280723,0,0,1,0.0013764463347795952
4609,PSME1,Ub-specific processing proteases,0.000481709219004677,1,0,1,0.00054399781155628
4610,PSME1,Orc1 removal from chromatin,0.0012188410961280723,0,0,1,0.0013764463347795952
4611,PSME1,Orc1 removal from chromatin,0.000481709219004677,1,0,1,0.00054399781155628
4612,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.0012188410961280723,0,0,1,0.0013764463347795952
4613,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.000481709219004677,1,0,1,0.00054399781155628
4614,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.0012188410961280723,0,0,1,0.0013764463347795952
4615,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.000481709219004677,1,0,1,0.00054399781155628
4616,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.0012188410961280723,0,0,1,0.0013764463347795952
4617,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.000481709219004677,1,0,1,0.00054399781155628
4618,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.0012188410961280723,0,0,1,0.0013764463347795952
4619,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.000481709219004677,1,0,1,0.00054399781155628
4620,PSME1,p53-Independent G1/S DNA damage checkpoint,0.0012188410961280723,0,0,1,0.0013764463347795952
4621,PSME1,p53-Independent G1/S DNA damage checkpoint,0.000481709219004677,1,0,1,0.00054399781155628
4622,PSME1,Negative regulation of NOTCH4 signaling,0.0012188410961280723,0,0,1,0.0013764463347795952
4623,PSME1,Negative regulation of NOTCH4 signaling,0.000481709219004677,1,0,1,0.00054399781155628
4624,PSME1,KEAP1-NFE2L2 pathway,0.0012188410961280723,0,0,1,0.0013764463347795952
4625,PSME1,KEAP1-NFE2L2 pathway,0.000481709219004677,1,0,1,0.00054399781155628
4626,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.0012188410961280723,0,0,1,0.0013764463347795952
4627,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.000481709219004677,1,0,1,0.00054399781155628
4628,PSME1,Degradation of beta-catenin by the destruction complex,0.0012188410961280723,0,0,1,0.0013764463347795952
4629,PSME1,Degradation of beta-catenin by the destruction complex,0.000481709219004677,1,0,1,0.00054399781155628
4630,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0012188410961280723,0,0,1,0.0013764463347795952
4631,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.000481709219004677,1,0,1,0.00054399781155628
4632,PSME1,Hedgehog ligand biogenesis,0.0012188410961280723,0,0,1,0.0013764463347795952
4633,PSME1,Hedgehog ligand biogenesis,0.000481709219004677,1,0,1,0.00054399781155628
4634,PSME1,Hedgehog 'on' state,0.0012188410961280723,0,0,1,0.0013764463347795952
4635,PSME1,Hedgehog 'on' state,0.000481709219004677,1,0,1,0.00054399781155628
4636,PSME1,MAPK6/MAPK4 signaling,0.0012188410961280723,0,0,1,0.0013764463347795952
4637,PSME1,MAPK6/MAPK4 signaling,0.000481709219004677,1,0,1,0.00054399781155628
4638,PSME1,Neddylation,0.0012188410961280723,0,0,1,0.0013764463347795952
4639,PSME1,Neddylation,0.000481709219004677,1,0,1,0.00054399781155628
4640,LRP1,Scavenging of heme from plasma,0.00039387043759192526,0,0,1,0.00044480082097959894
4641,LRP1,Scavenging of heme from plasma,0.0007613841886351448,1,0,1,0.0008598368393839091
4642,LRP1,Retinoid metabolism and transport,0.00039387043759192526,0,0,1,0.00044480082097959894
4643,LRP1,Retinoid metabolism and transport,0.0007613841886351448,1,0,1,0.0008598368393839091
4644,LG3BP,Platelet degranulation ,0.0007896174777030823,0,0,1,0.0008917209031718698
4645,LG3BP,Platelet degranulation ,0.0010805406873254156,1,0,1,0.001220262652263746
4646,BST1,Nicotinate metabolism,0.0008277839977769323,0,0,1,0.0009348226387745085
4647,BST1,Nicotinate metabolism,0.000305972549866224,1,0,1,0.00034553708120314087
4648,BST1,Neutrophil degranulation,0.0008277839977769323,0,0,1,0.0009348226387745085
4649,BST1,Neutrophil degranulation,0.000305972549866224,1,0,1,0.00034553708120314087
4650,BST1,Post-translational modification: synthesis of GPI-anchored proteins,0.0008277839977769323,0,0,1,0.0009348226387745085
4651,BST1,Post-translational modification: synthesis of GPI-anchored proteins,0.000305972549866224,1,0,1,0.00034553708120314087
4652,FBLN3,Molecules associated with elastic fibres,0.004360172874881468,0,0,1,0.004923975727189775
4653,FBLN3,Molecules associated with elastic fibres,0.004158563511667906,1,0,1,0.004696296770569332
4654,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0030579889697840597,0,0,1,0.003453409737025648
4655,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0036444457993620467,1,0,1,0.00411569980596361
4656,FSTL1,Post-translational protein phosphorylation,0.0030579889697840597,0,0,1,0.003453409737025648
4657,FSTL1,Post-translational protein phosphorylation,0.0036444457993620467,1,0,1,0.00411569980596361
4658,FSTL1,Signaling by BMP,0.0030579889697840597,0,0,1,0.003453409737025648
4659,FSTL1,Signaling by BMP,0.0036444457993620467,1,0,1,0.00411569980596361
4660,LMAN2,COPII-mediated vesicle transport,0.0001094186195841019,0,0,1,0.0001235672626740462
4661,LMAN2,COPII-mediated vesicle transport,0.00025368952318679703,1,0,1,0.0002864934694700826
4662,LMAN2,Cargo concentration in the ER,0.0001094186195841019,0,0,1,0.0001235672626740462
4663,LMAN2,Cargo concentration in the ER,0.00025368952318679703,1,0,1,0.0002864934694700826
4664,TRAP1,Respiratory electron transport,0.0007692751829833889,0,0,1,0.0008687481981187853
4665,TRAP1,Respiratory electron transport,7.565289527561331e-05,1,0,1,8.543537853160851e-05
4666,SPP24,Platelet degranulation ,0.00021049853005072387,0,0,1,0.00023771755898716946
4667,SPP24,Platelet degranulation ,0.00016094371425064366,1,0,1,0.00018175493613552655
4668,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00021049853005072387,0,0,1,0.00023771755898716946
4669,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00016094371425064366,1,0,1,0.00018175493613552655
4670,SPP24,Post-translational protein phosphorylation,0.00021049853005072387,0,0,1,0.00023771755898716946
4671,SPP24,Post-translational protein phosphorylation,0.00016094371425064366,1,0,1,0.00018175493613552655
4672,MMRN1,Platelet degranulation ,7.074123841956293e-05,0,0,1,7.98886078338676e-05
4673,MMRN1,Platelet degranulation ,9.67710615081215e-05,1,0,1,0.00010928428106725761
4674,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,2.4126712732796307e-05,0,0,1,2.7246476523341768e-05
4675,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,7.949120259376388e-05,1,0,1,8.977000759573296e-05
4676,APOF,LDL remodeling,0.0005114871503891788,0,0,1,0.0005776262514256959
4677,APOF,LDL remodeling,0.00047854807762990644,1,0,1,0.0005404279110394322
4678,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,0.00028450956028445296,0,0,1,0.0003212987670889463
4679,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,0.0003267088942279978,1,0,1,0.0003689547894541694
4680,TBB2A,Activation of NMDA receptors and postsynaptic events,0.0006647871265241857,0,0,1,0.0007507490571328129
4681,TBB2A,Activation of NMDA receptors and postsynaptic events,0.0010759499128113104,1,0,1,0.0012150782563865366
4682,TBB2A,Gap junction trafficking,0.0006647871265241857,0,0,1,0.0007507490571328129
4683,TBB2A,Gap junction trafficking,0.0010759499128113104,1,0,1,0.0012150782563865366
4684,TBB2A,RHO GTPase Effectors,0.0006647871265241857,0,0,1,0.0007507490571328129
4685,TBB2A,RHO GTPase Effectors,0.0010759499128113104,1,0,1,0.0012150782563865366
4686,TBB2A,COPI-mediated anterograde transport,0.0006647871265241857,0,0,1,0.0007507490571328129
4687,TBB2A,COPI-mediated anterograde transport,0.0010759499128113104,1,0,1,0.0012150782563865366
4688,TBB2A,Mitotic Metaphase and Anaphase,0.0006647871265241857,0,0,1,0.0007507490571328129
4689,TBB2A,Mitotic Metaphase and Anaphase,0.0010759499128113104,1,0,1,0.0012150782563865366
4690,TBB2A,L1CAM interactions,0.0006647871265241857,0,0,1,0.0007507490571328129
4691,TBB2A,L1CAM interactions,0.0010759499128113104,1,0,1,0.0012150782563865366
4692,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0006647871265241857,0,0,1,0.0007507490571328129
4693,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0010759499128113104,1,0,1,0.0012150782563865366
4694,TBB2A,G2/M Transition,0.0006647871265241857,0,0,1,0.0007507490571328129
4695,TBB2A,G2/M Transition,0.0010759499128113104,1,0,1,0.0012150782563865366
4696,TBB2A,Golgi-to-ER retrograde transport,0.0006647871265241857,0,0,1,0.0007507490571328129
4697,TBB2A,Golgi-to-ER retrograde transport,0.0010759499128113104,1,0,1,0.0012150782563865366
4698,TBB2A,Mitotic Prometaphase,0.0006647871265241857,0,0,1,0.0007507490571328129
4699,TBB2A,Mitotic Prometaphase,0.0010759499128113104,1,0,1,0.0012150782563865366
4700,TBB2A,HCMV Early Events,0.0006647871265241857,0,0,1,0.0007507490571328129
4701,TBB2A,HCMV Early Events,0.0010759499128113104,1,0,1,0.0012150782563865366
4702,TBB2A,Aggrephagy,0.0006647871265241857,0,0,1,0.0007507490571328129
4703,TBB2A,Aggrephagy,0.0010759499128113104,1,0,1,0.0012150782563865366
4704,TBB2A,MHC class II antigen presentation,0.0006647871265241857,0,0,1,0.0007507490571328129
4705,TBB2A,MHC class II antigen presentation,0.0010759499128113104,1,0,1,0.0012150782563865366
4706,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0006647871265241857,0,0,1,0.0007507490571328129
4707,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0010759499128113104,1,0,1,0.0012150782563865366
4708,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0006647871265241857,0,0,1,0.0007507490571328129
4709,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0010759499128113104,1,0,1,0.0012150782563865366
4710,TBB2A,Post-chaperonin tubulin folding pathway,0.0006647871265241857,0,0,1,0.0007507490571328129
4711,TBB2A,Post-chaperonin tubulin folding pathway,0.0010759499128113104,1,0,1,0.0012150782563865366
4712,TBB2A,Intraflagellar transport,0.0006647871265241857,0,0,1,0.0007507490571328129
4713,TBB2A,Intraflagellar transport,0.0010759499128113104,1,0,1,0.0012150782563865366
4714,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.0006647871265241857,0,0,1,0.0007507490571328129
4715,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.0010759499128113104,1,0,1,0.0012150782563865366
4716,TBB2A,Kinesins,0.0006647871265241857,0,0,1,0.0007507490571328129
4717,TBB2A,Kinesins,0.0010759499128113104,1,0,1,0.0012150782563865366
4718,DAG1,Signaling by ROBO receptors,0.0005466857864338253,0,0,1,0.0006173763334723254
4719,DAG1,Signaling by ROBO receptors,0.0009024377931783988,1,0,1,0.0010191297263712144
4720,DAG1,Diseases associated with O-glycosylation of proteins,0.0005466857864338253,0,0,1,0.0006173763334723254
4721,DAG1,Diseases associated with O-glycosylation of proteins,0.0009024377931783988,1,0,1,0.0010191297263712144
4722,DAG1,ECM proteoglycans,0.0005466857864338253,0,0,1,0.0006173763334723254
4723,DAG1,ECM proteoglycans,0.0009024377931783988,1,0,1,0.0010191297263712144
4724,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0005466857864338253,0,0,1,0.0006173763334723254
4725,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0009024377931783988,1,0,1,0.0010191297263712144
4726,KRT81,Formation of the cornified envelope,1.4841909901614077e-05,0,0,1,1.6761079479600226e-05
4727,KRT81,Formation of the cornified envelope,3.158562631004057e-05,1,0,1,3.5669883222911095e-05
4728,ITIH4,Platelet degranulation ,3.2428199773430764e-05,0,0,1,3.662140771543946e-05
4729,ITIH4,Platelet degranulation ,4.502762109198615e-05,1,0,1,5.085002812326919e-05
4730,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.0010272800542123445,0,0,1,0.001160115022298351
4731,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.004979296720960192,1,0,1,0.005623156901353401
4732,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.0010272800542123445,0,0,1,0.001160115022298351
4733,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.004979296720960192,1,0,1,0.005623156901353401
4734,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0022588213571810593,0,0,1,0.002550903795327098
4735,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0018710039111639036,1,0,1,0.0021129386628502994
4736,GANAB,SARS-CoV-1 Infection,0.0022588213571810593,0,0,1,0.002550903795327098
4737,GANAB,SARS-CoV-1 Infection,0.0018710039111639036,1,0,1,0.0021129386628502994
4738,GANAB,SARS-CoV-2 Infection,0.0022588213571810593,0,0,1,0.002550903795327098
4739,GANAB,SARS-CoV-2 Infection,0.0018710039111639036,1,0,1,0.0021129386628502994
4740,PCOC1,Crosslinking of collagen fibrils,0.0012657055025565708,0,0,1,0.0014293706582743043
4741,PCOC1,Crosslinking of collagen fibrils,0.0011233996052110596,1,0,1,0.0012686635476911476
4742,PON3,Arachidonic acid metabolism,0.0001873082955808953,0,0,1,0.0002115286543464608
4743,PON3,Arachidonic acid metabolism,0.00015123667603248454,1,0,1,0.00017079270552204006
4744,PON3,Atorvastatin ADME,0.0001873082955808953,0,0,1,0.0002115286543464608
4745,PON3,Atorvastatin ADME,0.00015123667603248454,1,0,1,0.00017079270552204006
4746,FCN2,Initial triggering of complement,7.061204651385713e-05,0,0,1,7.974271045179141e-05
4747,FCN2,Initial triggering of complement,4.956897970112153e-05,1,0,1,5.59786182506629e-05
4748,BGH3,Amyloid fiber formation,0.00030267863455154083,0,0,1,0.00034181723808628746
4749,BGH3,Amyloid fiber formation,0.00022940744495020176,1,0,1,0.0002590715375252469
4750,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.002476520163010977,0,0,1,0.0027967526794206803
4751,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.002650057926140167,1,0,1,0.0029927301688274896
4752,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.002476520163010977,0,0,1,0.0027967526794206803
4753,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.002650057926140167,1,0,1,0.0029927301688274896
4754,ECM1,Platelet degranulation ,0.0001327482822010993,0,0,1,0.0001499136245606135
4755,ECM1,Platelet degranulation ,0.00018291207372375732,1,0,1,0.00020656396823490907
4756,UGPA,Glucuronidation,0.002027608418475534,0,0,1,0.0022897933002462866
4757,UGPA,Glucuronidation,0.0013588773104986223,1,0,1,0.0015345902754615062
4758,UGPA,Glycogen synthesis,0.002027608418475534,0,0,1,0.0022897933002462866
4759,UGPA,Glycogen synthesis,0.0013588773104986223,1,0,1,0.0015345902754615062
4760,TKFC,Fructose catabolism,0.0002600999195674099,0,0,1,0.0002937327778841237
4761,TKFC,Fructose catabolism,0.0007047586885090625,1,0,1,0.0007958892400198837
4762,TKFC,SARS-CoV-2 Infection,0.0002600999195674099,0,0,1,0.0002937327778841237
4763,TKFC,SARS-CoV-2 Infection,0.0007047586885090625,1,0,1,0.0007958892400198837
4764,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0023469863826442077,0,0,1,0.0026504692157416298
4765,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0016001465232206064,1,0,1,0.0018070573957459355
4766,CTRB2,Activation of Matrix Metalloproteinases,0.0023469863826442077,0,0,1,0.0026504692157416298
4767,CTRB2,Activation of Matrix Metalloproteinases,0.0016001465232206064,1,0,1,0.0018070573957459355
4768,OLFM4,Neutrophil degranulation,0.0003029002406120863,0,0,1,0.00034206749946225496
4769,OLFM4,Neutrophil degranulation,0.00017723005565564707,1,0,1,0.0002001472228783183
4770,LDH6A,Pyruvate metabolism,0.0003850969310225731,0,0,1,0.0004348928346154104
4771,LDH6A,Pyruvate metabolism,0.001729190505079368,1,0,1,0.001952787726319063
4772,TBA1A,Activation of NMDA receptors and postsynaptic events,0.00415637332657683,0,0,1,0.004693823378220915
4773,TBA1A,Activation of NMDA receptors and postsynaptic events,0.007692904270674825,1,0,1,0.008687654133765776
4774,TBA1A,Gap junction trafficking,0.00415637332657683,0,0,1,0.004693823378220915
4775,TBA1A,Gap junction trafficking,0.007692904270674825,1,0,1,0.008687654133765776
4776,TBA1A,RHO GTPase Effectors,0.00415637332657683,0,0,1,0.004693823378220915
4777,TBA1A,RHO GTPase Effectors,0.007692904270674825,1,0,1,0.008687654133765776
4778,TBA1A,COPI-mediated anterograde transport,0.00415637332657683,0,0,1,0.004693823378220915
4779,TBA1A,COPI-mediated anterograde transport,0.007692904270674825,1,0,1,0.008687654133765776
4780,TBA1A,Mitotic Metaphase and Anaphase,0.00415637332657683,0,0,1,0.004693823378220915
4781,TBA1A,Mitotic Metaphase and Anaphase,0.007692904270674825,1,0,1,0.008687654133765776
4782,TBA1A,L1CAM interactions,0.00415637332657683,0,0,1,0.004693823378220915
4783,TBA1A,L1CAM interactions,0.007692904270674825,1,0,1,0.008687654133765776
4784,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.00415637332657683,0,0,1,0.004693823378220915
4785,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.007692904270674825,1,0,1,0.008687654133765776
4786,TBA1A,G2/M Transition,0.00415637332657683,0,0,1,0.004693823378220915
4787,TBA1A,G2/M Transition,0.007692904270674825,1,0,1,0.008687654133765776
4788,TBA1A,Golgi-to-ER retrograde transport,0.00415637332657683,0,0,1,0.004693823378220915
4789,TBA1A,Golgi-to-ER retrograde transport,0.007692904270674825,1,0,1,0.008687654133765776
4790,TBA1A,Mitotic Prometaphase,0.00415637332657683,0,0,1,0.004693823378220915
4791,TBA1A,Mitotic Prometaphase,0.007692904270674825,1,0,1,0.008687654133765776
4792,TBA1A,HCMV Early Events,0.00415637332657683,0,0,1,0.004693823378220915
4793,TBA1A,HCMV Early Events,0.007692904270674825,1,0,1,0.008687654133765776
4794,TBA1A,Aggrephagy,0.00415637332657683,0,0,1,0.004693823378220915
4795,TBA1A,Aggrephagy,0.007692904270674825,1,0,1,0.008687654133765776
4796,TBA1A,MHC class II antigen presentation,0.00415637332657683,0,0,1,0.004693823378220915
4797,TBA1A,MHC class II antigen presentation,0.007692904270674825,1,0,1,0.008687654133765776
4798,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00415637332657683,0,0,1,0.004693823378220915
4799,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.007692904270674825,1,0,1,0.008687654133765776
4800,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00415637332657683,0,0,1,0.004693823378220915
4801,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.007692904270674825,1,0,1,0.008687654133765776
4802,TBA1A,Post-chaperonin tubulin folding pathway,0.00415637332657683,0,0,1,0.004693823378220915
4803,TBA1A,Post-chaperonin tubulin folding pathway,0.007692904270674825,1,0,1,0.008687654133765776
4804,TBA1A,Anchoring of the basal body to the plasma membrane,0.00415637332657683,0,0,1,0.004693823378220915
4805,TBA1A,Anchoring of the basal body to the plasma membrane,0.007692904270674825,1,0,1,0.008687654133765776
4806,TBA1A,Intraflagellar transport,0.00415637332657683,0,0,1,0.004693823378220915
4807,TBA1A,Intraflagellar transport,0.007692904270674825,1,0,1,0.008687654133765776
4808,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.00415637332657683,0,0,1,0.004693823378220915
4809,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.007692904270674825,1,0,1,0.008687654133765776
4810,TBA1A,Kinesins,0.00415637332657683,0,0,1,0.004693823378220915
4811,TBA1A,Kinesins,0.007692904270674825,1,0,1,0.008687654133765776
4812,DCXR,Essential pentosuria,0.00024086807988986473,0,0,1,0.0002720141179871782
4813,DCXR,Essential pentosuria,0.00011212251157190289,1,0,1,0.00012662078804997223
4814,DCXR,Formation of xylulose-5-phosphate,0.00024086807988986473,0,0,1,0.0002720141179871782
4815,DCXR,Formation of xylulose-5-phosphate,0.00011212251157190289,1,0,1,0.00012662078804997223
4816,K2C1B,Formation of the cornified envelope,0.0001534521066916688,0,0,1,0.00017329460787869651
4817,K2C1B,Formation of the cornified envelope,0.00029628661604182144,1,0,1,0.0003345986839388303
4818,URP2,Platelet degranulation ,0.00024736087327837227,0,0,1,0.00027934647795640035
4819,URP2,Platelet degranulation ,0.0003382374101060178,1,0,1,0.000381974028365754
4820,C163A,Leishmania parasite growth and survival,0.0009637457500569876,0,0,1,0.001088365259047651
4821,C163A,Leishmania parasite growth and survival,0.001926818138378026,1,0,1,0.0021759700856678324
4822,C163A,Scavenging of heme from plasma,0.0009637457500569876,0,0,1,0.001088365259047651
4823,C163A,Scavenging of heme from plasma,0.001926818138378026,1,0,1,0.0021759700856678324
4824,K2C78,Formation of the cornified envelope,0.00039561331131924556,0,0,1,0.0004467690612707858
4825,K2C78,Formation of the cornified envelope,0.0007664300301165419,1,0,1,0.000865535145779231
4826,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0016312339988142385,0,0,1,0.0018421647136517218
4827,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009661403149357515,1,0,1,0.0010910694590136984
4828,LIRA3,Neutrophil degranulation,0.0016312339988142385,0,0,1,0.0018421647136517218
4829,LIRA3,Neutrophil degranulation,0.0009661403149357515,1,0,1,0.0010910694590136984
4830,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001983111252095834,0,0,1,0.0022395423185834727
4831,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002462630535104799,1,0,1,0.002781067019096586
4832,GOLM1,Post-translational protein phosphorylation,0.001983111252095834,0,0,1,0.0022395423185834727
4833,GOLM1,Post-translational protein phosphorylation,0.002462630535104799,1,0,1,0.002781067019096586
4834,TXND5,Lysosome Vesicle Biogenesis,0.0004629831748416524,0,0,1,0.00052285035030395
4835,TXND5,Lysosome Vesicle Biogenesis,0.0002431323408544522,1,0,1,0.00027457116477169475
4836,TXND5,Golgi Associated Vesicle Biogenesis,0.0004629831748416524,0,0,1,0.00052285035030395
4837,TXND5,Golgi Associated Vesicle Biogenesis,0.0002431323408544522,1,0,1,0.00027457116477169475
4838,TXND5,Neutrophil degranulation,0.0004629831748416524,0,0,1,0.00052285035030395
4839,TXND5,Neutrophil degranulation,0.0002431323408544522,1,0,1,0.00027457116477169475
4840,BHMT1,Choline catabolism,0.0011332524032686567,0,0,1,0.001279790385977767
4841,BHMT1,Choline catabolism,0.0016772781222760865,1,0,1,0.0018941626854780183
4842,H2B1A,Packaging Of Telomere Ends,0.02095695161426128,0,0,1,0.023666841665611338
4843,H2B1A,Packaging Of Telomere Ends,0.0054674182712989225,1,0,1,0.006174396206481064
4844,H2B1A,Inhibition of DNA recombination at telomere,0.02095695161426128,0,0,1,0.023666841665611338
4845,H2B1A,Inhibition of DNA recombination at telomere,0.0054674182712989225,1,0,1,0.006174396206481064
4846,H2B1A,Pre-NOTCH Transcription and Translation,0.02095695161426128,0,0,1,0.023666841665611338
4847,H2B1A,Pre-NOTCH Transcription and Translation,0.0054674182712989225,1,0,1,0.006174396206481064
4848,H2B1A,RHO GTPase Effectors,0.02095695161426128,0,0,1,0.023666841665611338
4849,H2B1A,RHO GTPase Effectors,0.0054674182712989225,1,0,1,0.006174396206481064
4850,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.02095695161426128,0,0,1,0.023666841665611338
4851,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.0054674182712989225,1,0,1,0.006174396206481064
4852,H2B1A,Transcriptional regulation by RUNX1,0.02095695161426128,0,0,1,0.023666841665611338
4853,H2B1A,Transcriptional regulation by RUNX1,0.0054674182712989225,1,0,1,0.006174396206481064
4854,H2B1A,Oxidative Stress Induced Senescence,0.02095695161426128,0,0,1,0.023666841665611338
4855,H2B1A,Oxidative Stress Induced Senescence,0.0054674182712989225,1,0,1,0.006174396206481064
4856,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.02095695161426128,0,0,1,0.023666841665611338
4857,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.0054674182712989225,1,0,1,0.006174396206481064
4858,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.02095695161426128,0,0,1,0.023666841665611338
4859,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.0054674182712989225,1,0,1,0.006174396206481064
4860,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.02095695161426128,0,0,1,0.023666841665611338
4861,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0054674182712989225,1,0,1,0.006174396206481064
4862,H2B1A,B-WICH complex positively regulates rRNA expression,0.02095695161426128,0,0,1,0.023666841665611338
4863,H2B1A,B-WICH complex positively regulates rRNA expression,0.0054674182712989225,1,0,1,0.006174396206481064
4864,H2B1A,SIRT1 negatively regulates rRNA expression,0.02095695161426128,0,0,1,0.023666841665611338
4865,H2B1A,SIRT1 negatively regulates rRNA expression,0.0054674182712989225,1,0,1,0.006174396206481064
4866,H2B1A,NoRC negatively regulates rRNA expression,0.02095695161426128,0,0,1,0.023666841665611338
4867,H2B1A,NoRC negatively regulates rRNA expression,0.0054674182712989225,1,0,1,0.006174396206481064
4868,H2B1A,Ub-specific processing proteases,0.02095695161426128,0,0,1,0.023666841665611338
4869,H2B1A,Ub-specific processing proteases,0.0054674182712989225,1,0,1,0.006174396206481064
4870,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.02095695161426128,0,0,1,0.023666841665611338
4871,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0054674182712989225,1,0,1,0.006174396206481064
4872,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.02095695161426128,0,0,1,0.023666841665611338
4873,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0054674182712989225,1,0,1,0.006174396206481064
4874,H2B1A,Assembly of the ORC complex at the origin of replication,0.02095695161426128,0,0,1,0.023666841665611338
4875,H2B1A,Assembly of the ORC complex at the origin of replication,0.0054674182712989225,1,0,1,0.006174396206481064
4876,H2B1A,Mitotic Prophase,0.02095695161426128,0,0,1,0.023666841665611338
4877,H2B1A,Mitotic Prophase,0.0054674182712989225,1,0,1,0.006174396206481064
4878,H2B1A,G2/M DNA damage checkpoint,0.02095695161426128,0,0,1,0.023666841665611338
4879,H2B1A,G2/M DNA damage checkpoint,0.0054674182712989225,1,0,1,0.006174396206481064
4880,H2B1A,RNA Polymerase I Promoter Opening,0.02095695161426128,0,0,1,0.023666841665611338
4881,H2B1A,RNA Polymerase I Promoter Opening,0.0054674182712989225,1,0,1,0.006174396206481064
4882,H2B1A,RNA Polymerase I Promoter Escape,0.02095695161426128,0,0,1,0.023666841665611338
4883,H2B1A,RNA Polymerase I Promoter Escape,0.0054674182712989225,1,0,1,0.006174396206481064
4884,H2B1A,Depurination,0.02095695161426128,0,0,1,0.023666841665611338
4885,H2B1A,Depurination,0.0054674182712989225,1,0,1,0.006174396206481064
4886,H2B1A,Depyrimidination,0.02095695161426128,0,0,1,0.023666841665611338
4887,H2B1A,Depyrimidination,0.0054674182712989225,1,0,1,0.006174396206481064
4888,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.02095695161426128,0,0,1,0.023666841665611338
4889,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.0054674182712989225,1,0,1,0.006174396206481064
4890,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.02095695161426128,0,0,1,0.023666841665611338
4891,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.0054674182712989225,1,0,1,0.006174396206481064
4892,H2B1A,Estrogen-dependent gene expression,0.02095695161426128,0,0,1,0.023666841665611338
4893,H2B1A,Estrogen-dependent gene expression,0.0054674182712989225,1,0,1,0.006174396206481064
4894,H2B1A,HCMV Early Events,0.02095695161426128,0,0,1,0.023666841665611338
4895,H2B1A,HCMV Early Events,0.0054674182712989225,1,0,1,0.006174396206481064
4896,H2B1A,HCMV Late Events,0.02095695161426128,0,0,1,0.023666841665611338
4897,H2B1A,HCMV Late Events,0.0054674182712989225,1,0,1,0.006174396206481064
4898,H2B1A,Transcriptional regulation of granulopoiesis,0.02095695161426128,0,0,1,0.023666841665611338
4899,H2B1A,Transcriptional regulation of granulopoiesis,0.0054674182712989225,1,0,1,0.006174396206481064
4900,H2B1A,Meiotic synapsis,0.02095695161426128,0,0,1,0.023666841665611338
4901,H2B1A,Meiotic synapsis,0.0054674182712989225,1,0,1,0.006174396206481064
4902,H2B1A,Meiotic recombination,0.02095695161426128,0,0,1,0.023666841665611338
4903,H2B1A,Meiotic recombination,0.0054674182712989225,1,0,1,0.006174396206481064
4904,H2B1A,Transcriptional regulation by small RNAs,0.02095695161426128,0,0,1,0.023666841665611338
4905,H2B1A,Transcriptional regulation by small RNAs,0.0054674182712989225,1,0,1,0.006174396206481064
4906,H2B1A,PRC2 methylates histones and DNA,0.02095695161426128,0,0,1,0.023666841665611338
4907,H2B1A,PRC2 methylates histones and DNA,0.0054674182712989225,1,0,1,0.006174396206481064
4908,H2B1A,DNA methylation,0.02095695161426128,0,0,1,0.023666841665611338
4909,H2B1A,DNA methylation,0.0054674182712989225,1,0,1,0.006174396206481064
4910,H2B1A,HDACs deacetylate histones,0.02095695161426128,0,0,1,0.023666841665611338
4911,H2B1A,HDACs deacetylate histones,0.0054674182712989225,1,0,1,0.006174396206481064
4912,H2B1A,HATs acetylate histones,0.02095695161426128,0,0,1,0.023666841665611338
4913,H2B1A,HATs acetylate histones,0.0054674182712989225,1,0,1,0.006174396206481064
4914,H2B1A,Amyloid fiber formation,0.02095695161426128,0,0,1,0.023666841665611338
4915,H2B1A,Amyloid fiber formation,0.0054674182712989225,1,0,1,0.006174396206481064
4916,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.02095695161426128,0,0,1,0.023666841665611338
4917,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0054674182712989225,1,0,1,0.006174396206481064
4918,H2B1A,Nonhomologous End-Joining (NHEJ),0.02095695161426128,0,0,1,0.023666841665611338
4919,H2B1A,Nonhomologous End-Joining (NHEJ),0.0054674182712989225,1,0,1,0.006174396206481064
4920,H2B1A,Defective pyroptosis,0.02095695161426128,0,0,1,0.023666841665611338
4921,H2B1A,Defective pyroptosis,0.0054674182712989225,1,0,1,0.006174396206481064
4922,CBPB2,Regulation of Complement cascade,0.0003767071077641395,0,0,1,0.00042541814467411714
4923,CBPB2,Regulation of Complement cascade,0.00029586789477559303,1,0,1,0.00033412581889184
4924,CBPB2,Metabolism of Angiotensinogen to Angiotensins,0.0003767071077641395,0,0,1,0.00042541814467411714
4925,CBPB2,Metabolism of Angiotensinogen to Angiotensins,0.00029586789477559303,1,0,1,0.00033412581889184
4926,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.0029198347699005856,0,0,1,0.0032973911693320347
4927,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.0014754650662422682,1,0,1,0.0016662536970373876
4928,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0029198347699005856,0,0,1,0.0032973911693320347
4929,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0014754650662422682,1,0,1,0.0016662536970373876
4930,PSB7,Antigen processing-Cross presentation,0.0029198347699005856,0,0,1,0.0032973911693320347
4931,PSB7,Antigen processing-Cross presentation,0.0014754650662422682,1,0,1,0.0016662536970373876
4932,PSB7,PTEN Regulation,0.0029198347699005856,0,0,1,0.0032973911693320347
4933,PSB7,PTEN Regulation,0.0014754650662422682,1,0,1,0.0016662536970373876
4934,PSB7,Host Interactions of HIV factors,0.0029198347699005856,0,0,1,0.0032973911693320347
4935,PSB7,Host Interactions of HIV factors,0.0014754650662422682,1,0,1,0.0016662536970373876
4936,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0029198347699005856,0,0,1,0.0032973911693320347
4937,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0014754650662422682,1,0,1,0.0016662536970373876
4938,PSB7,APC/C-mediated degradation of cell cycle proteins,0.0029198347699005856,0,0,1,0.0032973911693320347
4939,PSB7,APC/C-mediated degradation of cell cycle proteins,0.0014754650662422682,1,0,1,0.0016662536970373876
4940,PSB7,Degradation of AXIN,0.0029198347699005856,0,0,1,0.0032973911693320347
4941,PSB7,Degradation of AXIN,0.0014754650662422682,1,0,1,0.0016662536970373876
4942,PSB7,Degradation of DVL,0.0029198347699005856,0,0,1,0.0032973911693320347
4943,PSB7,Degradation of DVL,0.0014754650662422682,1,0,1,0.0016662536970373876
4944,PSB7,Downstream TCR signaling,0.0029198347699005856,0,0,1,0.0032973911693320347
4945,PSB7,Downstream TCR signaling,0.0014754650662422682,1,0,1,0.0016662536970373876
4946,PSB7,Transcriptional regulation by RUNX3,0.0029198347699005856,0,0,1,0.0032973911693320347
4947,PSB7,Transcriptional regulation by RUNX3,0.0014754650662422682,1,0,1,0.0016662536970373876
4948,PSB7,Transcriptional regulation by RUNX2,0.0029198347699005856,0,0,1,0.0032973911693320347
4949,PSB7,Transcriptional regulation by RUNX2,0.0014754650662422682,1,0,1,0.0016662536970373876
4950,PSB7,Transcriptional regulation by RUNX1,0.0029198347699005856,0,0,1,0.0032973911693320347
4951,PSB7,Transcriptional regulation by RUNX1,0.0014754650662422682,1,0,1,0.0016662536970373876
4952,PSB7,FCERI mediated NF-kB activation,0.0029198347699005856,0,0,1,0.0032973911693320347
4953,PSB7,FCERI mediated NF-kB activation,0.0014754650662422682,1,0,1,0.0016662536970373876
4954,PSB7,Mitotic Metaphase and Anaphase,0.0029198347699005856,0,0,1,0.0032973911693320347
4955,PSB7,Mitotic Metaphase and Anaphase,0.0014754650662422682,1,0,1,0.0016662536970373876
4956,PSB7,Regulation of ornithine decarboxylase (ODC),0.0029198347699005856,0,0,1,0.0032973911693320347
4957,PSB7,Regulation of ornithine decarboxylase (ODC),0.0014754650662422682,1,0,1,0.0016662536970373876
4958,PSB7,Signaling by ROBO receptors,0.0029198347699005856,0,0,1,0.0032973911693320347
4959,PSB7,Signaling by ROBO receptors,0.0014754650662422682,1,0,1,0.0016662536970373876
4960,PSB7,PCP/CE pathway,0.0029198347699005856,0,0,1,0.0032973911693320347
4961,PSB7,PCP/CE pathway,0.0014754650662422682,1,0,1,0.0016662536970373876
4962,PSB7,Interleukin-1 family signaling,0.0029198347699005856,0,0,1,0.0032973911693320347
4963,PSB7,Interleukin-1 family signaling,0.0014754650662422682,1,0,1,0.0016662536970373876
4964,PSB7,G2/M Transition,0.0029198347699005856,0,0,1,0.0032973911693320347
4965,PSB7,G2/M Transition,0.0014754650662422682,1,0,1,0.0016662536970373876
4966,PSB7,G1/S Transition,0.0029198347699005856,0,0,1,0.0032973911693320347
4967,PSB7,G1/S Transition,0.0014754650662422682,1,0,1,0.0016662536970373876
4968,PSB7,Hh mutants are degraded by ERAD,0.0029198347699005856,0,0,1,0.0032973911693320347
4969,PSB7,Hh mutants are degraded by ERAD,0.0014754650662422682,1,0,1,0.0016662536970373876
4970,PSB7,CLEC7A (Dectin-1) signaling,0.0029198347699005856,0,0,1,0.0032973911693320347
4971,PSB7,CLEC7A (Dectin-1) signaling,0.0014754650662422682,1,0,1,0.0016662536970373876
4972,PSB7,Degradation of GLI1 by the proteasome,0.0029198347699005856,0,0,1,0.0032973911693320347
4973,PSB7,Degradation of GLI1 by the proteasome,0.0014754650662422682,1,0,1,0.0016662536970373876
4974,PSB7,Degradation of GLI2 by the proteasome,0.0029198347699005856,0,0,1,0.0032973911693320347
4975,PSB7,Degradation of GLI2 by the proteasome,0.0014754650662422682,1,0,1,0.0016662536970373876
4976,PSB7,GLI3 is processed to GLI3R by the proteasome,0.0029198347699005856,0,0,1,0.0032973911693320347
4977,PSB7,GLI3 is processed to GLI3R by the proteasome,0.0014754650662422682,1,0,1,0.0016662536970373876
4978,PSB7,Defective CFTR causes cystic fibrosis,0.0029198347699005856,0,0,1,0.0032973911693320347
4979,PSB7,Defective CFTR causes cystic fibrosis,0.0014754650662422682,1,0,1,0.0016662536970373876
4980,PSB7,NIK-->noncanonical NF-kB signaling,0.0029198347699005856,0,0,1,0.0032973911693320347
4981,PSB7,NIK-->noncanonical NF-kB signaling,0.0014754650662422682,1,0,1,0.0016662536970373876
4982,PSB7,RAF/MAP kinase cascade,0.0029198347699005856,0,0,1,0.0032973911693320347
4983,PSB7,RAF/MAP kinase cascade,0.0014754650662422682,1,0,1,0.0016662536970373876
4984,PSB7,UCH proteinases,0.0029198347699005856,0,0,1,0.0032973911693320347
4985,PSB7,UCH proteinases,0.0014754650662422682,1,0,1,0.0016662536970373876
4986,PSB7,Ub-specific processing proteases,0.0029198347699005856,0,0,1,0.0032973911693320347
4987,PSB7,Ub-specific processing proteases,0.0014754650662422682,1,0,1,0.0016662536970373876
4988,PSB7,Orc1 removal from chromatin,0.0029198347699005856,0,0,1,0.0032973911693320347
4989,PSB7,Orc1 removal from chromatin,0.0014754650662422682,1,0,1,0.0016662536970373876
4990,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.0029198347699005856,0,0,1,0.0032973911693320347
4991,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.0014754650662422682,1,0,1,0.0016662536970373876
4992,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.0029198347699005856,0,0,1,0.0032973911693320347
4993,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.0014754650662422682,1,0,1,0.0016662536970373876
4994,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.0029198347699005856,0,0,1,0.0032973911693320347
4995,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.0014754650662422682,1,0,1,0.0016662536970373876
4996,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.0029198347699005856,0,0,1,0.0032973911693320347
4997,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.0014754650662422682,1,0,1,0.0016662536970373876
4998,PSB7,p53-Independent G1/S DNA damage checkpoint,0.0029198347699005856,0,0,1,0.0032973911693320347
4999,PSB7,p53-Independent G1/S DNA damage checkpoint,0.0014754650662422682,1,0,1,0.0016662536970373876
5000,PSB7,Negative regulation of NOTCH4 signaling,0.0029198347699005856,0,0,1,0.0032973911693320347
5001,PSB7,Negative regulation of NOTCH4 signaling,0.0014754650662422682,1,0,1,0.0016662536970373876
5002,PSB7,KEAP1-NFE2L2 pathway,0.0029198347699005856,0,0,1,0.0032973911693320347
5003,PSB7,KEAP1-NFE2L2 pathway,0.0014754650662422682,1,0,1,0.0016662536970373876
5004,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.0029198347699005856,0,0,1,0.0032973911693320347
5005,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.0014754650662422682,1,0,1,0.0016662536970373876
5006,PSB7,Neutrophil degranulation,0.0029198347699005856,0,0,1,0.0032973911693320347
5007,PSB7,Neutrophil degranulation,0.0014754650662422682,1,0,1,0.0016662536970373876
5008,PSB7,Degradation of beta-catenin by the destruction complex,0.0029198347699005856,0,0,1,0.0032973911693320347
5009,PSB7,Degradation of beta-catenin by the destruction complex,0.0014754650662422682,1,0,1,0.0016662536970373876
5010,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0029198347699005856,0,0,1,0.0032973911693320347
5011,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0014754650662422682,1,0,1,0.0016662536970373876
5012,PSB7,Hedgehog ligand biogenesis,0.0029198347699005856,0,0,1,0.0032973911693320347
5013,PSB7,Hedgehog ligand biogenesis,0.0014754650662422682,1,0,1,0.0016662536970373876
5014,PSB7,Hedgehog 'on' state,0.0029198347699005856,0,0,1,0.0032973911693320347
5015,PSB7,Hedgehog 'on' state,0.0014754650662422682,1,0,1,0.0016662536970373876
5016,PSB7,MAPK6/MAPK4 signaling,0.0029198347699005856,0,0,1,0.0032973911693320347
5017,PSB7,MAPK6/MAPK4 signaling,0.0014754650662422682,1,0,1,0.0016662536970373876
5018,PSB7,Neddylation,0.0029198347699005856,0,0,1,0.0032973911693320347
5019,PSB7,Neddylation,0.0014754650662422682,1,0,1,0.0016662536970373876
5020,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0011540541102749095,0,0,1,0.0013032819087504016
5021,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0012672862022799596,1,0,1,0.0014311557542540487
5022,PARK7,Aggrephagy,0.0011540541102749095,0,0,1,0.0013032819087504016
5023,PARK7,Aggrephagy,0.0012672862022799596,1,0,1,0.0014311557542540487
5024,PARK7,Chaperone Mediated Autophagy,0.0011540541102749095,0,0,1,0.0013032819087504016
5025,PARK7,Chaperone Mediated Autophagy,0.0012672862022799596,1,0,1,0.0014311557542540487
5026,PARK7,Late endosomal microautophagy,0.0011540541102749095,0,0,1,0.0013032819087504016
5027,PARK7,Late endosomal microautophagy,0.0012672862022799596,1,0,1,0.0014311557542540487
5028,RARR2,Platelet degranulation ,0.0002944935534975543,0,0,1,0.00033257376504257103
5029,RARR2,Platelet degranulation ,0.00040114144932775316,1,0,1,0.0004530120287290856
5030,FUCO2,Neutrophil degranulation,0.002028256910912182,0,0,1,0.002290525647588686
5031,FUCO2,Neutrophil degranulation,0.001806685029260748,1,0,1,0.0020403028701009734
5032,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002028256910912182,0,0,1,0.002290525647588686
5033,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001806685029260748,1,0,1,0.0020403028701009734
5034,FUCO2,Post-translational protein phosphorylation,0.002028256910912182,0,0,1,0.002290525647588686
5035,FUCO2,Post-translational protein phosphorylation,0.001806685029260748,1,0,1,0.0020403028701009734
5036,COL11,Initial triggering of complement,0.001506095072168852,0,0,1,0.0017008443910383171
5037,COL11,Initial triggering of complement,0.0021931393391708015,1,0,1,0.002476728602811562
5038,COL11,Scavenging by Class A Receptors,0.001506095072168852,0,0,1,0.0017008443910383171
5039,COL11,Scavenging by Class A Receptors,0.0021931393391708015,1,0,1,0.002476728602811562
5040,FHR5,Regulation of Complement cascade,0.00012512958826887993,0,0,1,0.00014130977671520992
5041,FHR5,Regulation of Complement cascade,0.00010117636678914958,1,0,1,0.00011425922515711389
5042,CHM4A,HIV Life Cycle,0.002182090755724608,0,0,1,0.0024642513551725296
5043,CHM4A,HIV Life Cycle,0.002764464701114572,1,0,1,0.003121930592564208
5044,CHM4A,Mitotic Metaphase and Anaphase,0.002182090755724608,0,0,1,0.0024642513551725296
5045,CHM4A,Mitotic Metaphase and Anaphase,0.002764464701114572,1,0,1,0.003121930592564208
5046,CHM4A,HCMV Late Events,0.002182090755724608,0,0,1,0.0024642513551725296
5047,CHM4A,HCMV Late Events,0.002764464701114572,1,0,1,0.003121930592564208
5048,CHM4A,SARS-CoV-1 Infection,0.002182090755724608,0,0,1,0.0024642513551725296
5049,CHM4A,SARS-CoV-1 Infection,0.002764464701114572,1,0,1,0.003121930592564208
5050,CHM4A,SARS-CoV-2 Infection,0.002182090755724608,0,0,1,0.0024642513551725296
5051,CHM4A,SARS-CoV-2 Infection,0.002764464701114572,1,0,1,0.003121930592564208
5052,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.002182090755724608,0,0,1,0.0024642513551725296
5053,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.002764464701114572,1,0,1,0.003121930592564208
5054,CHM4A,Pyroptosis,0.002182090755724608,0,0,1,0.0024642513551725296
5055,CHM4A,Pyroptosis,0.002764464701114572,1,0,1,0.003121930592564208
5056,CHM4A,Late endosomal microautophagy,0.002182090755724608,0,0,1,0.0024642513551725296
5057,CHM4A,Late endosomal microautophagy,0.002764464701114572,1,0,1,0.003121930592564208
5058,TBB1,Activation of NMDA receptors and postsynaptic events,0.0007442776337936686,0,0,1,0.0008405182794936525
5059,TBB1,Activation of NMDA receptors and postsynaptic events,0.0047944587100472134,1,0,1,0.005414417957895272
5060,TBB1,Gap junction trafficking,0.0007442776337936686,0,0,1,0.0008405182794936525
5061,TBB1,Gap junction trafficking,0.0047944587100472134,1,0,1,0.005414417957895272
5062,TBB1,RHO GTPase Effectors,0.0007442776337936686,0,0,1,0.0008405182794936525
5063,TBB1,RHO GTPase Effectors,0.0047944587100472134,1,0,1,0.005414417957895272
5064,TBB1,COPI-mediated anterograde transport,0.0007442776337936686,0,0,1,0.0008405182794936525
5065,TBB1,COPI-mediated anterograde transport,0.0047944587100472134,1,0,1,0.005414417957895272
5066,TBB1,Mitotic Metaphase and Anaphase,0.0007442776337936686,0,0,1,0.0008405182794936525
5067,TBB1,Mitotic Metaphase and Anaphase,0.0047944587100472134,1,0,1,0.005414417957895272
5068,TBB1,L1CAM interactions,0.0007442776337936686,0,0,1,0.0008405182794936525
5069,TBB1,L1CAM interactions,0.0047944587100472134,1,0,1,0.005414417957895272
5070,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0007442776337936686,0,0,1,0.0008405182794936525
5071,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0047944587100472134,1,0,1,0.005414417957895272
5072,TBB1,G2/M Transition,0.0007442776337936686,0,0,1,0.0008405182794936525
5073,TBB1,G2/M Transition,0.0047944587100472134,1,0,1,0.005414417957895272
5074,TBB1,Golgi-to-ER retrograde transport,0.0007442776337936686,0,0,1,0.0008405182794936525
5075,TBB1,Golgi-to-ER retrograde transport,0.0047944587100472134,1,0,1,0.005414417957895272
5076,TBB1,Mitotic Prometaphase,0.0007442776337936686,0,0,1,0.0008405182794936525
5077,TBB1,Mitotic Prometaphase,0.0047944587100472134,1,0,1,0.005414417957895272
5078,TBB1,HCMV Early Events,0.0007442776337936686,0,0,1,0.0008405182794936525
5079,TBB1,HCMV Early Events,0.0047944587100472134,1,0,1,0.005414417957895272
5080,TBB1,Aggrephagy,0.0007442776337936686,0,0,1,0.0008405182794936525
5081,TBB1,Aggrephagy,0.0047944587100472134,1,0,1,0.005414417957895272
5082,TBB1,MHC class II antigen presentation,0.0007442776337936686,0,0,1,0.0008405182794936525
5083,TBB1,MHC class II antigen presentation,0.0047944587100472134,1,0,1,0.005414417957895272
5084,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0007442776337936686,0,0,1,0.0008405182794936525
5085,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0047944587100472134,1,0,1,0.005414417957895272
5086,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0007442776337936686,0,0,1,0.0008405182794936525
5087,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0047944587100472134,1,0,1,0.005414417957895272
5088,TBB1,Post-chaperonin tubulin folding pathway,0.0007442776337936686,0,0,1,0.0008405182794936525
5089,TBB1,Post-chaperonin tubulin folding pathway,0.0047944587100472134,1,0,1,0.005414417957895272
5090,TBB1,Intraflagellar transport,0.0007442776337936686,0,0,1,0.0008405182794936525
5091,TBB1,Intraflagellar transport,0.0047944587100472134,1,0,1,0.005414417957895272
5092,TBB1,Carboxyterminal post-translational modifications of tubulin,0.0007442776337936686,0,0,1,0.0008405182794936525
5093,TBB1,Carboxyterminal post-translational modifications of tubulin,0.0047944587100472134,1,0,1,0.005414417957895272
5094,TBB1,Kinesins,0.0007442776337936686,0,0,1,0.0008405182794936525
5095,TBB1,Kinesins,0.0047944587100472134,1,0,1,0.005414417957895272
5096,RETN,FOXO-mediated transcription,0.002485972264223746,0,0,1,0.002807427007773746
5097,RETN,FOXO-mediated transcription,0.004343522745680991,1,0,1,0.004905172612177976
5098,RETN,Neutrophil degranulation,0.002485972264223746,0,0,1,0.002807427007773746
5099,RETN,Neutrophil degranulation,0.004343522745680991,1,0,1,0.004905172612177976
5100,SAE1,Processing and activation of SUMO,0.0009862501069319524,0,0,1,0.0011137795970081281
5101,SAE1,Processing and activation of SUMO,0.00186144485703296,1,0,1,0.00210214355176954
5102,GRHPR,Glyoxylate metabolism and glycine degradation,0.00014107060803145968,0,0,1,0.00015931208915327558
5103,GRHPR,Glyoxylate metabolism and glycine degradation,8.578730937077283e-05,1,0,1,9.688024790853934e-05
5104,CATZ,COPII-mediated vesicle transport,0.009605819296782014,0,0,1,0.010847923331115996
5105,CATZ,COPII-mediated vesicle transport,0.011150480361494618,1,0,1,0.012592320584994777
5106,CATZ,Cargo concentration in the ER,0.009605819296782014,0,0,1,0.010847923331115996
5107,CATZ,Cargo concentration in the ER,0.011150480361494618,1,0,1,0.012592320584994777
5108,CATZ,Lysosome Vesicle Biogenesis,0.009605819296782014,0,0,1,0.010847923331115996
5109,CATZ,Lysosome Vesicle Biogenesis,0.011150480361494618,1,0,1,0.012592320584994777
5110,CATZ,Neutrophil degranulation,0.009605819296782014,0,0,1,0.010847923331115996
5111,CATZ,Neutrophil degranulation,0.011150480361494618,1,0,1,0.012592320584994777
5112,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.009605819296782014,0,0,1,0.010847923331115996
5113,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.011150480361494618,1,0,1,0.012592320584994777
5114,FBLN5,Molecules associated with elastic fibres,0.00023944587078651282,0,0,1,0.00027040800664598886
5115,FBLN5,Molecules associated with elastic fibres,0.0002318653263746732,1,0,1,0.0002618472413383066
5116,DMBT1,Surfactant metabolism,0.0003374789629916325,0,0,1,0.0003811175083862127
5117,DMBT1,Surfactant metabolism,0.0004758844170190493,1,0,1,0.000537419819257363
5118,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0012636759730287799,0,0,1,0.0014270786954509887
5119,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0016742427724792959,1,0,1,0.0018907348423278006
5120,ZPI,Post-translational protein phosphorylation,0.0012636759730287799,0,0,1,0.0014270786954509887
5121,ZPI,Post-translational protein phosphorylation,0.0016742427724792959,1,0,1,0.0018907348423278006
5122,MINP1,Synthesis of IPs in the ER lumen,0.0026117602533419727,0,0,1,0.0029494803214756703
5123,MINP1,Synthesis of IPs in the ER lumen,0.004899184237267387,1,0,1,0.0055326852763816535
5124,TLN1,Semaphorin interactions,0.008933486622583291,0,0,1,0.010088653030751795
5125,TLN1,Semaphorin interactions,0.0046412837981166044,1,0,1,0.005241436388126378
5126,TLN1,IRE1alpha activates chaperones,0.008933486622583291,0,0,1,0.010088653030751795
5127,TLN1,IRE1alpha activates chaperones,0.0046412837981166044,1,0,1,0.005241436388126378
5128,TLN1,RAF/MAP kinase cascade,0.008933486622583291,0,0,1,0.010088653030751795
5129,TLN1,RAF/MAP kinase cascade,0.0046412837981166044,1,0,1,0.005241436388126378
5130,TLN1,Signaling by RAS mutants,0.008933486622583291,0,0,1,0.010088653030751795
5131,TLN1,Signaling by RAS mutants,0.0046412837981166044,1,0,1,0.005241436388126378
5132,TLN1,Signaling by moderate kinase activity BRAF mutants,0.008933486622583291,0,0,1,0.010088653030751795
5133,TLN1,Signaling by moderate kinase activity BRAF mutants,0.0046412837981166044,1,0,1,0.005241436388126378
5134,TLN1,Signaling by high-kinase activity BRAF mutants,0.008933486622583291,0,0,1,0.010088653030751795
5135,TLN1,Signaling by high-kinase activity BRAF mutants,0.0046412837981166044,1,0,1,0.005241436388126378
5136,TLN1,Signaling by BRAF and RAF1 fusions,0.008933486622583291,0,0,1,0.010088653030751795
5137,TLN1,Signaling by BRAF and RAF1 fusions,0.0046412837981166044,1,0,1,0.005241436388126378
5138,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.008933486622583291,0,0,1,0.010088653030751795
5139,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0046412837981166044,1,0,1,0.005241436388126378
5140,TLN1,Signaling by RAF1 mutants,0.008933486622583291,0,0,1,0.010088653030751795
5141,TLN1,Signaling by RAF1 mutants,0.0046412837981166044,1,0,1,0.005241436388126378
5142,TLN1,Platelet degranulation ,0.008933486622583291,0,0,1,0.010088653030751795
5143,TLN1,Platelet degranulation ,0.0046412837981166044,1,0,1,0.005241436388126378
5144,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.008933486622583291,0,0,1,0.010088653030751795
5145,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0046412837981166044,1,0,1,0.005241436388126378
5146,TLN1,p130Cas linkage to MAPK signaling for integrins,0.008933486622583291,0,0,1,0.010088653030751795
5147,TLN1,p130Cas linkage to MAPK signaling for integrins,0.0046412837981166044,1,0,1,0.005241436388126378
5148,TLN1,Smooth Muscle Contraction,0.008933486622583291,0,0,1,0.010088653030751795
5149,TLN1,Smooth Muscle Contraction,0.0046412837981166044,1,0,1,0.005241436388126378
5150,HYOU1,IRE1alpha activates chaperones,0.002323888664767335,0,0,1,0.0026243847907789406
5151,HYOU1,IRE1alpha activates chaperones,0.0031866966013981003,1,0,1,0.0035987602247603456
5152,HYOU1,Scavenging by Class F Receptors,0.002323888664767335,0,0,1,0.0026243847907789406
5153,HYOU1,Scavenging by Class F Receptors,0.0031866966013981003,1,0,1,0.0035987602247603456
5154,COL10,Initial triggering of complement,0.0002907244714631742,0,0,1,0.00032831731260739565
5155,COL10,Initial triggering of complement,0.00020302130986533368,1,0,1,0.0002292734784985683
5156,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,2.4743233036525718e-05,0,1,2,0.0004910823098982181
5157,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,0.0007794653010840626,1,1,2,0.015470153798285497
5158,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.0006806418796593808,0,1,2,0.013508791918306527
5159,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.0005868098456044508,1,1,2,0.011646494782030054
5160,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,0.0018583877912727255,0,1,2,0.0368836751396899
5161,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,0.0012292931241049492,1,1,2,0.024397947755505626
5162,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,0.0007074494101727609,0,1,2,0.014040844620867427
5163,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,0.00023538165457702128,1,1,2,0.004671651698333546
5164,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,0.0027313878705578372,0,1,2,0.05421022639690821
5165,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,0.00018808369532745403,1,1,2,0.0037329226709885135
5166,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),0.0005219947125384389,0,1,2,0.010360100024504592
5167,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),0.00020653979387742568,1,1,2,0.004099223368001302
5168,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,1.0969292917397599e-05,0,1,2,0.00021770904779798973
5169,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,0.0005184701613319159,1,1,2,0.010290147777548875
5170,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.0006971802569271022,0,1,2,0.013837031340317857
5171,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.000476703384366988,1,1,2,0.009461196876966787
5172,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.005018050343904474,0,1,2,0.09959392737531175
5173,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.003235809134465978,1,1,2,0.0642215437973513
5174,Downregulation of ERBB2 signaling,Signaling by ERBB2,0.00014003988051137576,0,1,2,0.0027793905468164824
5175,Downregulation of ERBB2 signaling,Signaling by ERBB2,0.00014126222334839972,1,1,2,0.0028036505512794054
5176,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,0.00033882678937590045,0,1,2,0.006724741351968362
5177,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,0.0003417828031280787,1,1,2,0.006783409758775495
5178,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,3.2848449867520997e-05,0,1,2,0.0006519476502405797
5179,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,2.279108314482775e-05,1,1,2,0.00045233772560450755
5180,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,9.144099875890146e-05,0,1,2,0.001814841933696903
5181,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,6.419964636291016e-05,1,1,2,0.0012741791092540878
5182,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,0.0001292045754379047,0,1,2,0.00256434077397244
5183,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,9.049506951008982e-05,1,1,2,0.0017960679472974303
5184,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,8.702291407519574e-05,0,1,2,0.0017271556063443965
5185,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,6.100789478630777e-05,1,1,2,0.001210831981797244
5186,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,2.826551090592272e-05,0,1,2,0.0005609894376229356
5187,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,1.9808037651824025e-05,1,1,2,0.00039313281616226784
5188,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,6.191642607638623e-05,0,1,2,0.001228863725825517
5189,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,4.330035640579144e-05,1,1,2,0.0008593880602337777
5190,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.0006953532571685917,0,1,2,0.013800770627731574
5191,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.0007991831446441968,1,1,2,0.01586149652004818
5192,Nuclear signaling by ERBB4,Signaling by ERBB4,0.00030516075070770245,0,1,2,0.006056566905650217
5193,Nuclear signaling by ERBB4,Signaling by ERBB4,0.0004010959181705218,1,1,2,0.007960605216592339
5194,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.002891561039616348,0,1,2,0.05738920505862379
5195,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.0024469405241845914,1,1,2,0.04856476124305433
5196,PTEN Regulation,PIP3 activates AKT signaling,0.00688385646282057,0,1,2,0.1366248350722552
5197,PTEN Regulation,PIP3 activates AKT signaling,0.0027492328428457666,1,1,2,0.05456439798791614
5198,Defensins,Antimicrobial peptides,4.182552765982234e-06,0,1,2,8.301169336107673e-05
5199,Defensins,Antimicrobial peptides,3.221941571701834e-06,1,1,2,6.394631239388753e-05
5200,Glycerophospholipid biosynthesis,Phospholipid metabolism,0.0009084455980647468,0,1,2,0.01803004328722701
5201,Glycerophospholipid biosynthesis,Phospholipid metabolism,0.0004212484982509998,1,1,2,0.008360576213176363
5202,Antagonism of Activin by Follistatin,Signaling by Activin,3.24326395377681e-05,0,1,2,0.0006436950060968998
5203,Antagonism of Activin by Follistatin,Signaling by Activin,2.2771581973244382e-05,1,1,2,0.0004519506832009241
5204,Methylation,Phase II - Conjugation of compounds,2.786518748751481e-06,0,1,2,5.530441643141526e-05
5205,Methylation,Phase II - Conjugation of compounds,5.553271738686479e-06,1,1,2,0.00011021653916046103
5206,Glucuronidation,Phase II - Conjugation of compounds,8.082107183644425e-05,0,1,2,0.001604066800296516
5207,Glucuronidation,Phase II - Conjugation of compounds,0.00016343457072446834,1,1,2,0.0032437081439647296
5208,Glutathione conjugation,Phase II - Conjugation of compounds,5.999141343556223e-05,0,1,2,0.001190657738239189
5209,Glutathione conjugation,Phase II - Conjugation of compounds,0.00011383284252012119,1,1,2,0.0022592559009786744
5210,Packaging Of Telomere Ends,Telomere Maintenance,0.0005345787213664706,0,1,2,0.010609856558500245
5211,Packaging Of Telomere Ends,Telomere Maintenance,0.00012948866241214058,1,1,2,0.0025699790867714915
5212,Inhibition of DNA recombination at telomere,Telomere Maintenance,0.0002890083767039504,0,1,2,0.005735988542895718
5213,Inhibition of DNA recombination at telomere,Telomere Maintenance,6.0796320589381904e-05,1,1,2,0.0012066328399475174
5214,Gap junction trafficking,Gap junction trafficking and regulation,0.000907046370095052,0,1,2,0.018002272619488578
5215,Gap junction trafficking,Gap junction trafficking and regulation,0.0014099477202970253,1,1,2,0.027983424085974345
5216,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.0018087536951563684,0,1,2,0.0358985804863538
5217,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.0023195843634339743,1,1,2,0.04603710620667095
5218,Methionine salvage pathway,Sulfur amino acid metabolism,4.286479240270638e-05,0,1,2,0.0008507433622499788
5219,Methionine salvage pathway,Sulfur amino acid metabolism,5.7232774444918076e-05,1,1,2,0.0011359066551571602
5220,Cysteine formation from homocysteine,Sulfur amino acid metabolism,1.3130145963105338e-05,0,1,2,0.0002605957919623553
5221,Cysteine formation from homocysteine,Sulfur amino acid metabolism,1.930892309753964e-05,1,1,2,0.00038322682174917025
5222,HIV Life Cycle,HIV Infection,0.0006959092717465288,0,1,2,0.013811805924649619
5223,HIV Life Cycle,HIV Infection,0.00035048120506350094,1,1,2,0.0069560481245284495
5224,Host Interactions of HIV factors,HIV Infection,0.0012563973781800483,0,1,2,0.024935889570935288
5225,Host Interactions of HIV factors,HIV Infection,0.0006231641208000723,1,1,2,0.012368023024171528
5226,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.00021188067285442377,0,1,2,0.004205224519145912
5227,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.00011439918654101523,1,1,2,0.002270496207755365
5228,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.0010135943709156444,0,1,2,0.020116945276888433
5229,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.0005433235010474939,1,1,2,0.010783415389675158
5230,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,4.888207152894234e-07,0,1,2,9.70169119112559e-06
5231,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,2.625706056010085e-07,1,1,2,5.2112745056222725e-06
5232,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.003171740375009119,0,1,2,0.06294996241831559
5233,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.0016430159573135982,1,1,2,0.032609161071478446
5234,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",0.00013036625451664794,0,1,2,0.002587396776577578
5235,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",0.00020822851576187605,1,1,2,0.004132739660822348
5236,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,2.32782948052177e-05,0,1,2,0.0004620074816642936
5237,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,0.00032842398033451365,1,1,2,0.006518275386670579
5238,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,0.00015897178054746325,0,1,2,0.0031551345406090345
5239,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,0.002242959777559839,1,1,2,0.04451632763377722
5240,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.0024319578773554034,0,1,2,0.04826739861455686
5241,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.0020376765338683232,1,1,2,0.04044204318814264
5242,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.0015001221210908173,0,1,2,0.02977312767766476
5243,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.0008418120061445374,1,1,2,0.016707557329604293
5244,Signaling by NTRK1 (TRKA),Signaling by NTRKs,0.00026605634926906953,0,1,2,0.005280456534086281
5245,Signaling by NTRK1 (TRKA),Signaling by NTRKs,0.0007446367555973948,1,1,2,0.01477890692109933
5246,Initial triggering of complement,Complement cascade,0.0017537638297450621,0,1,2,0.034807189151708384
5247,Initial triggering of complement,Complement cascade,0.0014058378191302975,1,1,2,0.027901854318780596
5248,Terminal pathway of complement,Complement cascade,0.001891424991063543,0,1,2,0.03753936893531855
5249,Terminal pathway of complement,Complement cascade,0.0015305973528931995,1,1,2,0.03037797374632948
5250,Activation of C3 and C5,Complement cascade,0.0015899375528275173,0,1,2,0.03155570676167752
5251,Activation of C3 and C5,Complement cascade,0.001281444735380822,1,1,2,0.02543300787446677
5252,Regulation of Complement cascade,Complement cascade,0.003389955931668525,0,1,2,0.06728091623756126
5253,Regulation of Complement cascade,Complement cascade,0.002693916216800884,1,1,2,0.05346652139055328
5254,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0016514759965345922,0,1,2,0.03277706862003293
5255,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0009251199261953719,1,1,2,0.018360980944496796
5256,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.00038933019529538215,0,1,2,0.007727089315149041
5257,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.00021952581705060077,1,1,2,0.004356958735358536
5258,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.0004562802890426712,0,1,2,0.009055856927561967
5259,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.00025683928280958,1,1,2,0.005097524163012146
5260,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0006166362976460354,0,1,2,0.012238464430581141
5261,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0003458898660619294,1,1,2,0.006864923195175477
5262,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.002772519608679154,0,1,2,0.05502657359522815
5263,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.001554794273513761,1,1,2,0.03085821331943733
5264,Virus Assembly and Release,Influenza Infection,4.8530567321155465e-05,0,1,2,0.0009631927673139034
5265,Virus Assembly and Release,Influenza Infection,0.00045167019373269253,1,1,2,0.008964359739206135
5266,Influenza Viral RNA Transcription and Replication,Influenza Infection,6.748194389470641e-05,0,1,2,0.0013393233145933127
5267,Influenza Viral RNA Transcription and Replication,Influenza Infection,0.0004110614620908494,1,1,2,0.008158392721586624
5268,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.0003247901969110631,0,1,2,0.006446155193055472
5269,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.0003818181726158488,1,1,2,0.0075779971797750026
5270,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,0.0008348500130634264,0,1,2,0.01656938170644622
5271,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,0.0004720010129041405,1,1,2,0.0093678682712601
5272,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.0010523293767157507,0,1,2,0.020885724202995497
5273,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.0005914608785405555,1,1,2,0.011738804465017048
5274,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.00019054082849718812,0,1,2,0.003781689727053471
5275,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.00010672193327178865,1,1,2,0.0021181247184047227
5276,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.0007285436748273744,0,1,2,0.014459505359215568
5277,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.0016765219267751126,1,1,2,0.033274158602490264
5278,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,0.0004403178686954774,0,1,2,0.008739048600853222
5279,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,0.0002374805897184137,1,1,2,0.004713309549433277
5280,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,0.0009413890828387953,0,1,2,0.018683877108177357
5281,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,0.0020466314949010153,1,1,2,0.040619773517178104
5282,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.0004379844668448807,0,1,2,0.008692737257100357
5283,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.00103891595149827,1,1,2,0.020619506129159974
5284,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.0004379844668448807,0,1,2,0.008692737257100357
5285,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.00103891595149827,1,1,2,0.020619506129159974
5286,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,0.00024552217708876664,0,1,2,0.004872912027219897
5287,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,0.002637854030059676,1,1,2,0.052353847548692094
5288,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,0.0008698377407042619,0,1,2,0.017263787893486836
5289,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,0.0004361096992913714,1,1,2,0.008655528490592743
5290,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,0.0020970985958325946,0,1,2,0.04162140093032825
5291,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,0.001065534616712372,1,1,2,0.021147810396450018
5292,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,0.0058456807194022355,0,1,2,0.11602001995348839
5293,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,0.001800477590416629,1,1,2,0.035734323510454524
5294,Bile acid and bile salt metabolism,Metabolism of steroids,0.00013565517841173085,0,1,2,0.002692366768148166
5295,Bile acid and bile salt metabolism,Metabolism of steroids,0.0004947492140729248,1,1,2,0.009819354912456304
5296,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,2.604454412576224e-05,0,1,2,0.0005169096079984735
5297,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,8.337468435923552e-06,1,1,2,0.00016547486951978883
5298,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.0017543200758067135,0,1,2,0.03481822904291517
5299,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.0005250643267629873,1,1,2,0.010421023075330747
5300,RHO GTPase Effectors,Signaling by Rho GTPases,0.000685444999192852,0,1,2,0.013604120084667503
5301,RHO GTPase Effectors,Signaling by Rho GTPases,0.0006859253318254311,1,1,2,0.013613653311727128
5302,RHO GTPase cycle,Signaling by Rho GTPases,0.0030681074875496153,0,1,2,0.060893146412100536
5303,RHO GTPase cycle,Signaling by Rho GTPases,0.0029945504565919434,1,1,2,0.05943325001866542
5304,Metabolism of steroid hormones,Metabolism of steroids,0.00033292334011361544,0,1,2,0.006607574791890694
5305,Metabolism of steroid hormones,Metabolism of steroids,0.0013827668368866384,1,1,2,0.027443961397709528
5306,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,1.2737496812650639e-05,0,1,2,0.00025280283089295003
5307,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,1.0608352236043146e-06,1,1,2,2.1054540902555753e-05
5308,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,6.229251234776365e-05,0,1,2,0.0012363279611821657
5309,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,2.886669922528645e-06,1,1,2,5.729213039284078e-05
5310,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,9.023451894361856e-05,0,1,2,0.0017908967647830391
5311,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,5.935140300820654e-06,1,1,2,0.00011779553642785668
5312,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,9.054349967360385e-05,0,1,2,0.0017970291473367345
5313,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,6.515217912885931e-06,1,1,2,0.00012930841565559308
5314,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.00043953033376143547,0,1,2,0.008723418287952563
5315,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,3.310942772828018e-05,1,1,2,0.000657127313322794
5316,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.0003266916678258724,0,1,2,0.006483893944805107
5317,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,2.1007136451457142e-05,1,1,2,0.00041693149305508737
5318,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.0025012680930812338,0,1,2,0.04964300788873455
5319,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.003822453744838908,1,1,2,0.07586475913327778
5320,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.0024611084047534448,0,1,2,0.04884595309481614
5321,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.003802010466970756,1,1,2,0.07545901861818166
5322,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,9.480809026957054e-05,0,1,2,0.0018816690566624888
5323,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,0.0001439518310700856,1,1,2,0.002857031561381675
5324,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0014036064054509672,0,1,2,0.027857567148128065
5325,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.002652961118406791,1,1,2,0.05265367998491359
5326,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,1.6426618768386795e-06,0,1,2,3.2602133588155787e-05
5327,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,3.0137201469227387e-06,1,1,2,5.981371346876445e-05
5328,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,0.0001414902449811089,0,1,2,0.002808176127623139
5329,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,0.00036758257282066284,1,1,2,0.0072954612953218
5330,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,0.00010364245590585251,0,1,2,0.002057005912470559
5331,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,0.0002242309148669353,1,1,2,0.004450341451373527
5332,Degradation of AXIN,TCF dependent signaling in response to WNT,3.3752232716347296e-05,0,1,2,0.0006698851513097743
5333,Degradation of AXIN,TCF dependent signaling in response to WNT,7.801456976406297e-05,1,1,2,0.0015483657721243038
5334,Degradation of DVL,TCF dependent signaling in response to WNT,3.51033076125541e-05,0,1,2,0.0006967001184523178
5335,Degradation of DVL,TCF dependent signaling in response to WNT,7.380450802140717e-05,1,1,2,0.0014648081043633638
5336,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,0.004955018334401545,0,1,2,0.09834292251355699
5337,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,0.004182536589923569,1,1,2,0.08301137231264129
5338,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0007857291172102326,0,1,2,0.01559447260850227
5339,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0006728782409989776,1,1,2,0.01335470592635318
5340,Downstream TCR signaling,TCR signaling,0.0001256356137586002,0,1,2,0.002493507106325863
5341,Downstream TCR signaling,TCR signaling,0.0007517718349522211,1,1,2,0.01492051781106277
5342,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.004555150677204318,0,1,2,0.0904066947594827
5343,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0027769253760899643,1,1,2,0.055114015459990964
5344,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0009395653679708575,0,1,2,0.018647681591260852
5345,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0005756567602910818,1,1,2,0.011425137981562795
5346,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.0011379672406536916,0,1,2,0.022585390530969363
5347,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.0006974506547480191,1,1,2,0.013842397962629958
5348,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,5.9644776315092844e-05,0,1,2,0.0011837779841842
5349,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,0.0005259939569413785,1,1,2,0.010439473571863738
5350,Catecholamine biosynthesis,Metabolism of amine-derived hormones,0.00027413956732619173,0,1,2,0.005440885261772868
5351,Catecholamine biosynthesis,Metabolism of amine-derived hormones,7.089478209943386e-05,1,1,2,0.0014070583784151006
5352,Ethanol oxidation,Phase I - Functionalization of compounds,0.0002944162984460703,0,1,2,0.005843320300914108
5353,Ethanol oxidation,Phase I - Functionalization of compounds,0.0003197007165858088,1,1,2,0.0063451435851294615
5354,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,0.00033843214402027276,0,1,2,0.006716908771943506
5355,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,0.0002507457198799752,1,1,2,0.0049765843911333835
5356,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.0002447239391313367,0,1,2,0.004857069289958988
5357,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.0006750696932239255,1,1,2,0.013398199976587855
5358,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.00020341933808304204,0,1,2,0.004037291257626757
5359,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.0005785398441293214,1,1,2,0.011482358938453225
5360,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.0004005749147919569,0,1,2,0.007950264791707977
5361,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.0011882840102919031,1,1,2,0.023584034298502622
5362,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.00013269449964077858,0,1,2,0.0026336057740792185
5363,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.0003829923686038834,1,1,2,0.00760130160718051
5364,Transcriptional regulation by RUNX3,Generic Transcription Pathway,7.221258015664171e-05,0,1,2,0.001433212895610073
5365,Transcriptional regulation by RUNX3,Generic Transcription Pathway,0.00020188960025113609,1,1,2,0.004006930342910313
5366,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.0004908753071504179,0,1,2,0.009742468955110831
5367,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.0014806458489262607,1,1,2,0.02938657945623154
5368,Transcriptional regulation by RUNX1,Generic Transcription Pathway,9.52523167649335e-05,0,1,2,0.0018904856803081862
5369,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.00028760084444168335,1,1,2,0.005708053058733643
5370,FOXO-mediated transcription,Generic Transcription Pathway,0.0010129526887014556,0,1,2,0.020104209722747256
5371,FOXO-mediated transcription,Generic Transcription Pathway,0.0034679755687283416,1,1,2,0.06882938258099328
5372,Arachidonic acid metabolism,Fatty acid metabolism,0.00023323217362008225,0,1,2,0.004628990657561
5373,Arachidonic acid metabolism,Fatty acid metabolism,0.002139767399011579,1,1,2,0.04246825446781044
5374,DAP12 signaling,DAP12 interactions,0.0020161987677841304,0,1,2,0.04001577104478493
5375,DAP12 signaling,DAP12 interactions,0.0018882459890756777,1,1,2,0.03747627485068266
5376,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.00019765093100265638,0,1,2,0.003922804898092119
5377,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.0007274798754316656,1,1,2,0.014438391987986276
5378,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,0.00040111223580392534,0,1,2,0.007960929074880866
5379,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,0.0005890822666224451,1,1,2,0.011691595830907967
5380,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0041631701688086,0,1,2,0.0826270043199234
5381,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.001732027980804486,1,1,2,0.03437579480281388
5382,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.002536995562711362,0,1,2,0.050352095835603974
5383,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0010540780369161337,1,1,2,0.020920430099721422
5384,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0015034624785564264,0,1,2,0.02983942420640357
5385,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0006275258917896032,1,1,2,0.012454591685979947
5386,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0008048961038549364,0,1,2,0.015974882398175863
5387,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.00033575518383549747,1,1,2,0.006663778779225724
5388,Retinoid cycle disease events,Diseases associated with visual transduction,0.003681074634007046,0,1,2,0.07305878870022334
5389,Retinoid cycle disease events,Diseases associated with visual transduction,0.004268418266827969,1,1,2,0.08471587762970664
5390,Retinoid metabolism disease events,Diseases associated with visual transduction,0.0015475275949107794,0,1,2,0.03071399056130494
5391,Retinoid metabolism disease events,Diseases associated with visual transduction,0.0017875864264792908,1,1,2,0.03547847082724698
5392,Mitotic Metaphase and Anaphase,M Phase,0.00029080952131707035,0,1,2,0.005771736104896445
5393,Mitotic Metaphase and Anaphase,M Phase,0.002319749197968445,1,1,2,0.04604037770008571
5394,Oxidative Stress Induced Senescence,Cellular Senescence,0.0018126205242768422,0,1,2,0.0359753259696001
5395,Oxidative Stress Induced Senescence,Cellular Senescence,0.0009090187786522836,1,1,2,0.01804141928027128
5396,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,0.0007257443442120412,0,1,2,0.014403946663926344
5397,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,0.00038764829507103714,1,1,2,0.007693708412743506
5398,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,0.000698734626054049,0,1,2,0.01386788111569558
5399,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,0.00037223936776840466,1,1,2,0.0073878853377370955
5400,EPH-Ephrin signaling,Axon guidance,0.0006761187064812428,0,1,2,0.01341901988531833
5401,EPH-Ephrin signaling,Axon guidance,0.0011752526100599655,1,1,2,0.023325398326491158
5402,SUMO E3 ligases SUMOylate target proteins,SUMOylation,0.00025882458441795045,0,1,2,0.005136926713933604
5403,SUMO E3 ligases SUMOylate target proteins,SUMOylation,0.0003435180536831781,1,1,2,0.0068178495124484465
5404,Processing and activation of SUMO,SUMOylation,0.0008394801207678629,0,1,2,0.016661276083515527
5405,Processing and activation of SUMO,SUMOylation,0.0011094034525925096,1,1,2,0.022018481146095465
5406,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,0.002017855678500636,0,1,2,0.04004865597703108
5407,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,0.0032252142733932257,1,1,2,0.0640112661492777
5408,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,0.00018283065407121894,0,1,2,0.0036286648470293535
5409,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,8.399443431803059e-05,1,1,2,0.001667048956884594
5410,HSF1 activation,Cellular response to heat stress,0.0005549489521819786,0,1,2,0.011014147298811849
5411,HSF1 activation,Cellular response to heat stress,0.00027928638377174887,1,1,2,0.0055430348274733265
5412,HSF1-dependent transactivation,Cellular response to heat stress,0.001552911646928311,0,1,2,0.030820848573654355
5413,HSF1-dependent transactivation,Cellular response to heat stress,0.000741815913676278,1,1,2,0.014722921287999773
5414,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,0.0003348199015033111,0,1,2,0.006645216103627953
5415,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,0.0004911404202484938,1,1,2,0.009747730690810252
5416,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0012132189629778507,0,1,2,0.02407892169434705
5417,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0020575049475247873,1,1,2,0.0408355804096391
5418,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.0020104710078859694,0,1,2,0.03990209141540185
5419,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.0012672718080720359,1,1,2,0.025151715859371416
5420,Semaphorin interactions,Axon guidance,0.0011115595280173736,0,1,2,0.022061273068169424
5421,Semaphorin interactions,Axon guidance,0.001971147838639578,1,1,2,0.039121639129416026
5422,L1CAM interactions,Axon guidance,2.0023018427520795e-05,0,1,2,0.0003973995688439823
5423,L1CAM interactions,Axon guidance,3.493733610146558e-05,1,1,2,0.0006934060593080528
5424,NCAM signaling for neurite out-growth,Axon guidance,0.00196583138065688,0,1,2,0.039016122665065316
5425,NCAM signaling for neurite out-growth,Axon guidance,0.003367863799210192,1,1,2,0.06684245068125337
5426,Signaling by ROBO receptors,Axon guidance,6.247952647041289e-05,0,1,2,0.001240039655898802
5427,Signaling by ROBO receptors,Axon guidance,0.00010902108101040978,1,1,2,0.0021637562161403905
5428,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.0004830486783925993,0,1,2,0.009587132790130628
5429,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.000787674920183914,1,1,2,0.015633091224651247
5430,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.0011381604591397124,0,1,2,0.022589225364529314
5431,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.0019178524471406924,1,1,2,0.03806387824887277
5432,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,1.5521662602586174e-05,0,1,2,0.0003080605478308624
5433,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,2.3929496855398703e-05,1,1,2,0.000474931977284622
5434,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),0.0038861107921197083,0,1,2,0.07712816920478333
5435,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),0.0011855772069428881,1,1,2,0.02353031200444702
5436,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),2.7369271562255916e-05,0,1,2,0.0005432016535261749
5437,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),8.84262661972356e-06,1,1,2,0.00017550081266950947
5438,PERK regulates gene expression,Unfolded Protein Response (UPR),0.0016249926911907355,0,1,2,0.032251450858489704
5439,PERK regulates gene expression,Unfolded Protein Response (UPR),0.0005232630100695456,1,1,2,0.010385272098028479
5440,PCP/CE pathway,Beta-catenin independent WNT signaling,0.00026443055971844495,0,1,2,0.005248189267850274
5441,PCP/CE pathway,Beta-catenin independent WNT signaling,0.0006092531201908327,1,1,2,0.012091929503890797
5442,G alpha (q) signalling events,GPCR downstream signalling,0.00014969271512943358,0,1,2,0.002970971667776046
5443,G alpha (q) signalling events,GPCR downstream signalling,0.00026042755977642875,1,1,2,0.005168741183796512
5444,G alpha (s) signalling events,GPCR downstream signalling,0.0007870787513583388,0,1,2,0.015621258980921393
5445,G alpha (s) signalling events,GPCR downstream signalling,0.001361072937244234,1,1,2,0.027013399622238813
5446,G alpha (i) signalling events,GPCR downstream signalling,0.00038840338951845043,0,1,2,0.007708694874895789
5447,G alpha (i) signalling events,GPCR downstream signalling,0.0006736427907697196,1,1,2,0.013369880049593013
5448,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.0009819331065456733,0,1,2,0.019488559858614623
5449,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.001996951224252837,1,1,2,0.03963376243163155
5450,Peroxisomal lipid metabolism,Fatty acid metabolism,1.9688224165062088e-05,0,1,2,0.0003907548616019582
5451,Peroxisomal lipid metabolism,Fatty acid metabolism,0.00017363170952521982,1,1,2,0.0034460921440359225
5452,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.0013767749601472045,0,1,2,0.02732503980547124
5453,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.000580345013048167,1,1,2,0.011518186371396791
5454,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,1.2314924987718978e-06,0,1,2,2.444159904352374e-05
5455,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,3.8451111432725965e-06,1,1,2,7.631444360024597e-05
5456,Adherens junctions interactions,Cell-cell junction organization,0.0010489913030571263,0,1,2,0.020819473001284394
5457,Adherens junctions interactions,Cell-cell junction organization,0.0027929459344524757,1,1,2,0.05543197765979353
5458,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,0.0002308808520288478,0,1,2,0.004582323658279522
5459,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,0.0009621644707581,1,1,2,0.01909620905660879
5460,Netrin-1 signaling,Axon guidance,1.6648303909245867e-05,0,1,2,0.0003304211510101014
5461,Netrin-1 signaling,Axon guidance,2.88698377881715e-05,1,1,2,0.0005729835954126725
5462,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0037126605465470724,0,1,2,0.07368567860048421
5463,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.00542056200214145,1,1,2,0.1075826309774717
5464,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,4.720476601974827e-06,0,1,2,9.368794086432723e-05
5465,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,1.4782090490121022e-05,1,1,2,0.0002933821595705428
5466,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,7.06069914372742e-05,0,1,2,0.001401346558018313
5467,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,0.0004028274405787245,1,1,2,0.007994970977226993
5468,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",0.00014706956630432206,0,1,2,0.002918909676429121
5469,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",0.0004967840003133127,1,1,2,0.009859739591596807
5470,Glycosphingolipid metabolism,Sphingolipid metabolism,0.0006180877963064456,0,1,2,0.012267272521824357
5471,Glycosphingolipid metabolism,Sphingolipid metabolism,0.0025267805531857357,1,1,2,0.050149357152826674
5472,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,0.0001204214790094032,0,1,2,0.0023900214651011963
5473,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,1.1216132576251461e-05,1,1,2,0.00022260810806491203
5474,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,3.61394126285553e-05,0,1,2,0.000717263835562523
5475,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,7.078410437874675e-05,1,1,2,0.001404861742646078
5476,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,0.004053138490756831,0,1,2,0.08044319064691333
5477,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,0.008851826320955445,1,1,2,0.17568340039055055
5478,Interleukin-1 family signaling,Signaling by Interleukins,0.0004974715487562004,0,1,2,0.009873385459014446
5479,Interleukin-1 family signaling,Signaling by Interleukins,0.00015990628370613204,1,1,2,0.0031736817518440747
5480,Interleukin-12 family signaling,Signaling by Interleukins,0.0005845347111090138,0,1,2,0.011601339878396443
5481,Interleukin-12 family signaling,Signaling by Interleukins,0.00019070609623621966,1,1,2,0.0037849698183380436
5482,Other interleukin signaling,Signaling by Interleukins,0.002864077996565555,0,1,2,0.05684374536689748
5483,Other interleukin signaling,Signaling by Interleukins,0.000920025188325933,1,1,2,0.018259864989376595
5484,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.00045363771238358074,0,1,2,0.009003409349352865
5485,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.00014438761401053973,1,1,2,0.002865680604645202
5486,Interleukin-10 signaling,Signaling by Interleukins,0.00044824616671220737,0,1,2,0.008896402609436893
5487,Interleukin-10 signaling,Signaling by Interleukins,0.00014818885636043607,1,1,2,0.002941124378339383
5488,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.0033893750516866476,0,1,2,0.06726938743359077
5489,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.001091838624007568,1,1,2,0.021669869605246046
5490,G2/M Transition,Mitotic G2-G2/M phases,0.0014474913199693834,0,1,2,0.0287285570126933
5491,G2/M Transition,Mitotic G2-G2/M phases,0.004506942136976974,1,1,2,0.089449893307679
5492,G1/S Transition,Mitotic G1 phase and G1/S transition,0.00035280971159810747,0,1,2,0.0070022623102793434
5493,G1/S Transition,Mitotic G1 phase and G1/S transition,0.0014436065080074602,1,1,2,0.028651454621548004
5494,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0014325585484451283,0,1,2,0.028432184266153335
5495,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0012849746711433882,1,1,2,0.0255030669894383
5496,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,0.003637936954897105,0,1,2,0.07220262931839615
5497,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,0.0007279209445385526,1,1,2,0.014447145946513647
5498,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,0.00019117866622071758,0,1,2,0.003794348979065877
5499,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,0.0033861965315976667,1,1,2,0.06720630291326755
5500,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.0003795798214719417,0,1,2,0.007533572320319872
5501,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.007038347087805489,1,1,2,0.13969103150920498
5502,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.0013730046984904054,0,1,2,0.02725021090980476
5503,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.004855831076111378,1,1,2,0.0963743395138454
5504,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,2.246966737017337e-05,0,1,2,0.0004459585430287304
5505,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,7.954097476251695e-05,1,1,2,0.0015786605396421309
5506,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,0.00033891630086570337,0,1,2,0.006726517898675495
5507,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,0.000876623015336073,1,1,2,0.017398456161556924
5508,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.0015017606731581616,0,1,2,0.029805648243305154
5509,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.003851568896353285,1,1,2,0.07644261150356466
5510,RA biosynthesis pathway,Signaling by Retinoic Acid,0.0022521629801899347,0,1,2,0.044698984847544594
5511,RA biosynthesis pathway,Signaling by Retinoic Acid,0.0010521696656788722,1,1,2,0.020882554396333984
5512,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.0006657527329586402,0,1,2,0.013213284999569615
5513,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.0015625129142947652,1,1,2,0.03101140623236082
5514,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,6.439784138926145e-05,0,1,2,0.0012781127128865333
5515,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,1.144482924382453e-05,1,1,2,0.00022714708191735964
5516,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,2.56459994318159e-05,0,1,2,0.0005089996372758954
5517,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,2.8378092025735674e-06,1,1,2,5.6322385041317454e-05
5518,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,0.00012367789103276674,0,1,2,0.002454651917235443
5519,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,2.9875347972354108e-05,1,1,2,0.0005929400927364317
5520,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.00266609801969173,0,1,2,0.05291440985066676
5521,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0022789489838605224,1,1,2,0.04523061030393004
5522,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.002181683454736355,0,1,2,0.04330016812423356
5523,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.001875638506444467,1,1,2,0.03722605242892408
5524,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),0.0014480435002688554,0,1,2,0.02873951621016538
5525,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),0.00012961184598982517,1,1,2,0.0025724239279845042
5526,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,1.4244252534056529e-05,0,1,2,0.0002827076165379006
5527,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,6.818091005826482e-06,1,1,2,0.00013531957910653343
5528,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,5.7026029658510625e-05,0,1,2,0.001131803363274547
5529,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,2.4080229558649514e-05,1,1,2,0.0004779235897380286
5530,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,1.3116968972470777e-05,0,1,2,0.00026033426643783006
5531,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,8.214315220302666e-06,1,1,2,0.00016303063090678218
5532,Defective CFTR causes cystic fibrosis,ABC transporter disorders,0.0006852237651825821,0,1,2,0.013599729223189094
5533,Defective CFTR causes cystic fibrosis,ABC transporter disorders,0.0006634927971399659,1,1,2,0.013168431746139958
5534,Defective ABCA1 causes TGD,ABC transporter disorders,0.0025065742253443627,0,1,2,0.0497483194171252
5535,Defective ABCA1 causes TGD,ABC transporter disorders,0.0024737811226649624,1,1,2,0.049097470250051664
5536,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.0016415966532767371,0,1,2,0.03258099195130564
5537,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.0011087534372185251,1,1,2,0.022005580202598934
5538,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,0.0005666102805094519,0,1,2,0.011245591267475258
5539,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,0.0003729514358240194,1,1,2,0.007402017849241951
5540,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.0009492328804437679,0,1,2,0.018839554025601116
5541,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,0.0006408454698712052,1,1,2,0.012718947162951248
5542,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,1.2899326250631643e-05,0,1,2,0.0002560146817491388
5543,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,8.718425668555171e-06,1,1,2,0.00017303577950665273
5544,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),0.0008221296311372673,0,1,2,0.016316918557032222
5545,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),6.337315335085482e-05,1,1,2,0.0012577755900827765
5546,Fructose biosynthesis,Fructose metabolism,0.0003856296911744075,0,1,2,0.007653644906779548
5547,Fructose biosynthesis,Fructose metabolism,0.00023034619151048486,1,1,2,0.004571712178284913
5548,Fructose catabolism,Fructose metabolism,0.0005165689519279962,0,1,2,0.010252414216041419
5549,Fructose catabolism,Fructose metabolism,0.0003252942018232642,1,1,2,0.006456158247066982
5550,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.001139411542510227,0,1,2,0.022614055786267677
5551,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.0015346025809033327,1,1,2,0.030457466051154063
5552,Essential pentosuria,Diseases of carbohydrate metabolism,0.0003782052905440595,0,1,2,0.00750629181812784
5553,Essential pentosuria,Diseases of carbohydrate metabolism,0.0005102181961691376,1,1,2,0.010126369903115301
5554,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,0.0006000502074171605,0,1,2,0.01190927804294326
5555,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,0.0008076313872133774,1,1,2,0.01602916993885038
5556,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,0.0015644666893530747,0,1,2,0.03105018307155721
5557,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,0.0005502273419514851,1,1,2,0.010920436858668194
5558,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.004065063118142106,0,1,2,0.0806798603477722
5559,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.00033218001877098987,1,1,2,0.006592821992149676
5560,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,0.00031851358616578055,0,1,2,0.006321582446293752
5561,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,0.0007612350358991756,1,1,2,0.015108335246771404
5562,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,0.00018374889619680366,0,1,2,0.0036468893233300996
5563,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,0.00043915739007587283,1,1,2,0.008716016423923813
5564,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,9.797749534378722e-05,0,1,2,0.0019445726700484947
5565,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,0.00023415715964469671,1,1,2,0.004647348980942617
5566,UCH proteinases,Deubiquitination,0.0003822932224715361,0,1,2,0.007587425558843469
5567,UCH proteinases,Deubiquitination,0.0016756562830602985,1,1,2,0.0332569780539988
5568,Ub-specific processing proteases,Deubiquitination,6.31311686672113e-05,0,1,2,0.001252972887168884
5569,Ub-specific processing proteases,Deubiquitination,0.00029849456531877796,1,1,2,0.005924262217973782
5570,Metalloprotease DUBs,Deubiquitination,2.471361569235464e-05,0,1,2,0.000490494490442001
5571,Metalloprotease DUBs,Deubiquitination,0.00011458134989704473,1,1,2,0.0022741116286474415
5572,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,0.001118245456299182,0,1,2,0.02219396959572496
5573,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,0.0021052241832405557,1,1,2,0.04178267056828101
5574,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,0.00022047758272312448,0,1,2,0.00437584855805288
5575,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,0.0004897360543089299,1,1,2,0.009719858049085327
5576,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),0.0018047787457472222,0,1,2,0.03581968912503935
5577,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),0.004222590836035046,1,1,2,0.08380633438055776
5578,Signaling by RAS mutants,Oncogenic MAPK signaling,0.000732925395801329,0,1,2,0.014546469971077027
5579,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0018323959142952414,1,1,2,0.036367810823743366
5580,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0003071131434018734,0,1,2,0.006095316308877618
5581,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0007764512821051013,1,1,2,0.015410334153856635
5582,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0009518969669621643,0,1,2,0.018892428512912115
5583,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0023371384792654926,1,1,2,0.046385505130046786
5584,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.00011106300650900661,0,1,2,0.002204282589109143
5585,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.0002731776273268792,1,1,2,0.005421793507831556
5586,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.000316550380458803,0,1,2,0.006282618435731159
5587,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.0007910671116714031,1,1,2,0.015700416510269103
5588,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.0003097630085529847,0,1,2,0.006147908542778724
5589,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.0007873336824046918,1,1,2,0.015626318632056026
5590,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,0.00023559755497218492,0,1,2,0.004675936702827841
5591,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,0.0005866780170643712,1,1,2,0.011643878363073111
5592,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.004401296890598691,0,1,2,0.08735313774042437
5593,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.0034292619831997164,1,1,2,0.06806102878592636
5594,MET Receptor Activation,Signaling by MET,0.001936634540241445,0,1,2,0.038436649004053594
5595,MET Receptor Activation,Signaling by MET,0.0013354970240119848,1,1,2,0.026505790995293887
5596,MET promotes cell motility,Signaling by MET,0.0008130187431335134,0,1,2,0.016136093524203945
5597,MET promotes cell motility,Signaling by MET,0.0005427756322988358,1,1,2,0.010772541764138232
5598,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0005330098938429728,0,1,2,0.010578719825360565
5599,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0013103059178033872,1,1,2,0.02600581968566156
5600,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,0.000802269659219617,0,1,2,0.01592275499443568
5601,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0019674286139044,1,1,2,0.039047823170471396
5602,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,0.006200146142199522,0,1,2,0.12305514338903044
5603,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,0.0011576682130617158,1,1,2,0.022976398408682503
5604,Mitotic Prophase,M Phase,8.525631346584762e-05,0,1,2,0.0016920936438827566
5605,Mitotic Prophase,M Phase,0.0006408832600316388,1,1,2,0.012719697189402914
5606,Mitotic Prometaphase,M Phase,3.652474313623528e-05,0,1,2,0.0007249115425338149
5607,Mitotic Prometaphase,M Phase,0.00034139726272160213,1,1,2,0.006775757885914253
5608,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.00499618230482119,0,1,2,0.09915990943068378
5609,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.001006094399197878,1,1,2,0.019968092318590903
5610,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,0.0006726103611210678,0,1,2,0.013349389277998254
5611,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,0.00013542797109879627,1,1,2,0.0026878573537197047
5612,Cyclin A:Cdk2-associated events at S phase entry,S Phase,5.0940354891439585e-06,0,1,2,0.00010110201488299814
5613,Cyclin A:Cdk2-associated events at S phase entry,S Phase,7.493146432522325e-06,1,1,2,0.00014871749593339893
5614,Ubiquitin-dependent degradation of Cyclin D,S Phase,0.0009404777246423959,0,1,2,0.018665789258155017
5615,Ubiquitin-dependent degradation of Cyclin D,S Phase,0.001380422729743245,1,1,2,0.027397437584555154
5616,G2/M DNA damage checkpoint,G2/M Checkpoints,0.0016129437282944507,0,1,2,0.03201231345384049
5617,G2/M DNA damage checkpoint,G2/M Checkpoints,0.005198526709709259,1,1,2,0.10317586634305363
5618,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,1.4683975542870225e-05,0,1,2,0.0002914348588738094
5619,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,1.2312215495411078e-05,1,1,2,0.0002443622147730493
5620,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.0006376321076634571,0,1,2,0.012655171126360106
5621,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.00047197119446245966,1,1,2,0.009367276460594267
5622,Glycolysis,Glucose metabolism,0.001485856189652521,0,1,2,0.029489989796967184
5623,Glycolysis,Glucose metabolism,0.00017758695218091197,1,1,2,0.0035245923827354484
5624,Gluconeogenesis,Glucose metabolism,0.0002985974908593737,0,1,2,0.005926304995170629
5625,Gluconeogenesis,Glucose metabolism,3.5648858928964976e-05,1,1,2,0.0007075277495963797
5626,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0008056008738939394,0,1,2,0.015988870064952865
5627,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.002919095854300339,1,1,2,0.05793569226899249
5628,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,3.1902137315168154e-05,0,1,2,0.0006331660563636155
5629,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,0.00011113755457986118,1,1,2,0.002205762154806143
5630,mRNA Splicing - Major Pathway,mRNA Splicing,0.0007398743550281328,0,1,2,0.014684386909556726
5631,mRNA Splicing - Major Pathway,mRNA Splicing,0.004022508377426772,1,1,2,0.07983527062351278
5632,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,0.0005512572202251202,0,1,2,0.010940876992776141
5633,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,0.0025550145274713673,1,1,2,0.050709720678859316
5634,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,0.0007817832961682789,0,1,2,0.01551615936185147
5635,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,0.003713469504236393,1,1,2,0.0737017340937213
5636,Depurination,"Base-Excision Repair, AP Site Formation",0.0021053410449996296,0,1,2,0.04178498993950062
5637,Depurination,"Base-Excision Repair, AP Site Formation",0.0030460795174887035,1,1,2,0.060455954295617106
5638,Depyrimidination,"Base-Excision Repair, AP Site Formation",0.0009359625108829029,0,1,2,0.01857617519683074
5639,Depyrimidination,"Base-Excision Repair, AP Site Formation",0.0013573504827779524,1,1,2,0.026939519562381886
5640,Utilization of Ketone Bodies,Ketone body metabolism,7.785569528651398e-06,0,1,2,0.00015452125687695338
5641,Utilization of Ketone Bodies,Ketone body metabolism,0.0004831917811750061,1,1,2,0.009589972970507761
5642,Synthesis of Ketone Bodies,Ketone body metabolism,1.0327878806853056e-05,0,1,2,0.00020497881474628853
5643,Synthesis of Ketone Bodies,Ketone body metabolism,0.0006411654575075482,1,1,2,0.012725298001071805
5644,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.002133830607171458,0,1,2,0.04235042615305757
5645,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.0030501638981371483,1,1,2,0.06053701755361499
5646,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,0.00070668266332453,0,1,2,0.014025626891931983
5647,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,0.0015832933376845786,1,1,2,0.031423838120460006
5648,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,0.0010273497425218297,0,1,2,0.02038995000718791
5649,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,0.000311250452814697,1,1,2,0.006177430051257759
5650,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.0022424527299123383,0,1,2,0.04450626419018455
5651,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.001244513884114613,1,1,2,0.024700036248667297
5652,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,9.36008176635251e-05,0,1,2,0.0018577081531225815
5653,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0016764546343447503,1,1,2,0.03327282304047651
5654,Extra-nuclear estrogen signaling,ESR-mediated signaling,0.0007940062715662982,0,1,2,0.015758750416279468
5655,Extra-nuclear estrogen signaling,ESR-mediated signaling,8.796101489048948e-05,1,1,2,0.00174577422075957
5656,Estrogen-dependent gene expression,ESR-mediated signaling,0.005078916853355235,0,1,2,0.10080195326313317
5657,Estrogen-dependent gene expression,ESR-mediated signaling,0.0003483616634544832,1,1,2,0.006913981294064326
5658,Pyrimidine catabolism,Nucleotide catabolism,0.0005876944159709513,0,1,2,0.011664050970350606
5659,Pyrimidine catabolism,Nucleotide catabolism,0.0002396547463203792,1,1,2,0.004756460331087299
5660,Pyrimidine salvage,Nucleotide salvage,6.287972270376305e-05,0,1,2,0.0012479824049484532
5661,Pyrimidine salvage,Nucleotide salvage,6.391397290429102e-05,1,1,2,0.0012685093092838007
5662,Vitamin D (calciferol) metabolism,Metabolism of steroids,9.474398904345888e-05,0,1,2,0.001880396830913341
5663,Vitamin D (calciferol) metabolism,Metabolism of steroids,0.00036825811683201704,1,1,2,0.007308868909154802
5664,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,0.0006613445175066473,0,1,2,0.013125794548200625
5665,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,0.00020165193251415735,1,1,2,0.0040022133190237615
5666,VLDL assembly,Plasma lipoprotein assembly,0.004791097623716536,0,1,2,0.09508956588370508
5667,VLDL assembly,Plasma lipoprotein assembly,0.00530045839633171,1,1,2,0.10519891838497883
5668,Chylomicron assembly,Plasma lipoprotein assembly,0.004363920744083027,0,1,2,0.08661132827927145
5669,Chylomicron assembly,Plasma lipoprotein assembly,0.004834837539341339,1,1,2,0.09595767793551628
5670,HDL assembly,Plasma lipoprotein assembly,0.002809121057986244,0,1,2,0.05575300753556305
5671,HDL assembly,Plasma lipoprotein assembly,0.0031171619311077896,1,1,2,0.0618667366223111
5672,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.0016514278179964067,0,1,2,0.032776112414035725
5673,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.0017888033680627338,1,1,2,0.03550262363229578
5674,Chylomicron remodeling,Plasma lipoprotein remodeling,0.009293853582135936,0,1,2,0.18445637553644434
5675,Chylomicron remodeling,Plasma lipoprotein remodeling,0.010457944341812301,1,1,2,0.20756024310092774
5676,LDL remodeling,Plasma lipoprotein remodeling,0.0024858537600095753,0,1,2,0.04933707752469537
5677,LDL remodeling,Plasma lipoprotein remodeling,0.002739931049995095,1,1,2,0.05437978404063772
5678,HDL remodeling,Plasma lipoprotein remodeling,0.0012025510815301967,0,1,2,0.0238671948009657
5679,HDL remodeling,Plasma lipoprotein remodeling,0.0013063961095833966,1,1,2,0.025928221190384182
5680,HDL clearance,Plasma lipoprotein clearance,7.384806816634441e-05,0,1,2,0.0014656726484818994
5681,HDL clearance,Plasma lipoprotein clearance,7.066707898211358e-05,1,1,2,0.0014025391236895926
5682,Chylomicron clearance,Plasma lipoprotein clearance,7.519823721275334e-05,0,1,2,0.0014924696371003549
5683,Chylomicron clearance,Plasma lipoprotein clearance,7.115904076013159e-05,1,1,2,0.0014123031559797172
5684,LDL clearance,Plasma lipoprotein clearance,0.001161316906281943,0,1,2,0.023048814519061215
5685,LDL clearance,Plasma lipoprotein clearance,0.0011005663784394552,1,1,2,0.021843090533986788
5686,VLDL clearance,Plasma lipoprotein clearance,0.001599943677998629,0,1,2,0.03175429968827311
5687,VLDL clearance,Plasma lipoprotein clearance,0.001518504165904759,1,1,2,0.03013795862011102
5688,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,6.937370799185808e-05,0,1,2,0.0013768694138132634
5689,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,0.0005182856249180977,1,1,2,0.010286485258256253
5690,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,7.904482304253308e-05,0,1,2,0.0015688133490041906
5691,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,2.3865388740268643e-05,1,1,2,0.0004736596148081899
5692,NADPH regeneration,Metabolism of cofactors,0.0005355809840638437,0,1,2,0.0106297486025118
5693,NADPH regeneration,Metabolism of cofactors,0.00016060877625498362,1,1,2,0.003187624216964419
5694,Triglyceride catabolism,Triglyceride metabolism,0.0004509174820303983,0,1,2,0.00894942056772016
5695,Triglyceride catabolism,Triglyceride metabolism,0.0014936409006899856,1,1,2,0.02964449401525284
5696,Glycogen synthesis,Glycogen metabolism,0.0005972147645512025,0,1,2,0.011853002622906455
5697,Glycogen synthesis,Glycogen metabolism,0.00015358444876846758,1,1,2,0.003048211434387959
5698,Glycogen breakdown (glycogenolysis),Glycogen metabolism,0.0007116725502256776,0,1,2,0.014124661855630103
5699,Glycogen breakdown (glycogenolysis),Glycogen metabolism,0.00023520743014541996,1,1,2,0.004668193842353886
5700,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,0.00042430075279349547,0,1,2,0.008421154724032782
5701,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,0.000981916427428522,1,1,2,0.01948822882590901
5702,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,0.00028271536861867216,0,1,2,0.005611090355897898
5703,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,3.3643489834115465e-05,1,1,2,0.0006677269165426133
5704,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,0.00032538634180123086,0,1,2,0.00645798696173604
5705,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,3.837578237376473e-05,1,1,2,0.0007616493699283321
5706,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,0.0007982239857561848,0,1,2,0.015842459963200942
5707,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,9.698300670934628e-05,1,1,2,0.001924834918920829
5708,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.00015789792798137468,0,1,2,0.003133821642740497
5709,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),4.109863548907421e-05,1,1,2,0.0008156902058775332
5710,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.0005436143552001594,0,1,2,0.010789188011584495
5711,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.00014151848150449118,1,1,2,0.0028087365417414395
5712,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.00469561003899863,0,1,2,0.09319441080834975
5713,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.00039026808711791145,1,1,2,0.007745703781656406
5714,Interferon gamma signaling,Interferon Signaling,3.2209717363655975e-05,0,1,2,0.0006392706394012092
5715,Interferon gamma signaling,Interferon Signaling,0.0014568637483913557,1,1,2,0.028914572873758166
5716,Interferon alpha/beta signaling,Interferon Signaling,7.202515229668861e-06,0,1,2,0.00014294929893929193
5717,Interferon alpha/beta signaling,Interferon Signaling,0.0003223061975129578,1,1,2,0.00639685491930359
5718,HCMV Early Events,HCMV Infection,5.010071308912685e-05,0,1,2,0.0009943556638308643
5719,HCMV Early Events,HCMV Infection,0.00024617695320151416,1,1,2,0.004885907457745874
5720,HCMV Late Events,HCMV Infection,9.79526781492701e-06,0,1,2,0.00019440801198150357
5721,HCMV Late Events,HCMV Infection,5.11192201953365e-05,1,1,2,0.0010145701128330153
5722,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.002286529046595838,0,1,2,0.04538105283954118
5723,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.0015441295626939058,1,1,2,0.03064654935393695
5724,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,4.701065354588144e-05,0,1,2,0.0009330268319850053
5725,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,3.238987119864409e-05,1,1,2,0.0006428461770559848
5726,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00019788478012542742,0,1,2,0.0039274461334233525
5727,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0002701002897457481,1,1,2,0.00536071717049732
5728,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.001682530457886055,0,1,2,0.03339341073630403
5729,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.002285020111701457,1,1,2,0.045351104803553935
5730,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0027391658270320717,0,1,2,0.054364596556459165
5731,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.003745486902936981,1,1,2,0.07433718775847102
5732,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00011744112357709484,0,1,2,0.0023308699456592885
5733,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.00016092774034016051,1,1,2,0.0031939547405258313
5734,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.002357146042016622,0,1,2,0.04678259794798024
5735,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0032188156523155383,1,1,2,0.06388427184686153
5736,Parasite infection,Leishmania infection,0.002503348868485034,0,1,2,0.04968430532105349
5737,Parasite infection,Leishmania infection,0.0032461836712782363,1,1,2,0.06442744863987399
5738,Cell recruitment (pro-inflammatory response),Leishmania infection,0.00021401224733515127,0,1,2,0.004247530167650717
5739,Cell recruitment (pro-inflammatory response),Leishmania infection,0.0002855713310147187,1,1,2,0.0056677730298379855
5740,Leishmania parasite growth and survival,Leishmania infection,0.0013936412869721784,0,1,2,0.027659788086929836
5741,Leishmania parasite growth and survival,Leishmania infection,0.0018574118956139086,1,1,2,0.03686430640587715
5742,Lipophagy,Selective autophagy,0.0009694201973690013,0,1,2,0.019240214449065447
5743,Lipophagy,Selective autophagy,0.001356268383451468,1,1,2,0.02691804298993863
5744,Aggrephagy,Selective autophagy,9.90670093512198e-05,0,1,2,0.0019661964026725467
5745,Aggrephagy,Selective autophagy,0.00014911600051325572,1,1,2,0.002959525534384884
5746,SARS-CoV-1 Infection,SARS-CoV Infections,0.00010164300328128567,0,1,2,0.0020173225044068325
5747,SARS-CoV-1 Infection,SARS-CoV Infections,4.5230276416728644e-05,1,1,2,0.0008976914450618955
5748,Potential therapeutics for SARS,SARS-CoV Infections,0.0026461148035320597,0,1,2,0.052517800242843894
5749,Potential therapeutics for SARS,SARS-CoV Infections,0.00114350388876719,1,1,2,0.02269527713878075
5750,SARS-CoV-2 Infection,SARS-CoV Infections,0.0012094582606306144,0,1,2,0.02400428252359704
5751,SARS-CoV-2 Infection,SARS-CoV Infections,0.0005157693924352338,1,1,2,0.010236545250089105
5752,ALK mutants bind TKIs,Signaling by ALK in cancer,0.000258032645719796,0,1,2,0.005121208998927914
5753,ALK mutants bind TKIs,Signaling by ALK in cancer,0.0001284558972315031,1,1,2,0.0025494816558277976
5754,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,0.0011015584548354103,0,1,2,0.02186278040908928
5755,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,0.0005218258507423846,1,1,2,0.01035674860148168
5756,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.002147561677443933,0,1,2,0.04262294857148315
5757,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.0006032579422672516,1,1,2,0.011972942392601948
5758,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0011431959517694435,0,1,2,0.02268916547132269
5759,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0003369455146461922,1,1,2,0.006687403436650082
5760,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.0007198497173126709,0,1,2,0.014286955202484835
5761,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.00021002755774905124,1,1,2,0.0041684454917201
5762,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,0.0003098884971936299,0,1,2,0.006150399132889687
5763,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,0.00026527132421059725,1,1,2,0.0052648760350272675
5764,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.00013513449578932536,0,1,2,0.0026820327093549073
5765,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.00011461727295719,1,1,2,0.0022748245985058555
5766,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0016457409692336071,0,1,2,0.032663244753518006
5767,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0006418827473135948,1,1,2,0.012739534149367373
5768,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.0010090396621894497,0,1,2,0.02002654735359072
5769,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.00039263049312042306,1,1,2,0.007792590774755418
5770,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.004615250837204382,0,1,2,0.09159951080557156
5771,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.00162023430722708,1,1,2,0.03215701056506463
5772,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.004591107669849006,0,1,2,0.09112033808082556
5773,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0003226984539060371,1,1,2,0.00640464008526397
5774,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,0.007099973092907224,0,1,2,0.14091413121046412
5775,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,0.004391413017378562,1,1,2,0.08715697116492001
5776,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.001623992573118803,0,1,2,0.03223160137915083
5777,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0028716711957209036,1,1,2,0.056994448622822894
5778,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.002202461343119748,0,1,2,0.0437125496997157
5779,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0006872078202615213,1,1,2,0.013639107034071462
5780,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.005837414276555386,0,1,2,0.11585595473849084
5781,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.004998035519221339,1,1,2,0.09919669042882652
5782,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0019069540989045987,0,1,2,0.037847577249809486
5783,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001394137806828393,1,1,2,0.027669642584017596
5784,MHC class II antigen presentation,MHC class II antigen presentation,0.0008742312091751882,0,1,2,0.017350985659517752
5785,MHC class II antigen presentation,MHC class II antigen presentation,0.0014630509720906409,1,1,2,0.02903737154366588
5786,Rap1 signalling,Rap1 signalling,0.00028169651737273846,0,1,2,0.005590869076707859
5787,Rap1 signalling,Rap1 signalling,0.00029923347411858954,1,1,2,0.00593892744137769
5788,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.0033649509397281722,0,1,2,0.06678463876311287
5789,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.001865429758909897,1,1,2,0.03702343802873459
5790,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.002344641622386667,0,1,2,0.04653442103161891
5791,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.0008500451337249384,1,1,2,0.016870961331979472
5792,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.008416594762728416,0,1,2,0.16704530048504437
5793,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.004363942675592099,1,1,2,0.08661176355691357
5794,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0022242795933790855,0,1,2,0.04414557947878604
5795,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0035596315014450267,1,1,2,0.0706484903381704
5796,Collagen degradation,Collagen degradation,0.001771483976715225,0,1,2,0.035158883317664695
5797,Collagen degradation,Collagen degradation,0.0010171849769322222,1,1,2,0.020188208522639403
5798,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.006604261192413955,0,1,2,0.1310756697297468
5799,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.0043592711836257705,1,1,2,0.08651904782077234
5800,Fibronectin matrix formation,Fibronectin matrix formation,0.0006436486474269472,0,1,2,0.012774582208989754
5801,Fibronectin matrix formation,Fibronectin matrix formation,0.00010684450449119182,1,1,2,0.0021205574060596745
5802,Integrin cell surface interactions,Integrin cell surface interactions,0.009469065566645903,0,1,2,0.18793383161293964
5803,Integrin cell surface interactions,Integrin cell surface interactions,0.0036578009736506732,1,1,2,0.07259687319909532
5804,Laminin interactions,Laminin interactions,0.0006936736753403072,0,1,2,0.013767435738847839
5805,Laminin interactions,Laminin interactions,0.0012529927258066412,1,1,2,0.024868316972420576
5806,ECM proteoglycans,ECM proteoglycans,0.01016646144491488,0,1,2,0.20177514241934322
5807,ECM proteoglycans,ECM proteoglycans,0.005199194242449807,1,1,2,0.1031891149561058
5808,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0017449458125715148,0,1,2,0.03463217676606276
5809,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.001695351796498762,1,1,2,0.03364787758680092
5810,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0021291349099731537,0,1,2,0.04225723001238663
5811,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0002784080642812525,1,1,2,0.005525602701138628
5812,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,0.0026771229931725387,0,1,2,0.0531332239981765
5813,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,0.004304423438961887,1,1,2,0.08543047717592223
5814,Meiotic synapsis,Meiotic synapsis,0.001089324528791086,0,1,2,0.021619972015695342
5815,Meiotic synapsis,Meiotic synapsis,0.004539351787584772,1,1,2,0.09009313204935746
5816,Meiotic recombination,Meiotic recombination,0.00014415796773925007,0,1,2,0.0028611227838786935
5817,Meiotic recombination,Meiotic recombination,0.0014660711671526515,1,1,2,0.02909731376565465
5818,Nephrin family interactions,Nephrin family interactions,0.0011358858478553405,0,1,2,0.02254408084513684
5819,Nephrin family interactions,Nephrin family interactions,0.0025440818342961713,1,1,2,0.050492738031120504
5820,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.006622714766754005,0,1,2,0.1314419203284221
5821,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.006428432026609122,1,1,2,0.127585964372187
5822,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,0.00014911005761633777,0,1,2,0.0029594075849018213
5823,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,0.0003244910229594024,1,1,2,0.006440217446964407
5824,Cristae formation,Cristae formation,0.0007174714085194495,0,1,2,0.014239752584536636
5825,Cristae formation,Cristae formation,0.0007296605073335121,1,1,2,0.014481671285797349
5826,Signaling by Hippo,Signaling by Hippo,0.002715434279259729,0,1,2,0.05389359330153698
5827,Signaling by Hippo,Signaling by Hippo,0.0010191654898155347,1,1,2,0.020227516031083616
5828,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.0001181696183802296,0,1,2,0.0023453284810553768
5829,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.00019427082862406226,1,1,2,0.003855719546662008
5830,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0007992854607714043,0,1,2,0.015863527202134665
5831,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.001227643758898127,1,1,2,0.024365212580015973
5832,mTORC1-mediated signalling,mTORC1-mediated signalling,0.0011188620977697014,0,1,2,0.02220620816282226
5833,mTORC1-mediated signalling,mTORC1-mediated signalling,0.0006454493652504448,1,1,2,0.012810321300438828
5834,Neutrophil degranulation,Neutrophil degranulation,0.00835296960351374,0,1,2,0.16578252330032237
5835,Neutrophil degranulation,Neutrophil degranulation,0.004546940184569431,1,1,2,0.09024373999594834
5836,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0006500903120276543,0,1,2,0.012902430802059025
5837,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.00015537653657794656,1,1,2,0.00308377924477556
5838,Heme biosynthesis,Heme biosynthesis,0.0013342633481507678,0,1,2,0.026481306062759082
5839,Heme biosynthesis,Heme biosynthesis,0.0002478640174565602,1,1,2,0.004919390851370779
5840,Heme degradation,Heme degradation,0.0014255472123281625,0,1,2,0.028293029325054505
5841,Heme degradation,Heme degradation,0.00016210835252994664,1,1,2,0.003217386511159778
5842,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,0.00014955278679343363,0,1,2,0.0029681944910683123
5843,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,6.598854266054922e-05,1,1,2,0.0013096835772723186
5844,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.001114773246996348,0,1,2,0.0221250561856476
5845,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0024659991918570038,1,1,2,0.04894302121135898
5846,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),0.0005168253469468818,0,1,2,0.010257502922837934
5847,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),0.0008241338606599984,1,1,2,0.01635669677284323
5848,eNOS activation,eNOS activation,0.00018551621327866355,0,1,2,0.0036819655057190844
5849,eNOS activation,eNOS activation,0.0008900052648295322,1,1,2,0.017664055486559485
5850,PECAM1 interactions,PECAM1 interactions,0.005389419794413568,0,1,2,0.10696454734693878
5851,PECAM1 interactions,PECAM1 interactions,0.0019848603125292865,1,1,2,0.039393792462904684
5852,Basigin interactions,Basigin interactions,0.0003306380264622958,0,1,2,0.006562217861166431
5853,Basigin interactions,Basigin interactions,0.0003787935844405086,1,1,2,0.007517967767068738
5854,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,0.0006017774236530331,0,1,2,0.011943558338390258
5855,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,0.0002764696214791431,1,1,2,0.00548713016331545
5856,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,0.0008015712328830753,0,1,2,0.015908893231983846
5857,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,0.001352382428485541,1,1,2,0.02684091791343748
5858,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.00047598921560050345,0,1,2,0.00944702267236771
5859,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0003325405937614263,1,1,2,0.006599978373004742
5860,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,0.0008308324420871719,0,1,2,0.01648964442909501
5861,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,0.0018687606310509712,1,1,2,0.03708954630094783
5862,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.00028471664685273676,0,1,2,0.005650809997081517
5863,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.0047635592279133155,1,1,2,0.09454300759837617
5864,DNA methylation,DNA methylation,0.00020068158547764867,0,1,2,0.003982954709472288
5865,DNA methylation,DNA methylation,0.0046655816376219746,1,1,2,0.09259843304389068
5866,Abacavir metabolism,Abacavir metabolism,0.004243469019396808,0,1,2,0.08422070652411061
5867,Abacavir metabolism,Abacavir metabolism,0.0006256307257211715,1,1,2,0.012416978067373506
5868,Scavenging of heme from plasma,Scavenging of heme from plasma,0.0019938274256253927,0,1,2,0.039571763975594795
5869,Scavenging of heme from plasma,Scavenging of heme from plasma,0.006216411409279206,1,1,2,0.12337796235601067
5870,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.004068066907170829,0,1,2,0.08073947695698794
5871,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.00498679849182468,1,1,2,0.09897366761842034
5872,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.0041611967622736815,0,1,2,0.08258783785214185
5873,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.007410900383662832,1,1,2,0.14708514742040152
5874,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.0033045721515202967,0,1,2,0.0655862927451043
5875,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.0055860658823323394,1,1,2,0.11086740898773742
5876,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0022662071057316167,0,1,2,0.044977720516457736
5877,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0030736218477106034,1,1,2,0.061002590667888414
5878,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.0012666171082463303,0,1,2,0.025138721942924734
5879,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.004030363792296115,1,1,2,0.07999117811036187
5880,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.0016092683206640921,0,1,2,0.0319393671389321
5881,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.002536116948387902,1,1,2,0.05033465785767937
5882,Retinoid metabolism and transport,Retinoid metabolism and transport,0.0016092683206640921,0,1,2,0.0319393671389321
5883,Retinoid metabolism and transport,Retinoid metabolism and transport,0.002536116948387902,1,1,2,0.05033465785767937
5884,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0001579311704481393,0,1,2,0.0031344814104976603
5885,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0003847856133610281,1,1,2,0.007636892379665719
5886,Heme signaling,Heme signaling,0.0044685270094199266,0,1,2,0.0886874630485491
5887,Heme signaling,Heme signaling,0.000782871708620659,1,1,2,0.015537761231762641
5888,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.002186121479126502,0,1,2,0.043388250197650594
5889,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.001701210697268982,1,1,2,0.033764159986900244
5890,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",0.0019726130206062257,0,1,2,0.03915071879509838
5891,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",0.002121982729435617,1,1,2,0.042115279712925044
5892,Syndecan interactions,Syndecan interactions,0.00040732911508301387,0,1,2,0.00808431632311259
5893,Syndecan interactions,Syndecan interactions,0.0014264288100354682,1,1,2,0.02831052651460389
5894,HDACs deacetylate histones,HDACs deacetylate histones,0.0002127834127598219,0,1,2,0.0042231413207751
5895,HDACs deacetylate histones,HDACs deacetylate histones,0.0010796033710335573,1,1,2,0.021427034876098223
5896,PKMTs methylate histone lysines,PKMTs methylate histone lysines,0.0018325943220879523,0,1,2,0.03637174865017868
5897,PKMTs methylate histone lysines,PKMTs methylate histone lysines,0.002822781245810391,1,1,2,0.056024123140400256
5898,HDMs demethylate histones,HDMs demethylate histones,0.001013239027845418,0,1,2,0.020109892734665052
5899,HDMs demethylate histones,HDMs demethylate histones,0.003266479003332971,1,1,2,0.06483025285429811
5900,HATs acetylate histones,HATs acetylate histones,0.0005326107192983731,0,1,2,0.010570797353906442
5901,HATs acetylate histones,HATs acetylate histones,0.0002487450560877774,1,1,2,0.004936876944861028
5902,RMTs methylate histone arginines,RMTs methylate histone arginines,0.00039294496632764957,0,1,2,0.0077988321672516165
5903,RMTs methylate histone arginines,RMTs methylate histone arginines,0.002183433349698139,1,1,2,0.04333489852743688
5904,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0022436721306009445,0,1,2,0.04453046580142785
5905,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0005835140316933201,1,1,2,0.011581082315272637
5906,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.003891083973930879,0,1,2,0.07722687262028963
5907,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.0011563513465049707,1,1,2,0.02295026237910385
5908,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0020022066212912223,0,1,2,0.039738067011119316
5909,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0009682179985192385,1,1,2,0.019216354245056255
5910,Intracellular oxygen transport,Intracellular oxygen transport,0.0028741048639498385,0,1,2,0.057042749967017775
5911,Intracellular oxygen transport,Intracellular oxygen transport,0.0022717551180506646,1,1,2,0.045087832671201616
5912,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.005641500420069445,0,1,2,0.11196762579448583
5913,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.005931214834768047,1,1,2,0.11771762716944668
5914,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,2.6725151295383586e-05,0,1,2,0.0005304177110219362
5915,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,0.0003044735781628416,1,1,2,0.006042928498731818
5916,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00816107334161052,0,1,2,0.1619739321021893
5917,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008732500120135838,1,1,2,0.1733151170605844
5918,Surfactant metabolism,Surfactant metabolism,0.002818429420068671,0,1,2,0.055937751863277194
5919,Surfactant metabolism,Surfactant metabolism,0.0034935639114568227,1,1,2,0.0693372378978397
5920,Amyloid fiber formation,Amyloid fiber formation,0.01014084823458836,0,1,2,0.20126679355189778
5921,Amyloid fiber formation,Amyloid fiber formation,0.007534469098596111,1,1,2,0.149537632504748
5922,Striated Muscle Contraction,Striated Muscle Contraction,0.00016460339270387174,0,1,2,0.00326690591269034
5923,Striated Muscle Contraction,Striated Muscle Contraction,0.0002069029061679287,1,1,2,0.004106430106995735
5924,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0009192328181844981,0,1,2,0.018244138711457462
5925,Smooth Muscle Contraction,Smooth Muscle Contraction,0.005766126264722336,1,1,2,0.11444109187609339
5926,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.002161188535084995,0,1,2,0.042893402667645464
5927,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.009187223971230427,1,1,2,0.1823400831525943
5928,Platelet sensitization by LDL,Platelet sensitization by LDL,0.005021111587823352,0,1,2,0.09965468429954331
5929,Platelet sensitization by LDL,Platelet sensitization by LDL,0.005669395138168599,1,1,2,0.11252125605686382
5930,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.00015725718389596646,0,1,2,0.003121104707768766
5931,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.0025270656525360675,1,1,2,0.05015501555839174
5932,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.00012707924848634464,0,1,2,0.002522159121028367
5933,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,7.011984580902735e-05,1,1,2,0.0013916781125074477
5934,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0006960998061774913,0,1,2,0.013815587487403932
5935,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0015579662178129298,1,1,2,0.030921167329166162
5936,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.00019603481534147992,0,1,2,0.0038907296308551475
5937,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0016238058841583996,1,1,2,0.032227896137973486
5938,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,0.001078353109156053,0,1,2,0.021402220758643314
5939,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,0.0022151572614851193,1,1,2,0.043964527317512936
5940,Pyroptosis,Pyroptosis,0.0005388350852308345,0,1,2,0.010694333190765461
5941,Pyroptosis,Pyroptosis,0.0004958261174786845,1,1,2,0.009840728360754555
5942,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,0.0005839343157738417,0,1,2,0.011589423750556027
5943,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,0.00041476366476978844,1,1,2,0.008231870841466952
5944,Hedgehog 'on' state,Hedgehog 'on' state,0.0005004489503958466,0,1,2,0.009932478354131823
5945,Hedgehog 'on' state,Hedgehog 'on' state,0.0008635262786713976,1,1,2,0.017138523448482476
5946,Physiological factors,Physiological factors,0.005370052968657712,0,1,2,0.10658017132325817
5947,Physiological factors,Physiological factors,0.007785433839514927,1,1,2,0.154518563836215
5948,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,0.0010296428704188961,0,1,2,0.020435462028309852
5949,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,0.00016275297056015658,1,1,2,0.0032301803328406483
5950,Intraflagellar transport,Intraflagellar transport,0.0008849800431165433,0,1,2,0.01756431922804701
5951,Intraflagellar transport,Intraflagellar transport,0.00012270653987775056,1,1,2,0.002435373378807442
5952,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0036340716012326886,0,1,2,0.0721259131187268
5953,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.004243305439544903,1,1,2,0.08421745993255131
5954,Metallothioneins bind metals,Metallothioneins bind metals,0.001312747316997555,0,1,2,0.026054274467374437
5955,Metallothioneins bind metals,Metallothioneins bind metals,0.006061759106058457,1,1,2,0.12030855706913435
5956,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0003929502034659124,0,1,2,0.007798936109446704
5957,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.00024661542253857146,1,1,2,0.004894609818287998
5958,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.0028487879242093555,0,1,2,0.056540281222171154
5959,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.0011334442133051808,1,1,2,0.0224956213922816
5960,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),0.00014360934599534433,0,1,2,0.002850234213542719
5961,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),0.0009911216471608973,1,1,2,0.019670926073379554
5962,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.0007616021677900965,0,1,2,0.01511562176332179
5963,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.0020446863455677875,1,1,2,0.04058116787392007
5964,RAB geranylgeranylation,RAB geranylgeranylation,0.0001578223204033669,0,1,2,0.003132321048860988
5965,RAB geranylgeranylation,RAB geranylgeranylation,3.0880561155011255e-05,1,1,2,0.0006128906954305382
5966,Protein methylation,Protein methylation,0.0013977997400916092,0,1,2,0.02774232147132948
5967,Protein methylation,Protein methylation,0.0002988834811024708,1,1,2,0.005931981082405517
5968,Neddylation,Neddylation,0.0007708697506681402,0,1,2,0.015299556740622635
5969,Neddylation,Neddylation,5.747585310866944e-05,1,1,2,0.0011407310704429792
5970,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,0.0011079412482598657,0,1,2,0.021989460577919995
5971,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,0.001027599192259447,1,1,2,0.02039490087004289
5972,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.00304972382667439,0,1,2,0.06052828339546627
5973,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.003478093424640291,1,1,2,0.06903019304279197
5974,Formation of the cornified envelope,Formation of the cornified envelope,0.0009241643058788578,0,1,2,0.018342014618159142
5975,Formation of the cornified envelope,Formation of the cornified envelope,0.002183199622329643,1,1,2,0.043330259708579295
5976,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,1.4673565740667809e-05,0,1,2,0.00029122825411429394
5977,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,3.296955497295282e-05,1,1,2,0.0006543512397322252
5978,Choline catabolism,Choline catabolism,0.0006199760257909405,0,1,2,0.012304748469106383
5979,Choline catabolism,Choline catabolism,0.000646197122875081,1,1,2,0.01282516214767202
5980,Urea cycle,Urea cycle,8.37523833907944e-05,0,1,2,0.001662244939225112
5981,Urea cycle,Urea cycle,0.0004310896723569007,1,1,2,0.008555895333555748
5982,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,0.0003313995715095378,0,1,2,0.00657733234925047
5983,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,0.000113882571442935,1,1,2,0.0022602428776703665
5984,Tryptophan catabolism,Tryptophan catabolism,0.0003296749186637069,0,1,2,0.0065431029297541195
5985,Tryptophan catabolism,Tryptophan catabolism,0.0002745032775999392,1,1,2,0.005448103869022048
5986,Threonine catabolism,Threonine catabolism,4.236037786568392e-05,0,1,2,0.0008407321783589502
5987,Threonine catabolism,Threonine catabolism,0.0002192298293058751,1,1,2,0.004351084226349674
5988,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,0.00016156274229989475,0,1,2,0.003206557710748674
5989,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,0.00020826131141715043,1,1,2,0.004133390560651121
5990,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,0.00027125837339110777,0,1,2,0.005383701814047298
5991,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,0.00010995124427475086,1,1,2,0.002182217292902703
5992,Alanine metabolism,Alanine metabolism,0.00015035753732184918,0,1,2,0.002984166484210952
5993,Alanine metabolism,Alanine metabolism,0.0005597310392765168,1,1,2,0.011109058031497976
5994,Lactose synthesis,Lactose synthesis,0.0008523680580372937,0,1,2,0.01691706472660645
5995,Lactose synthesis,Lactose synthesis,0.0010309017790587412,1,1,2,0.020460447759232454
5996,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,0.0001522226648283756,0,1,2,0.003021183923395541
5997,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,4.062266318473361e-05,1,1,2,0.0008062435188452399
5998,Galactose catabolism,Galactose catabolism,5.11346416616559e-05,0,1,2,0.0010148761847715922
5999,Galactose catabolism,Galactose catabolism,3.1661358629344016e-05,1,1,2,0.0006283872890523984
6000,Pentose phosphate pathway,Pentose phosphate pathway,0.0010747939923206147,0,1,2,0.021331582482951347
6001,Pentose phosphate pathway,Pentose phosphate pathway,0.001776394736243951,1,1,2,0.035256347829645054
6002,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,0.0004591039993669588,0,1,2,0.009111899490249212
6003,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,0.0037215610665888503,1,1,2,0.07386232843177179
6004,GPVI-mediated activation cascade,GPVI-mediated activation cascade,0.0001811439578517737,0,1,2,0.0035951887578570528
6005,GPVI-mediated activation cascade,GPVI-mediated activation cascade,0.0014455146247847241,1,1,2,0.028689325274633276
6006,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.0007779164707475327,0,1,2,0.01543941395203417
6007,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,0.0004853882828683709,1,1,2,0.00963356723822858
6008,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0019209251330153743,0,1,2,0.038124862263156714
6009,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0014364840664462361,1,1,2,0.028510094555592284
6010,Signaling by SCF-KIT,Signaling by SCF-KIT,0.0003351280375361246,0,1,2,0.0066513317213620455
6011,Signaling by SCF-KIT,Signaling by SCF-KIT,0.0005202243766630344,1,1,2,0.010324963927709725
6012,Signaling by PDGF,Signaling by PDGF,0.00133395677480875,0,1,2,0.026475221459961663
6013,Signaling by PDGF,Signaling by PDGF,0.00010398183268384013,1,1,2,0.0020637415695212748
6014,Signaling by MST1,Signaling by MST1,0.00016541576287999984,0,1,2,0.003283029134017016
6015,Signaling by MST1,Signaling by MST1,0.00024525955248043895,1,1,2,0.004867699680914817
6016,Signaling by BMP,Signaling by BMP,0.002027434179013321,0,1,2,0.04023876177889564
6017,Signaling by BMP,Signaling by BMP,0.0015361319599805523,1,1,2,0.030487819845617475
6018,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,0.0012889801217881292,0,1,2,0.025582563712922213
6019,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,0.0021916921469170205,1,1,2,0.04349881199861675
6020,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.00016465114005334583,0,1,2,0.003267853560826565
6021,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,4.6100221294726896e-05,1,1,2,0.0009149573593238213
6022,Mitochondrial protein import,Mitochondrial protein import,0.0011100377776686026,0,1,2,0.022031070682116655
6023,Mitochondrial protein import,Mitochondrial protein import,0.0012993513084097108,1,1,2,0.025788402063755083
6024,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.010171766017196077,0,1,2,0.2018804229865604
6025,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.010430754293116793,1,1,2,0.2070205985080031
6026,Late endosomal microautophagy,Late endosomal microautophagy,0.008577574389981671,0,1,2,0.17024028503218835
6027,Late endosomal microautophagy,Late endosomal microautophagy,0.005593390753882734,1,1,2,0.1110127867092084
6028,Defective pyroptosis,Defective pyroptosis,0.0009375013901378136,0,1,2,0.018606717542612332
6029,Defective pyroptosis,Defective pyroptosis,0.002043286666937697,1,1,2,0.0405533882618635
6030,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,0.0010348725901550388,0,1,2,0.020539256986889194
6031,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,0.008382200079212532,1,1,2,0.16636266452537551
6032,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,9.13792205297769e-05,0,1,2,0.001813615812784768
6033,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.0020069188901431843,1,1,2,0.0398315920516533
6034,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0007772525138077491,0,1,2,0.015426236308385882
6035,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.002639681344608384,1,1,2,0.05239011450896222
6036,Aspirin ADME,Aspirin ADME,0.003087246067623128,0,1,2,0.06127299241269385
6037,Aspirin ADME,Aspirin ADME,0.0045270924049037806,1,1,2,0.08984981841463477
6038,Paracetamol ADME,Paracetamol ADME,0.00023078495892086905,0,1,2,0.004580420454728879
6039,Paracetamol ADME,Paracetamol ADME,0.0015234985769381226,1,1,2,0.03023708337487628
6040,Atorvastatin ADME,Atorvastatin ADME,0.004028243467658327,0,1,2,0.07994909573901927
6041,Atorvastatin ADME,Atorvastatin ADME,0.0012853823781771665,1,1,2,0.025511158806365133
6042,Kinesins,Kinesins,0.0017203454727184046,0,1,2,0.03414393047660201
6043,Kinesins,Kinesins,0.00034075051024296145,1,1,2,0.0067629217015452
6044,Stimuli-sensing channels,Stimuli-sensing channels,0.00023219726873658655,0,1,2,0.004608450759643788
6045,Stimuli-sensing channels,Stimuli-sensing channels,5.7512932771885225e-05,1,1,2,0.0011414669955597727
6046,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.0005965822608513594,0,2,3,0.016991355561129854
6047,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.002401723068106747,1,2,3,0.06840386194408991
6048,Signaling by Activin,Signaling by TGFB family members,2.664593555402397e-05,0,2,3,0.0007589071867662811
6049,Signaling by Activin,Signaling by TGFB family members,1.622730194885939e-05,1,2,3,0.00046217240321126966
6050,RAB geranylgeranylation,Post-translational protein modification,5.1537463312038174e-05,0,2,3,0.0014678468022228156
6051,RAB geranylgeranylation,Post-translational protein modification,7.096079246962128e-05,1,2,3,0.0020210457716765572
6052,Phospholipid metabolism,Metabolism of lipids,7.817567527085261e-05,0,2,3,0.0022265340120286217
6053,Phospholipid metabolism,Metabolism of lipids,0.00010974806829678902,1,2,3,0.0031257524283688325
6054,Post-chaperonin tubulin folding pathway,Protein folding,8.161813050991889e-05,0,2,3,0.002324579134736055
6055,Post-chaperonin tubulin folding pathway,Protein folding,0.00032997458797387875,1,2,3,0.009398059443471166
6056,Paracetamol ADME,Paracetamol ADME,0.00027994963008944664,0,2,3,0.00797329055220051
6057,Paracetamol ADME,Paracetamol ADME,0.0013536300209083779,1,2,3,0.03855295487775896
6058,Fibronectin matrix formation,Fibronectin matrix formation,0.00025086983820757515,0,2,3,0.007145064310938463
6059,Fibronectin matrix formation,Fibronectin matrix formation,0.0002334084940523403,1,2,3,0.006647744952676864
6060,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,0.00012069065302758013,0,2,3,0.003437409948411969
6061,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,0.00024768434781265977,1,2,3,0.007054337845388967
6062,Basigin interactions,Cell surface interactions at the vascular wall,0.00044402531197478966,0,2,3,0.012646356502686931
6063,Basigin interactions,Cell surface interactions at the vascular wall,7.151453409910966e-05,1,2,3,0.002036816976308437
6064,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,0.00023429093900532156,0,2,3,0.006672878009663559
6065,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,0.0009626921145248387,1,2,3,0.027418589333253727
6066,Nucleotide salvage,Metabolism of nucleotides,0.0003303099531272006,0,2,3,0.00940761103247546
6067,Nucleotide salvage,Metabolism of nucleotides,3.9461374919499364e-05,1,2,3,0.0011239057816292053
6068,Lactose synthesis,Metabolism of carbohydrates,0.000611219517035407,0,2,3,0.017408241614542803
6069,Lactose synthesis,Metabolism of carbohydrates,0.00041085834148126303,1,2,3,0.011701722668390903
6070,O-linked glycosylation,Post-translational protein modification,0.000544557982850285,0,2,3,0.015509643711257124
6071,O-linked glycosylation,Post-translational protein modification,0.000754352845202623,1,2,3,0.021484845012147008
6072,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0030193018660819165,0,2,3,0.0859932232644155
6073,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0001707097150114729,1,2,3,0.004862010917588739
6074,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,0.003348397668934165,0,2,3,0.09536625388714676
6075,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,0.0037482017906412817,1,2,3,0.10675313953982528
6076,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0018594981271872265,0,2,3,0.05296066597623045
6077,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0005034157003520995,1,2,3,0.01433786372985856
6078,Neurotransmitter release cycle,Transmission across Chemical Synapses,0.002713449068868599,0,2,3,0.07728218043286803
6079,Neurotransmitter release cycle,Transmission across Chemical Synapses,0.0004652065276209653,1,2,3,0.013249622120654756
6080,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,5.560801797993311e-05,0,2,3,0.0015837809260342043
6081,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,4.878776489604125e-05,1,2,3,0.0013895321982897297
6082,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,2.388927822739488e-05,0,2,3,0.0006803943849774617
6083,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.00035263969692806975,1,2,3,0.010043588065999818
6084,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.00529142201708632,0,2,3,0.150705843630013
6085,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.004809170249739643,1,2,3,0.13697075328844438
6086,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,2.0675985434099414e-05,0,2,3,0.0005888760748369885
6087,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.00011379747036648188,1,2,3,0.0032410841016202933
6088,Pre-NOTCH Expression and Processing,Signaling by NOTCH,0.0015676957409838448,0,2,3,0.044649795166072176
6089,Pre-NOTCH Expression and Processing,Signaling by NOTCH,0.00020522385012049346,1,2,3,0.005845013564508469
6090,PECAM1 interactions,Cell surface interactions at the vascular wall,0.004600651529121217,0,2,3,0.1310318979860365
6091,PECAM1 interactions,Cell surface interactions at the vascular wall,0.0007490200690244358,1,2,3,0.021332961353986952
6092,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.00453980557230246,0,2,3,0.12929893447939572
6093,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.0031216304192214915,1,2,3,0.08890765928530765
6094,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.004101658055162427,0,2,3,0.1168199843991026
6095,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.0024089738287103746,1,2,3,0.06861037202591677
6096,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,3.3194662585070355e-05,0,2,3,0.0009454225372202148
6097,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,1.8100292208478534e-05,1,2,3,0.0005155173407866948
6098,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0027402243811063738,0,2,3,0.07804477241782422
6099,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.005020156298507508,1,2,3,0.14297988096169562
6100,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,0.0002326264365339813,0,2,3,0.006625471046401592
6101,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,0.0008004054966962026,1,2,3,0.022796478004625764
6102,Diseases of glycosylation,Diseases of metabolism,0.0006849677849688795,0,2,3,0.01950867792434336
6103,Diseases of glycosylation,Diseases of metabolism,0.0025475642761184506,1,2,3,0.07255758890414944
6104,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.000784450266119304,0,2,3,0.022342054510026684
6105,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.001907446340571604,1,2,3,0.05432628677255156
6106,Physiological factors,Cardiac conduction,0.005545758242780334,0,2,3,0.157949634681855
6107,Physiological factors,Cardiac conduction,0.007943910135306077,1,2,3,0.22625178539842455
6108,Asparagine N-linked glycosylation,Post-translational protein modification,4.904179064367273e-05,0,2,3,0.0013967671465658126
6109,Asparagine N-linked glycosylation,Post-translational protein modification,6.809136310098184e-05,1,2,3,0.0019393210911764634
6110,Infection with Mycobacterium tuberculosis,Infectious disease,0.00099047496628996,0,2,3,0.02820987721393873
6111,Infection with Mycobacterium tuberculosis,Infectious disease,0.0006838638382979403,1,2,3,0.01947723624121372
6112,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,0.0017640107284078944,0,2,3,0.05024107397570452
6113,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,0.00022222122454526664,1,2,3,0.006329118526068722
6114,Alanine metabolism,Metabolism of amino acids and derivatives,2.4527900914030705e-05,0,2,3,0.0006985831006837386
6115,Alanine metabolism,Metabolism of amino acids and derivatives,4.299880338248148e-05,1,2,3,0.0012246558520399744
6116,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",0.0003601881747960165,0,2,3,0.010258577481234137
6117,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",0.0002623412938053403,1,2,3,0.007471784687416275
6118,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.00245196592558511,0,2,3,0.06983483686882831
6119,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.0017464137346564134,1,2,3,0.0497398911594208
6120,Metallothioneins bind metals,Response to metal ions,0.0013468950817853136,0,2,3,0.0383611359906884
6121,Metallothioneins bind metals,Response to metal ions,0.004127876167681995,1,2,3,0.11756670668904458
6122,Defects in vitamin and cofactor metabolism,Diseases of metabolism,0.0007025611646983131,0,2,3,0.020009757809082443
6123,Defects in vitamin and cofactor metabolism,Diseases of metabolism,0.0026583776401599923,1,2,3,0.07571368219238732
6124,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0013652652431005085,0,2,3,0.03888433951701577
6125,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0032120060883234916,1,2,3,0.09148166328870479
6126,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.0002847178749894267,0,2,3,0.00810909570400386
6127,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.0016139084758981367,1,2,3,0.04596598752026725
6128,Cristae formation,Mitochondrial biogenesis,0.0006468658019205896,0,2,3,0.01842348920177935
6129,Cristae formation,Mitochondrial biogenesis,0.000638615090026506,1,2,3,0.018188499346022062
6130,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0001310164159284447,0,2,3,0.003731499666463822
6131,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.00012094998859547698,1,2,3,0.0034447961265351578
6132,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.0006790610316456508,0,2,3,0.01934044673057029
6133,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.001239595916835759,1,2,3,0.035305131173400596
6134,Cell-extracellular matrix interactions,Cell junction organization,0.00362065218112474,0,2,3,0.10312037854574871
6135,Cell-extracellular matrix interactions,Cell junction organization,0.00924034135387785,1,2,3,0.26317565196439713
6136,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0027285443596079505,0,2,3,0.07771211184230169
6137,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0018720626927728897,1,2,3,0.05331851939452095
6138,Signaling by BMP,Signaling by TGFB family members,0.0015587734270056115,0,2,3,0.04439567730307059
6139,Signaling by BMP,Signaling by TGFB family members,0.0014935918749182434,1,2,3,0.04253923100853566
6140,Anchoring of the basal body to the plasma membrane,Cilium Assembly,0.0009321580143990515,0,2,3,0.026548942704411615
6141,Anchoring of the basal body to the plasma membrane,Cilium Assembly,0.0002075811970027487,1,2,3,0.005912153541148337
6142,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.00019589479164155564,0,2,3,0.005579311145800951
6143,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.00023472836580551098,1,2,3,0.0066853364328881785
6144,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,0.002971153041411535,0,2,3,0.08462188882571219
6145,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,0.0004894158804293091,1,2,3,0.013939132601379385
6146,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.00034408255475415765,0,2,3,0.009799870720035509
6147,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.005743217070436733,1,2,3,0.16357349138957175
6148,ER to Golgi Anterograde Transport,Membrane Trafficking,0.0021810143254540355,0,2,3,0.06211782065866777
6149,ER to Golgi Anterograde Transport,Membrane Trafficking,0.004157897247053827,1,2,3,0.11842174189107649
6150,Syndecan interactions,Non-integrin membrane-ECM interactions,0.00024365503723085825,0,2,3,0.006939578401043586
6151,Syndecan interactions,Non-integrin membrane-ECM interactions,0.001237914207437368,1,2,3,0.03525723413687493
6152,Signaling by NOTCH4,Signaling by NOTCH,8.39213624649208e-05,0,2,3,0.002390177855407611
6153,Signaling by NOTCH4,Signaling by NOTCH,1.1050544592331227e-05,1,2,3,0.0003147323422665472
6154,HDACs deacetylate histones,Chromatin modifying enzymes,3.9493781502148534e-05,0,2,3,0.0011248287587347053
6155,HDACs deacetylate histones,Chromatin modifying enzymes,0.0004054959854923757,1,2,3,0.011548996542873
6156,Galactose catabolism,Metabolism of carbohydrates,9.226479875541359e-05,0,2,3,0.0026278086096494283
6157,Galactose catabolism,Metabolism of carbohydrates,3.774825690685862e-05,1,2,3,0.0010751141912969419
6158,Rab regulation of trafficking,Membrane Trafficking,0.0002988629512678534,0,2,3,0.008511963902168294
6159,Rab regulation of trafficking,Membrane Trafficking,0.0005480927853374671,1,2,3,0.015610318990827736
6160,Metabolism of cofactors,Metabolism of vitamins and cofactors,7.504318820589696e-05,0,2,3,0.0021373171428656903
6161,Metabolism of cofactors,Metabolism of vitamins and cofactors,5.940026325368949e-06,1,2,3,0.00016917884751179729
6162,ABC transporter disorders,Disorders of transmembrane transporters,0.0010425675942859912,0,2,3,0.029693535751038218
6163,ABC transporter disorders,Disorders of transmembrane transporters,0.0016386027996974045,1,2,3,0.04666931053797859
6164,Telomere Maintenance,Chromosome Maintenance,0.00017017915151801543,0,2,3,0.004846899853186278
6165,Telomere Maintenance,Chromosome Maintenance,0.000686513556659146,1,2,3,0.01955270329708603
6166,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,0.001209422452540756,0,2,3,0.03444575587180209
6167,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,0.0032654621710452407,1,2,3,0.09300415459968378
6168,Beta-catenin independent WNT signaling,Signaling by WNT,6.0715480977549344e-05,0,2,3,0.001729247403170094
6169,Beta-catenin independent WNT signaling,Signaling by WNT,0.0006760505743772098,1,2,3,0.01925470541171734
6170,Diseases of carbohydrate metabolism,Diseases of metabolism,0.0001628991335282159,0,2,3,0.004639556487026543
6171,Diseases of carbohydrate metabolism,Diseases of metabolism,0.0006105718981831358,1,2,3,0.01738979667759257
6172,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,0.0004137283332393561,0,2,3,0.011783463366395703
6173,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,0.001948405873280983,1,2,3,0.0554928618277495
6174,Tryptophan catabolism,Metabolism of amino acids and derivatives,2.8073500619263055e-05,0,2,3,0.0007995658975625251
6175,Tryptophan catabolism,Metabolism of amino acids and derivatives,5.392000533680717e-05,1,2,3,0.0015357043657789513
6176,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0013790615757528857,0,2,3,0.03927727509173708
6177,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.002673131571649775,1,2,3,0.07613389129399503
6178,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.00022232205013415527,0,2,3,0.006331990155922454
6179,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,9.048159882767032e-05,1,2,3,0.002577021004993486
6180,MHC class II antigen presentation,Adaptive Immune System,0.00018910505401738636,0,2,3,0.00538593153378499
6181,MHC class II antigen presentation,Adaptive Immune System,0.0001748110662277047,1,2,3,0.0049788221628587846
6182,Stimuli-sensing channels,Ion channel transport,0.00045832586465852554,0,2,3,0.013053652849419183
6183,Stimuli-sensing channels,Ion channel transport,0.0001248727733531416,1,2,3,0.003556521591707625
6184,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0036295854724858836,0,2,3,0.1033748090573629
6185,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.00027914814515225323,1,2,3,0.00795046333047704
6186,Laminin interactions,Laminin interactions,0.0015035163351750653,0,2,3,0.04282189116127858
6187,Laminin interactions,Laminin interactions,0.0016967350368708287,1,2,3,0.04832498415785459
6188,Cellular response to heat stress,Cellular responses to stress,0.0013174967768883952,0,2,3,0.03752383812888942
6189,Cellular response to heat stress,Cellular responses to stress,0.00010164806545103279,1,2,3,0.0028950549413165
6190,TCR signaling,Adaptive Immune System,4.542632026571397e-05,0,2,3,0.0012937943517915213
6191,TCR signaling,Adaptive Immune System,4.0823412102089946e-05,1,2,3,0.0011626981822343624
6192,Influenza Infection,Infectious disease,0.00024498173143757974,0,2,3,0.006977364192654499
6193,Influenza Infection,Infectious disease,0.00016790214587977085,1,2,3,0.004782048088470881
6194,Kinesins,Factors involved in megakaryocyte development and platelet production,0.002022369417863033,0,2,3,0.05759942946648827
6195,Kinesins,Factors involved in megakaryocyte development and platelet production,0.0006139995352226796,1,2,3,0.017487419760770197
6196,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.00020273803585932633,0,2,3,0.0057742146877364006
6197,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.001901745814908272,1,2,3,0.05416392918201107
6198,ECM proteoglycans,ECM proteoglycans,0.008663518156627014,0,2,3,0.24674705747952247
6199,ECM proteoglycans,ECM proteoglycans,0.005260352163827404,1,2,3,0.14982093812980418
6200,Pentose phosphate pathway,Metabolism of carbohydrates,0.0003316694142108991,0,2,3,0.009446330062792715
6201,Pentose phosphate pathway,Metabolism of carbohydrates,0.00024737748938646913,1,2,3,0.007045598161076374
6202,Integrin cell surface interactions,Integrin cell surface interactions,0.008839750205279507,0,2,3,0.2517663508719335
6203,Integrin cell surface interactions,Integrin cell surface interactions,0.0032882494782880633,1,2,3,0.09365316357137357
6204,SUMOylation,Post-translational protein modification,0.0005806057117325015,0,2,3,0.016536324889699937
6205,SUMOylation,Post-translational protein modification,0.0008077615511957923,1,2,3,0.023005986978880563
6206,HDMs demethylate histones,Chromatin modifying enzymes,0.00022604950658627632,0,2,3,0.006438152444131013
6207,HDMs demethylate histones,Chromatin modifying enzymes,0.0025627981578259904,1,2,3,0.07299146754529377
6208,Cell-cell junction organization,Cell junction organization,0.0014049473391765455,0,2,3,0.040014531693492256
6209,Cell-cell junction organization,Cell junction organization,0.0031237600859949544,1,2,3,0.08896831466805906
6210,Chaperonin-mediated protein folding,Protein folding,0.0003411836245490823,0,2,3,0.009717305821456324
6211,Chaperonin-mediated protein folding,Protein folding,0.0014272842660834682,1,2,3,0.040650713310218294
6212,Transcriptional regulation by small RNAs,Gene Silencing by RNA,0.00021687120371388844,0,2,3,0.006176743720160694
6213,Transcriptional regulation by small RNAs,Gene Silencing by RNA,0.0011863573760132254,1,2,3,0.03378883570832846
6214,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0014932897331260938,0,2,3,0.042530625659437674
6215,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0003691732037558662,1,2,3,0.010514481539738978
6216,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,0.0005538241003257658,0,2,3,0.015773553497096904
6217,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,0.00031698705003742214,1,2,3,0.009028159281459846
6218,Rap1 signalling,Adaptive Immune System,3.959662667468017e-05,0,2,3,0.0011277579086757998
6219,Rap1 signalling,Adaptive Immune System,3.748774181738942e-05,1,2,3,0.001067694419029671
6220,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0029387286643209267,0,2,3,0.08369840491385658
6221,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.007855235880269163,1,2,3,0.22372623964334232
6222,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,0.0001962184295305559,0,2,3,0.0055885287286992595
6223,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,0.0003627779541080959,1,2,3,0.010332337403384025
6224,S Phase,"Cell Cycle, Mitotic",0.00024042491903273705,0,2,3,0.006847580883835431
6225,S Phase,"Cell Cycle, Mitotic",0.0006372950145323834,1,2,3,0.018150902063031847
6226,Homology Directed Repair,DNA Double-Strand Break Repair,0.00046018530181219074,0,2,3,0.013106611778798702
6227,Homology Directed Repair,DNA Double-Strand Break Repair,0.00185105340557674,1,2,3,0.05272015049845917
6228,Selective autophagy,Macroautophagy,0.0001910737835827792,0,2,3,0.0054420032379646635
6229,Selective autophagy,Macroautophagy,0.0006226848243312618,1,2,3,0.017734786880242586
6230,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.0002380055064680113,0,2,3,0.006778673204485973
6231,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.003860484430943007,1,2,3,0.1099510795221279
6232,Diseases associated with surfactant metabolism,Diseases of metabolism,0.0003325979520512395,0,2,3,0.009472775898736064
6233,Diseases associated with surfactant metabolism,Diseases of metabolism,0.0012715604563413878,1,2,3,0.03621551837685658
6234,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,0.00013879353421718065,0,2,3,0.003953001026387432
6235,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,5.584230624588733e-05,1,2,3,0.0015904537279122688
6236,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0006553491217094552,0,2,3,0.01866510400049241
6237,Smooth Muscle Contraction,Smooth Muscle Contraction,0.004958199253635981,1,2,3,0.14121527237707782
6238,SLC transporter disorders,Disorders of transmembrane transporters,0.00032131654685320333,0,2,3,0.00915146837833567
6239,SLC transporter disorders,Disorders of transmembrane transporters,0.0005072958004158752,1,2,3,0.01444837348538212
6240,Phase II - Conjugation of compounds,Biological oxidations,0.0003470823089397702,0,2,3,0.00988530720266071
6241,Phase II - Conjugation of compounds,Biological oxidations,0.0009400045233023728,1,2,3,0.026772420389617413
6242,Post-translational protein phosphorylation,Post-translational protein modification,0.001656018450856135,0,2,3,0.047165328506639445
6243,Post-translational protein phosphorylation,Post-translational protein modification,0.0022561023746730745,1,2,3,0.06425641549528192
6244,ROS and RNS production in phagocytes,Innate Immune System,0.003986731082966863,0,2,3,0.1135467307737732
6245,ROS and RNS production in phagocytes,Innate Immune System,0.0023350935842402203,1,2,3,0.06650617687109578
6246,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.008062063027241238,0,2,3,0.22961691696398795
6247,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.009998192561277411,1,2,3,0.2847601343943329
6248,C-type lectin receptors (CLRs),Innate Immune System,0.0013301436061555697,0,2,3,0.037884034512356814
6249,C-type lectin receptors (CLRs),Innate Immune System,0.0007835015130954646,1,2,3,0.022315032922182704
6250,mTORC1-mediated signalling,MTOR signalling,0.0011660020588956262,0,2,3,0.0332090926395166
6251,mTORC1-mediated signalling,MTOR signalling,0.0007525668155962156,1,2,3,0.021433976814956793
6252,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.0001608376740104746,0,2,3,0.004580843726122737
6253,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.00014887981674268865,1,2,3,0.004240270065256185
6254,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,0.0008079440853050862,0,2,3,0.023011185762278213
6255,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,6.636042717859447e-05,1,2,3,0.0018900220260838392
6256,Amyloid fiber formation,Amyloid fiber formation,0.008956258603446138,0,2,3,0.25508464534532577
6257,Amyloid fiber formation,Amyloid fiber formation,0.006788723869563162,1,2,3,0.19335073910757258
6258,Metabolism of polyamines,Metabolism of amino acids and derivatives,7.320316934479394e-05,0,2,3,0.0020849112690075394
6259,Metabolism of polyamines,Metabolism of amino acids and derivatives,0.00017603365818865825,1,2,3,0.005013643001623076
6260,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.0017231930120993491,0,2,3,0.04907853801628446
6261,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.0004779502135714183,1,2,3,0.01361257709493528
6262,Unfolded Protein Response (UPR),Cellular responses to stress,0.0022721497113296412,0,2,3,0.06471346227798673
6263,Unfolded Protein Response (UPR),Cellular responses to stress,0.00017591985897380592,1,2,3,0.005010401867836472
6264,Axon guidance,Nervous system development,0.0009436749639155493,0,2,3,0.026876958800524056
6265,Axon guidance,Nervous system development,0.00308004349375468,1,2,3,0.08772321535582775
6266,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,0.001815859916349915,0,2,3,0.051717799057374725
6267,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,0.007343799746698369,1,2,3,0.20915994466180918
6268,Intraflagellar transport,Cilium Assembly,0.000698548290418487,0,2,3,0.01989546648970373
6269,Intraflagellar transport,Cilium Assembly,0.0001424889384605905,1,2,3,0.004058250430471758
6270,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.009919681145631127,0,2,3,0.28252403810653853
6271,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.009315707633061438,1,2,3,0.265322171113492
6272,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,0.006433508963797473,0,2,3,0.18323380610345527
6273,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,0.003891603615326124,1,2,3,0.11083739003003897
6274,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,0.0023234031961812418,0,2,3,0.06617322104389062
6275,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,0.00663354474020564,1,2,3,0.1889310573040649
6276,Choline catabolism,Metabolism of amino acids and derivatives,5.905609947636124e-05,0,2,3,0.001681986291084709
6277,Choline catabolism,Metabolism of amino acids and derivatives,0.00014293567188259043,1,2,3,0.004070973917092713
6278,Transferrin endocytosis and recycling,Iron uptake and transport,2.5319579731792703e-06,0,2,3,7.21131032738595e-05
6279,Transferrin endocytosis and recycling,Iron uptake and transport,9.20751220224629e-06,1,2,3,0.0002622406396035769
6280,DNA Double Strand Break Response,DNA Double-Strand Break Repair,9.449019456453039e-05,0,2,3,0.002691190466500135
6281,DNA Double Strand Break Response,DNA Double-Strand Break Repair,0.00034782063109010724,1,2,3,0.009906335474867686
6282,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0006317787907613505,0,2,3,0.017993793604401814
6283,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0004574058384836287,1,2,3,0.013027449435591709
6284,Nucleosome assembly,Chromosome Maintenance,0.000409545662219658,0,2,3,0.011664336038691549
6285,Nucleosome assembly,Chromosome Maintenance,0.0016592112830769138,1,2,3,0.04725626407591512
6286,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0011513446197707058,0,2,3,0.032791631752510465
6287,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00275712380618809,1,2,3,0.07852608766835203
6288,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0001633870500902815,0,2,3,0.004653452917299863
6289,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0006642047809400722,1,2,3,0.01891732345888007
6290,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,5.685191104829141e-05,0,2,3,0.001619208445072969
6291,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,0.0001366732549793938,1,2,3,0.0038926130115532237
6292,Aflatoxin activation and detoxification,Biological oxidations,0.0005285554613466292,0,2,3,0.01505387331614813
6293,Aflatoxin activation and detoxification,Biological oxidations,0.001488567586337585,1,2,3,0.042396133435379756
6294,Hedgehog 'on' state,Signaling by Hedgehog,0.0011299390148474576,0,2,3,0.03218197526736298
6295,Hedgehog 'on' state,Signaling by Hedgehog,0.00045750729916181827,1,2,3,0.013030339153526218
6296,Pyroptosis,Regulated Necrosis,0.0002817447950781635,0,2,3,0.008024418935687226
6297,Pyroptosis,Regulated Necrosis,1.8924701330122263e-05,1,2,3,0.0005389974699036707
6298,GPCR downstream signalling,Signaling by GPCR,0.0004921279284995568,0,2,3,0.014016374879744643
6299,GPCR downstream signalling,Signaling by GPCR,0.0009193488502837208,1,2,3,0.026184122835959847
6300,Complement cascade,Innate Immune System,0.003575191892763874,0,2,3,0.10182561674316233
6301,Complement cascade,Innate Immune System,0.0020948937909188916,1,2,3,0.05966500782894507
6302,Heme signaling,Cellular responses to stress,0.0032672697623103127,0,2,3,0.09305563689795093
6303,Heme signaling,Cellular responses to stress,0.0002392637408534398,1,2,3,0.006814509180888533
6304,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.006926206452580889,0,2,3,0.19726640272147744
6305,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.008487564953103741,1,2,3,0.24173570592019636
6306,p75 NTR receptor-mediated signalling,Death Receptor Signalling,0.00463572791470262,0,2,3,0.1320309141793145
6307,p75 NTR receptor-mediated signalling,Death Receptor Signalling,0.0030322052233469517,1,2,3,0.08636072586315122
6308,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,0.0008973664815979655,0,2,3,0.025558039449098006
6309,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,0.0012939869314503058,1,2,3,0.03685425043036193
6310,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,0.00028843042160163343,0,2,3,0.008214833342657836
6311,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,0.0005286888042577131,1,2,3,0.015057671077098229
6312,DAP12 interactions,Innate Immune System,0.0019647512426903455,0,2,3,0.05595839692933994
6313,DAP12 interactions,Innate Immune System,0.001163228738529733,1,2,3,0.03313010525501984
6314,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00019970046408618634,0,2,3,0.005687701116303318
6315,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0007975800363240565,1,2,3,0.02271600561220413
6316,Diseases associated with visual transduction,Diseases of the neuronal system,0.003041792976412391,0,2,3,0.08663379620408744
6317,Diseases associated with visual transduction,Diseases of the neuronal system,0.003643904895384159,1,2,3,0.10378264284971798
6318,Fatty acid metabolism,Metabolism of lipids,0.0003753498146382294,0,2,3,0.010690398590164192
6319,Fatty acid metabolism,Metabolism of lipids,0.000526301361589254,1,2,3,0.014989673937519002
6320,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0016483372834982634,0,2,3,0.04694655994064842
6321,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0009867159228564432,1,2,3,0.028102815291820113
6322,Nephrin family interactions,Nephrin family interactions,0.0008528432202363519,0,2,3,0.024289965263558692
6323,Nephrin family interactions,Nephrin family interactions,0.003157486798723942,1,2,3,0.08992889061121317
6324,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.004466203544671508,0,2,3,0.1272026632632303
6325,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.0011915472524623542,1,2,3,0.0339366494162648
6326,Molecules associated with elastic fibres,Elastic fibre formation,0.006082600811339778,0,2,3,0.17323953443470141
6327,Molecules associated with elastic fibres,Elastic fibre formation,0.005681436780394294,1,2,3,0.16181391698774025
6328,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.0007612628996035977,0,2,3,0.02168165138568242
6329,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,6.559278773123201e-05,1,2,3,0.0018681587632133152
6330,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.006562563667084483,0,2,3,0.186909433915882
6331,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.003718679835756905,1,2,3,0.10591231998279682
6332,Regulation of insulin secretion,Integration of energy metabolism,0.0001435078683553094,0,2,3,0.004087270737090206
6333,Regulation of insulin secretion,Integration of energy metabolism,0.0006967446783635538,1,2,3,0.01984409752396215
6334,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0012332874708766116,0,2,3,0.03512545930689708
6335,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0025948110415825094,1,2,3,0.07390323164915415
6336,Switching of origins to a post-replicative state,Synthesis of DNA,0.0048599484649033,0,2,3,0.13841697582173593
6337,Switching of origins to a post-replicative state,Synthesis of DNA,0.00109006258442485,1,2,3,0.031046248223028355
6338,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.00013769804959834513,0,2,3,0.003921800352328134
6339,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.000630920135062514,1,2,3,0.017969338092998072
6340,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.0003227330383608002,0,2,3,0.009191811701351263
6341,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.0020398708790804994,1,2,3,0.05809789140526756
6342,Leishmania infection,Infectious disease,0.0031080647111658495,0,2,3,0.08852129216691068
6343,Leishmania infection,Infectious disease,0.0022122202283610605,1,2,3,0.06300660101084031
6344,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.00012001398481397632,0,2,3,0.003418137651917854
6345,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.00027822345279257093,1,2,3,0.00792412701828834
6346,Degradation of beta-catenin by the destruction complex,Signaling by WNT,1.3577298029184618e-05,0,2,3,0.000386697214302157
6347,Degradation of beta-catenin by the destruction complex,Signaling by WNT,0.00014188619920118035,1,2,3,0.004041083716441953
6348,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,0.00010190695461154706,0,2,3,0.0029024284052390496
6349,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,0.001505510201370391,1,2,3,0.04287867878586827
6350,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,0.0009909857944691751,0,2,3,0.028224426193674237
6351,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,0.0008417571002540951,1,2,3,0.023974219692875682
6352,Generic Transcription Pathway,RNA Polymerase II Transcription,0.00018038217695108782,0,2,3,0.00513749386562839
6353,Generic Transcription Pathway,RNA Polymerase II Transcription,0.003719570490825321,1,2,3,0.10593768687340496
6354,Formation of the cornified envelope,Keratinization,0.0013350496982671332,0,2,3,0.03802376571281904
6355,Formation of the cornified envelope,Keratinization,0.0012022907275916757,1,2,3,0.03424263606364508
6356,Intracellular oxygen transport,Intracellular oxygen transport,0.002190198192342189,0,2,3,0.06237938785226823
6357,Intracellular oxygen transport,Intracellular oxygen transport,0.002384988288513295,1,2,3,0.06792723598825995
6358,Neutrophil degranulation,Innate Immune System,0.006796944296243955,0,2,3,0.1935848664052871
6359,Neutrophil degranulation,Innate Immune System,0.003992370775514306,1,2,3,0.11370735576653163
6360,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,0.0004883543477235019,0,2,3,0.013908898917229275
6361,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,0.0017516215149842695,1,2,3,0.049888214790613894
6362,Sphingolipid metabolism,Metabolism of lipids,0.00078106980973519,0,2,3,0.02224577518670352
6363,Sphingolipid metabolism,Metabolism of lipids,0.0011057246578053623,1,2,3,0.03149232226025001
6364,"Base-Excision Repair, AP Site Formation",Base Excision Repair,0.003795893444937623,0,2,3,0.10811145323539378
6365,"Base-Excision Repair, AP Site Formation",Base Excision Repair,0.003911870815574019,1,2,3,0.11141462342807729
6366,HATs acetylate histones,Chromatin modifying enzymes,3.9346716948476504e-05,0,2,3,0.001120640189469648
6367,HATs acetylate histones,Chromatin modifying enzymes,0.0003114356110088096,1,2,3,0.008870047851400765
6368,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,0.0014166041835197035,0,2,3,0.04034653215671872
6369,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,0.0019180264319813229,1,2,3,0.0546276200618707
6370,Urea cycle,Metabolism of amino acids and derivatives,2.4986728055951225e-05,0,2,3,0.0007116510304916799
6371,Urea cycle,Metabolism of amino acids and derivatives,5.7982870349197526e-05,1,2,3,0.0016514194792720742
6372,ESR-mediated signaling,Signaling by Nuclear Receptors,0.005049564013923022,0,2,3,0.14381744684599201
6373,ESR-mediated signaling,Signaling by Nuclear Receptors,0.0013705802083294365,1,2,3,0.03903571589865823
6374,Mitochondrial protein import,Mitochondrial protein import,0.001007172966914885,0,2,3,0.02868545566203603
6375,Mitochondrial protein import,Mitochondrial protein import,0.0011329042487706856,1,2,3,0.03226642857282933
6376,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00035226530518844016,0,2,3,0.01003292495449845
6377,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0014069383762431741,1,2,3,0.04007123874121137
6378,Cellular response to chemical stress,Cellular responses to stress,0.001146577895409385,0,2,3,0.032655869907413836
6379,Cellular response to chemical stress,Cellular responses to stress,9.332686569601363e-05,1,2,3,0.0026580575094268103
6380,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.0005091650894654532,0,2,3,0.014501613008197599
6381,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.001945967502251733,1,2,3,0.05542341418931517
6382,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,0.0015633965867245334,0,2,3,0.04452735026043944
6383,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,0.00038201517592713726,1,2,3,0.010880235819721779
6384,Toll-like Receptor Cascades,Innate Immune System,0.003482969612959636,0,2,3,0.09919901912261685
6385,Toll-like Receptor Cascades,Innate Immune System,0.0020546850810852137,1,2,3,0.058519817081128744
6386,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,6.880397140914542e-05,0,2,3,0.0019596170032985293
6387,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,3.049068652681768e-05,1,2,3,0.0008684101591300778
6388,Meiotic recombination,Meiosis,0.0005644579735781931,0,2,3,0.016076418555749726
6389,Meiotic recombination,Meiosis,0.0014673413269737084,1,2,3,0.04179158492002547
6390,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.0006385117313182832,0,2,3,0.01818555556998815
6391,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.0008672252462541659,1,2,3,0.02469958206545516
6392,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.000184498743288566,0,2,3,0.005254738455219862
6393,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,8.432314733606757e-05,1,2,3,0.002401621155104446
6394,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0008133732375366899,0,2,3,0.0231658143223548
6395,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.001920763806738989,1,2,3,0.054705583673703866
6396,Late endosomal microautophagy,Late endosomal microautophagy,0.008367491231220455,0,2,3,0.2383158668871758
6397,Late endosomal microautophagy,Late endosomal microautophagy,0.004577293995292715,1,2,3,0.13036664829901962
6398,Antimicrobial peptides,Innate Immune System,0.0028887106599711676,0,2,3,0.08227383406732809
6399,Antimicrobial peptides,Innate Immune System,0.0016970948789603103,1,2,3,0.048335232878424186
6400,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",0.0005889458876841618,0,2,3,0.016773862785705786
6401,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",0.0015378354364287505,1,2,3,0.043799339017518264
6402,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,9.083748218333963e-05,0,2,3,0.0025871569762270863
6403,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,0.0001254059221020245,1,2,3,0.003571706287186691
6404,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.0017422548034890237,0,2,3,0.04962143997027793
6405,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.003293198994880892,1,2,3,0.09379413155148825
6406,Retinoid metabolism and transport,Visual phototransduction,0.0008420005437314066,0,2,3,0.023981153245804552
6407,Retinoid metabolism and transport,Visual phototransduction,0.0023563391438757453,1,2,3,0.06711127508059875
6408,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,0.00038918889957795694,0,2,3,0.011084551799674682
6409,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,0.00039416041157532217,1,2,3,0.01122614623445239
6410,Cellular Senescence,Cellular responses to stress,0.0008963173564681831,0,2,3,0.02552815914712119
6411,Cellular Senescence,Cellular responses to stress,6.83132737080788e-05,1,2,3,0.0019456413629569047
6412,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0015498668319778148,0,2,3,0.04414200713403083
6413,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0010565478891996075,1,2,3,0.030091710784583
6414,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.0018404183092940085,0,2,3,0.052417250606483064
6415,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.0013664029529951997,1,2,3,0.0389167428159649
6416,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.0035117612089176553,0,2,3,0.10001903720930447
6417,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.0007137533250016038,1,2,3,0.020328523531246208
6418,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.002289871259568852,0,2,3,0.06521819255071801
6419,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.0011328701353603104,1,2,3,0.03226545698328817
6420,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,0.0016228741364573368,0,2,3,0.04622133994423033
6421,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,0.0028951659036359385,1,2,3,0.08245768690295435
6422,Surfactant metabolism,Surfactant metabolism,0.0025405153427698513,0,2,3,0.07235682709691461
6423,Surfactant metabolism,Surfactant metabolism,0.0026733688956958614,1,2,3,0.07614065055841653
6424,Signaling by MET,Signaling by Receptor Tyrosine Kinases,0.00015603781483942438,0,2,3,0.004444138163167716
6425,Signaling by MET,Signaling by Receptor Tyrosine Kinases,6.654579513392168e-05,1,2,3,0.0018953015207072792
6426,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0030628018184824433,0,2,3,0.08723215242244108
6427,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0018000497514025354,1,2,3,0.0512675072003596
6428,Nucleotide catabolism,Metabolism of nucleotides,0.0006191944020184532,0,2,3,0.01763537559957394
6429,Nucleotide catabolism,Metabolism of nucleotides,7.395514041559066e-05,1,2,3,0.0021063282783188074
6430,DNA methylation,Epigenetic regulation of gene expression,0.0002498576234533,0,2,3,0.0071162352593177065
6431,DNA methylation,Epigenetic regulation of gene expression,0.0042353521566376355,1,2,3,0.1206277476593599
6432,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0006243683608098657,0,2,3,0.017782735954134377
6433,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0008729872734150418,1,2,3,0.024863691290063366
6434,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.0031006733602064137,0,2,3,0.08831077790849198
6435,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.002100517671333087,1,2,3,0.059825182473787
6436,Clathrin-mediated endocytosis,Membrane Trafficking,0.0007534976636223495,0,2,3,0.021460488447674203
6437,Clathrin-mediated endocytosis,Membrane Trafficking,0.0013914113660529654,1,2,3,0.03962901146048963
6438,Eukaryotic Translation Elongation,Translation,0.0004951921364685922,0,2,3,0.014103647080967702
6439,Eukaryotic Translation Elongation,Translation,0.0034955417563628196,1,2,3,0.09955708836594998
6440,Deubiquitination,Post-translational protein modification,0.0007189327116597047,0,2,3,0.02047603847775296
6441,Deubiquitination,Post-translational protein modification,0.0009896950595372851,1,2,3,0.028187664563967686
6442,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.00018937190337172226,0,2,3,0.005393531713271233
6443,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",0.00013805413854252175,1,2,3,0.003931942178961157
6444,Heme degradation,Metabolism of porphyrins,0.0008533356260810012,0,2,3,0.024303989553813105
6445,Heme degradation,Metabolism of porphyrins,0.0001666132404720722,1,2,3,0.004745338565737809
6446,Threonine catabolism,Metabolism of amino acids and derivatives,4.2960310461919235e-06,0,2,3,0.00012235595289630428
6447,Threonine catabolism,Metabolism of amino acids and derivatives,7.0033645379771424e-06,1,2,3,0.00019946395459221667
6448,GPCR ligand binding,Signaling by GPCR,0.0010217614772159611,0,2,3,0.02910095337609654
6449,GPCR ligand binding,Signaling by GPCR,0.0018749923677431736,1,2,3,0.05340195993971517
6450,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,2.047805867782884e-05,0,2,3,0.0005832388909789651
6451,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,4.958305960445163e-05,1,2,3,0.00141218311510915
6452,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,0.00017569687603826293,0,2,3,0.0050040510548966625
6453,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,0.0034990336487145364,1,2,3,0.0996565415150338
6454,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,0.0005166630869610755,0,2,3,0.014715164683808556
6455,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,0.0018366260364235658,1,2,3,0.05230924227141362
6456,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0005297140164403401,0,2,3,0.015086870310571512
6457,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0017036254531344155,1,2,3,0.04852123121443271
6458,Apoptotic execution phase,Apoptosis,0.0002093465328456207,0,2,3,0.005962432355922749
6459,Apoptotic execution phase,Apoptosis,0.0010145358003770932,1,2,3,0.028895157709018172
6460,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006458698181655001,0,2,3,0.18395122427863403
6461,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007326922336016124,1,2,3,0.2086792564069422
6462,Uptake and actions of bacterial toxins,Infectious disease,0.0005891447501088053,0,2,3,0.0167795266184856
6463,Uptake and actions of bacterial toxins,Infectious disease,0.00043385516600842887,1,2,3,0.012356698935637544
6464,Triglyceride metabolism,Metabolism of lipids,0.00041584333386136276,0,2,3,0.011843701040122778
6465,Triglyceride metabolism,Metabolism of lipids,0.0005763767394686335,1,2,3,0.016415878848795213
6466,TCF dependent signaling in response to WNT,Signaling by WNT,7.03763703983023e-05,0,2,3,0.002004400752434145
6467,TCF dependent signaling in response to WNT,Signaling by WNT,0.0005565616654817619,1,2,3,0.015851522531695604
6468,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.0019089012556126681,0,2,3,0.054367724442419045
6469,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.004506345303322314,1,2,3,0.12834594716361236
6470,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.004196356814424093,0,2,3,0.11951711503036976
6471,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.00427288405297603,1,2,3,0.12169669965042156
6472,SARS-CoV Infections,Infectious disease,0.001015500925762718,0,2,3,0.02892264560073795
6473,SARS-CoV Infections,Infectious disease,0.0007375102846930217,1,2,3,0.021005149330666155
6474,Ketone body metabolism,Metabolism of lipids,2.2772765302027342e-05,0,2,3,0.0006485948003293291
6475,Ketone body metabolism,Metabolism of lipids,2.9905299992246057e-05,1,2,3,0.0008517376708542619
6476,HCMV Infection,Infectious disease,0.0002951899510238031,0,2,3,0.008407352590002035
6477,HCMV Infection,Infectious disease,0.00021220012035075048,1,2,3,0.006043705841753964
6478,Regulation of Apoptosis,Apoptosis,0.00010997389124019539,0,2,3,0.003132184128030507
6479,Regulation of Apoptosis,Apoptosis,0.0005338211045399554,1,2,3,0.015203844948942188
6480,Cellular response to hypoxia,Cellular responses to stress,0.00023328472710132413,0,2,3,0.006644219926189433
6481,Cellular response to hypoxia,Cellular responses to stress,1.905281992635969e-05,1,2,3,0.0005426464363002853
6482,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,3.494660683361821e-05,0,2,3,0.000995319943837489
6483,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,1.5310645787509952e-05,1,2,3,0.0004360649712830022
6484,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.0009928926083450722,0,2,3,0.028278734467118417
6485,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.0013730431741267811,1,2,3,0.039105864024648204
6486,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,1.744517724370733e-05,0,2,3,0.000496858905847715
6487,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,2.9271868070535845e-05,1,2,3,0.0008336967941607633
6488,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,1.404272993524514e-05,0,2,3,0.0003999532554624876
6489,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,2.297278193095637e-05,1,2,3,0.0006542915061874983
6490,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",0.0015044576564943624,0,2,3,0.04284870108554724
6491,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",0.003887715179480253,1,2,3,0.11072664286176155
6492,Protein methylation,Post-translational protein modification,0.0003587480323172888,0,2,3,0.01021756055109641
6493,Protein methylation,Post-translational protein modification,0.0004991855516499098,1,2,3,0.01421738418262431
6494,Neurotransmitter clearance,Transmission across Chemical Synapses,0.0006612062471656384,0,2,3,0.018831921734982427
6495,Neurotransmitter clearance,Transmission across Chemical Synapses,0.00017003069103158877,1,2,3,0.004842671526135363
6496,Type I hemidesmosome assembly,Cell junction organization,0.0010512537925107036,0,2,3,0.029940928763193694
6497,Type I hemidesmosome assembly,Cell junction organization,0.0022550272751779197,1,2,3,0.06422579541321696
6498,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.004171542241238058,0,2,3,0.11881036717048549
6499,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.005353573114390492,1,2,3,0.1524759790532529
6500,Atorvastatin ADME,Atorvastatin ADME,0.0038018919678996163,0,2,3,0.10828229813504497
6501,Atorvastatin ADME,Atorvastatin ADME,0.0026296211826775107,1,2,3,0.07489466489028705
6502,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,0.0010883394136583446,0,2,3,0.030997170318592417
6503,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,0.0031146847661868266,1,2,3,0.08870983902134638
6504,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,0.0003815942831130401,0,2,3,0.010868248303620908
6505,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,0.00014623093283796664,1,2,3,0.004164826775673527
6506,RMTs methylate histone arginines,Chromatin modifying enzymes,9.086064463585287e-05,0,2,3,0.002587816669771709
6507,RMTs methylate histone arginines,Chromatin modifying enzymes,0.0010263788180548679,1,2,3,0.029232460605005478
6508,Metabolism of steroids,Metabolism of lipids,0.0007310017705062335,0,2,3,0.02081977928871325
6509,Metabolism of steroids,Metabolism of lipids,0.0010262173484430412,1,2,3,0.029227861762956518
6510,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,3.905223207392657e-05,0,2,3,0.0011122529182763811
6511,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,7.954917129821753e-05,1,2,3,0.0022656527738393615
6512,Signaling by Hippo,Signaling by Hippo,0.0033554937566398894,0,2,3,0.0955683587052298
6513,Signaling by Hippo,Signaling by Hippo,0.001446307429968176,1,2,3,0.04119251510801471
6514,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,0.0028259564926233238,0,2,3,0.08048652250893845
6515,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,0.0028265275942814076,1,2,3,0.0805027881473438
6516,Striated Muscle Contraction,Striated Muscle Contraction,0.0008366884643609073,0,2,3,0.0238298590567613
6517,Striated Muscle Contraction,Striated Muscle Contraction,0.00034082047966017706,1,2,3,0.009706963033323818
6518,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,0.0002520788824240345,0,2,3,0.007179499294207445
6519,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,0.00010331658632669864,1,2,3,0.0029425763533999713
6520,Hedgehog 'off' state,Signaling by Hedgehog,0.0001900721054432883,0,2,3,0.005413474281368447
6521,Hedgehog 'off' state,Signaling by Hedgehog,7.695901068163856e-05,1,2,3,0.002191881991694543
6522,Interferon Signaling,Cytokine Signaling in Immune system,1.4454350021529424e-05,0,2,3,0.0004116766735074331
6523,Interferon Signaling,Cytokine Signaling in Immune system,1.703631983573026e-06,1,2,3,4.8521417208907706e-05
6524,Aspirin ADME,Aspirin ADME,0.003225959879024129,0,2,3,0.09187908345148631
6525,Aspirin ADME,Aspirin ADME,0.003194501107767801,1,2,3,0.09098310111508609
6526,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.0006729192778375005,0,2,3,0.019165522450095902
6527,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.001242688794644693,1,2,3,0.03539321992495638
6528,Phase I - Functionalization of compounds,Biological oxidations,0.0002159851248169549,0,2,3,0.0061515071642303755
6529,Phase I - Functionalization of compounds,Biological oxidations,0.0005887072057562273,1,2,3,0.016767064847232453
6530,Signaling by Interleukins,Cytokine Signaling in Immune system,0.0034218763073394845,0,2,3,0.09745901083488233
6531,Signaling by Interleukins,Cytokine Signaling in Immune system,0.00042764771063181985,1,2,3,0.01217990339819851
6532,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.0038280602743656217,0,2,3,0.10902760189074497
6533,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.0031494034431900015,1,2,3,0.0896986672589328
6534,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.0003120727748107595,0,2,3,0.008888195016377078
6535,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,0.00018351761538463687,1,2,3,0.005226794793196094
6536,Platelet sensitization by LDL,Platelet homeostasis,0.004587516280475869,0,2,3,0.13065779085150916
6537,Platelet sensitization by LDL,Platelet homeostasis,0.003951196809978724,1,2,3,0.11253467341543659
6538,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,0.005860867149546402,0,2,3,0.16692430226198135
6539,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,0.0015221862209718754,1,2,3,0.043353631188892856
6540,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,2.4445935833234775e-05,0,2,3,0.0006962486400019663
6541,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,9.450664690818028e-05,1,2,3,0.002691659048352318
6542,Glucose metabolism,Metabolism of carbohydrates,0.0006853981964189092,0,2,3,0.01952093654224896
6543,Glucose metabolism,Metabolism of carbohydrates,0.00043507211519100024,1,2,3,0.012391359061520921
6544,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.005523598763995998,0,2,3,0.15731850699371916
6545,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.004279057516477533,1,2,3,0.12187252705978502
6546,MAPK6/MAPK4 signaling,MAPK family signaling cascades,0.0028016587449076675,0,2,3,0.07979449443860631
6547,MAPK6/MAPK4 signaling,MAPK family signaling cascades,0.0005771416904858159,1,2,3,0.016437665542052306
6548,Heme biosynthesis,Metabolism of porphyrins,0.0014663064584503796,0,2,3,0.04176211066275573
6549,Heme biosynthesis,Metabolism of porphyrins,0.00025884888240280414,1,2,3,0.007372316755162385
6550,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,6.008337328553514e-05,0,2,3,0.0017112442420760792
6551,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,0.00022709758797581284,1,2,3,0.0064680030191735976
6552,Fructose metabolism,Metabolism of carbohydrates,0.000161287599563749,0,2,3,0.004593658128349202
6553,Fructose metabolism,Metabolism of carbohydrates,0.00010893711467892923,1,2,3,0.0031026555276246225
6554,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.00037679654658323824,0,2,3,0.010731603195953527
6555,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.0018212563144179004,1,2,3,0.05187149474083619
6556,Meiotic synapsis,Meiosis,0.001419574337190627,0,2,3,0.04043112558231243
6557,Meiotic synapsis,Meiosis,0.0036977250227967023,1,2,3,0.10531550257623218
6558,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0027786516390922882,0,2,3,0.07913922534833236
6559,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0013890654277966504,1,2,3,0.03956219641476464
6560,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.001561713867632363,0,2,3,0.04447942446666246
6561,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.0010581591441177114,1,2,3,0.030137601195695883
6562,PIP3 activates AKT signaling,Intracellular signaling by second messengers,0.0057722908516501924,0,2,3,0.16440154644001764
6563,PIP3 activates AKT signaling,Intracellular signaling by second messengers,0.0022492898706563034,1,2,3,0.06406238746996754
6564,Hedgehog ligand biogenesis,Signaling by Hedgehog,0.000821070941359546,0,2,3,0.02338505386607131
6565,Hedgehog ligand biogenesis,Signaling by Hedgehog,0.00033343528475932564,1,2,3,0.009496624106602238
6566,Defective pyroptosis,Diseases of programmed cell death,0.0008526419027623376,0,2,3,0.024284231508121906
6567,Defective pyroptosis,Diseases of programmed cell death,0.0030505358797943026,1,2,3,0.08688280424496796
6568,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,0.0004921820394523875,0,2,3,0.014017916022516782
6569,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,0.0009145084183502394,1,2,3,0.026046261713616285
6570,HIV Infection,Infectious disease,0.00035651554739170164,0,2,3,0.010153976787976497
6571,HIV Infection,Infectious disease,0.0002557110551433329,1,2,3,0.00728294779105843
6572,Collagen degradation,Degradation of the extracellular matrix,0.0005095287572976535,0,2,3,0.014511970690362407
6573,Collagen degradation,Degradation of the extracellular matrix,0.0004146873284575639,1,2,3,0.011810776663828881
6574,Abacavir metabolism,Abacavir ADME,0.0031387059385580987,0,2,3,0.08939398990470154
6575,Abacavir metabolism,Abacavir ADME,0.0003676387259382388,1,2,3,0.010470777829603905
6576,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,0.00010622444327774469,0,2,3,0.0030253954960704514
6577,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,4.619771082401098e-05,1,2,3,0.0013157644506573817
6578,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,0.0016130860577934147,0,2,3,0.04594256409762425
6579,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,0.0011435942497723657,1,2,3,0.032570892214958375
6580,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0019530713247159067,0,2,3,0.0556257393023007
6581,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.004721018524671613,1,2,3,0.13446008979365595
6582,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,0.0008309270732253732,0,2,3,0.023665767946893398
6583,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,7.438493911506162e-05,1,2,3,0.0021185694443769474
6584,PKMTs methylate histone lysines,Chromatin modifying enzymes,0.00020432392456594585,0,2,3,0.005819382639690081
6585,PKMTs methylate histone lysines,Chromatin modifying enzymes,0.002316518421379405,1,2,3,0.0659771346626942
6586,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,0,2,3,0.0
6587,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,1,2,3,0.0
6588,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,0.00029908066204684634,0,2,3,0.008518164557967348
6589,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,0.0008664368664364798,1,2,3,0.024677128092753377
6590,Neddylation,Post-translational protein modification,0.000345064607104339,0,2,3,0.009827840711362038
6591,Neddylation,Post-translational protein modification,0.00047190670212448314,1,2,3,0.013440450870990753
6592,Protein ubiquitination,Post-translational protein modification,0.0006144357127785153,0,2,3,0.017499842604064956
6593,Protein ubiquitination,Post-translational protein modification,0.0008546012943624732,1,2,3,0.02434003725620748
6594,Glycogen metabolism,Metabolism of carbohydrates,0.0003232309242734404,0,2,3,0.009205992070305705
6595,Glycogen metabolism,Metabolism of carbohydrates,0.00020191427989482293,1,2,3,0.0057507531612932495
6596,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,1.3664833914729803e-05,0,2,3,0.00038919033797220055
6597,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,2.8836695853898408e-05,1,2,3,0.0008213025840938066
6598,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.001962866289335035,0,2,3,0.05590471126890727
6599,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.001167483588184678,1,2,3,0.033251288314072175
6600,Gap junction trafficking and regulation,Membrane Trafficking,0.0003217510889563588,0,2,3,0.009163844642038949
6601,Gap junction trafficking and regulation,Membrane Trafficking,0.0005927507450365821,1,2,3,0.01688222954143549
6602,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",0.0007648608342941456,0,2,3,0.021784124743716198
6603,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",0.0019987893567377994,1,2,3,0.05692784194365403
6604,M Phase,"Cell Cycle, Mitotic",0.0007949512345543193,0,2,3,0.02264113428514591
6605,M Phase,"Cell Cycle, Mitotic",0.002032051038246938,1,2,3,0.05787517325765642
6606,Advanced glycosylation endproduct receptor signaling,Innate Immune System,5.6911714067942265e-05,0,2,3,0.0016209117045179729
6607,Advanced glycosylation endproduct receptor signaling,Innate Immune System,3.307302943208586e-05,1,2,3,0.0009419582837785661
6608,Intrinsic Pathway for Apoptosis,Apoptosis,0.00011738529665677644,0,2,3,0.0033432695606766313
6609,Intrinsic Pathway for Apoptosis,Apoptosis,0.0005716099300383954,1,2,3,0.01628011458083703
6610,RIPK1-mediated regulated necrosis,Regulated Necrosis,0.0035811665935942968,0,2,3,0.1019957831608433
6611,RIPK1-mediated regulated necrosis,Regulated Necrosis,0.0005028483067362317,1,2,3,0.014321703700801432
6612,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,1.513901465201778e-05,0,2,3,0.0004311767172401377
6613,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,1.973678609659845e-05,1,2,3,0.000562126587074005
6614,G2/M Checkpoints,Cell Cycle Checkpoints,0.0018735815445481956,0,2,3,0.05336177805682521
6615,G2/M Checkpoints,Cell Cycle Checkpoints,0.005560534057100446,1,2,3,0.1583704670318816
6616,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.005943288531815952,0,3,4,0.2815220021016208
6617,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.0051797283776792895,1,3,4,0.24535364477438615
6618,Integrin signaling,Signal Transduction,0.0017456763620107545,0,3,4,0.08268928924178978
6619,Integrin signaling,Signal Transduction,0.0012672684706373687,1,3,4,0.060028039215030846
6620,Fibronectin matrix formation,Extracellular matrix organization,0.00028181352257343874,0,3,4,0.013348957680495401
6621,Fibronectin matrix formation,Extracellular matrix organization,0.00016228611043100634,1,3,4,0.00768717696898725
6622,Inositol phosphate metabolism,Metabolism,0.0007510182626878867,0,3,4,0.035574272356952805
6623,Inositol phosphate metabolism,Metabolism,0.0010411831635746456,1,3,4,0.04931881856230072
6624,Integrin cell surface interactions,Extracellular matrix organization,0.005687401676003887,0,3,4,0.2694011401286467
6625,Integrin cell surface interactions,Extracellular matrix organization,0.003218669187078704,1,3,4,0.1524620904400765
6626,Keratinization,Developmental Biology,0.0014793833121573901,0,3,4,0.07007550612506133
6627,Keratinization,Developmental Biology,0.001083554813135956,1,3,4,0.05132588107541812
6628,Biological oxidations,Metabolism,0.0003687661531371928,0,3,4,0.017467734434016256
6629,Biological oxidations,Metabolism,0.0004983531376811977,1,3,4,0.023606017497314415
6630,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,0.0030488997070251154,0,3,4,0.14442044082730995
6631,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,0.007506865161816178,1,3,4,0.3555855817108835
6632,Diseases of metabolism,Disease,0.000401784402403819,0,3,4,0.019031744592646536
6633,Diseases of metabolism,Disease,0.0008264462649025388,1,3,4,0.03914714991191583
6634,Apoptosis,Programmed Cell Death,0.0002464615596334181,0,3,4,0.0116744040504942
6635,Apoptosis,Programmed Cell Death,3.3156582721142694e-05,1,3,4,0.00157056274494081
6636,Smooth Muscle Contraction,Muscle contraction,0.0009990561381440378,0,3,4,0.047323343417804094
6637,Smooth Muscle Contraction,Muscle contraction,0.0026587721881212024,1,3,4,0.12594086010212358
6638,Macroautophagy,Autophagy,0.0016297296970151365,0,3,4,0.07719712154846078
6639,Macroautophagy,Autophagy,0.0009280072822386806,1,3,4,0.04395789749431731
6640,MTOR signalling,Signal Transduction,0.0008282497884802577,0,3,4,0.03923257931109759
6641,MTOR signalling,Signal Transduction,0.0005743139597609743,1,3,4,0.02720413369152343
6642,Elastic fibre formation,Extracellular matrix organization,0.0034771854039293425,0,3,4,0.1647075001242823
6643,Elastic fibre formation,Extracellular matrix organization,0.0019782976915585695,1,3,4,0.09370810854952953
6644,Transmission across Chemical Synapses,Neuronal System,0.003519673978768641,0,3,4,0.16672010116008446
6645,Transmission across Chemical Synapses,Neuronal System,0.00033147256513557134,1,3,4,0.015701209806519914
6646,Fertilization,Reproduction,0.004998973668296984,0,3,4,0.23679164624407834
6647,Fertilization,Reproduction,0.0028051381461298816,1,3,4,0.13287393045829807
6648,Diseases of hemostasis,Disease,0.002026096103400235,0,3,4,0.09597222622224698
6649,Diseases of hemostasis,Disease,0.003832269052666187,1,3,4,0.18152712097405477
6650,Meiosis,Cell Cycle,0.0012945013707020582,0,3,4,0.06131800864999992
6651,Meiosis,Cell Cycle,0.003971152636871653,1,3,4,0.18810576585647398
6652,Meiosis,Reproduction,0.0012945013707020582,0,3,4,0.06131800864999992
6653,Meiosis,Reproduction,0.003971152636871653,1,3,4,0.18810576585647398
6654,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0016494417346242477,0,3,4,0.07813084237717577
6655,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0011948509186160276,1,3,4,0.056597760822318016
6656,Signaling by NOTCH,Signal Transduction,0.00013538363528411062,0,3,4,0.006412859118810611
6657,Signaling by NOTCH,Signal Transduction,9.77617233625235e-05,1,3,4,0.00463078242669688
6658,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,0.0012023877635899715,0,3,4,0.056954766489338185
6659,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,0.004318299317138705,1,3,4,0.20454942796854225
6660,Signaling by TGFB family members,Signal Transduction,0.001524935134054851,0,3,4,0.07223320720777006
6661,Signaling by TGFB family members,Signal Transduction,0.0011041588827376777,1,3,4,0.052301855722226245
6662,Signaling by WNT,Signal Transduction,0.0004290095169260913,0,3,4,0.020321345241635074
6663,Signaling by WNT,Signal Transduction,0.0003046089634862426,1,3,4,0.014428733318209715
6664,Response to metal ions,Cellular responses to stimuli,0.001375630890317072,0,3,4,0.06516095597946145
6665,Response to metal ions,Cellular responses to stimuli,0.0009608919452166724,1,3,4,0.045515579930638914
6666,Cell Cycle Checkpoints,Cell Cycle,0.0012576459788989512,0,3,4,0.05957224052295929
6667,Cell Cycle Checkpoints,Cell Cycle,0.004165936067349164,1,3,4,0.19733227758154007
6668,Post-translational protein modification,Metabolism of proteins,0.0021484765304960675,0,3,4,0.10176914869532491
6669,Post-translational protein modification,Metabolism of proteins,0.001900959292590396,1,3,4,0.0900447392212022
6670,Metabolism of vitamins and cofactors,Metabolism,4.613919478004802e-05,0,3,4,0.002185523792139865
6671,Metabolism of vitamins and cofactors,Metabolism,5.479277701191201e-05,1,3,4,0.0025954271280159372
6672,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,0.0004528474030474929,0,3,4,0.021450499478526366
6673,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,0.0003438330970801027,1,3,4,0.01628670413031682
6674,Amyloid fiber formation,Metabolism of proteins,0.005005769096763099,0,3,4,0.237113532455168
6675,Amyloid fiber formation,Metabolism of proteins,0.004386035735511116,1,3,4,0.20775797017767636
6676,Atorvastatin ADME,Drug ADME,0.003342770424460653,0,3,4,0.15834052434481236
6677,Atorvastatin ADME,Drug ADME,0.002910585212973232,1,3,4,0.13786875263705795
6678,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.0020875570195398193,0,3,4,0.09888351011331005
6679,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.001506449662652988,1,3,4,0.07135758643132853
6680,Regulated Necrosis,Programmed Cell Death,0.0031209523466931,0,3,4,0.14783343403257843
6681,Regulated Necrosis,Programmed Cell Death,0.0002782027307527531,1,3,4,0.01317792150463251
6682,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,0.0007373349576228804,0,3,4,0.0349261208467836
6683,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,0.002322649380527815,1,3,4,0.1100193773675817
6684,Chaperone Mediated Autophagy,Autophagy,0.008982679215007222,0,3,4,0.42549201899049915
6685,Chaperone Mediated Autophagy,Autophagy,0.004482450120041435,1,3,4,0.21232493178808257
6686,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0011339214388545553,0,3,4,0.05371165003741577
6687,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.002283017595906814,1,3,4,0.10814209692029449
6688,Reversible hydration of carbon dioxide,Metabolism,0.00046993455654799083,0,3,4,0.02225988465946223
6689,Reversible hydration of carbon dioxide,Metabolism,0.0006190869913035815,1,3,4,0.029324944991960582
6690,Paracetamol ADME,Drug ADME,0.001799341361215669,0,3,4,0.08523129573164352
6691,Paracetamol ADME,Drug ADME,0.0015476388516386754,1,3,4,0.07330863809003871
6692,Intracellular oxygen transport,Transport of small molecules,0.0013550029137422363,0,3,4,0.06418384890590015
6693,Intracellular oxygen transport,Transport of small molecules,0.0021640282392568016,1,3,4,0.10250580284949996
6694,Infectious disease,Disease,0.002183452821931228,0,3,4,0.10342590749783043
6695,Infectious disease,Disease,0.0040371541074491315,1,3,4,0.19123212696769293
6696,Nucleotide Excision Repair,DNA Repair,6.536125552294978e-05,0,3,4,0.003096035371022815
6697,Nucleotide Excision Repair,DNA Repair,5.9303428701977866e-05,1,3,4,0.0028090879132483177
6698,Disorders of transmembrane transporters,Disease,0.0001540460762035293,0,3,4,0.00729686259661798
6699,Disorders of transmembrane transporters,Disease,0.0003074012053665623,1,3,4,0.014560996377674442
6700,Signaling by Hippo,Signal Transduction,0.0015885358750772885,0,3,4,0.07524585043583028
6701,Signaling by Hippo,Signal Transduction,0.0011290352186424477,1,3,4,0.053480199302783235
6702,Platelet homeostasis,Hemostasis,0.004900769421547565,0,3,4,0.2321399023464401
6703,Platelet homeostasis,Hemostasis,0.0008069999978846137,1,3,4,0.0382260181184681
6704,Diseases of the neuronal system,Disease,0.0002828024150450324,0,3,4,0.013395799590824327
6705,Diseases of the neuronal system,Disease,0.000568216347720128,1,3,4,0.026915301685372543
6706,ABC-family proteins mediated transport,Transport of small molecules,0.0011872687593800061,0,3,4,0.05623860870696113
6707,ABC-family proteins mediated transport,Transport of small molecules,0.0019400756115694813,1,3,4,0.09189760306499627
6708,Cell junction organization,Cell-Cell communication,0.0021709228970989737,0,3,4,0.10283238936286597
6709,Cell junction organization,Cell-Cell communication,0.006637351314954136,1,3,4,0.3143984043236046
6710,Cytokine Signaling in Immune system,Immune System,0.0020465343119295877,0,3,4,0.09694034435310202
6711,Cytokine Signaling in Immune system,Immune System,0.001373786419378864,1,3,4,0.06507358698356584
6712,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,1.9859996646557405e-05,0,3,4,0.0009407293601412948
6713,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,2.5067574985057473e-05,1,3,4,0.0011874022033168262
6714,Gene Silencing by RNA,Gene expression (Transcription),0.00022581796789557205,0,3,4,0.010696557317074515
6715,Gene Silencing by RNA,Gene expression (Transcription),0.0006789401387706056,1,3,4,0.03216007201243047
6716,Cilium Assembly,Organelle biogenesis and maintenance,0.0012043721698443784,0,3,4,0.05704876394861228
6717,Cilium Assembly,Organelle biogenesis and maintenance,0.0008627453177914239,1,3,4,0.040866565348162395
6718,Chromosome Maintenance,Cell Cycle,0.0011883447380149,0,3,4,0.056289575719229226
6719,Chromosome Maintenance,Cell Cycle,0.0035892705274107608,1,3,4,0.17001675411714795
6720,Peptide hormone metabolism,Metabolism of proteins,0.0015045403896194126,0,3,4,0.07126714788638941
6721,Peptide hormone metabolism,Metabolism of proteins,0.0013460375710566284,1,3,4,0.06375917808454121
6722,Membrane Trafficking,Vesicle-mediated transport,0.00239905200590047,0,3,4,0.11363842092328097
6723,Membrane Trafficking,Vesicle-mediated transport,0.006593281228851808,1,3,4,0.31231089017955754
6724,Collagen formation,Extracellular matrix organization,0.004651816204208961,0,3,4,0.22034747332341417
6725,Collagen formation,Extracellular matrix organization,0.0026683250120841705,1,3,4,0.1263933587673629
6726,"Platelet activation, signaling and aggregation",Hemostasis,0.000716733836418313,0,3,4,0.03395028585980613
6727,"Platelet activation, signaling and aggregation",Hemostasis,0.00012316956144151872,1,3,4,0.0058343022300484096
6728,Chromatin modifying enzymes,Chromatin organization,0.0016222958421088793,0,3,4,0.0768449943203548
6729,Chromatin modifying enzymes,Chromatin organization,0.005683648715571023,1,3,4,0.2692233697025245
6730,Epigenetic regulation of gene expression,Gene expression (Transcription),0.001501360153630175,0,3,4,0.07111650630167533
6731,Epigenetic regulation of gene expression,Gene expression (Transcription),0.00426968704563903,1,3,4,0.20224675934896666
6732,Translation,Metabolism of proteins,0.002176891447122913,0,3,4,0.10311510795264807
6733,Translation,Metabolism of proteins,0.001965998241153125,1,3,4,0.09312550753927158
6734,Ion channel transport,Transport of small molecules,8.551599837908743e-05,0,3,4,0.004050726285039325
6735,Ion channel transport,Transport of small molecules,0.00013385157045529478,1,3,4,0.006340288191848408
6736,Nephrin family interactions,Cell-Cell communication,0.0006847417518407281,0,3,4,0.03243488312385076
6737,Nephrin family interactions,Cell-Cell communication,0.0021586852327821217,1,3,4,0.10225271503928486
6738,Sensory processing of sound,Sensory Perception,4.399557107582228e-05,0,3,4,0.0020839845123731917
6739,Sensory processing of sound,Sensory Perception,0.004926668713534095,1,3,4,0.23336670136419443
6740,Dissolution of Fibrin Clot,Hemostasis,0.002383376449981213,0,3,4,0.11289590037042187
6741,Dissolution of Fibrin Clot,Hemostasis,0.0004001184784770922,1,3,4,0.018952833020931564
6742,Striated Muscle Contraction,Muscle contraction,0.0005691850477112174,0,3,4,0.02696118711722856
6743,Striated Muscle Contraction,Muscle contraction,0.0015696144041127814,1,3,4,0.07434957720929586
6744,DNA Double-Strand Break Repair,DNA Repair,0.00033641445239472747,0,3,4,0.015935297380749298
6745,DNA Double-Strand Break Repair,DNA Repair,0.0002943861326830209,1,3,4,0.01394449773390943
6746,Signaling by Nuclear Receptors,Signal Transduction,0.003105986863540912,0,3,4,0.1471245482436977
6747,Signaling by Nuclear Receptors,Signal Transduction,0.002232335729112386,1,3,4,0.10574139560252496
6748,Mitochondrial protein import,Protein localization,0.0004815325029560738,0,3,4,0.022809256791673553
6749,Mitochondrial protein import,Protein localization,0.0006743789299481033,1,3,4,0.03194401643430392
6750,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.0016272832798478454,0,3,4,0.07708123953209482
6751,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.0002931137030753945,1,3,4,0.013884225221687493
6752,Cellular responses to stress,Cellular responses to stimuli,0.003419473058193265,0,3,4,0.16197377871220117
6753,Cellular responses to stress,Cellular responses to stimuli,0.0022994104366460557,1,3,4,0.10891859385803178
6754,Intracellular signaling by second messengers,Signal Transduction,0.004674459751804719,0,3,4,0.22142005407054027
6755,Intracellular signaling by second messengers,Signal Transduction,0.003291557574373443,1,3,4,0.15591467138265164
6756,Metabolism of porphyrins,Metabolism,0.000238380433376022,0,3,4,0.011291616839165085
6757,Metabolism of porphyrins,Metabolism,0.00029320502641022004,1,3,4,0.013888551030189142
6758,MAPK family signaling cascades,Signal Transduction,0.0022481401979002192,0,3,4,0.10649002250688694
6759,MAPK family signaling cascades,Signal Transduction,0.0016309974893591588,1,3,4,0.07725717440253772
6760,Visual phototransduction,Sensory Perception,1.840917652506653e-05,0,3,4,0.0008720068367260247
6761,Visual phototransduction,Sensory Perception,0.0019426094264685541,1,3,4,0.09201762494169353
6762,Peroxisomal protein import,Protein localization,0.0012927446857113674,0,3,4,0.06123479790345889
6763,Peroxisomal protein import,Protein localization,0.0018916828238740942,1,3,4,0.0896053309657446
6764,Signaling by Hedgehog,Signal Transduction,0.0026625864473889525,0,3,4,0.1261215341346635
6765,Signaling by Hedgehog,Signal Transduction,0.0018716894923697515,1,3,4,0.08865828579308425
6766,Metabolism of nucleotides,Metabolism,0.0003831408859400769,0,3,4,0.018148637529445694
6767,Metabolism of nucleotides,Metabolism,0.00013706252681987478,1,3,4,0.006492384940908865
6768,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.0034246088204416976,0,3,4,0.1622170497670653
6769,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.009635135691505778,1,3,4,0.4563976115029191
6770,Death Receptor Signalling,Signal Transduction,0.002893614647720898,0,3,4,0.13706489001436045
6771,Death Receptor Signalling,Signal Transduction,0.0020567617644461317,1,3,4,0.09742479885896073
6772,Degradation of the extracellular matrix,Extracellular matrix organization,0.006284588997014136,0,3,4,0.29768874039245885
6773,Degradation of the extracellular matrix,Extracellular matrix organization,0.003590610511346867,1,3,4,0.17008022654633545
6774,Late endosomal microautophagy,Autophagy,0.0044810575517471455,0,3,4,0.21225896854026563
6775,Late endosomal microautophagy,Autophagy,0.002327521286826069,1,3,4,0.11025015007999397
6776,RNA Polymerase II Transcription,Gene expression (Transcription),0.0007723928534262991,0,3,4,0.036586745089273946
6777,RNA Polymerase II Transcription,Gene expression (Transcription),0.002178218107330976,1,3,4,0.10317794926278859
6778,ECM proteoglycans,Extracellular matrix organization,0.006321152244531484,0,3,4,0.2994206702136879
6779,ECM proteoglycans,Extracellular matrix organization,0.0036059654865746014,1,3,4,0.17080756181622714
6780,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.0009246339122841034,0,3,4,0.043798107529829114
6781,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.0005274636148869415,1,3,4,0.02498492410452747
6782,Metabolism of lipids,Metabolism,0.00014696481420585234,0,3,4,0.006961437007851718
6783,Metabolism of lipids,Metabolism,0.00019049902510092409,1,3,4,0.009023567787046795
6784,RNA Polymerase I Transcription,Gene expression (Transcription),0.0020896072354969013,0,3,4,0.09898062485002333
6785,RNA Polymerase I Transcription,Gene expression (Transcription),0.0059427135833184505,1,3,4,0.2814947679111124
6786,Abacavir ADME,Drug ADME,0.0009990802082306407,0,3,4,0.04732448357092554
6787,Abacavir ADME,Drug ADME,0.0008599120394626944,1,3,4,0.04073235847206255
6788,Adaptive Immune System,Immune System,0.0025768526280870816,0,3,4,0.12206049009675835
6789,Adaptive Immune System,Immune System,0.0017386338602471388,1,3,4,0.0823556996498183
6790,Cell surface interactions at the vascular wall,Hemostasis,0.002070222487986362,0,3,4,0.09806240711581987
6791,Cell surface interactions at the vascular wall,Hemostasis,0.0003625793267993746,1,3,4,0.017174676520379097
6792,Diseases of programmed cell death,Disease,0.000601765958470488,0,3,4,0.0285044814025628
6793,Diseases of programmed cell death,Disease,0.001234296410841707,1,3,4,0.05846621696167765
6794,Synthesis of DNA,DNA Replication,0.0027016843528768074,0,3,4,0.12797352576724166
6795,Synthesis of DNA,DNA Replication,0.00013182106022502246,1,3,4,0.006244106877033557
6796,Diseases of Immune System,Disease,0.001433683032447163,0,3,4,0.06791077288491085
6797,Diseases of Immune System,Disease,0.002706639432825643,1,3,4,0.12820823825348598
6798,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.010636387814219266,0,3,4,0.503824974432693
6799,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.01774712051409722,1,3,4,0.840646532962589
6800,"Cell Cycle, Mitotic",Cell Cycle,0.0013475125275469282,0,3,4,0.06382904390073692
6801,"Cell Cycle, Mitotic",Cell Cycle,0.0043055077581941196,1,3,4,0.20394351673525732
6802,Base Excision Repair,DNA Repair,0.004707229175100512,0,3,4,0.22297227782756662
6803,Base Excision Repair,DNA Repair,0.004110178475669729,1,3,4,0.1946911490618781
6804,Protein folding,Metabolism of proteins,0.0010863636072392948,0,3,4,0.05145892818144876
6805,Protein folding,Metabolism of proteins,0.0009790825840036402,1,3,4,0.046377235060353746
6806,Integration of energy metabolism,Metabolism,0.0007688610688456733,0,3,4,0.036419451332491526
6807,Integration of energy metabolism,Metabolism,0.0011098995211639168,1,3,4,0.052573778583525146
6808,Metabolism of carbohydrates,Metabolism,0.0007604249453614906,0,3,4,0.036019848593952096
6809,Metabolism of carbohydrates,Metabolism,0.0009221276615182875,1,3,4,0.04367939131243798
6810,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.004998983257612081,0,3,4,0.2367921004712575
6811,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.0008341768375569049,1,3,4,0.0395133320818372
6812,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0011429028073244498,0,3,4,0.0541370799689632
6813,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.001836668842489407,1,3,4,0.08699942581742662
6814,Aspirin ADME,Drug ADME,0.004986607326382138,0,3,4,0.23620587671330362
6815,Aspirin ADME,Drug ADME,0.004453029984637544,1,3,4,0.2109313572751397
6816,Platelet Adhesion to exposed collagen,Hemostasis,0.0018118637641135432,0,3,4,0.08582445756722674
6817,Platelet Adhesion to exposed collagen,Hemostasis,0.0003220395560743911,1,3,4,0.015254386539816625
6818,Activation of HOX genes during differentiation,Developmental Biology,0.0028429597024220814,0,3,4,0.1346654639154035
6819,Activation of HOX genes during differentiation,Developmental Biology,0.0021060176989563554,1,3,4,0.0997579565416936
6820,Nervous system development,Developmental Biology,0.001361518064611123,0,3,4,0.06449245891310144
6821,Nervous system development,Developmental Biology,0.0009949047885060153,1,3,4,0.04712670207096999
6822,DNA Replication Pre-Initiation,DNA Replication,0.005505145235202242,0,3,4,0.2607680075059037
6823,DNA Replication Pre-Initiation,DNA Replication,0.0001940031637496034,1,3,4,0.009189552009878468
6824,Laminin interactions,Extracellular matrix organization,0.0023662542719228505,0,3,4,0.11208485614439674
6825,Laminin interactions,Extracellular matrix organization,0.0013629204603866438,1,3,4,0.06455888766956346
6826,Innate Immune System,Immune System,0.015597438068145151,0,3,4,0.738820262400856
6827,Innate Immune System,Immune System,0.010455631494348062,1,3,4,0.4952628996166629
6828,Cardiac conduction,Muscle contraction,0.0025223567124531806,0,3,4,0.11947912471402651
6829,Cardiac conduction,Muscle contraction,0.009699976293909066,1,3,4,0.4594689845497315
6830,Transcriptional regulation of granulopoiesis,Developmental Biology,0.0017287728218166724,0,3,4,0.08188860146555806
6831,Transcriptional regulation of granulopoiesis,Developmental Biology,0.0012763652492620093,1,3,4,0.06045893590082604
6832,Iron uptake and transport,Transport of small molecules,7.699491941071394e-06,0,3,4,0.0003647099370680255
6833,Iron uptake and transport,Transport of small molecules,1.2369674283270735e-05,1,3,4,0.0005859273785766031
6834,Mitochondrial biogenesis,Organelle biogenesis and maintenance,0.0009431774955660076,0,3,4,0.044676480952844586
6835,Mitochondrial biogenesis,Organelle biogenesis and maintenance,0.0006204052957760668,1,3,4,0.029387390507181126
6836,Transcriptional regulation of testis differentiation,Developmental Biology,0.004245615092789882,0,3,4,0.20110651782707012
6837,Transcriptional regulation of testis differentiation,Developmental Biology,0.0031143702301586777,1,3,4,0.14752165199222866
6838,Miscellaneous transport and binding events,Transport of small molecules,0.00014044314598391923,0,3,4,0.006652518286330362
6839,Miscellaneous transport and binding events,Transport of small molecules,0.00022816043146662112,1,3,4,0.0108075152540553
6840,SLC-mediated transmembrane transport,Transport of small molecules,0.0024043933841811143,0,3,4,0.11389143160911581
6841,SLC-mediated transmembrane transport,Transport of small molecules,0.0038552553576613868,1,3,4,0.18261593747160917
6842,Surfactant metabolism,Metabolism of proteins,0.002253901172041666,0,3,4,0.10676290863140767
6843,Surfactant metabolism,Metabolism of proteins,0.002052973673695481,1,3,4,0.09724536437810777
6844,Signaling by GPCR,Signal Transduction,0.00025812403539933124,0,3,4,0.01222683281270311
6845,Signaling by GPCR,Signal Transduction,0.00018620034285709962,1,3,4,0.00881994758163328
6846,Metabolism of amino acids and derivatives,Metabolism,0.0003331766455772678,0,3,4,0.015781928778032136
6847,Metabolism of amino acids and derivatives,Metabolism,0.0003606972774280408,1,3,4,0.017085527507297263
6848,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.0022070301250691794,0,3,4,0.10454271842632909
6849,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.0016234711440332378,1,3,4,0.07690066608339441
6850,Signal Transduction,root,0.004159634360327943,0,4,5,0.5269199846451688
6851,Signal Transduction,root,0.001355691164845957,1,4,5,0.1717316249180864
6852,Organelle biogenesis and maintenance,root,0.001026448349654261,0,4,5,0.130024925699537
6853,Organelle biogenesis and maintenance,root,0.0019174885666252337,1,4,5,0.24289708146458294
6854,Immune System,root,0.008148659466213144,0,4,5,1.0322281116259522
6855,Immune System,root,0.005249427101792895,1,4,5,0.664969035320348
6856,Sensory Perception,root,0.0003701382235223792,0,4,5,0.04688710837546447
6857,Sensory Perception,root,0.0033755918203094894,1,4,5,0.4276017159319754
6858,Neuronal System,root,0.0030225084978695946,0,4,5,0.38287503018937885
6859,Neuronal System,root,0.0006722266905283593,1,4,5,0.0851540416219059
6860,Extracellular matrix organization,root,0.0072632654041003405,0,4,5,0.9200711802228226
6861,Extracellular matrix organization,root,0.002535040252401758,1,4,5,0.3211251891777113
6862,Developmental Biology,root,0.003575391351046049,0,4,5,0.452911239930503
6863,Developmental Biology,root,0.00300000168248387,1,4,5,0.3800239885376019
6864,DNA Replication,root,0.004991862595293726,0,4,5,0.6323421565965692
6865,DNA Replication,root,0.000422968501560819,1,4,5,0.05357936228083417
6866,Hemostasis,root,0.003067666079836004,0,4,5,0.38859534845179394
6867,Hemostasis,root,0.0009710630419604843,1,4,5,0.1230090144555324
6868,Cellular responses to stimuli,root,0.0020434473532945337,0,4,5,0.25885285934994473
6869,Cellular responses to stimuli,root,0.0005343962557093489,1,4,5,0.06769442755314817
6870,Programmed Cell Death,root,0.0008072914593489037,0,4,5,0.10226331607924395
6871,Programmed Cell Death,root,0.0031171857017721167,1,4,5,0.3948682263468005
6872,Transport of small molecules,root,0.00352634521609593,0,4,5,0.4466983408061712
6873,Transport of small molecules,root,0.011194132402055273,1,4,5,1.4180121526214922
6874,Metabolism of proteins,root,0.005551828735784733,0,4,5,0.7032756388668892
6875,Metabolism of proteins,root,0.0016159723251669485,1,4,5,0.2047026346558151
6876,Chromatin organization,root,0.0024378286021038286,0,4,5,0.30881094305770423
6877,Chromatin organization,root,0.004160348386243742,1,4,5,0.5270104335865895
6878,Cell Cycle,root,0.006045470017243087,0,4,5,0.7658074466928421
6879,Cell Cycle,root,0.005390653183797805,1,4,5,0.6828587916102873
6880,Cell-Cell communication,root,0.002610943024578566,0,4,5,0.33074014185994083
6881,Cell-Cell communication,root,0.0051099392609094,1,4,5,0.6472994700149194
6882,Protein localization,root,0.00024249817038322493,0,4,5,0.030718356746321448
6883,Protein localization,root,0.0007122596852873749,1,4,5,0.09022520489166447
6884,DNA Repair,root,0.0032539547536530127,0,4,5,0.4121933901651258
6885,DNA Repair,root,0.0020063091211655025,1,4,5,0.25414838895470665
6886,Reproduction,root,0.002862667237556896,0,4,5,0.3626272037859563
6887,Reproduction,root,0.0019160764510567515,1,4,5,0.24271820230136645
6888,Metabolism of RNA,root,0.0031355710827834435,0,4,5,0.397197186981557
6889,Metabolism of RNA,root,0.0020122238538325815,1,4,5,0.254897635300934
6890,Autophagy,root,0.00683475396471096,0,4,5,0.8657896685551649
6891,Autophagy,root,0.001341048867939877,1,4,5,0.1698768179344472
6892,Muscle contraction,root,0.0030275781338722422,0,4,5,0.3835172242606051
6893,Muscle contraction,root,0.005602823144893356,1,4,5,0.7097353348249701
6894,Metabolism,root,0.003490345740270447,0,4,5,0.4421381219008485
6895,Metabolism,root,0.00566160328479999,1,4,5,0.7171812850537789
6896,Vesicle-mediated transport,root,0.0022552686487560913,0,4,5,0.2856852354877657
6897,Vesicle-mediated transport,root,0.008794929410879344,1,4,5,1.1140940930612295
6898,Drug ADME,root,0.0017305469689025013,0,4,5,0.21921633088201503
6899,Drug ADME,root,0.003757395527624476,1,4,5,0.4759665447050554
6900,Disease,root,0.007050392525140205,0,4,5,0.8931055951745722
6901,Disease,root,0.0008080590060916652,1,4,5,0.10236054474957315
6902,Gene expression (Transcription),root,0.002271397714167012,0,4,5,0.2877283782648614
6903,Gene expression (Transcription),root,0.002184866873689279,1,4,5,0.2767671193689555
6904,Circadian Clock,root,0.004676211312139019,0,4,5,0.5923571591507858
6905,Circadian Clock,root,0.005951631304850508,1,4,5,0.7539204661051728
